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ABSTRACT 
 
MINING GENOMIC VARIANTS AND CAUSAL PATHWAYS LINKING HDL AND 
TRIGLYCERIDES TO CORONARY DISEASE 
Sumeet A. Khetarpal 
Daniel J. Rader 
Blood lipids are important biomarkers of risk of coronary heart disease (CHD), 
the leading cause of death in the world. Myriad data support a causal role of low-density 
lipoprotein cholesterol (LDL-C) in increasing risk of CHD. Long-standing epidemiology 
suggests that high-density lipoprotein cholesterol (HDL-C) may protect from disease 
while high triglycerides (TGs) increase CHD risk. However, the causality of HDL-C and 
TG to CHD remains controversial. New genetic methodologies have allowed a better 
look into causal pathways underlying relationships between these traits and disease. 
Using a combination of approaches for interrogating rare genetic variation in humans, 
we investigated how HDL and TG may relate to CHD. First, through sequencing and 
exome-wide genotyping of subjects with extremely high HDL-C, we identified the first 
homozygote for a loss-of-function (LOF) variant in SCARB1, which encodes scavenger 
receptor class BI (SR-BI), a hepatic receptor for HDL-C. Despite markedly elevated 
HDL-C, carriers of this variant had an increased risk of CHD. These findings suggest 
that HDL functionality in driving cholesterol removal through SR-BI (the reverse 
cholesterol transport hypothesis) is protective from CHD in humans. Next, we 
functionally examined one of the first novel loci from genome-wide association studies 
(GWAS) for HDL-C, GALNT2. Through discovery of humans with genetic GALNT2 LOF 
and additional studies in rodents and nonhuman primates, we showed that GALNT2 
LOF lowers HDL-C across mammals. We also identify one physiological mechanism 
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linking GALNT2 to HDL-C through its enzymatic function. Thirdly, we studied the 
mechanism of protection of the APOC3 A43T variant recently reported to lower TGs and 
CHD risk from exome sequencing. Studies in human carriers and animal models 
suggest that A43T accelerates renal clearance of circulating ApoC-III, thus hindering its 
function in delaying TG-rich lipoprotein turnover. These data establish ApoC-III 
clearance mechanisms as potential therapeutic targets for TG lowering. Finally, we 
adapted a targeted sequencing approach to increase discovery of causal rare coding 
and noncoding variants at candidate loci influencing HDL-C and TGs. Collectively, this 
work provides a sampling of approaches for leveraging the spectrum of genomic 
methods to identify clinically relevant variants impacting HDL, TG and CHD risk.  
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CHAPTER 1 - INTRODUCTION 
Heart Disease – Epidemiology and Pathophysiology 
Coronary heart disease (CHD), also called coronary artery disease (CAD) and ischemic 
heart disease (IHD), is a chronic, multifactorial disorder involving the pathological 
narrowing, stiffening, and remodeling of the coronary arteries, the blood vessels 
supplying the heart muscle or myocardium with oxygen [1,2]. CHD is the predominant 
form of cardiovascular diseases that together are the leading cause of mortality 
worldwide [3,4]. In the United States in 2013, the American Heart Association estimated 
that cardiovascular diseases accounted for 402,851 male deaths and 398,086 female 
deaths, or approximately one in four deaths overall [5]. More than 50% of these deaths 
were due to CHD. The prevalence of cardiovascular diseases in the United States is 
also profound, with an estimated 85.6 million individuals having one or more 
cardiovascular diseases, or 35% of the population. While the incidence and mortality 
from cardiovascular diseases has been decreasing in developed countries since the 
mid-1990s, disease burden has sustained in developing countries, and globally, 
cardiovascular diseases accounted for more than 17.3 million deaths in 2013 
(approximately 31% of all deaths worldwide), a statistic that is projected to increase to 
more than 23.6 million deaths by 2030 [5,6].  In addition to significant mortality and 
morbidity, cardiovascular diseases impose a significant direct and indirect cost 
worldwide, with an estimated total cost of disease of 863 billion dollars in 2010 [5]. Thus, 
cardiovascular diseases as a whole and CHD in particular constitute a pressing burden 
of morbidity, mortality and financial strain across societies.  
 CHD is caused by the pathological narrowing of the lumen of the coronary 
arteries due to the thickening, stiffening, and remodeling of the arterial wall, a process 
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called atherosclerosis [1,2,7]. Atherosclerosis occurs due to the deposition of fat in the 
intima (innermost layer of artery adjacent a layer of endothelial cells in direct contact with 
blood flow) of arteries. This fat includes oxidized phospholipids, cholesterol and 
triglycerides carried on low-density lipoproteins (LDLs), one class of circulating particles 
in the blood comprised of several protein and lipid components. Both circulating free 
radicals, and enzymes in the intima such as lipoprotein phospholipase A2, contribute to 
the oxidization of phospholipids on the surface of LDLs, rendering them prone to 
aggregation. This in turn enhances their susceptibility to phagocytosis by macrophages 
in the arterial wall [1,8]. Accumulation of modified lipoproteins in macrophages causes a 
profound phenotypic change in the cells [9,10], which are often termed foam cells due to 
a change their appearance after internalization of fatty deposits. Foam cell formation 
after uptake of oxidized proatherogenic lipoproteins is the initial step in lesion formation 
in the arterial wall and the first step in atherogenesis [7,10,11].  
Augmenting this lesion (also termed plaque) formation is the subsequent 
proliferation of vascular smooth muscle cells, which secrete collagen and other 
extracellular matrix components, and T cells, which induce inflammation in the vessel 
[2]. The foam cells eventually die and release cellular lipid contents in the intima. This 
process perpetuates further inflammation through the release of inflammatory cytokines 
from these dying cells [12]. Concurrently, smooth muscle cells block the proliferating 
plaques from access to flow from the luminal surface of the vessels, and thus promote 
formation and proliferation of a “necrotic core” of inflammatory cells, cell debris, and fat-
laden lesions. As a plaque develops in the arterial wall, the lumen of the coronary artery 
diminishes in volume. This may reduce blood flow and cause inadequate oxygenation of 
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the myocardium supplied by such an artery during times of increased demand such as 
exercise; this manifests in chest pain and is known as stable angina [1,8,12]. 
The initially walled-off atherosclerotic plaque may also rupture and the 
endothelium lining the lumen may erode thus leading to release of the atherosclerotic 
plaque into the coronary lumen [2].  Partial obstruction of blood flow through the adjacent 
arterial lumen may also diminish oxygenation of the myocardium and may cause chest 
pain at rest as well; this is termed unstable angina. Obstruction of blood flow due to 
plaque rupture that leads to myocardial ischemia initially may then result in death of the 
myocardial cells, a process termed myocardial infarction or MI [13]. 
Depending on the site and extent of vessel obstruction, a MI may have profound 
consequences for the function of the heart, which can lead to a patient’s death from 
several mechanisms [2].  Acutely, a MI may severely reduce or completely inactivate the 
heart muscle from maintaining forward blood flow due to death of the contractile 
myocardial cells, which results in systemic loss of perfusion of tissues. Additionally, 
myocardial scarring of dead tissue can cause abnormal electrical impulse conduction 
throughout the heart, which can cause the sudden disorganized movement of the heart 
muscle known as ventricular fibrillation; this also leads to inability of the heart to pump 
blood and perfuse the body and is known as sudden cardiac death. Both of these acute 
consequences are predominant causes of mortality in the setting of an MI. Additional 
consequences include long-term impairment in cardiac contractility and subsequent 
compensatory remodeling of the heart to attempt to maintain forward blood flow; this 
disease is known as ischemic cardiomyopathy and is the prevailing cause of heart 
failure, another major cardiovascular disorder with profound morbidity and mortality 
worldwide. Heart valve dysfunction due to myocardial contractile and anatomical 
	4 
 
changes after an MI, as well as risk of future arrhythmias are also long-term 
consequences of an MI from CHD [2].   
 The etiology of CHD is complex with many recognized risk factors [14,15]. These 
include high blood levels of atherogenic lipoproteins, particularly LDL-cholesterol (LDL-
C) and triglyceride-rich lipoproteins (TRLs) whose importance is becoming increasingly 
apparent, low levels of high-density lipoprotein cholesterol (HDL-C), hypertension, 
obesity, diabetes mellitus and insulin resistance, smoking, lack of physical activity and 
consumption of unhealthy diet, the latter two of which may exacerbate several of the 
other above mentioned contributors. Among these risk factors, high LDL-C levels are a 
predominant cause of CHD with substantial evidence from epidemiology and human 
genetics, an established pathophysiology, and significant pharmacological success in 
reducing LDL-C levels to decrease incidence, morbidity and mortality from disease. Yet 
despite the effectiveness of targeting LDL-C to lower CHD risk over the last four 
decades, disease burden remains high and not all patients can benefit maximally from 
LDL-C lowering alone. In addition, some patients develop CHD or remain susceptible to 
complications from pre-existing CHD despite optimally low LDL-C concentrations; this 
signals the need for additional orthogonal therapeutic targets for risk and mortality 
reduction from disease. In this regard, efforts to target the other plasma lipid classes 
associated with cardiovascular disease risk (discussed in the next section) have been at 
the forefront of research endeavors in this field, and human genetics has played a key 
role in helping to refine our understanding of how these traits contribute to disease risk.  
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Blood Lipids and CHD Risk – the Evidence for Causality 
Plasma lipoproteins are circulating complexes of proteins and lipids (cholesterol, 
triglycerides, phospholipids) that mediate the delivery of their lipid cargo as nutrients and 
substrates for biosynthetic and signaling processes throughout the body [16]. 
Lipoproteins have traditionally been categorized by their density, lipid and protein 
content, and putative roles in physiology and disease. Broadly speaking, lipoproteins can 
be grouped into two categories: those containing apolipoprotein B (ApoB) as a critical 
constitutional protein vs. those that contain apolipoprotein A-I as their key structural 
protein. Using this categorization, the former group includes the LDLs, the very low-
density lipoproteins (VLDLs) and the chylomicrons as well as remnant particles of these 
classes. The latter group containing ApoA-I includes the HDLs. The blood 
concentrations of each of these lipoprotein classes have been studied for more than 
seven decades and have been related to risk or protection from CHD and other vascular 
diseases through large epidemiological studies [17]. Because these traits are easily 
measureable and have a polygenic etiology of inheritance, they have also served as 
invaluable tools for understanding the architecture of complex trait genetics [18].  The 
potential role and causality of each of these traits to risk of CHD has been a central topic 
of translational medical discovery of the early twenty-first century and certainly not a field 
without controversy, as will be discussed below.  
 
Low-density lipoproteins 
 LDLs are the lipoproteins with the most profound evidence for a causal 
relationship to CHD. The defining protein component of LDL, ApoB, serves as a scaffold 
for cholesterol, cholesterol esters (CEs), triglycerides (TGs) and phospholipids [19,20]. 
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LDL is generated from the lipolytic processing and remodeling of VLDLs in the 
circulation by the action of extracellular lipases: enzymes on the capillary luminal surface 
of tissues that hydrolyze TGs and phospholipids of lipoproteins to provide nutrient 
sources for underlying tissues and thereby alter the structure and composition of the 
lipoproteins. Circulating LDLs deliver CEs to peripheral tissues and are eventually 
cleared from the circulation by the LDL receptor in the liver. Internalization of LDL by the 
LDL receptor occurs through receptor-mediated endocytosis and yields catabolic 
products that ultimately may be recycled for storage or re-secretion. Importantly, LDLs 
may also traverse the arterial wall, where oxidation of their surface phospholipids 
promotes macrophage activation, LDL uptake, and foam cell formation in the intima, as 
mentioned above [20].  
 Evidence for a role of LDL-C in promoting atherogenesis and CHD has 
developed since the 1910s from the discovery of cholesterol in arterial lesions from 
humans and cholesterol-fed rabbits [21-23]. From those early studies to the subsequent 
elucidation of the cholesterol and lipoprotein metabolic pathways, and finally to the 
therapeutics to lower LDL-C levels that are now the mainstay of treatment and 
prevention for cardiovascular diseases, human genetics has proven pivotal. The 
identification of families with an autosomal dominant inheritance pattern of extremely 
high cholesterol levels and MIs at an early age fueled a subsequent career of study by 
Drs. Michael Brown and Joseph Goldstein of the University of Texas Southwestern 
Medical Center that uncovered the LDLR gene and receptor-mediated uptake pathway 
of LDL clearance by the liver and showed that these patients who suffered from Familial 
Hypercholesterolemia (FH) inherited loss-of-function (LOF) mutations in the LDL 
receptor gene LDLR [20,24,25]. The understanding of this Mendelian disorder of LDL 
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metabolism in the 1970s complemented earlier evidence showing LDL-C as a major risk 
factor in MI patients [26,27], which together solidified the evidence supporting the notion 
that LDL-C lowering could reduce CHD and MI risk. These findings and the 
serendipitous discovery of statins [28], inhibitors of the rate-limiting cholesterol 
biosynthetic enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. 
Statins function by reducing hepatic cholesterol synthesis, which induces a 
compensatory upregulation of LDL receptor-mediated clearance from the circulation. 
Thus, the discovery of the first major efficacious drug and pathway for lowering LDL-C 
and disease risk was driven by human genetics, and was motivated by a desire to 
elucidate the cause of FH.  
 Subsequent studies of additional Mendelian disorders of LDL metabolism that 
confer increased CHD risk have affirmed the importance of the hepatic LDL clearance 
pathway as a critical phenomenon and target for lowering LDL-C and disease. These 
efforts have uncovered mutations in APOB [29], the gene encoding the key LDL 
structural protein ApoB that interacts with the LDL receptor for uptake; ARH [29,30], a 
gene encoding an adapter for the LDL receptor that when mutated results in an 
autosomal recessive hypercholesterolemia; and PCSK9 [20,31], a gene encoding a 
secreted protein that reduces cell-surface LDL receptor levels by promoting lysosomal 
turnover, and thus inhibits LDL uptake via this pathway. This last example of PCSK9 is 
particularly notable because it offers an impressive demonstration of the translation of 
genetics discovery to the development of novel medicines for reducing CHD risk in less 
than a decade. Through positional cloning in a large family and additional sequencing of 
probands with autosomal dominant hypercholesterolemia absent of APOB or LDLR 
mutations, two variants in the PCSK9 gene were identified that segregated with 
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extremely high LDL-C levels [32]. Subsequent studies in humans confirmed that these 
variants were likely gain-of-function mutations that increased PCSK9 function [33-35], 
and additional work in mice demonstrated that indeed PCSK9 overexpression increased 
LDL-C levels in vivo [36,37]. Following this work, sequencing of human subjects with 
extremely low LDL-C levels in the Dallas Heart Study identified PCSK9 mutations that 
were demonstrated to confer LOF [38]. Caucasians heterozygous for a low-frequency 
missense variant [3% minor allele frequency (MAF)] demonstrated a 15% reduction in 
LDL-C levels and 46% lower incidence of CHD adverse events, and African Americans 
heterozygous for either of two nonsense variants demonstrated even more profound 
LDL-C and disease risk reductions [38,39]. This and other studies [40,41] not only 
further established the causal and direct relationship of LDL-C levels to CHD risk 
through an example of genetic gain- and LOF in PCSK9 conferring opposing LDL-C 
phenotypes and disease risk, but they also paved the way for the development of 
therapies targeting PCSK9 [42-50]. In 2015, two PCSK9 inhibitory monoclonal 
antibodies were approved for the treatment of hypercholesterolemia in addition to statins 
in patients on maximally tolerated statin therapy who require additional LDL-C lowering, 
as well as for heterozygous and homozygous FH patients [51]. This marked the success 
of a bench-to-bedside journey that started only 12 years earlier with the initial report of 
PCSK9 gain-of-function mutations with hypercholesterolemia.   
 PCSK9 inhibitors, statins, and other LDL-C lowering therapies currently approved 
largely function through enhancing hepatic LDL clearance from the blood. Thus, human 
genetics has not only helped unveil a key pathway of LDL regulation but also has 
conclusively demonstrated their causality to the development of atherosclerosis and has 
helped facilitate targeted therapies that have been efficacious for disease reduction. As 
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will be discussed below, additional investigations of both low-frequency and common 
genetic variants have also supported a causal role of smaller heritable variations in LDL-
C with direct effects on CHD risk. While LDL-C lowering through current therapies has 
been remarkably efficacious, it has not eliminated risk of CHD in all patients, and many 
patients are still at risk of MI even with optimal LDL-C lowering through one or more of 
these medications. Additionally, many patients are intolerant to their adverse effects 
(e.g. statins) or not able to access them due to still limited use or high cost (e.g. PCSK9 
inhibitors). This has signaled the need for additional therapies targeting orthogonal 
pathways to those of LDL-C focused drugs. In this vein, HDL-C and TRLs have 
remained candidates for possible therapeutic intervention.  
 
High-density lipoproteins 
 HDLs are formed through the secretion of ApoA-I from the liver and small 
intestinal enterocytes [52,53]. ApoA-I in the circulation quickly acquires phospholipids 
and free cholesterol from cells via ATP-binding cassette transporter proteins on the cell 
surface (particularly ABCA1 and ABCG1), which efflux lipids to lipid-poor ApoA-I 
acceptors. This allows the nascent particles to mature into HDLs. Esterification of the 
cholesterol of these HDLs with fatty acyl chains by the lecithin:cholesterol 
acyltransferase (LCAT) enzyme to CEs further matures and stabilizes these particles. 
HDLs traverse the blood and may acquire free cholesterol from cells via ABC-transporter 
mediated efflux. Subsequent LCAT activity facilitates this flux by converting the free 
cholesterol to CE and thereby promoting a concentration gradient for the mobility of the 
free cholesterol. CEs on HDLs exchange for TGs from ApoB-containing lipoproteins via 
facilitation by cholesteryl ester transfer protein (CETP). Additionally, phospholipids on 
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HDLs may redistribute to ApoB-containing lipoproteins through the actions of 
phospholipid transfer protein (PLTP) in the circulation [19,52,53]. HDLs also have a 
diverse and dynamic proteome that changes with their metabolism [54]. Like LDLs, 
HDLs are susceptible to lipolysis by extracellular lipases, which promote their catabolism 
largely through the kidneys. HDL-C is also selectively taken up by the liver and other 
tissues involved in steroid hormone biosynthesis via the scavenger receptor class BI 
(SR-BI) through a process distinct from receptor-mediated endocytosis that retains the 
CE-reduced HDLs in the circulation where they can re-mature through the subsequent 
re-accumulation of lipids by the above described processes.  
 In contrast to case for LDL, epidemiological studies have strongly supported an 
inverse relationship between HDL-C levels and CHD risk. The earliest studies of 
separation of lipoprotein classes from plasma of MI patients demonstrated that a 
majority of them harbored low HDL-C levels in addition to their elevated LDL [26]. The 
Framingham Heart Study and other large community-based prospective studies affirmed 
this relationship and showed that it was independent of the relationship of LDL-C or TGs 
to vascular risk [17,55,56]. Mechanistically, HDLs are thought to promote 
atheroprotection through several putative mechanisms. Of these, perhaps the most 
attractive is the reverse cholesterol transport (RCT) hypothesis [57,58]: the notion that 
HDL can accept cholesterol from arterial plaque macrophages via ABC transporter-
mediated efflux and deliver this cholesterol after esterification to the liver via SR-BI-
mediated selective cholesterol uptake. The CE in the liver is then recycled for bile acid 
synthesis and later excreted via the bile, thus providing a unidirectional sink for 
cholesterol removal from the plaques and ultimately the body. Animal model 
investigations studying the disruption of this pathway of macrophage-to-feces RCT have 
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strongly supported its potential role in reducing atherosclerosis in vivo. Additional 
potentially anti-atherogenic functions of HDL include its ability to reduce inflammation, 
oxidative stress, and promote endothelial cell function [59].  
 Despite the epidemiology and animal physiology studies that link higher HDL-C 
to lower CHD risk, neither human genetics, nor pharmacological interventions that 
specifically target HDL-C have supported a causal role thus far. Mendelian disorders of 
HDL metabolism have offered unclear evidence [60]. APOA1 mutations that confer 
ApoA-I deficiency or structural alterations and low-to-absent HDL-C levels are extremely 
rare, but the preponderance of evidence has not supported a definitive increase in CHD 
risk, especially for the structural mutations. Likewise, both homozygous LOF of ABCA1 
(Tangier Disease) and LCAT (Fish Eye Disease and Familial LCAT Deficiency) cause 
profound reductions or complete loss of circulating HDL-C with unsubstantiated 
evidence of increased atherosclerotic risk, in large part because of the rarity of patients 
and possibly also because of variable effects for the other lipoproteins in the few 
identified patients. Consistent with these findings, additional methods to assess causality 
of more common genetic variants that impact HDL-C to CHD risk (Mendelian 
randomization; discussed below) have also failed to support a direct link between HDL-C 
itself and CHD or MI risk [19].  
In addition to weak support from these genetic cases of extreme HDL-C 
deficiency, efforts to raise HDL-C specifically have not translated to reduced CHD risk. 
Multiple trials of CETP inhibitors that robustly increased HDL-C have met with either no 
benefit or adverse effects on cardiovascular mortality (though the latter finding was later 
ascribed to off-target effects) [19,61-64]. Similarly, two large trials of nicotinic acid 
(niacin), a potential elevator of HDL-C used for decades, have shown that when added 
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to statins, it failed to show any additional benefit in lowering adverse cardiovascular 
events in at-risk patients [65,66].  
While the exact reasons for why each of these medications failed to reduce CHD 
risk or adverse events despite potent HDL-C elevation will be difficult to determine, one 
prevailing notion is that these therapies raised HDL-C levels and did not necessarily 
improve the functionality of the HDL particles in mediating RCT or other atheroprotective 
roles. In the last five years, there has been increasing evidence from both cross-
sectional and prospective studies that HDL cholesterol efflux capacity, one metric of its 
functionality in potentially mediating delivery of CE to the liver through the RCT pathway, 
is a more reliable measure of CHD risk than the static measure of HDL-C alone [19,53]. 
Indeed, the cholesterol efflux capacity of HDL has been demonstrated to be a significant 
predictor of incident cardiovascular events even after adjusting for HDL-C 
concentrations. Pharmacological studies in limited numbers of subjects involving the 
infusion of recombinant HDL that promotes cholesterol efflux showed preliminary 
efficacy in reducing atherosclerotic plaques [19,53,67-70]. Larger studies evaluating 
these and other developing therapies targeting HDL’s ability to promote RCT will be 
more suited to test the hypothesis that HDL functionality is a causal contributor to CHD 
risk. Likewise, human genetics efforts to find variants that specifically alter the RCT 
pathway at different nodes will be able to assess the lifelong and heritable contribution of 
this phenomenon to disease risk and potentially rectify the current controversy 
surrounding the direct relevance of HDL to vascular disease beyond serving as a 
biomarker.  
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Triglyceride-rich lipoproteins 
Independently of LDL-C, plasma TRL levels have recently emerged as an important 
and independent risk factor for development of CHD [71]. TRLs are produced from two sites 
in the body: the liver, which secretes VLDLs, and the small intestinal enterocytes, which 
secrete TG-rich chylomicrons into the lymph in the setting of dietary consumption. In both 
cases, assembly of TRLs involves the lipidation of ApoB through the secretory pathway in 
part by the actions of microsomal triglyceride transfer protein (MTP) in the respective cell type 
to yield a buoyant, lipid-laden particle that delivers fatty acid nutrients to peripheral tissues. 
Other than the site of origin, chylomicrons and VLDL differ also in the nature of their ApoB (a 
shorter form of the protein, ApoB48, is incorporated into chylomicrons due to RNA editing that 
occurs in the enterocytes but not hepatocytes in certain organisms including humans), their 
size and TG content (chylomicrons typically are larger, less dense and more enriched in 
TGs), and the exact milieu of lipids and proteins on the TRL surfaces. Circulating TRLs are 
modified by extracellular lipases that hydrolyze the TGs to fatty acids that are taken up by 
nearby tissues [19,71,72]. In this regard, lipoprotein lipase (LPL) is a critical regulator of TRL 
metabolism with a complex regulation, as detailed below. The actions of LPL and other 
lipases remodel the TRL lipid and protein content to yield smaller, denser particles such as 
chylomicron remnants from chylomicrons and intermediate density lipoproteins (IDLs) and 
LDLs from VLDLs. Remnants are cleared from the circulation by hepatic receptors such as 
the LDL receptor and related family members via receptor-mediated endocytosis utilizing 
apolipoprotein E (ApoE) and other surface proteins as ligands [73]. 
While recognized for decades as a correlative biomarker of risk [74], recent 
prospective studies have demonstrated that elevated TGs are independent predictors of CAD 
risk. Furthermore, TGs are strongly associated with incident CHD even in statin-treated 
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patients with low LDL-C levels. The ACCORD study found that among dyslipidemic patients 
with elevated TG and low HDL-C, the addition of TG-lowering fenofibrate therapy reduced 
incidence of cardiovascular events [75]. Moreover, a large meta-analysis in 2012 by 
Boekholdt and colleagues demonstrated that TRLs beyond LDL-C, including non-HDL-C, 
were the strongest predictors of vascular risk for patients already maximally treated on statins 
[76]. Mechanistically, TRLs are cholesterol-rich particles that can cause plaque accumulation 
similarly to LDL-C but also directly damage the vascular endothelium and augment 
inflammation, promote foam cell formation, and cause lipotoxicity to vascular smooth muscle 
cells [71].  
Human genetics has also causally implicated TRLs and specifically the LPL pathway 
with cardiovascular risk. Several studies of a gain-of-function variant, LPL S447X, have 
demonstrated an association with lower TG levels and reduced risk of CHD [77-83]. Using 
newer methods to interrogate common and low-frequency variants such as genome-wide 
association studies (GWAS) and Mendelian randomization (both discussed below), single-
nucleotide polymorphisms (SNPs) at the LPL gene locus and loci of LPL pathway regulators 
have also been implicated in regulating fasting TG levels and CHD [84-88]. Additional 
approaches such as population based exome or candidate gene sequencing in participants 
at the phenotypic extremes of lipid traits (also described below) have uncovered rare variants 
in LPL pathway genes associated with TGs and CHD or MI risk that have collectively posited 
that activation of the LPL pathway is atheroprotective in a manner that may be independent 
and synergistic with LDL-C lowering [87,89-92]. These studies have identified a few key 
regulators, namely ApoC-III, ApoA-V, and the angiopoietin-like proteins ANGPTL3 and 
ANGPTL4 as particularly critical to influencing disease risk through impacting TRL levels. 
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ApoC-III 
ApoC-III may act at multiple nodes influencing TRL homeostasis. A small (8.8 kDa) 
apolipoprotein, ApoC-III is expressed primarily in the liver and circulates on HDLs and TRLs 
[93,94]. ApoC-III undergoes O-glycosylation and exists in nonglycosylated (ApoC-III-0), 
monosialylated (ApoC-III-1) or disialylated (ApoC-III-2) forms, though this modification does 
not appear to impact plasma TG or ApoC-III binding to lipoproteins [95-97]. Like ApoE, ApoC-
III exchanges between lipoproteins. Several studies have demonstrated that ApoC-III may 
inhibit LPL activity [98]. Further insight gained from studies of human APOC3 and mouse 
Apoc3 transgenic mice and Apoc3 knockout (Apoc3 KO) mice suggested that ApoC-III may 
compete for lipoprotein binding with ApoE and delay the catabolism of TRL remnants by the 
liver [99,100]. Additionally, ApoC-III may promote VLDL secretion [101]. Preclinical studies 
utilizing an antisense oligonucleotide (ASO) to silence Apoc3 expression in the liver have 
shown efficacy in lowering plasma TG in rodents and nonhuman primates as well as in 
human clinical studies [102-104].  
In the past decade, human genetics studies have identified APOC3 variants that 
provide insight into its role in TRL metabolism and CHD. In 2008, genotyping and sequencing 
in an Amish population identified the R19X nonsense mutation in APOC3, which was 
associated with plasma TG and reduced coronary artery calcification (CAC), a surrogate 
marker of atherosclerosis [105]. More recently, two large exome sequencing studies identified 
this and three other rare coding variants in APOC3 associated with reduced TG levels and 
collectively associated with a highly significant 40% reduction in risk of CHD [106] [91].  
These data strongly support that genetic deficiency of ApoC-III reduces not only TRL levels 
but also risk of CHD.  While many variants in APOC3 have been identified, most have not 
been mechanistically investigated to understand how they impact TG metabolism.  
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ApoA-V  
Like ApoC-III, ApoA-V exchanges between HDLs and TRLs and is primarily secreted 
from the liver. A 39 kDa protein, ApoA-V has a very low concentration in human plasma 
(~150 ng/ml) [107]. Despite this, ApoA-V plays a crucial role in TG metabolism. Apoa5 KO 
mice demonstrate profound hypertriglyceridemia (hyperTG) while human APOA5 transgenic 
mice have significantly lower plasma TG than controls [108]. ApoA-V has been shown to 
enhance LPL activity and may do so by facilitating proximity between TRLs and LPL, in part 
through interaction with glycosylphosphatidylinositol-anchored HDL binding protein 1 
(GPIHBP1), a required chaperone for LPL on capillary luminal surface. A wealth of human 
genetic data from common, low-frequency, and rare (MAF < 1%) variants has suggested that 
LOF of ApoA-V augments risk of CAD and MI [73,109].  Most notably in this regard was a 
recent exome sequencing study in ~4,700 early MI cases and ~5,000 healthy controls that 
identified several rare coding variants in APOA5 associated together with increased 
frequency of MI, a finding that was second only to that for LDLR variants in the same cohort 
[92]. As with the APOC3 mutations, the mechanisms of action of these APOA5 variants as 
they relate to TRL metabolism and CHD risk remain largely unknown.  
 
Angiopoietin-like Proteins 3 and 4 
The angiopoietin-like (ANGPTL) proteins ANGPTL3 and ANGPTL4 are additional 
regulators of LPL activity and TRL metabolism that have generated considerable interest as 
putative therapeutic targets [110]. Like ApoC-III, ANGPTL3 and ANGPTL4 are thought to 
inhibit LPL activity, leading to elevated plasma TG levels, though their respective 
mechanisms conferring LPL inhibition may be distinct [110-115]. Both common and rare 
variants in ANGPTL3 are associated with plasma TG levels, and rare ANGPTL3 LOF 
	17 
 
mutations underlie the Mendelian condition familial combined hypolipidemia, characterized by 
very low plasma TG in addition to other lipid classes [115-118]. While common variants at the 
ANGPTL4 locus are associated primarily with HDL-C levels, rare coding mutations are 
robustly associated with reduced plasma TG [115-117,119]. Prior evidence linking ANGPTL3 
and ANGPTL4 LOF to CHD risk have been smaller and/or inconsistent [120-123], but two 
recent large exome sequencing studies have suggested a robust relationship between 
ANGPTL4 LOF, lower TGs and decreased CHD [89,90].  
While epidemiology and recent human genetics efforts have positioned TRLs as 
possibly the next ‘holy grail’ for lipid lowering therapies to reduce CHD risk, so far, existing 
TG-lowering therapies have not been applied appropriately to test the question of whether 
reducing TRLs specifically in hyperTG patients would yield a clinical benefit for MI risk [124]. 
Now with the discovery of a key pathway and several putative therapeutic targets, rational 
therapies may be designed that mimic the beneficial effects of protective variants in the 
implicated genes. Such efforts will require a deep study of the mechanisms of action of the 
identified variants for these LPL pathway genes that integrates the findings in humans with 
experimental models before new treatment strategies can be devised.  
In summary, the plasma lipoproteins all exhibit a complex biology with multiple nodes 
of regulation that have been studied from the vantage points of animal physiology, human 
genetics, and in some cases pharmacological interventions in humans. Regarding the 
causality of these traits to vascular disease risk, while the case for LDL-C lowering has and 
will remain salient, the potential value in modulating HDLs and TRLs has been more tenuous. 
What is clear for all the lipoproteins is that human genetic discoveries and developing 
approaches will undoubtedly inform strategies to better determine which facets of these traits 
are causally related to disease risk and worthy of therapeutic pursuits. As the last decade has 
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brought myriad new genomic paradigms for the study of rare and common genetic variation 
for complex traits such as lipids, I will now review the key methodologies as they have been 
applied to the study of plasma lipids and relevant discoveries that have informed the goals of 
this dissertation.  
 
Next-generation Genomic Approaches to Studying Plasma Lipids 
Complex traits, including continuously distributed traits such as blood pressure, 
height, body-mass-index, plasma lipids, and others, are subject to immense genetic 
variation and environmental influence [18,125]. This property has made pinpointing the 
exact genetic contributors for a given trait challenging. Given that many of these traits, 
as well as diseases with polygenic inheritance, have significant clinical implications or 
burden, there remains a major interest in comprehensively identifying all the genes that 
contribute to these phenotypes, the magnitude of their contribution, and the mechanisms 
of their effects. Recent human genetics advances focused on genotyping common 
variants have provided a route to better interrogate the heritability of such traits. Such 
GWAS determine genotypes at thousands to millions of common single nucleotide 
polymorphisms (SNPs) across the genome in individuals measured for a trait or disease 
of interest, and test the association of the allele at each SNP with a quantitative trait or 
disease status [126-128]. These studies have been applied to numerous complex traits 
and have uncovered hundreds of novel loci significantly associated with diseases and 
their risk factors.  
 While useful as starting points for uncovering new loci influencing a trait, GWAS 
themselves always require further validation of causal genes and variants. This is 
because GWAS interrogate many common variants with usually small effect sizes 
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[129,130]. Thus, the actual contribution of all genetic variation at a given locus to a trait 
cannot be ascertained from the effect of the associated common variant alone. 
Moreover, since most common variants that are genotyped on SNP genotyping arrays 
are noncoding in nature, it is often difficult to assign an associated variant at a locus to a 
single gene without further experimental follow-up [129,130]. However, when GWAS is 
coupled with candidate gene sequencing at the extremes of a phenotypic distribution, it 
can be a powerful tool for establishing a novel gene influencing a trait as well as 
providing a directionality of the relationship between a gene’s expression or function and 
the trait. A recent example is the identification of variants at or near the GCKR gene with 
plasma triglyceride (TG) levels.  Initially reported in the first GWAS for plasma lipids, 
common non-coding variants at this locus were robustly and consistently associated with 
plasma TG, as well as with fasting glucose levels, in subsequent follow-up studies and 
meta-analyses [131,132]. Subsequently, several groups sought to identify functional 
coding variants in GCKR that influenced its role in TG and glucose metabolism 
[133,134]. One study, which involved sequencing GCKR in individuals from the ClinSeq 
medical resequencing project, identified 19 missense variants, many of which were rare 
in frequency and deleterious to protein function in vitro, and demonstrated association of 
these variants to TG in that cohort [135]. Similar approaches are underway to establish 
causality and identify functional variants in novel loci for plasma lipids and other complex 
traits identified through GWAS.  
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Genome-wide association studies for plasma lipids  
Plasma high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol 
(LDL-C) and triglycerides (TG) have been among the most commonly interrogated 
complex traits since the advent of GWAS in the mid-2000s. Because of their clinical 
utility, ease of measurement, and high degree of heritability, they have been commonly 
studied in multi-ethnic populations. The first large GWAS for lipids were published in 
2008 and involved almost 9,000 individuals [131,132,136]. These studies identified both 
known loci previously shown to regulate lipid metabolism as well as 8 novel loci 
associated with at least one lipid trait. These included the SORT1/CELSR2/PSRC1 gene 
locus and the NCAN/CILP2/PBX4 gene locus for LDL-C, the GALNT2 gene locus and 
MVK/MMAB gene locus for HDL-C, and the TBL2, MLXIPL, TRIB1, and ANGPTL3 gene 
loci for TG. Several of the lead SNPs for these loci were also associated with additional 
lipid traits. For example, SNPs near the GALNT2 gene associated with decreased HDL-
C were also associated with increased plasma TG. Shortly after these loci were initially 
reported, a meta-analysis in almost 20,000 individuals, including association testing in 
the participants of the Framingham Heart Study and additional European cohorts, 
replicated the previously reported associations for these loci and identified 11 new loci 
associated with at least one lipid trait [137]. Since these first reports, follow-up studies 
and meta-analyses subsequently validated these loci and identified additional ones 
[86,88,117].  
Of note are two large meta-analyses from the Global Lipids Genetics Consortium 
(GLGC), a collaborative organization led by the groups who reported the initial 2008 
study. In 2010, the GLGC reported a GWAS for total cholesterol (TC), HDL-C, LDL-C, 
and TG in more than 100,000 European individuals [86]. This study yielded 95 genetic 
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loci associated with at least one plasma lipid trait, 59 of which were novel associations. 
The results included replications in a smaller sample of East Asian, South Asian and 
African American cohorts, as well as sex-specific analyses and testing of the lipid-
associated SNPs with incidence of coronary artery disease (CAD).  
A second study from the consortium, published in late 2013, expanded this effort 
to include more than 188,000 individuals and identified an additional 62 novel loci, 30 of 
which had never been previously connected to lipid metabolism [117]. As part of this 
effort, the investigators selected 65 loci to interrogate on a cardiovascular trait- and 
metabolic trait-centric array (Metabochip) in a fine-mapping effort for the common 
variants [117]. Additionally, to assess the potential pleiotropic effects of the lipid-
associated SNPs on other cardiometabolic traits, they tested the association of these 
SNPs with fasting glucose, systolic and diastolic blood pressure, BMI, waist-to-hip ratio, 
and incidence of type 2 diabetes and CAD in subsets of the 188,000 subjects. They 
found that several lipid-associated SNPs were also associated with one or more of these 
traits as well. In total, the authors note 240 genes within 1 kilobase (kb) of the lead SNPs 
for the 62 novel loci, highlighting the challenging task of identifying the causal gene(s) at 
these loci.  
 
Upstream issues—from locus to causal variant 
Despite the wealth of novel loci for complex traits, few of the causal functional 
variants that biologically underlie the genetic associations have been conclusively 
identified. This is in part due to the limitation of SNPs that can be interrogated on GWAS 
genotyping arrays and the need for indirect imputation of SNPs in linkage disequilibrium 
with the genotyped SNPs [130,138,139]. While this approach often allows identification 
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of a causal ‘region’ containing SNPs associated with the trait, it is usually insufficient to 
identify which SNP at a given region drives the association and may underestimate the 
extent of variation at a locus contributing to a trait. For common noncoding variants that 
are within (or in LD with SNPs within) defined promoter or known regulatory regions of 
nearby genes, one may assess the effects of variants in these known regulatory regions 
on gene expression through gene reporter assays, binding affinity for specific 
transcription factors, and related functional approaches. Such strategies have been 
successfully applied to a limited number of lipid-associated SNPs, such as those at the 
LDL cholesterol-associated chromosome 1p13 locus (containing SORT1) (discussed 
below) [140].  
Another approach to refining the subset of potentially functional SNPs at a locus 
is to test the association of a denser region of SNPs from a trait-associated LD block in 
ethnically diverse populations from that of the initial association [141,142]. Because the 
sizes and compositions of SNP haplotype blocks may be ethnicity-specific, genotyping 
SNPs corresponding to a haplotype across diverse ethnicities may filter out 
nonfunctional SNPs part of the haplotype of the originally tested population. Most of the 
initial GWASs for lipids have been done using populations of European ancestry. Thus, 
testing the association of lipid-associated SNPs in non-European populations may allow 
the filtering of some SNPs at novel lipid loci.  Using this approach, Deo et al. studied 
approx. 4,400 subjects of the Jackson Heart Study and identified African American-
specific SNPs at the LPL locus that masked the protective effect of the gain-of-function 
coding variant, S447X, in LD with the noncoding variant [143]. This approach is limited 
by the need to amass sufficient numbers of subjects in non-European cohorts to 
compare to original European cohorts so that power does not confound interpretation of 
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multiethnic association comparisons. This concern is even more important when 
considering populations that have undergone extensive migration and diversification 
such as those of African ancestry.   
The Encyclopedia of DNA Elements (ENCODE) project offers new potential to 
comprehensively focus the search for causal variants at the many novel loci[144-146]. 
This collaborative project used chromatin immunoprecipitation-sequencing (ChIP-Seq) 
for many transcription factors across cell lines spanning several tissue types to annotate 
DNA regulatory elements functionally important to transcription at a genome-wide level. 
Overlaying trait-associated SNPs with important transcriptional regulatory regions 
informed from the ENCODE project offers one systematic means to localize the subset 
of potentially causal variants at each locus. An analogous method of prioritizing SNPs is 
to overlay them with regions with chromatin marks or regions of DNase I 
hypersensitivity, suggesting open chromatin and active transcription. Maurano et al. 
utilized the latter approach to catalogue the distribution of more than 5,600 noncoding 
GWAS-significant SNPs for various traits in terms of their presence in regions of active 
transcription (DNase I hypersensitivity) [147]. This work demonstrated a preponderance 
of trait- or disease-associated SNPs in regions of open chromatin that were 
developmentally- or tissue type-specific in their regulatory nature. An analogous study 
demonstrated the cell-type specificity of chromatin marks and showed that GWAS-
associated SNPs were consistently proximal to such marks [148,149]. They also showed 
that marks such as histone 3 lysine 4 trimethylation (H3K4me3) were highly cell-type 
specific and overlapped with 37 GWAS-associated SNPs for LDL-C in liver. Such 
integrative studies utilizing the breadth of genome-wide regulatory DNA annotation data 
currently available provide possible paradigms for further honing in on functional SNPs.  
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Downstream issues—from variants to causal genes and biological mechanisms 
 An equally if not more important problem in the post-GWAS era for traits such as 
plasma lipids is the correct identification of the causal gene at the locus harboring trait-
associated SNPs and the elucidation of the biological mechanisms involved.  A few 
properties of the trait-associated loci assist in identifying causal genes: lack of multiple 
genes at a given locus, proximity within or very near a gene (as opposed to within 
regulatory elements many thousands of kb up or downstream of genes), presence of an 
expression quantitative trait locus (eQTL) for a SNP with expression of a particular gene 
at the locus (cis-acting eQTL), and biological plausibility of a particular gene at the locus 
regulating the associated trait. However, these properties are rarely met and are not in 
any case definitive proof of the causal gene, and thus the identification of the causal 
gene influencing a trait can be especially difficult to ascertain for novel loci.  
 A major focus in identifying causal genes at novel lipid loci has been to better 
characterize SNPs at these loci for potential eQTLs in tissues of relevance to the trait. 
For lipid traits, these studies have largely focused on the liver as the tissue underlying 
allele-specific expression of causal genes, because of the predominant role that 
hepatocytes play in regulating lipoprotein metabolism. Additional tissues of potential 
interest to interrogate for lipid traits include enterocytes, adipocytes, skeletal myocytes, 
as well as endothelial cells and macrophages, which mediate the interplay of lipoproteins 
and their role in atherosclerosis. The results of the lipid GWAS suggested that of the 157 
loci associated with lipids, 47 have significant eQTLs for at least one gene proximal to 
the associated SNPs in liver, subcutaneous, or omental fat [117]. Methods for measuring 
allele-specific expression of candidate genes from tissues of subjects heterozygous for 
trait-associated SNPs have allowed better attempts to define new eQTLs from existing 
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SNPs. Ongoing efforts to utilize catalogues of human tissue for which gene expression 
and SNP genotypes have been interrogated, such as the Genotype Tissue Expression 
consortium efforts, will undoubtedly help in this regard [150,151].  
 Common variant association studies for lipids have also uncovered trans-eQTLs, 
SNPs influencing the expression of genes indirectly through affecting expression of their 
transcriptional regulators. The study of KLF14, a HDL-C and type 2 diabetes candidate 
gene, offers a striking example. SNPs at the locus containing KLF14 were associated 
with these traits in GWAS and were also shown in initial studies to be maternally 
restricted cis-eQTLs for KLF14 expression in adipose tissue [152]. Subsequent work in 
2011 showed that these same SNPs were strongly correlated with expression of several 
genes in adipose tissue in trans. This study also demonstrated that many of those genes 
whose expression was strongly associated with the KLF14 noncoding SNP allele were 
themselves correlated significantly with signatures of metabolic diseases including 
plasma lipids, BMI, and measures of insulin resistance [153]. Taking a more global 
approach, a recent eQTL meta-analysis in approx. 8000 subjects identified several 
SNPs existing as cis-eQTLs at one locus while also acting as trans-eQTLs at other loci, 
including one at the 3’ UTR of the FADS1 gene which altered the expression of the 
LDLR gene in trans [154]. Such studies highlight both the complexity and the value 
gained from careful study of casual variants as determined through gene expression 
measurements.  
 Because it is not always possible to identify eQTLs from a given spectrum of 
SNPs at a locus or because eQTLs may be identified at loci for genes with unknown 
biological function, additional experimental approaches may allow further identification of 
causal genes. One approach has been the in vivo overexpression or knockdown of 
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candidate genes at a locus in animal models. The initial GLGC GWAS reported such 
work for three candidate genes influencing HDL-C: GALNT2, PPP1R3B and TTC39B 
[86].  In accompanying work, hepatic SORT1 (but not PSRC1) overexpression in 
hypercholesterolemic mice demonstrated substantial reduction in LDL-C levels, 
directionally consistent with the eQTL data in human liver and providing strong evidence 
that the causal gene at the LDL-associated chromosome 1p13 locus was SORT1 (see 
below for more discussion) [140]. An ongoing effort in our laboratory has utilized this 
approach of somatic overexpression and knockdown in mice to systematically 
interrogate gene(s) at many of the novel loci reported in the 2010 GLGC GWAS for 
effects on plasma lipids in vivo. Others are utilizing complementary approaches in 
cellular models through overexpression and siRNA knockdown [155,156] or genome 
editing using transcription activator-like effector nuclease (TALEN) and clustered 
regularly interspaced palindromic repeat DNAs (CRISPR)/Cas9 nuclease genome-
editing methodologies [129,157,158]. 
  
New biology inspired by common variant studies 
Among the multiple novel lipid loci borne from recent GWAS, several have 
revealed new biological paradigms for the genetic and physiological regulation of 
lipoprotein metabolism. Additionally, synergistic common and low-frequency (MAF 
between 0.01-0.05) variant-focused approaches that have emerged in the post-GWAS 
era have allowed for further studies of loci that were lipid candidate genes before the 
emergence of GWAS. In an effort to illustrate examples of how follow-up studies may be 
performed for such loci (an approach taken in this dissertation), I discuss three of the six 
original novel lipid loci from GWAS: SORT1, TRIB1, and GALNT2. Functional studies of 
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these genes benefited from localization of their tissue sites of action with regard to 
lipoprotein metabolism (in the case of these three, the liver), development of tools for 
somatic gene manipulation in liver, and in the case of GALNT2, identification of 
functional coding variation through sequencing at the phenotypic extremes.  
 
SORT1 (sortilin) 
SNPs at the chromosome 1p13 locus were among the first associated with both 
CAD and LDL-C levels in GWAS, dating back to the original Wellcome Trust Case 
Control Consortium GWAS for CAD in 2007 [159]. Subsequent studies have validated 
the associations between this locus and LDL-C and CAD in large European and non-
European cohorts. Homozygosity for the minor allele of the lead SNP at this locus 
(approximately 25% minor allele frequency in Europeans) was associated with a 16 
mg/dL decrease in plasma LDL-C and 40% reduction in risk of MI [131].  The locus 
contains several genes in close proximity to the lead SNPs, including SORT1, CELSR2, 
and PSRC1, none of which were previously implicated in LDL metabolism.  
Initial work aimed at identifying both the casual variant and the causal gene at 
this locus underlying the association with lipids and protection from disease [140]. The 
lead SNPs for association with plasma lipids occur in a noncoding region between 
PSRC1 and CELSR2, but this region is also close in proximity to SORT1. Adding further 
complexity, expression of all three genes is elevated by the minor allele of the SNP at 
the locus in eQTL analyses of human liver samples but not in subcutaneous or omental 
adipose samples. Through fine mapping, generation of bacterial artificial chromosome 
constructs expressing different alleles of the SNP haplotype, luciferase reporter assays, 
and additional functional studies, Musunuru et al. showed that the minor allele of the 
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causal variant within a cis-regulatory region, rs12740374, created a de novo CEBP 
transcription factor binding site that caused CEBP-dependent upregulation of expression 
of the nearby genes [140].  
In the same study, as noted above, adeno-associated virus (AAV) vectors were 
used to effect liver-directed gene transfer and demonstrated that hepatic SORT1 
overexpression, but not PSRC1 overexpression, markedly reduced plasma LDL-C levels 
in hypercholesterolemic mice. This finding was directionally consistent with the human 
genetics data showing that the minor allele at rs12740374 substantially increased 
SORT1 expression and reduced plasma LDL-C.  By contrast, the lack of effect on LDL-C 
by PSRC1 overexpression suggested that this gene was probably not the causal gene at 
the locus underlying the LDL-C association.  
SORT1 encodes sortilin, a multi-ligand cell-surface receptor and intracellular 
trafficking chaperone with endolysosomal sorting motifs.  It was hypothesized that it may 
promote trafficking and presecretory degradation of VLDL in hepatocytes (a process 
previously described but without a molecular mechanism [160]) as a mechanism to 
reduce VLDL secretion and eventually circulating LDL-C levels. Indeed, overexpression 
of SORT1 was shown to reduce VLDL TG and ApoB secretion in mice [140].  
However, studies of SORT1 knock-out (KO) mouse models have highlighted its 
complexity in VLDL and LDL metabolism. Soon after the initial report by Musunuru et al., 
Kjolby, et al reported a SORT1 KO mouse, which when crossed to an LDLR-deficient 
background exhibited lower LDL-C and reduced VLDL secretion [161].  The mouse 
model used in these studies was a SORT1 deletion mutation resulting from disruption of 
exon 14, resulting in some aberrant protein being expressed [162,163].  Yet another 
SORT1 KO model, demonstrating complete lack of SORT1 expression [164], was 
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subsequently also shown to have reduced VLDL secretion [165]. Thus, both hepatic 
overexpression and complete deficiency of SORT1 reduce VLDL secretion in mice.  This 
paradoxical finding has yet to be fully resolved.  
 Sortilin traffics to the plasma membrane and has several known extracellular 
ligands that it binds and chaperones to the lysosome [166].  LDL was shown to have 
high affinity for sortilin by surface plasmon resonance and to be taken up and degraded 
at a higher rate by liver cells overexpressing sortilin [165]. Moreover, hepatic 
overexpression of sortilin resulted in faster catabolism of LDL in vivo in mice, and this 
also occurred in LDLR deficient mice, indicating that the effect was independent of the 
LDL receptor.  In contrast, sortilin deficient mice had slower catabolism of LDL and this 
was also true in LDLR deficient mice [165].  These studies demonstrated that sortilin 
binds LDL directly and is a physiologically relevant cell-surface LDL receptor in the liver, 
suggesting a complex orchestration of LDL metabolism by this protein.  Recent work has 
also indicated that sortilin may facilitate hepatic PCSK9 secretion [167] and also may 
regulate vascular disease in extrahepatic tissues through multiple mechanisms [168-
170]. Returning to the human genetics, increased expression of sortilin in the liver might 
be expected to both reduce VLDL production and increase LDL catabolism, perhaps 
accounting for the very strong association of the minor allele (causing elevated sortilin 
expression) with lower levels of LDL-C.  While much more work on the cell biology and 
physiology is needed, it is safe to say that GWAS first put sortilin on the map as a 
molecule relevant to LDL metabolism in humans. 
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TRIB1 (tribbles-1) 
TRIB1 was also among the initial loci implicated in influencing plasma lipids in 
the first GWAS for plasma lipids [131,132]. Lead SNPs are located on chromosome 
8p24 approximately 40 kb away from the TRIB1 gene. SNPs at this locus are among the 
handful of SNPs associated with all major plasma lipid traits (TG, HDL-C, LDL-C); the 
minor allele at the lead SNP is associated with the atheroprotective lipid profile of 
reduced TG, reduced LDL-C and increased HDL-C [86]. Indeed, in addition to being 
associated with a favorable lipid profile, these SNPs have been associated with 
significantly reduced risk of CAD in both GWAS of large European populations and in 
gene-centric array association studies [86,88,171,172].  Additionally, these SNPs have 
been associated with related metabolic phenotypes such as plasma adiponectin levels 
and serum transaminases [173,174].   
TRIB1 encodes a protein called tribbles-1 that is a cytosolic scaffolding protein 
with a poorly defined molecular function in the liver [175,176]. Additionally, no known 
liver eQTLs exist for the SNPs at this locus. However, given the high level of expression 
of TRIB1 in the liver, the association of TRIB1 SNPs with serum transaminases, and the 
prominent role of the liver in lipoprotein metabolism, the liver has been the focus of much 
work on relating TRIB1 to plasma lipid levels. Using a design similar to the initial in vivo 
validation of SORT1, TRIB1 was somatically overexpressed in the liver in mice and 
produced a reduction in plasma TG and cholesterol through impaired VLDL secretion 
[177].  In contrast, TRIB1 KO mice demonstrated elevated plasma TG and cholesterol 
and increased VLDL secretion. Differences in plasma lipids in the overexpression and 
KO models were accompanied by reciprocal differences in hepatic expression of 
lipogenic genes, and subsequent studies in a liver-specific Trib1 KO model have 
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demonstrated that TRIB1 is a key regulator hepatic lipogenesis in vivo through 
modulation of CEBPα turnover [178].  
Additionally, TRIB1 may influence lipid metabolism through extrahepatic roles. 
One recent study of mice with TRIB1 deficiency in the spleen and hematopoietic cells 
including macrophages demonstrated increased lipolysis in these mice [179]. 
Consequently, these mice exhibited elevated serum free fatty acids, lower adipose 
mass, elevated cholesterol, TG, fasting glucose, and insulin resistance on a high-fat diet 
relative to wild-type controls. The results of this study and the previous one focused on 
hepatic TRIB1 function suggest that this gene may contribute to metabolic phenotypes 
through actions in multiple tissues.  
 
GALNT2 (polypeptide N-acetylgalactosaminyltransferase 2) 
SNPs within intron 1 of GALNT2 at chromosome 1q42 have been consistently 
associated with HDL-C and TG in multiple GWAS [86,88,117,131,132]. The lead SNP at 
this locus, rs4846914, has a minor allele frequency of 40% in Europeans and is 
associated with decreased HDL-C and increased TG. In addition to fasting lipids, this 
SNP has been associated with rare Fredrickson hyperlipoproteinemias in a smaller 
case-control study of 386 cases and 242 controls [180]. In addition to lipid traits, SNPs at 
this locus have also been related to several non-lipid traits in a recent ‘phenome’-wide 
association study, including serum calcium levels and circulating white blood cell count, 
among other traits [181]. GALNT2 encodes an O-glycosyltransferase enzyme that, like 
SORT1 and TRIB1, had never been implicated previously in lipoprotein metabolism.  
Given the presence of the lipid-associated SNPs within an intron of GALNT2 and 
lack of any genes for several 100 kb either upstream or downstream, GALNT2 has 
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regularly been considered to be the causal gene driving the lipid association signal at 
this locus [130]. Allelic imbalance and eQTL studies using human liver samples from 
subjects heterozygous for the GWAS SNPs have both shown that SNP alleles 
associated with higher HDL-C from the multiple GWAS studies were also correlated with 
increased hepatic GALNT2 transcript levels [182,183].  
This directionality conflicts with initial physiological studies of GALNT2 
expression or activity in animals and humans. Somatic AAV-mediated overexpression of 
mouse GALNT2 in the livers of mice resulted in decreased plasma HDL-C and increased 
TG, while AAV-mediated short hairpin RNA (shRNA) knockdown had reciprocal effects 
[86]. Additionally, sequencing of the gene in individuals with elevated HDL-C identified 
humans heterozygous for a missense variant D314A in GALNT2 that was reported to 
have reduced catalytic activity in vitro [184]. Compared with non-carrier controls, these 
individuals had improved postprandial TG clearance and reduced sialylation of ApoC-III, 
suggesting that the missense variant confers loss-of-function. Indeed, ApoC-III was 
found independently to be a target of GALNT2 in liver cells in vitro; a number of other 
plausible candidate proteins have also been identified as GALNT2 targets [185,186]. 
The true directional relationship of GALNT2 expression, function, and 
glycosyltransferase activity and repertoire of targets with respect to lipoprotein 
metabolism has remained unclear and has been one of the foci of efforts in this 
dissertation.  
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Looking ahead – leveraging low-frequency variants, Mendelian randomization, and 
sequencing for rare causal variants  
As the field of lipid genetics moves beyond GWAS to focusing on identification of 
causal variants, causal loci, and biological mechanisms underlying novel genes, 
additional tools and approaches have emerged to aid these efforts. These 
methodologies include searching for low-frequency and rare coding variants through 
exome-wide and targeted genotyping arrays, exome and targeted gene sequencing, and 
most recently whole-genome sequencing. In the last decade, these tools have 
developed and matured from limited applications in small sample sizes to large 
population-based or case-control study designs to uncover new variants or new 
associations between variants and lipid traits and disease risk. As a central goal of this 
dissertation work is to demonstrate through examples the utility of these approaches as 
complementary tools for understanding causal variation influencing CHD risk, I will now 
briefly review these developing methods and major findings to date.   
 One focus has been the attempt to identify low-frequency variants of strong effect 
sizes on plasma lipids that also associate with disease risk. This effort has been fueled 
in part by the discovery of functional low-frequency coding variants in PCSK9, as 
described above [32,38,39]. To increase the throughput of identifying functional coding 
variants of low-frequency at a cost more manageable than currently possible for exome 
sequencing, an exome-wide SNP array focused on coding SNPs (the “exome chip”) has 
been developed [187]. Peloso et al. recently used this array to genotype >200,000 low-
frequency and rare coding sequence variants in >56,000 individuals of European and 
African American ancestry [188]. This study identified four new low-frequency variants in 
novel genes influencing HDL-C and/or TG: ANGPTL8, PAFAH1B2, COL18A1, and 
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PCSK7.  Overexpression of one of these, PCSK7, in mice resulted in elevated TG and 
reduced HDL-C levels.  Despite their robust lipid association, the coding SNPs in these 
genes were not associated with changes in risk of CHD in this study. Another recent 
study applied the exome array to genotype >80,000 coding variants in >5,600 individuals 
of European ancestry and subsequently followed up on 10 loci with genome-wide 
associations for a coding variant with a lipid trait in an additional cohort. This work 
identified a novel candidate gene, TM6SF2, at a known locus on chromosome 19 
containing NCAN/CILP2/PBX4. The coding variant, Glu167Lys, was common (MAF 
0.087) and associated with lower total cholesterol. Adenoviral overexpression of this 
gene in mice raised total cholesterol while adenoviral knockdown with shRNA reduced 
plasma cholesterol, suggesting a physiological role for this newly identified gene in 
regulating plasma cholesterol levels. This variant was also associated with reduced risk 
of MI, thus providing another example of the utility of the exome array coding variant 
genotyping-focused approach for elucidating variants of relevance to both intermediary 
lipid traits and disease risk [189]. 
Currently, low-frequency variants influencing lipids, whether coding or noncoding, 
have also allowed preliminary interrogation of the causality of these lipid biomarkers with 
risk of disease. These causality studies have been informally called Mendelian 
randomization studies and ascertain the effects of randomized collections of variants 
assigned at meiosis and independent assortment [190,191]. Using variants with robust 
associations with an intermediary phenotype (e.g. plasma lipid type), one can interrogate 
the deviation of the predicted effect of a variant on a secondary trait (e.g. disease risk) 
based on the impact the variant has on the intermediary trait. These approaches allow 
study of the causality of variants without traditional limitations of observational 
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epidemiological studies such as confounding and reverse causation (the onset of 
disease before alteration in intermediary biomarker) [192]. These studies rely on lack of 
pleiotropic effects of the variants of interest, which can rarely be measured 
comprehensively, thus adding a caveat to interpretation of results of these efforts. 
Mendelian randomization using variants associated with HDL-C at the LCAT, CETP, 
APOA1, ABCA1, LIPC, and LIPG loci have been used to test the causal relationship 
between HDL-C and CHD. These investigations have largely failed to support a strong 
causal relationship between HDL-C and risk of CHD [193-196]. Whether it will be 
possible to perform analogous studies to investigate the causal relationship of functional 
aspects of HDL, such as cholesterol efflux capacity, as opposed to HDL-C levels, will 
depend on the identification and ability to test low-frequency genetic variants specifically 
influencing such traits.  
Similarly to these HDL-C-focused efforts, a recent Mendelian randomization 
study was carried out to test the association of TG-regulating loci with risk of CHD [197]. 
Using a modified approach, the investigators tested 185 SNPs for association and effect 
sizes on all lipid traits in the >188,000 individuals of the most recent GLGC cohort. Then, 
focusing on SNPs with large effect sizes on TG but not on LDL-C, they tested the 
relationship of the effect size of a SNP on TG with that on CAD risk in >86,000 subjects 
in the CARDIoGRAM study. This approach demonstrated highly significant causal 
relationships between SNPs at multiple TG loci with CAD.  
Candidate gene and whole exome sequencing permit the identification of very 
rare and private mutations that may be causal for lipid traits.  An example of the power of 
candidate gene sequencing is the work by Johansen, Hegele and colleagues, who 
resequenced candidate genes for hyperTG identified from GWAS in a case-control 
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design. They found a significant burden of rare missense or nonsense coding variants in 
these candidate genes in HTG cases relative to controls [109]. Motazacker et al recently 
reported a targeted sequencing study of 195 lipid candidate genes and 78 non-lipid 
genes in a small cohort of subjects at extremes of the HDL-C distribution. The authors 
showed an increased frequency of rare nonsynonymous variants in lipid genes, but not 
non-lipid genes, in individuals with extremely high or extremely low HDL-C levels relative 
to general population and normal HDL-C participants [198]. The diagnostic yield of 
coding sequence-only targeted sequencing efforts for HDL-C from this study was 
relatively low, and similar results have recently been reported for the sequencing of key 
LDL-C genes in hypercholesterolemic patients [199]. This suggests that perhaps the 
ability to ascertain causal variants at the lipid phenotypic extremes may be augmented 
by the inclusion of key noncoding regions likely to harbor functional variants. Indeed, the 
development of approaches to simultaneously and efficiently capture both the coding 
and noncoding genome for lipid genes while enriching for extreme phenotypes to 
increase variant burden yield is one goal of the current dissertation work.  
Exome sequencing of individuals at extremes of lipid traits or even whole 
populations has revealed additional insights, especially for genes conferring risk by 
recessive modes of inheritance.  Exome sequencing in a family with familial combined 
hypolipidemia identified loss-of-function mutations in ANGPTL3 as a cause of this 
inherited lipid disorder [118]. Another recent example by the National Heart Blood and 
Lung Institute GO Exome Sequencing Project involved sequencing in three family 
members with autosomal recessive hypercholesterolemia lacking mutations in known 
candidate genes. Exome sequencing of these family members revealed a novel splice-
site mutation in the LIPA gene that segregated with the hypercholesterolemia diagnosis 
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and with accumulation of hepatic cholesterol, the latter of which had been reported 
previously in patients with other mutations in LIPA [200]. Using a case-control design, 
another recent study sequenced the exomes of 2500 subjects with either extremely high 
or extremely low LDL-C and followed up by additional sequencing in another >1300 
subjects and exome array genotyping in >55000 subjects. This work identified significant 
associations of rare or low-frequency variants in known LDL-C modifying genes PCSK9, 
LDLR, and APOB, but also a novel gene, PNPLA5. The authors noted that the effect 
sizes of the low-frequency variants on LDL-C were greater than those found for LDL-C 
associated common SNPs from GWAS, suggesting that low-frequency focused 
approaches may be useful for identifying more functionally significant SNPs for certain 
traits [201]. Demonstrating the medical utility of population-based exome sequencing, an 
effort from the Myocardial Infarction Genetics Consortium investigators demonstrated 
through exome sequencing of ~7,300 CHD cases and ~14,700 controls across 
ethnicities that inactivating mutations in NPC1L1, a gene encoding an enterocyte 
transporter protein critical for cholesterol absorption, were associated with protection 
from CHD risk [202]. Soon after this study was published, a large clinical trial of 
ezetimibe, an LDL-C drug which targets the product of NPC1L1, was released showing 
that this medication improved cardiovascular outcomes and offered additional LDL-C 
lowering when added to statin therapy [203]. This example highlights the potential of rare 
variant genetics uncovered from exome sequencing to inform and relate to ongoing 
pharmacological interventions. 
As mentioned earlier, several key results from sequencing efforts aimed at 
identifying variants underlying TG levels are likely to further shape the development of 
future TRL-focused therapies. These include the discovery of APOC3 LOF coding 
	38 
 
variants that were associated with marked decreases in TG levels, minimal effects on 
LDL-C but 40% reductions in CHD or ischemic vascular disease risk. Two seminal 
studies in 2014 identified the same LOF variants in low TG individuals through different 
approaches. The first of these implemented exome sequencing in an initial population 
cohort of ~3,700 individuals followed by replication sequencing and exome chip 
genotyping in ultimately >110,000 subjects (stratified as CHD cases vs. healthy controls) 
[106], and the second performing targeted sequencing of APOC3 codons in a large 
population-based cohort of ~75,700 individuals from the Copenhagen City Heart Study 
[91]. These complementary investigations demonstrate the utility of the varied 
approaches in arriving at a similar conclusion, namely that APOC3 is a critical node in 
the relationship between TGs and CHD risk and that intervention to lower ApoC-III levels 
or function may have clinical benefit. Similar parallels were observed in the even more 
recent reports of ANGPTL4 LOF variants associated with reduced TGs and CHD risk. 
Here, one group of investigators (the Myocardial Infarction Genetics and CARDIoGRAM 
Exome consortia) again combined sequencing in a smaller discovery cohort with 
genotyping in a larger cohort of CHD cases vs. controls to relate LPL and ANGPTL4 
variants with TGs and CHD risk[90]. A second study also implemented exome 
sequencing in a large BioBank initiative of phenotyped patients from a single community 
health system to relate ANGPTL4 variants with CHD and related measures[89]. Both 
studies found an association between LOF variants in ANGPTL4, low TGs, and 
protection from CHD. Notably, the second study also demonstrated preliminary efficacy 
of a monoclonal antibody targeting ANGPTL4 in mice and a nonhuman primate, further 
highlighting the potential for translation of the findings from current genomics discoveries 
to novel therapies.  
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Overall Summary and Dissertation Goals  
The last decade has yielded much excitement and also some controversy 
regarding the study of plasma lipid traits, still a prevailing and modifiable set of risk 
factors for CHD and MI. Novel therapies and insight have reaffirmed our ability to 
drastically lower disease risk through reduction of LDL-C levels, but at the same time, 
the role and future of efforts to target HDL-C and TG remain uncertain. Likewise, the 
advent of genomics has allowed the unprecedented study of coding and noncoding 
heritable variation in literally hundreds of thousands of individuals, thus providing new 
opportunities to better understand the mechanisms by which these traits impact disease, 
if at all. Moreover, the current ability to dive deeply into the coding genome may allow a 
better understanding of TG- and HDL-modifying variants that protect from disease in a 
manner that could influence the development of novel therapies based on these genetic 
mechanisms. 
 As the realm for investigation in this current era of lipid genetics is inconceivably 
vast, a goal of this dissertation was to take a sophisticated sampling of the ways in which 
the modern genomics toolkit can be applied in concert to address key topics relevant to 
the relationship of HDL, TG, and CHD. Namely, I sought to address the following 
questions:  
1) How does genetic variation that impacts HDL functionality influence CHD risk? – 
Here, my colleagues and I utilized the sequencing and genotyping approaches 
above coupled with functional biology for the identification and interrogation of a 
human genetic variant in SR-BI causally disrupting the HDL reverse cholesterol 
transport pathway to assess how this may impact HDL metabolism and CHD risk 
in humans (Chapter 2). 
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2) What is the mechanism and directional relationship underlying a novel GWAS- 
locus for HDL-C and TG to these traits and how does this novel association 
refine biological understanding of these traits? – Here, I combined interrogation 
in multiple model systems and exome sequencing in humans to study loss-of-
function of GALNT2 across mammalian species and defined plausible 
mechanisms relating inactivation of this gene to low HDL levels, thus outlining 
one strategy to approach novel GWAS loci for complex traits (Chapter 3). 
3) What is the mechanism of protection from high TGs and CHD for coding variants 
in APOC3, a critical regulator of TRL metabolism? Here I interrogated a 
missense variant in APOC3 that was shown in exome and targeted sequencing 
studies to protect from CHD by unknown mechanisms. Through study in humans, 
animal models, and biochemical approaches, I outline a mechanism of protection 
via ApoC-III lowering that may inform therapeutic efforts targeting this pathway, 
and outline how structure-function studies can be applied to the evaluation of the 
many coding variants arising from population-based exome sequencing for 
complex diseases (Chapter 4). 4) How can we improve the detection of causal noncoding variation underlying 
phenotypic extremes? Here I apply a novel sequencing methodology to perform 
one of the first targeted sequencing studies for noncoding variants at HDL-C 
candidate genes in humans with extremely high HDL levels. I demonstrate a 
proof-of-principle approach that validates previous variants and discovers novel 
regulatory mutations and highlights the potential for larger systematic efforts to 
capture rare noncoding variation influencing complex traits (Chapter 5).	
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Figure 1.1 
 
 
Figure 1.1: Chylomicron Metabolism. Chylomicrons are made in the small intestinal 
enterocytes after dietary intake and contain the apolipoproteins B48, A-V, C-II, and C-III. 
ApoB48 is the key structural component of chylomicrons and remnants. ApoC-II is a 
required cofactor for lipoprotein lipase (LPL) activity, and ApoA-V also promotes LPL 
function. ApoC-III and the angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit LPL 
activity. LPL hydrolyzes TGs on chylomicrons to yield fatty acids which can be taken up 
by peripheral tissues such as the muscles, heart, and adipose. LPL-mediated 
remodeling of chylomicrons yields remnant particles which can acquire ApoE, a critical 
ligand for the LDL receptor family members that mediate remnant particle clearance by 
the liver. ApoC-III on remnant particles can inhibit their clearance by this pathway.  
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Figure 1.2 
 
Figure 1.2: VLDL and LDL metabolism. VLDL is synthesized in the liver through the 
lipidation of ApoB100 with TGs. This process is in part mediated by the microsomal 
triglyceride transfer protein (MTP). Secretion of VLDL yields a TG-rich particle containing 
ApoB100, ApoA-V, ApoC-II and ApoC-III. ApoA-V and ApoC-II activate LPL-mediated 
lipolysis of VLDL-TGs, while ApoC-III and the circulating ANGPTL3 and ANGPTL4 
proteins inhibit this process. LPL and hepatic lipase (HL) mediated remodeling of VLDLs 
yield smaller, denser lipoproteins, the intermediate density lipoproteins (IDLs) and LDLs. 
These particles can be cleared from the circulation through LDLR and related receptors 
in the liver through ApoE or ApoB as ligands for receptor-mediated endocytosis.  
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Figure 1.3: HDL metabolism. HDL is initially synthesized through the hepatic or 
intestinal secretion of ApoA-I, which then quickly acquires free cholesterol (FC) and 
some phospholipids to become lipid-poor HDLs. These particles are cleared rapidly from 
the kidney unless they mature. Maturation of HDL occurs through the further acquisition 
of FC and esterification of the FC using phospholipid-derived fatty acids to yield 
cholesteryl esters (CE); this process is mediated by the enzyme lecithin:cholesterol 
acyltransferase (LCAT) and results in a mature, spherical HDL particle. Lipid-poor HDLs 
and mature HDLs can also acquire FC from macrophages and other cells in peripheral 
tissues through efflux by ATP-binding cassette transporters ABCA1 and ABCG1 on the 
cell surface. ABCA1 effluxes FC to lipid-poor HDLs while ABCG1 effluxes FC to mature 
spherical HDLs. In both cases, LCAT esterifies the FC to CE and promotes further 
remodeling of the particles. HDL CEs and phospholipids can be transferred to ApoB-
containing lipoproteins (such as VLDL and LDL) through the actions of cholesteryl ester 
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transfer protein (CETP) and phospholipid transfer protein (PLTP), respectively. HDL CEs 
are also cleared from the circulation by the scavenger receptor BI (SR-BI) on the surface 
of liver cells and other tissues. SR-BI mediates the selective uptake of HDL CEs to yield 
CE depleted lipid-poor particles which can re-mature through the above mentioned 
processes or be cleared by the kidney. CEs taken up by the liver can be hydrolyzed to 
FCs and incorporated into bile acids (BA) and effluxed to the bile through ABCB11 or 
FCs directly can be incorporated into bile through efflux by ABCG5 and ABCG8. Biliary 
excretion of of cholesterol originally present in peripheral tissues such as arterial plaque 
macrophages through the delivery by lipoproteins to the liver and selective uptake is 
known as reverse cholesterol transport and is thought to be one of the key 
atheroprotective processes mediated by HDL.  
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CHAPTER 2 – RARE VARIANT IN SCAVENGER RECEPTOR BI RAISES HDL 
CHOLESTEROL AND INCREASES RISK OF CORONARY HEART DISEASE 
 
Introduction 
The strong inverse association between plasma high density lipoprotein (HDL) 
cholesterol concentrations and coronary heart disease (CHD) led to intense interest in a 
potential causal relationship between HDL metabolism and CHD.  Recent clinical trials 
with the HDL cholesterol raising drugs niacin and CETP inhibitors have been 
disappointing, suggesting the possibility that higher HDL-C levels are not causally 
protective against CHD [61,64].  Recent studies of human genetic variants that are 
associated with HDL-C levels have likewise generally failed to show association with 
CHD [193,194].  Most notably, a loss-of-function variant in the gene LIPG encoding the 
enzyme endothelial lipase that in the heterozygous state clearly raises HDL-C by ~5 
mg/dL was found to have no association with CHD [204].  Additionally, early studies of 
genetic variants in the CETP and LIPC genes suggested that some genetic variants 
could be associated with increased HDL-C and an increased risk of CHD[205,206]. 
Thus, human genetics can provide insight into the complex relationship between HDL 
and CHD. 
The scavenger receptor class BI (SR-BI) was discovered to be an HDL receptor 
2 decades ago by Krieger and colleagues [207].  SR-BI promotes the selective uptake of 
HDL cholesteryl esters into cells (particularly hepatocytes and steroidogenic 
cells)[207,208]. In mice, overexpression of SR-BI in the liver markedly reduces HDL-C 
levels [209-212], and genetic deletion of SR-BI results in markedly increased HDL-C 
levels [213-215].  Remarkably, effects of these genetic manipulations in mice have 
	46 
 
effects on atherosclerosis opposite to the direction predicted by the human 
epidemiology: overexpression reduces atherosclerosis despite the lower HDL-C [216-
218] and gene deletion increases atherosclerosis despite the higher HDL-C levels [219-
222].  One potential explanation relates to the flux of cholesterol from macrophages 
through the reverse cholesterol transport (RCT) pathway: SR-BI overexpression 
increases macrophage RCT and knockout reduces macrophage RCT [223].  The 
relevance of these observations in mice to humans has been of great interest. 
SR-BI is encoded by the gene SCARB1, and common gene variants at the 
SCARB1 locus have been genome-wide significantly associated with plasma HDL-C 
levels [86,117].   A rare missense variant in SCARB1 was reported in one extended 
family to be associated in the heterozygous state with modestly elevated HDL-C levels, 
but non-invasive imaging failed to show any relationship with atherosclerosis [224].  
Thus, human genetics has not yet clarified the relationship between SR-BI function, 
HDL-C levels, and cardiovascular disease in humans. 
Through targeted sequencing of a number of individuals with extremely high 
levels of HDL-C, we identified a homozygote for a rare missense variant in SCARB1 - 
P376L.  We established that this mutation causes virtually complete loss of function of 
SR-BI due to impaired processing and cell-surface presentation.  This variant was seen 
much more frequently in other subjects with very high HDL-C compared with those with 
low HDL-C; furthermore, after genotyping > 100,000 subjects we found it to be 
definitively associated with higher HDL-C levels.  In a separate genotyping experiment, 
we found this variant to be significantly associated with increased risk of CHD.  Thus, 
this series of studies identifies the first SCARB1 ‘knockout’ human, establishes the first 
example in which a coding gene variant raises HDL-C (without affecting other plasma 
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lipids) but increases risk of CHD, and extends our understanding of SR-BI as a protein 
that not only modulates HDL metabolism but also cardiovascular risk in humans.  
 
Materials and Methods 
Subject Identification and Ascertainment 
Individuals with high HDL-C levels above the 95th percentile for age and sex were 
systematically recruited.  For this study, 341 individuals of European ancestry with HDL-
C > 95th percentile were selected for targeted sequencing, as were 407 individuals of 
European ancestry with low HDL-C levels below the 25th percentile for age and sex. 
Briefly, using customized hybrid capture (Agilent) baits, we targeted and enriched for 
sequencing the exons of the ~990 genes located within 300 kb of each of the 95 loci with 
significant associations (P < 5 x 10-8) with plasma lipid levels identified by the Global 
Lipids Genetics Consortium as of 2010 [86]. We performed next-generation sequencing 
using Illumina Genome Analyzers at the Broad Institute as described previously [225]. 
Base pairs were called and sequencing reads were aligned to the human genome 
reference GRCh37 (hg19), and sequencing metrics were processed using the Picard 
pipeline with an output of Binary Alignment Map (BAM) files. 
The Genome Analysis Toolkit Unified Genotyper was used to genotype all variant 
sites, calculate initial quality control metrics, and filter based on these values, and 
variants were annotated using SnpEFF [226]. Variants were indexed by individuals 
bearing them in a Variant Call Format (VCF) file. Genotypes for each individual were 
computed at each site and tabulated.  
Additionally, SCARB1 mutation carriers were identified by genotyping subjects 
with high vs. low HDL-C using the Exome Chip (HumanExome BeadChip v1.0, Illumina, 
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Inc., San Diego, CA). The Exome Chip contains >240,000 coding SNPs derived from all 
mutations found >2 times across >1 dataset among 23 separate datasets comprising a 
total of >12,000 individual exome and whole genome sequences. The P376L variant is 
included. In total, 353 high HDL-C males (HDL-C ≥ 70 mg/dL), 747 high HDL-C females 
(HDL-C ≥80 mg/dL), 1106 low HDL-C males (HDL-C ≤40 mg/dL), and 573 low HDL-C 
females (HDL-C ≤50 mg/dL) were genotyped using the Exome Chip. Subject samples 
were drawn from previous research studies conducted in our laboratory. After removing 
subjects from analysis for which demographic covariates were not available, there 
remained 805 subjects with high HDL-C and 989 subjects with low HDL-C analyzed for 
association of SCARB1 P376L allele frequency with HDL-C.  
To confirm the presence of the P376L mutation in carriers, a nearby region of 
995 bp of SCARB1 was amplified by PCR using the following primers: forward -  
TGGTTTGGTTGGTCAGTGGCG, reverse - AGGGCTGCCTCCAGCTCACAT; and the 
following PCR conditions: 95ºC, 2 min; (95ºC, 30 s; 62.6ºC, 30 s; 72ºC; 100.0 s) repeat 
29 times; 72ºC, 5 min; 4ºC forever. PCR products were purified using a QIAquick PCR 
Purification Kit (Qiagen, Germantown, MD, USA) and sequenced by Sanger sequencing 
[227] by Genewiz Inc (South Plainfield, NJ, USA). Sequences were compared with 
SCARB1 NCBI reference sequence NG_028199.1 using Sequencher (Gene Codes, Ann 
Arbor, MI, USA). 
 
In silico analysis 
To predict the effect of the P376L mutation on SR-BI protein structure and 
function we used the publicly available algorithms Condel and Raptor X [228-231]. 
Condel generated a “consensus deleteriousness” score, obtained by combining 3 
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prediction algorithms (PolyPhen-2, MutationAssessor, and SIFT). Raptor X was used to 
predict effects on local secondary structure of the SR-BI due to the P376L variant. 
Protein alignment data were generated by MacVector (MacVector, Inc., Cary, NC) using 
a Gonnet similarity matrix with open gap penalty = 10 and extended gap penalty = 0.1. 
 
DNA cloning and adeno-associated virus generation 
The coding sequence of SR-BI (CCDS 9259.1) was obtained from Thermo 
Scientific (cDNA clone MGC:120767 IMAGE:7939577) in a pCR4-TOPO cloning vector 
(Invitrogen). The P376L and the P297S mutations were inserted in the sequence by site 
directed mutagenesis using the Quickchange II site directed mutagenesis kit (Agilent 
technologies) and following primers: P376L-F 5'-cctggacatccacctggtcacgggaatcc-3'; 
P376L-R 5'-ggattcccgtgaccaggtggatgtccagg-3'; P297S-F 5'-
ggtgtttgaaggcatctccacctatcgcttcgt-3'; P297S-R 5'-acgaagcgataggtggagatgccttcaaacacc-
3'. The wild type and the mutated coding sequences were then amplified by PCR and 
subcloned into a pcDNA3.1/V5-His TOPO expression plasmid (Invitrogen) according to 
manufacturer`s instructions. For in vivo studies, SCARB1 WT and P376L cDNA 
sequences were amplified by PCR using the following primers containing KpnI and NotI 
sites, and then subcloned by KpnI/NotI double digestion followed by ligation into adeno-
associated virus serotype 8 vector (AAV8) containing the liver-specific thyroxine-binding 
globulin (TBG) promoter provided by the University of Pennsylvania Vector Core [232-
237]. Virus production, purification and quantification were carried out by the core facility.  
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Radioactive labeling of HDL 
Total human HDL (1.063<d<1.21 g/ml) and HDL3 (1.125<d<1.21 g/ml) were 
obtained by sequential ultracentrifugation as described before[238]. HDL was labeled 
with 125I by a modification of the iodine monochloride method for the binding experiment 
at 4 °C and they were labeled with 125I-tyramine-cellobiose (125I-TCB) for all the other 
experiments[239]. To further label 125I-TC-HDL with 3H-cholesteryl-ether (3H-CE), 500 
μCi of 3H-CE resuspended in 50 μL of ethanol were added to a solution containing heat-
inactivated human lipoprotein deficient serum (200 mg protein) and iodinated HDL (6 mg 
protein). The solution was incubated overnight at 37 °C with gentle shaking, followed by 
reisolation of the dual-labeled HDL by sequential ultracentrifugation.  
 
Cell culture and in vitro assays 
COS7 cells were cultured in Dulbecco modified Eagle medium (DMEM) 
supplemented with 10% fetal bovine serum at 37°C in a humidified 5% CO2 incubator 
and were passaged using trypsin. For selective cholesterol uptake COS7 cells were 
plated at a density of 3x104 cells/cm2 in 6 well plates. One day following plating (Day 1), 
cells were transfected using Lipofectamine 2000 (4 μg DNA/well, 3:1 Lipofectamine:DNA 
ratio) with a pcDNA3.1/V5-His-TOPO plasmid encoding either SCARB1 WT, SCARB1 
P376L, or SCARB1 P297S cDNAs. One group received a mock transfection with 
plasmid containing no cDNA. Each experimental group was tested in quintuplicate. On 
Day 2, culture medium was changed to DMEM 0.5% BSA containing 20 μg/mL of 3H-
cholesteryl hexadecyl ether/125I-TCB-labeled HDL3 and incubated for 3 hours at 37 °C. In 
one well per plate a 40-fold excess of nonradiolabeled (“cold”) HDL was added to a final 
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concentration of 800 μg/mL. After incubation cells were washed with PBS and lipids 
were extracted in two consecutive steps using a 3:2 hexane-isopropanol mixture.  After 
drying, proteins were solubilized using 2 mL of 0.1N NaOH. The hexane/isopropanol 
fraction was dried under nitrogen, resuspended in 600 μL of toluene, and counted 
separately in scintillation and gamma counters. The NaOH fraction was counted in the 
gamma counter and measured for protein concentration using a Lowry protein assay 
[240]. Counts from wells with 40-fold excess of cold HDL (non receptor-specific counts) 
were subtracted from counts from other wells to calculate the receptor-specific activity 
internalized. Data analysis was performed as previously described [241], with the 
following difference: 125I activity (counts per minute) in the NaOH fraction were 
considered as cell-surface associated lipoproteins (it has been shown previously that 
when performing this experiment under similar conditions, the fraction of cell associated 
counts that is trichloroacetic acid-soluble is approximately 5%) [242]. A negligible 
amount of 125I counts were found in the hexane-isopropanol fraction. SR-BI protein 
expression was determined by western blotting. Human β-actin was used as a loading 
control. 
The binding of 125I-HDL3 at 4°C to COS7 cells was measured using a modification 
of the method from Nieland et al [243]. Briefly, COS7 cells were seeded at a 
concentration of 3x104 cells/cm2 in 12 well plates. The next day, cells were transfected 
using Lipofectamine 2000 (1.6 μg DNA/well, 3:1 Lipofectamine:DNA ratio) with a 
pcDNA3.1/V5-His-TOPO plasmid encoding either SCARB1 WT, SCARB1 P376L, or 
SCARB1 P297S cDNAs. An additional plate of cells was transfected with a plasmid 
encoding GFP (pAAV-CB-EGFP), which was used as a control. On the following day, 
cell plates were precooled for 30 minutes on ice, washed with cold DMEM and then 
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exposed for 2 hours to the assay medium (DMEM, 1% P/S, 0,5%BSA + lipoproteins) at 4 
°C. After the incubation, cells were washed twice with ice-cold PBS containing 2 mg/mL 
of bovine serum albumin (BSA) and a third time with PBS without BSA. Cells were then 
lysed in 0.1N NaOH. Lysates were used for 125I counting and for measuring protein 
content using a Lowry assay. In parallel to this, cells were seeded in 10 cm plates, 
transfected as described above and lysed after 24 hours in RIPA buffer to check SR-BI 
protein expression.  
 
Cell surface biotinylation assay  
COS7 cells were seeded and transfected as described above in 175 cm2 flasks. 
24 hours after transfection, cell-surface-associated proteins were isolated using the 
Pierce Cell Surface Protein Isolation Kit (Pierce Biotechnology Inc., Rockford, IL) 
according to the manufacturer`s instructions. After lysis, protein concentration was 
determined by bicinchoninic acid (BCA) assay and the same amount of proteins was 
loaded on NeutrAvidin Agarose beads to isolate biotinylated proteins. After multiple 
washing steps, proteins were eluted from the beads and loaded on a 10% Bis-Tris 
polyacrylamide gels for western blotting. Blots for β-actin and Na+/K+-ATPase were used 
as intracellular and surface-associated controls, respectively.  
 
Induced pluripotent stem cell differentiation to hepatocyte-like cells 
We generated induced pluripotent stem cells (iPSC) from peripheral blood mononuclear 
cells (PBMCs) and differentiated them into hepatocyte-like cells as described elsewhere 
[244,245]. After complete differentiation of iPSCs to hepatocyte-like cells (approx. 20-22 
	53 
 
days from initiation of differentiation), we performed selective cholesterol uptake as 
described above.  
 
Endoglycosidase H sensitivity assays 
For Endoglycosidase H sensitivity assays, 100 μg of liver homogenates from 
mice transduced with human SCARB1 or Null AAV8 vectors were treated with 
Endoglycosidase H (New England Biolabs, Ipswich, MA), Sialidase A, or a combination 
of Sialidase A and PNGase F (Prozyme, Hayward, CA) according to manufacturer’s 
instructions. The digestion products were then loaded on a 10% Bis-Tris polyacrylamide 
gel for western blotting. Non-treated homogenates were used as controls. 
Endoglycosidase H sensitivity assays were also performed using lysates from 
transfected COS7 cells and from iPSC-derived hepatocytes. In these experiments, cell 
lysate in RIPA buffer plus Complete Protease Inhibitor Cocktail (Roche) was used.  
 
AAV-mediated overexpression of SCARB1 WT and P376L in Scarb1 KO mice 
AAV serotype 8 vectors expressing SCARB1 WT or P376L were expressed in 
Scarb1 KO mice, which were subsequently studied for effects on lipoprotein metabolism. 
Male Scarb1 KO mice (6 per group) were weighed, bled through retro-orbital bleeding 
and injected with 1012 genome copies (GC) of AAV-SCARB1-WT, AAV-SCARB1-P376L, 
or Null vector via intraperitoneal injection. Mice were fasted for 5 hours, weighed, and 
bled again at 12 days after injection. Plasma lipid levels were determined as described 
above. At 2 weeks after injection, HDL kinetics using radiolabeled human HDL was 
measured [246]. Briefly, mice were injected via tail-vein injection with a mixture of 125I-
TCB-HDL (3x106 cpm/mouse) and 3H-cholesteryl-ether (CE)-HDL (3x106 cpm/mouse) 
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and bled at 2 minutes post-injection and 1, 3, 6, 9, and 24 hours. Plasma 3H and 125I 
activity at each timepoint were determined using scintillation counting and gamma 
counting, respectively. At 24 hours post-injection of radiolabeled HDLs, mice were 
weighed, anesthetized, terminally bled, and sacrificed. Livers were lysed in phosphate 
buffered saline (PBS) and 3H and 125I were counted in the lysates to determine liver-
associated counts. Liver-associated counts were then expressed as μg of HDL 
component/mg of liver to allow a direct comparison between liver associated 3H and 125I 
counts. Selective cholesterol uptake was calculated as the difference between liver-
associated 3H counts and liver associated 125I counts expressed as μg of HDL 
component/mg of liver. SR-BI protein expression levels in liver homogenates were 
determined by western blot followed by densitometric analysis performed with ImageJ 
(U.S. National Institutes of Health, Bethesda, MD) [247].  
 
Subject selection and study visit 
Carriers of the P376L variant identified through next-generation sequencing were 
recruited through a comprehensive recall protocol approved by the institutional review 
board of the Perelman School of Medicine at the University of Pennsylvania, 
Philadelphia. Additionally, control subjects were chosen from a database of previous 
participants in studies conducted in our laboratory. All subjects recruited gave informed 
consent. Two groups of controls were selected: those having HDL-C levels between the 
25th and the 75th percentile for age and sex (normal HDL-C control group) and those with 
HDL-C levels greater than the 75th percentile for age and sex but confirmed to lack the 
P376L variant (high HDL-C control group). The two control groups were selected to 
match on aggregate the age, gender and race of the carrier group. Study visits were 
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performed in the Clinical and Translational Research Center (CTRC) facility at the 
Perelman School of Medicine at the University of Pennsylvania. Venous blood after 
overnight fasting was drawn from each subject to measure a comprehensive metabolic 
panel, complete blood count, standard urinalysis, reticulocyte count, T- and B-cell 
counts, anti-nuclear antibody screen, anti double-stranded DNA antibody screen, and 
anti-neutrophil cytoplasmic antibody screen, which were measured by the William 
Pepper Laboratory of the Hospital of the University of Pennsylvania. A comprehensive 
lipid panel (total cholesterol [TC], VLDL cholesterol [VLDL-C], LDL cholesterol [LDL-C], 
HDL-C, triglycerides [TG], lipoprotein(a) [Lp(a)], and apolipoproteins A-I, A-II, C-II, C-III, 
and E [ApoA-1, ApoA-II, ApoC-II, ApoC-III, ApoE]) was also performed by the Lipid 
Research Laboratory of the Hospital of the University of Pennsylvania per standard 
protocols as described previously [248]. HDL-C and LDL-C levels were measured both 
directly and after precipitation with phosphotungstic acid (PTA). Lipoproteins were 
separated by fast protein liquid chromatography on a Superose 6 column as described 
previously [249]. 
Blood was also collected in BD Vacutainer CPT Cell Preparation tubes (BD, 
Franklin Lakes, NJ, USA) for PBMC isolation and storage and in sodium citrate tubes for 
platelet isolation and testing. Platelet aggregation studies (PAS) were performed at the 
Translational Core Laboratory (TCL) using a photometric aggregometer (Biodata Corp, 
Horsham, PA).   
To induce platelet aggregation the following stimuli were used at the 
concentrations reported in brackets: arachidonic acid (200, 250, 300, 400, 500 mg/ml), 
collagen (0.04, 0.08, 0.12, 0.16, 0.2 mg/ml), ADP (0.625, 1.25, 2.5, 5, 10 mM), TRAP (1, 
2, 3, 4, 5 µM). Arachidonic acid, collagen and ADP were obtained from Biodata Corp. 
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(Horsham, PA) while TRAP was obtained from Sigma Chemical Corp (St. Louis, MO). 
To correct for possibly unreported intake of drugs with antiaggregant action, subjects 
whose platelets failed to reach 95% aggregation with 500 mg/ml of arachidonic acid 
were excluded from the analysis. Additional blood was also drawn and frozen for later 
batch measurement of adrenocorticotropic hormone (ACTH), cortisol, estradiol, 
progesterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and 
testosterone also by the TCL using standard radioimmunoassay methods (“Coat-A-
Count”) from SIEMENS Healthcare Diagnostics.  Subjects taking exogenous steroids 
were excluded from the analysis. Study subjects were also given the option of 
performing a 24-hour urine collection according to standard methods the day before their 
visit or on a later date. Collected urine was frozen in single-use aliquots for batch 
measurement of cortisol by the Translational Core Laboratory as per standard protocols. 
The acquisition of carotid intima-media thickness (IMT) ultrasound images was 
performed according to a standardized protocol, adopted from the Atherosclerosis Risk 
in Communities (ARIC) study[250] and as per American Society of Echocardiography 
and Society for Vascular Medicine Guidelines for IMT analysis [251]. The scanner used 
was a Siemens Sequoia (Mountain View, CA, USA) with a 9 Linear probe and a custom 
designed carotid IMT preset. One heterozygous subject who was unable to travel to the 
study site had blood drawn locally. These samples were shipped to the study site for the 
lipid panel and autoimmune tests; the subject also sent the results of a recent 
comprehensive metabolic panel and complete blood count. Data from clinical 
phenotyping studies were collected and managed using REDCap (Research Electronic 
Data Capture) electronic data capture tools hosted at the Perelman School of Medicine 
at the University of Pennsylvania [252]. 
	57 
 
 
Platelet separation and cholesterol measurement 
Approximately 4.5 mL of blood was drawn from each subject into tubes 
containing 25 g sodium citrate, 8 g citric acid and 500 mL H2O2. Tubes were centrifuged 
using a tabletop centrifuge at 200xg for 15 min. at room temperature. Platelet-rich 
plasma (PRP) was collected as supernatant from this spin and was centrifuged at 900xg 
for 5 min. The pellet from this spin was resuspended in 8 mL 1xPBS and centrifuged 
again at 900xg for 5 min. Platelet pellets were collected and resuspended in 200 μL 
1xPBS and stored at -20 °C. For measurement of cholesterol, platelet extracts were 
dried using a centrifugal evaporator (Genevac). D7-cholesterol (Cat. No. 700041; Avanti 
Polar Lipids, Inc.) was added to each sample as an internal standard. Lipids were 
extracted by addition of 1 mL chloroform:methanol (2:1) at 4 °C for 2 hours. The 
nonpolar phase from the platelet extracts was collected and dried through centrifugal 
evaporation along with cholesterol standards (1.0-100.0 nmol) containing equivalent 
amounts of D7-cholesterol internal standard. All samples were derivativized using 
pentaflurobenzoyl chloride and extracted with petroleum ether before measurement by 
gas chromatography-mass spectrometry using negative chemical ionization. Peak areas 
for cholesterol and D7-cholesterol from platelet extracts were compared to that from the 
standard curve generated from cholesterol standards to yield cholesterol content in each 
sample. For platelet protein measurement, aqueous extracts from chloroform:methanol 
extraction of platelet samples were spun to remove excess methanol and dried using 
centrifugal evaporation and then resuspended in 200 μL RIPA buffer containing 0.1 N 
NaOH and heated at 55°C for approximately 24 hrs with periodic vortexing. Protein 
concentrations from these extracts were measured by a Lowry assay[240] (Pierce). 
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Cholesterol measurements for each sample were then normalized to the corresponding 
protein concentrations. 
 
Fractionation of plasma lipoproteins from study subjects 
VLDL, LDL, and HDL subfractions were isolated from EDTA plasma by single 
step, isopycnic non-denaturing density gradient ultracentrifugation based on a 
modification of the method developed by Chapman et al. as previously 
described[253,254]. Using this procedure, five subfractions of LDL (LDL1, d 1.019-1.023 
g/ml; LDL2, d 1.023-1.029 g/ml; LDL3, d 1.029-1.039 g/mL; LDL4, d 1.039-1.050 g/ml; 
and LDL5, d 1.050-1.063 g/ml) were isolated, followed by two subfractions of large, light 
HDL2 (HDL2b, d 1.063–1.087 g/ml and HDL2a, d 1.088–1.110 g/ml), and three 
subfractions of small, dense HDL3 (HDL3a, d 1.110–1.129 g/ml; HDL3b, d 1.129–1.154 
g/ml; and HDL3c, d 1.154–1.170 g/ml). Total HDL was prepared as a mixture of HDL2b, 
2a, 3a, 3b and 3c subfractions at their equivalent plasma concentrations. 
 
Protein quantification and chemical composition of HDL 
Overall chemical composition of HDL subfractions was assessed using 
commercially available enzymatic kits (total protein: Thermo Scientific, Villebon-sur-
Yvette, France; total cholesterol, free cholesterol, phospholipids: DiaSys, Holzheim, 
Germany; triglycerides: Biomérieux, Marcy l’Etoile, France). Cholesteryl ester (CE) 
concentration was calculated by multiplying the difference between total and free 
cholesterol concentrations by 1.67. Total lipoprotein mass was calculated as the sum of 
total protein, CE, FC, PL and TG and expressed as plasma concentrations (mg/dl). HDL 
apoplipoproteins (ApoA-I, ApoA-II, ApoC-III) were quantified using automated enzymatic 
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methods (Konelab, Thermo Scientific, Waltham, MA, USA). 
 
Cellular cholesterol efflux capacity of HDL 
The cholesterol efflux capacity of total HDL was assessed in a human THP-1 
monocytic cell line (ATCC, Manassas, VA, USA) as previously reported[255]. THP-1 
monocytes were cultured at 37°C and 5% CO2 in RPMI 1640 media with 10% FBS, 2 
mM glutamine, 100 µg/ml penicillin, and 100 µg/ml streptomycin (complete media) using 
standard cell culture procedures and differentiated into macrophage-like cells using 50 
ng/ml phorbol 12-myristate 13-acetate (PMA). Cells were loaded for 24 h with [3H] 
cholesterol-labeled acetylated LDL (acLDL, 1 µCi/mL) in serum-free RPMI 1640 culture 
medium supplemented with 50 mM glucose, 2 mM glutamine, 0.2% BSA, 100 µg/ml 
penicillin and 100 µg/ml streptomycin (serum-free media). After equilibration in serum-
free media, cells were incubated for 4 h with HDL from subjects. Efflux capacity was 
normalized to HDL-phospholipid content because PL has been shown to represent the 
key component in determining cholesterol efflux capacity of HDL (15 µg/ml HDL-PL in 
serum-free media, total volume 250 µL)[256]. Cholesterol efflux capacity was measured 
as the percent of radioactivity counts in the media over counts in the cell lysate, after 
adjustment for non-specific diffusion to non-HDL containing media. 
 
Statistical analysis 
Data analysis was conducted using Excel (Microsoft Corp.) and GraphPad Prism 
6.0 (GraphPad Software Inc.). In vitro and in vivo data were compared by Student`s 
unpaired T-test. A p-value of less than 0.05 was considered statistically significant. The 
same test was employed to compare HDL subclasses and composition between controls 
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and heterozygotes.  For data regarding clinical samples, Chi-square testing (for 
categorical variables) and one-way ANOVA (for continuous variables) were used to 
determine the effect of SCARB1 P376L carrier status on a number of variables. A P 
value less than 0.05 was considered statistically significant. Tukey's multiple comparison 
test (α=0.05) was used following ANOVA where appropriate to determine which groups 
were responsible for statistically significant differences among groups. Data are reported 
as mean ± SD. The association of P376L and CHD was tested among CHD cases and 
controls of European ancestry assembled from the MICAD Exome Consortium and the 
CHD Exome+ Consortium. The summary OR of CHD for P376L carriers was calculated 
using a Mantel-Haenszel fixed-effects meta-analysis without continuity correction, a 
method that is well suited to low (and even zero) counts and resultant ORs.  The 
association of the P376L variant with HDL-C, LDL-C and TG in the Global Lipids 
Genetics Consortium Exome Chip Genotyping study was assessed through meta-
analysis of single variant score statistics in up to 301,025 individuals [257]. 
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Results 
 
Identification of SCARB1 P376L Homozygote and Association with High HDL-C  
 We hypothesized that humans with extremely high levels of HDL-C may harbor 
loss-of-function variants in SCARB1 and undertook a targeted resequencing discovery 
experiment in 328 participants with very high HDL-C (> 95th percentile, mean HDL-C 
106.8 mg/dL) and a control group of 398 subjects with low HDL-C < 25th percentile, 
mean HDL-C 30.4 mg/dL).  In this cohort, we sequenced the exons of ~990 genes 
located within 300 kb of each of the 95 loci with significant associations (P < 5 x 10-8) 
with plasma lipid levels identified by the Global Lipids Genetics Consortium as of 2010 
[86]. Among the high HDL-C subjects, we identified a homozygote for SCARB1 P376L 
(g.125284671 G>A, c.1127C>T, p.P376L, rs74830677), a 67-year-old  female with an 
HDL-C of 152 mg/dL, and confirmed this finding by Sanger sequencing. This subject 
harbored no mutations in other high HDL-C genes such as CETP and LIPG.  In addition 
to this homozygote, four P376L heterozygotes were identified by targeted sequencing in 
the high HDL-C group; no heterozygotes were found in the low HDL-C group (P=0.008, 
Fisher exact test).   
To identify additional P376L carriers, we  genotyped an expanded cohort of very 
high vs. low HDL-C subjects.  Among 524 additional subjects with very high HDL-C 
(mean HDL-C 95.0 mg/dL) we identified 11 heterozygotes for P376L; whereas among 
758 subjects with low HDL-C (mean HDL-C 33.5 mg/dL) we identified 3 heterozygotes. 
In total, our combined sequencing and genotyping for discovery of the P376L variant 
showed that this variant is significantly over-represented in subjects with high HDL-C 
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[minor allele frequency (MAF)  = 0.010 in high HDL-C vs. 0.0013 in low HDL-C controls, 
P=0.000127, Fisher exact test, Table 2.1].  
Because this variant is present on the Exome Array, we expanded our analysis to 
the Global Lipid Genetics Consortium Exome Array data in > 300,000 individuals.  The 
P376L variant was very rare in this population (MAF ~ 0.0003).  It was significantly 
associated with higher HDL-C levels with a relatively large effect size (beta = 8.4 mg/dL; 
p = 1.4 x 10-15). Notably, this variant was not associated with plasma levels of low 
density lipoprotein-cholesterol (LDL-C) or triglycerides (TGs) (Table 2.2). Thus, we 
conclude that SCARB1 P376L is associated specifically with elevated HDL-C levels.  
 
Conservation of SR-BI Proline 376 Across Species and Paralogues  
The proline at position 376 of SR-BI is highly conserved down through 
Drosophila and Anopheles, as well as in the closely related human genes CD36 and 
LIMP2 and is in a sequence of highly invariant residues (Figure 2.1). The “consensus 
deleteriousness” score according to Condel was 0.906 (on a scale from 0 to 1, with 1 
indicating maximum deleteriousness). Raptor X, a secondary structure prediction 
program, predicts that substitution of proline 376 with leucine increases the probability of 
this region to be in a beta-sheet confirmation from 36% to 61%. This finding is in 
agreement with the suggestion from the recently reported structure of another scavenger 
receptor LIMP-2 [258] that the region containing P376 in SR-BI is a disordered linker 
sequence joining beta strands 15 and 16 on the extracellular loop proximal to the C-
terminal transmembrane domain.  
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SCARB1 P376L results in complete loss-of-function of SR-BI through abolishing post-
translational processing and cell-surface localization 
Given the profound HDL phenotype of the P376L carriers, we sought to 
understand the impact of the variant on SR-BI function. We first tested the functional 
impact of the P376L variant on HDL-CE selective uptake in transfected COS7 cells.  
Studies with transfected COS7 cells revealed that the P376L variant was defective in 
promoting selective CE uptake (Figure 2.2 A) despite similar protein expression in total 
cell lysates (Figure 2.2 B).  Notably, the P376L variant had less activity in this assay 
than one previously reported P297S variant [224]  (Figure 2.2 A).  In studies of 125I-
labeled HDL3 binding at 4 ºC, the P376L variant abrogated cell-surface binding (Figure 
2.2 C), despite equal SR-BI protein levels in total cell lysates among groups (Figure 2.2 
D). 
We next generated induced pluripotent stem cells (iPSCs) using peripheral blood 
mononuclear cells from the P376L homozygote and a noncarrier control and 
differentiated these cells into hepatocyte-like cells (HLCs) to study HDL metabolism in 
the setting of endogenous cellular SCARB1 expression. HLCs differentiated through this 
protocol recapitulate phenotypes of cultured primary hepatocytes such as albumin and 
VLDL secretion [259-262]. The cell lines from the control donor and the P376L 
homozygous subject demonstrated expression of hepatocyte-specific genes ALB 
(albumin) and AFP (alpha-fetoprotein) and exhibited comparable SCARB1 gene 
expression (Figure 2.3).  Compared to control iPSC-hepatocyte lines, those from the 
P376L homozygote demonstrated a profound reduction in selective cholesterol uptake 
from HDL in vitro (Figure 2.4 A).  
	64 
 
To evaluate the physiological impact of the P376L variant on HDL-C levels and 
catabolism in vivo, we used adeno-associated virus (AAV) vectors to direct hepatic 
overexpression of WT SR-BI or the P376L variant in Scarb1 KO mice.  The two groups 
of mice demonstrated similar hepatic expression levels of SCARB1 mRNA (Figure 2.5 
A) and SR-BI protein (Figure 2.5 B). Mice expressing WT SCARB1 demonstrated a 
robust 73% decrease in HDL-C. In contrast, mice expressing the P376L variant had no 
reduction in HDL-C; their HDL-C levels were comparable to those in  the control AAV-
null injected mice (Figure 2.4 B). While the clearance of 125I-HDL protein was not 
different among the three groups, the clearance of 3H-HDL-CE was much slower in mice 
expressing the P376L variant compared with those expressing WT SR-BI and was 
comparable to that in the control mice (Figure 2.4 C-D). Selective HDL-CE clearance 
from plasma was increased by WT SR-BI but was undetectable in the P376L-expressing 
mice (Figure 2.4 E & Figure 5 C), as was hepatic uptake of 3H-CE at 24 hours (Figure 
2.5 D). This indicates that the P376L sequence variant results in complete loss of the 
canonical function of SR-BI--namely,  selective uptake of HDL cholesteryl ester. 
We hypothesized that the markedly reduced HDL-CE uptake could be due to 
aberrant processing of the P376L SR-BI protein, leading to impaired cell-surface 
localization. To test this, we isolated cell-surface proteins from COS7 cells transfected 
with WT and P376L SR-BI using biotinylation and found markedly reduced cell surface 
SR-BI in the P376L transfected cell lysates after streptavidin cell-surface protein pull-
down (Figure 2.2 E). Given that SR-BI undergoes N-glycosylation in the endoplasmic 
reticulum concomitant with proper folding, we hypothesized that altered post-
translational modification may underlie its reduced cell-surface localization 
[256,263,264]. We measured the molecular weights of SR-BI forms after 
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endoglycosidase-H (Endo-H) treatment of transfected COS7 (Figure 2.2 F) and iPSC-
derived HLC lysates as well as mouse liver lysates expressing WT or mutant SR-BI 
(Figure 2.4 F-G). Higher molecular weight forms represent N-glycosylation modified 
Endo-H resistant and partially sensitive forms at the cell surface after modification by 
alpha-mannosidase II in the Golgi apparatus [263]. In the iPSC-derived differentiated 
hepatocyte-like cells from the P376L homozygote (Figure 2.4 F), we found much less 
total cellular SR-BI in the mutant cell lines relative to that of WT cells, despite 
comparable SCARB1 gene expression (Figure 2.3 C). After Endo-H treatment, the SR-
BI from SCARB1 WT cell and liver lysates across models was predominantly the 
partially sensitive form, along with small amounts of the fully resistant form. In contrast, 
the SR-BI from cell and tissue lysates across P376L-expressing groups was all the 
immature, fully Endo-H sensitive form (Figure 2.2 F & Figure 2.4 F-G). Together these 
data are consistent with a model in which the P376L sequence variant alters the 
endogenous post-translational N-glycosylation of SR-BI to prevent either transit from the 
ER to the Golgi or further post-translational modifications in the Golgi, ultimately 
resulting in reduced cell surface expression.  
 
HDL-related phenotypes of SCARB1 P376L homozygote and heterozygotes  
We next recruited the P376L homozygote, eight heterozygous carriers, and both 
high HDL-C and normal HDL-C non-carrier controls for deep phenotyping of HDL 
metabolism and related traits. All of the P376L study participants were of European 
ancestry, almost exclusively of Ashkenazi Jewish descent. Clinical characteristics and 
lipid profiles of the subjects are reported in Table 2.3. FPLC (fast protein liquid 
chromatography) analysis of plasma lipoproteins confirmed the increase in large HDL 
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particles in the homozygote (Figure 2.6 A). Cholesterol and apoA-I levels in HDL were 
significantly increased in the homozygote and heterozygotes compared with controls, but 
HDL apoA-II levels were not elevated (Table 2.3 & Figure 2.6 B). There were no 
differences between  P376L carriers and controls in the absolute amount of HDL free 
cholesterol or the ratio of free-to-esterified cholesterol in their HDL (Figure 2.6 C). 
P376L heterozygotes had a 2.8-fold increase and the homozygote a 6.1-fold increase in 
large HDL-2b particles  compared with noncarrier controls (Figure 2.6 D). There was a 
higher amount of apoA-I (Figure 2.6 E) and apoC-III (Figure 2.6 F) in large HDL 
particles in the homozygote and heterozygous carriers.  Cholesterol efflux capacity was 
similar in carriers and controls (Figure 2.6 G).  
Previous in vitro, mouse and human genetics studies have suggested that SR-BI 
in platelets is necessary for proper platelet activity and thrombosis [208,224,265-267]. 
To test the effects of the P376L variant on platelet activity, we isolated platelets from 
carriers and controls and performed light transmission aggregometry (LTA) after 
stimulation with known platelet activators arachidonic acid, collagen, ADP and TRAP 
over a range of doses. We found only a slight decrease in ADP-induced maximal 
aggregation in platelets isolated from the P376L homozygote relative to heterozygotes 
and control subjects at a dose of 5 mmol (Figure 2.7 A). No differences in platelet 
activity in response to other stimulants were observed between the groups. We also 
extracted lipids from platelets and measured platelet cholesterol content among groups. 
We observed that platelet cholesterol increased in a genotype dose-dependent manner 
from controls (mean 122 nmol/mg protein) to heterozygotes (mean 139 nmol/mg protein) 
to the homozygote subject (244 nmol/mg protein) (Figure 2.7 B).  However, the 
difference between normal HDL-C controls and heterozygotes was not significant, and 
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these differences were reduced when the values normalized to plasma total cholesterol 
levels, suggesting that elevated platelet cholesterol in carriers reflects increased plasma 
HDL-C levels rather than a platelet SR-BI specific function (Figure 2.7 C). There was 
also no difference in total circulating platelet levels among groups (data not shown).  
SR-BI also takes up HDL-cholesteryl esters in adrenal glands and reproductive 
tissues for steroid hormone production in mice and humans [208,220,268], so we 
evaluated the impact of SCARB1 loss-of-function on steroid hormones in our recruited 
participants. We found no difference in morning serum cortisol, ACTH and 24-hr urinary 
cortisol-to-creatinine (Figure 2.8) across participants, moderately higher testosterone in 
male P376L heterozygotes relative to normal HDL-C controls, but no differences across 
groups in FSH and LH. 
 
SCARB1 P376L is associated with increased risk of CHD in humans 
 Despite a profound increase in HDL-C, SR-BI deficiency in mice causes 
accelerated atherosclerosis [219-222]. The relationship of reduced SR-BI function to 
atherosclerotic cardiovascular disease in humans has not been established.  The P376L 
homozygous subject did not have clinical CHD, but her carotid intimal-medial thickness 
(cIMT) was 0.789 mm (left-right average), which is > 75th percentile for females of her 
age; in addition, she had detectable plaque throughout the left internal carotid artery and 
at the bifurcation of her right internal carotid artery. cIMT measurements were not 
significantly different in the P376L heterozygotes compared with both groups of controls 
(Figure 2.9), but due to small sample size the statistical power is limited.  
 To achieve greater statistical power to address this question, we performed a 
meta-analysis of large Exome Array genotyping studies of CHD cases and healthy 
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controls to determine the relationship of the P376L variant with risk of CHD (Table 2.4).   
Among 16 sample sets from two consortia (The MICAD Exome Consortium and the 
CHD Exome+ Consortium), we tested the association between P376L carrier status and 
CHD in 137,995 individuals. Across 49,846 CHD cases and 88,149 CHD controls, we 
found that P376L carriers had significantly higher risk of CHD compared with non-
carriers (Odds Ratio for disease among carriers = 1.79; P = 0.018, Table 2.4) Thus, 
carriers of this SCARB1 P376L variant have significantly increased HDL-C levels and 
significantly increased risk of CHD. 
 
Discussion 
Studies of mice have provided important insights into the effects of SR-BI on 
HDL metabolism, reverse cholesterol transport (RCT), and atherosclerosis. These 
studies revealed that  overexpression of SR-BI reduces HDL-C [209-212] and reduces 
[216-218], whereas gene deletion of SR-BI increases HDL-C [213-215] and accelerates 
atherosclerosis [219-222]. The clinical relevance of these findings has remained 
uncertain, however.  Studies of injected labeled HDL-CE in humans suggested that the 
majority of the HDL-CE was transported to the liver via CETP-mediated exchange to 
apoB-containing lipoproteins rather than via direct uptake from HDL by the liver [269], 
bringing into question the importance of hepatic SR-BI in human physiology.  Common 
genetic variants near the SCARB1 locus were found to be significantly associated with 
plasma HDL-C levels, suggesting that SR-BI may play a role in HDL metabolism in 
humans [86,117]. A family with a rare SCARB1 variant P297S was reported in which the 
heterozygous carriers of the variant had modestly elevated HDL-C levels [224].  
However, the variant retains substantial SR-BI activity, no homozygotes were identified, 
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the apparent effect on HDL-C was modest, and there was insufficient power to address 
its effects on atherosclerosis.   
Through sequencing of subjects with extremely high plasma levels of  HDL-C, we 
identified a homozygote for a P376L variant in SR-BI. Our complementary approaches 
consistently demonstrated that this variant confers virtually complete loss-of-function of 
SR-BI. Our results demonstrate many similarities in the consequences of SR-BI 
deficiency on HDL composition between mice and humans, including a shift toward 
large, buoyant HDL particles and a significant increase in apoA-I but not apoA-II in 
plasma and HDL [214,270,271].  The homozygote is a woman who had two healthy 
children without fertility issues or delivery complications, suggesting that in humans, SR-
BI deficiency may not impair reproductive function in the same manner as it does in mice 
[220,272]. In mice, SR-BI-mediated CE uptake from HDL is a critical process underlying 
steroid hormone synthesis in adrenal and gonadal tissues, and SR-BI deficiency alters 
adrenal cholesterol content, impairs adrenal glucocorticoid response under stress, and 
can lead to fasting-induced hypoglycemia [208,273,274]. We did not observe any 
differences in fasting glucose, serum cortisol, ACTH, or female gonadal hormones in 
P376L heterozygous subjects versus controls and we saw only a modest increase in 
testosterone in male P376L heterozygotes relative to noncarriers. We postulate that 
differences in expression or capacity for upregulation of apoB-containing lipoprotein 
receptors relative to SR-BI between mouse models and humans in steroidogenic tissues 
may account at least partially for the lack of recapitulation of some of the phenotypes of 
SR-BI deficiency in mice.  We also observed no differences in platelet levels, cholesterol 
content, and activation from the P376L carriers, despite reports of thrombocytopenia and 
altered platelet activity in Scarb1 KO mice [224]. These results suggest a relatively 
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different contribution of SR-BI to platelet function between mice and humans. 
Interestingly, the phenotypes of human SCARB1 P376L homozygote (elevated HDL-C 
and large HDL particles but relatively normal steroidogenesis, reproductive viability, and 
platelet function) are comparable to those observed in mice lacking the PDZ domain 
containing 1 (PDZK1), an adaptor protein for SR-BI [275].  
 Perhaps the most important finding of our study is that despite the elevation in 
HDL-C, P376L carriers exhibit increased risk of CHD, consistent with the results in 
Scarb1 KO mice. Our results are consistent with a growing theme in HDL biology that 
steady-state concentrations of HDL-C are not causally protective against CHD and that 
HDL function and cholesterol flux may be more important than absolute levels.  Using an 
in vivo assay of macrophage RCT, we previously showed that Scarb1 KO mice have 
impaired macrophage RCT even though they have  elevated HDL-C levels [223]. Our 
results suggest that reduced hepatic SR-BI function in humans causes impaired RCT, 
leading to increased risk of CHD despite elevation in HDL-C levels.  However, SR-BI is 
also expressed in vascular cell types, including endothelial cells, vascular smooth 
muscle cells, and macrophages, where it could have protective effects against 
atherosclerosis as well [276,277].  Our results are consistent with the previously 
suggested concept [277] that upregulation or enhancement of SR-BI could be a novel 
therapeutic approach to reducing CHD risk in the general population.  
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Figure 2.1 
 
 
Figure 2.1: SR-BI Protein Sequence Alignment Across Species. Amino acid 
sequence alignment of SR-BI across 12 species and human SR-BI paralogues CD36 
and LIMP-2. Shown is the ~60 residue sequence alignment adjacent human SR-BI 
residue Pro376 (indicated by red box). Dark grey shading indicates full conservation of a 
given residue across indicated species. Light grey shading indicates a different but 
conservative amino acid for the given species compared to the others listed. 
Contributions: This data was generated by a collaborator Paolo Zanoni and analyzed in 
part by SAK. 
  
Figure S1  
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Figure 2.2  
 
Figure 2.2: SCARB1 P376L abrogates SR-BI function in transfected COS7 cells. A. 
Selective cholesterol uptake in COS7 cells expressing SR-BI WT vs. P376L. Cells were 
transfected with plasmids expressing WT, P376L or P297S forms of SR-BI and 
A. B. B. 
D. 
NTC WT P376L P297S 
GFP WT P376L P297S 
β-actin 
SR-BI 
β-actin 
SR-BI 
P297S P376L WT 
125I HDL concentration 
(µg protein/ml medium)	
B
ou
nd
 H
D
L 
(n
g 
H
D
L 
pr
ot
ei
n/
m
g 
ce
ll 
pr
ot
ei
n)
 	
β-actin 
SR-BI 
Na+/K+ ATPase 
C. 
GFP WT P376L P297S GFP WT P376L P297S 
Whole Cell Lysate   Cell Surface E. 
P297S 
P376L 
WT 
A. B. B. 
D. 
NTC WT P376L P297S 
GFP WT P376L P297S 
β-actin 
SR-BI 
β-actin 
SR-BI 
P297S P376L WT 
125I HDL concentration 
(µg protein/ml medium)	
B
ou
nd
 H
D
L 
(n
g 
H
D
L 
pr
ot
ei
n/
m
g 
ce
ll 
pr
ot
ei
n)
 	
β-actin 
SR-BI 
Na+/K+ ATPase 
C. 
GFP WT P376L P297S GFP WT P376L P297S 
Whole Cell Lysate   Cell Surface E. 
P297S 
P376L 
WT 
WT P376L 
A. 
GFP P297S WT P376L GFP P297S 
β-actin 
SR-BI 
M15-10 
- EndoH: 
Control HLC Lines P376L HLC Lines 
+ 
M15-4 
- + 
M14-11 
- + 
M14-5 
- + 
β-actin 
SR-BI 
EndoH: - - - + + + 
- - + + EndoH: 
Null WT P376L Null WT P376L 
SR-BI 
B. 
C. 
- + 
45 
52 
65 Mature  
Partially EndoH sensitive 
Fully EndoH sensitive 
Mature  
Partially EndoH sensitive 
Fully EndoH sensitive 
Mature  
Partially EndoH sensitive 
Fully EndoH sensitive 
kDa 
kDa 
kDa 
- + 
64 
56 
50 
52 
60 
75 
F. 
Figure S2  
	73 
 
incubated at 37 °C for 3 hrs with 125I/3H-labeled HDL3 to determine HDL cholesterol ester 
(CE) specific uptake. Data represent the mean of a quintuplicate determination after 
subtraction of the determinations done with the addition of a 40-fold excess of cold HDL. 
B. Western blot showing SR-BI expression levels in whole cell lysates from COS7 cells 
transfected for selective cholesterol uptake experiment in (A). C. Binding of HDL to SR-
BI at 4 °C in transfected COS7 cells. Transfected cells were exposed to 125I-labeled 
HDL3 for 2 hrs at 4 °C to measure HDL binding. Radioactive counts from cells were then 
quantified to determine the amount of cell-associated 125I-HDL3. Data points represent 
the mean +/- S.D. ** P<0.01, one-way ANOVA. D. Western blot showing SR-BI 
expression levels in whole cell lysates from COS7 cells transfected in panel (C). E. 
Immunoblot of SR-BI after cell-surface biotinylation in transfected COS7 cells. Cells 
were transfected with GFP, SR-BI WT, P376L or P297S plasmids and biotinylated 
before collection of whole cell lysate (left) or incubation with NeutrAvidin beads and 
elution of cell-surface localized proteins (right). Whole cell lysates (lanes 1-4) and cell-
surface proteins (lanes 5-8) were separated by SDS-PAGE and immunoblotted for 
human SR-BI. Actin and Na/K-ATPase were used respectively as intracellular and 
surface-associated controls. F. Endo-H sensitivity of SR-BI from transfected COS7 cells. 
Cells were transfected with plasmids encoding GFP or different forms of SR-BI (WT, 
P376L, P297S) and cell lysates were treated with Endo-H to release complex N-linked 
glycans and molecular forms of SR-BI were monitored by immunoblotting. For A & C, 
data represent mean Error bars indicate mean values ±  S.D. ** P<0.01, Student’s 
unpaired T-test. Contributions: Data in panels A-D generated by Paolo Zanoni; data in 
panels E-F generated by SAK and collaborator; all data analyzed by SAK.  
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Figure 2.3 
 
Figure 2.3. Gene expression in control and SCARB1 P376L iPSC-derived 
hepatocyte-like cells (HLCs). A. ALB Gene expression by quantitative RT-PCR of 
mRNA from control and P376L mutant iPSC-derived HLCs. Cells were differentiated 21-
25 days before experiments and RNA isolation for gene expression analysis. B.  AFP 
gene expression in iPSC-derived HLCs. C. SCARB1 gene expression in iPSC-derived 
HLCs. Contributions: All data in this figure was generated and analyzed by SAK. 
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Figure 2.4 
 
Figure 2.4: SCARB1 P376L is a null variant in vitro and in vivo. A. 3H cholesterol ether (CE) uptake (left panel) and selective 
cholesterol uptake from HDL (right panel) in iPSC-derived hepatocyte-like cells (HLCs) from the P376L homozygote vs. a noncarrier 
control. Cells were incubated with 3H cholesteryl ether (CE)/125I tyramine cellobiose (TC) dual-labeled human HDL. All values are 
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normalized to relative ALB gene expression in each cell line. All data represents mean values for wells of respective cell lines ± S.D. 
B. Plasma HDL cholesterol before and 12 days after AAV administration to Scarb1 knockout mice. C. 3H cholesterol ether (CE) 
clearance (left panel) and fractional catabolic rate (right panel) from plasma of Scarb1 knockout mice injected with Null or SR-BI 
AAVs after administration of 3H-CE/125I-TC dual-labeled human HDL. D. 125I tyramine cellobiose (TC) clearance (left panel) and 
fractional catabolic rate (right panel) from plasma after administration of dual-labeled HDL. E. Selective cholesterol uptake in mice 
expressing Null, SR-BI WT, or P376L measured by relative differences in 3H and 125I fractional catabolic rates. F. Sensitivity to 
endoglycosidase-H (Endo-H) in P376L homozygous vs. noncarrier iPSC-derived HLCs. Cell lysates of each genotype were treated 
with Endo-H to remove complex N-linked glycans from mature forms of proteins and then immunoblotted for SR-BI. Molecular 
weights of different forms of SR-BI after Endo-H treatment are given on the left. G. SR-BI Endo-H sensitivity from liver lysates from 
mice expressing Null, SR-BI WT, or SR-BI P376L AAV. Lysates were treated with Endo-H followed by immunoblotting for SR-BI. 
Molecular weights of different forms of SR-BI after Endo-H treatment are given on the left. For A, data represent mean values for 
wells of respective cell lines ± S.D. For B-E, data represent mean values ± S.D. for each of the 3 groups. *P<0.05, ** P<0.01, 
***P<0.001, ANOVA (B, C – plasma clearance), Unpaired T-test (E). Contributions: All data in this figure generated by SAK; data in 
panels C-E generated by SAK and Paolo Zanoni; all data analyzed by SAK and collaborator. 
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Figure 2.5 
 
Figure 2.5: Hepatic SCARB1 expression and impact on selective cholesterol 
uptake from HDL in mice. A. Human SCARB1 transcript expression levels measured 
by quantitative RT-PCR from livers of mice expressing Null or SR-BI AAV vectors. Gene 
expression was measured from total hepatic RNA after reverse transcription and 
normalized to expression levels of actin. B. SR-BI immunoblot (right) from livers of 
Scarb1 KO mice expressing Null, SR-BI WT, and SR-BI P376L 2 weeks after AAV 
administration. C. Liver 3H CE uptake from dual-labeled HDL administration in mice 
expressing Null or SR-BI AAVs. D. Hepatic selective cholesterol uptake measured by 
relative difference of hepatic 3H CE and 125I TC uptake in livers of mice expressing Null 
or SR-BI AAVs after dual-labeled HDL administration. All data represent mean values ± 
S.D. for each of the 3 groups. *P<0.05, ** P<0.01, ***P<0.001, Unpaired T-test. 
Contributions: Data in panels A, C, and D generated and analyzed by SAK; data in panel 
B generated by Paolo Zanoni. 
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Figure 2.6  
 
Figure 2.6: HDL composition and functionality in SCARB1 P376L homozygote, heterozygous carriers, and controls. A. FPLC 
fractionation of plasma lipoproteins from the P376L homozygote subject (red) and from a control with normal HDL-C. B.  Cholesterol, 
apoA-I and apoA-II content in total HDL. C. Free cholesterol (FC) and esterified cholesterol (CE) in total HDL (left panel) and the 
FC/CE ratio in total HDL (right panel). D.  HDL subclass concentrations after separation by density gradient ultracentrifugation. E. 
ApoA-I content in the same HDL subclasses. F. ApoC-III content in the same HDL subclasses. G. Cholesterol efflux capacity from 
THP-1 macrophages. All data are reported as mean values ± S.D. Contributions: All data generated by collaborators (Paolo Zanoni, 
Will Hancock-Cerutti, and Anatol Kontush) and analyzed by SAK and collaborators.  
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Figure 2.7 
 
Figure 2.7: Platelet aggregation and cholesterol content. A. Platelet aggregation 
measured by light transmission aggregometry after stimulation with increasing doses of 
ADP. Data represent the percentage maximal aggregation. B. Platelet cholesterol 
content measured by LC/MS. C. Platelet cholesterol content after normalization for 
plasma total cholesterol levels. Bars represent mean values ± S.D.. * P<0.05, one-way 
ANOVA followed by Tukey's multiple comparisons test. Contributions: All data generated 
by core facility and analyzed by SAK and Paolo Zanoni. 
 
 
 
 
 
 
 
 
 
 
Figure S5  
A. B. C. 
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Figure 2.8 
 
Figure 2.8: Impact of SCARB1 P376L on adrenal and gonadic steroidogenesis. A. 
Morning serum cortisol in carriers vs. controls. B. Morning plasma ACTH. C. Cortisol / 
creatinine ratio in 24 hr urine. D. Serum testosterone in males. E. Serum LH in males. F. 
Serum FSH in males. Bars represent mean values ± S.D.. * P<0.05, one-way ANOVA 
followed by Tukey's multiple comparisons test. Contributions: All data generated by core 
facilities and analyzed by SAK and Paolo Zanoni.  
 
 
 
 
 
 
 
Figure S6  
A. B. C. 
D. E. F. 
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Figure 2.9 
 
Figure 2.9: Carotid intima media thickness (cIMT) in SCARB1 P376L carriers vs. 
controls. A. cIMT for all subjects (male and female combined). B & C. cIMT results for 
males and females, respectively. Dotted lines represent the 25th and the 75th percentile 
values from the ARIC study. Bars represent mean values ± S.D.. All data shows the 
average left / right cIMT. Contributions: All data generated by clinical laboratories and 
analyzed by SAK, Paolo Zanoni, and Emil Mohler. 
 
Figure S7  
A. B. C. 
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Table 2.1 
 
Table 2.1: Association of SCARB1 P376L with HDL-C in High vs. Low HDL-C Cohorts. Carriers of the P376L variant were 
ascertained from the Penn High HDL Study through 2 approaches, targeted sequencing of the SCARB1 gene in a total of 726 
subjects (328 high HDL-C and 398 low HDL-C subjects) and genotyping on the Exome Array (Illumina) in an additional 1282 subjects 
(524 high HDL-C subjects and 758 low HDL-C subjects). The association of the P376L variant with the high HDL-C cohort from both 
approaches individually and combined together was tested using a Fisher exact test. Contributions: Sequencing and genotyping 
completed by core facilities; data QC and analysis performed by SAK. 
Table 2.1: Association of SCARB1 P376L with HDL-C in High vs. Low HDL-C Cohorts 
Discovery 
Cohort 
High HDL-C (>95th percentile) Low HDL-C (<25th percentile) 
Association of 
P376L Carriers with 
Higher HDL-C 
(Fisher Exact Test) 
No. of Participants No. of Participants 
Total Noncarriers Heterozygotes Homozygotes Total Noncarriers Heterozygotes Homozygotes 
Targeted 
Sequencing of 
SCARB1 
328 323 4 1 398 398 0 0 P=0.008398 
Exome Array 
Genotyping 524 513 11 0 758 755 3 0 P=0.005296 
Combined 852 836 15 1 1156 1153 3 0 P=0.000127 
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Table 2.2 
Table 2.2: Association of SCARB1 P376L with Plasma Lipid Traits in Global Lipids 
Genetics Consortium Exome Array Genotyping 
Trait 
Number of 
Subject 
included 
Minor 
Allele 
Frequency 
Beta (SE) in Standard 
Deviation Units 
P-value (Score 
Test) 
HDL-C 301025 0.00033 +0.57 (0.071) 1.41 x 10-15 
LDL-C 280551 0.00033 +0.065 (0.074) 0.381 
TG 290277 0.00034 -0.052 (0.072) 0.474 
 
Table 2.2: Association of SCARB1 P376L with plasma lipid traits in Global Lipids 
Genetics Consortium Exome Array genotyping. The relationship between the 
frequency of P376L carriers and plasma lipid traits was measured in the Global Lipids 
Genetics Consortium cohort by genotyping of the variant on the Exome Array and using 
the Score test. Contributions: Genotyping data and analysis performed by Gina Peloso, 
Sekar Kathiresan, and Global Lipids Genetics Consortium members.  
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Table 2.3 
Table 2.3: Characteristics of SCARB1 P376L Carriers and Controls 
Recruited for Deep Phenotyping 
Measure 
1: Normal 
HDL-C 
controls 
2: High 
HDL-C 
controls 
3: P376L 
Heterozygotes 
P376L 
Homozygote 
ANOVA/Chi-
square 
Tukey`s 
multiple 
comparison 
Number of 
Subjects 11 10 8 1 - - 
Age (years)1 61.6 (9.7) 64.2 (12.5) 67.5 (15.3) 65 n.s. - 
Sex (M/F) 6/5 5/5 6/2 0/1    n.s.** - 
BMI - Kg/m2 26.4 (2) 22.9 (1.3) 25.6 (3.9) 21 * 1/22 
TC (mg/dl) 185.8 (22.3) 215.8 (29.9) 228 (33.2) 280 * 1/3 
Glucose (mg/dl) 93.5 (2.9) 91.6 (7.0) 98.8 (5.3) 86 n.s. - 
LDL-C  (mg/dl) 109.1 (17.3) 97.4 (21.6) 116.6 (27.1) 109 n.s. - 
HDL-C (PTA)  
(mg/dl) 51 (11.4) 110.1 (19.8) 86.9 (19.9) 152 * 1/2, 1/3, 2/3 
TG  (mg/dl) 121.2 (35) 71.5 (32.3) 99.5 (23.7) 57 * 1/2 
Alcohol >1/day (n) 4 4 2 0    n.s.** - 
VLDL-C (mg/dl) 26.9 (8.8) 19 (6.2) 23.1 (9.2) 13 n.s. - 
Lp(a) (mg/dl) 22.3 (18.8) 19 (22.7) 15.9 (21.2) 17 n.s. - 
apoA-I (mg/dl) 172.2 (33.3) 241.7 (41.2) 229.6 (36.1) 327 * 1/2, 1/3 
apoA-II (mg/dl) 40.5 (7) 49.5 (11.5) 46.6 (5.5) 45 n.s. - 
apoB (mg/dl) 99.7 (13.4) 82.8 (17.1) 95.9 (18.2) 92 n.s. - 
 apoC-II (mg/dl) 4.32 (1.55) 6.09 (2.69) 4.49 (2.17) 5.3 n.s. - 
apoC-III (mg/dl) 11.4 (4.3) 15.5 (6.9) 13.7 (2.7) 16.1 n.s. - 
apoE (mg/dl) 4.52 (0.89) 6.03 (1.86) 4.94 (1.12) 6.4 * 1/2 
 
Table 2.3: Characteristics of SCARB1 P376L carriers and controls recruited for 
deep phenotyping. Demographic, plasma lipid and apolipoprotein traits measured from 
1 P376L homozygote, 8 heterozygotes, and noncarrier controls from subjects identified 
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from sequencing or genotyping of the Penn HHDL Study cohort for deep phenotyping. 
Lipid measurements were performed using an autoanalzyer from plasma.  
1Where applicable, data is presented as mean values ± S.D.  
2Numbers correspond to groups for comparison. Group 1 – Normal HDL-C controls, 
Group 2 – High HDL-C controls, Group 3 – SCARB1 P376L heterozygotes 
Contributions: Data measurements performed by core laboratory and analyzed by SAK 
and Paolo Zanoni. 
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Table 2.4 
Table 2.4: Meta-analysis of Association of SCARB1 P376L Variant with CHD 
Consortium Study Cohort Case P376L Carriers 
Control 
P376L 
Carriers 
Total 
CHD 
Cases 
Total 
Controls 
Frequency 
of Cases 
Frequency 
of 
Controls 
MICAD 
Exome 
Consortium 
BioVU 6 10 4587 16546 0.0013 0.0006 
BHF 1 0 2833 5912 0.0004 0 
GoDARTS-CAD 1 0 1568 2772 0.0006 0 
MHI 0 4 2483 8085 0 0.0005 
North German 0 1 4464 2886 0 0.0004 
Ottawa 0 1 1024 2267 0 0.0004 
PAS 1 1 728 808 0.0014 0.0012 
Penn 3 0 683 156 0.0044 0 
South German 4 0 5255 2921 0.0008 0 
WHI-EA 8 29 2860 14929 0.0028 0.0019 
CHD Exome+ 
Consortium 
CCHS 1 1 2020 6087 0.0003 0.0001 
CIHDS/CGPS 4 3 8079 10367 0.0003 0.0001 
EPIC-CVD 4 2 9810 10970 0.0002 0.0001 
MORGAM 0 0 2153 2118 0 0 
PROSPER 1 0 640 638 0.0008 0 
WOSCOPS 0 0 659 687 0 0 
Total 34 52 49846 88149 0.00068 0.00059 
Meta-analysis Summary 
OR 1.79 
P-value 0.018 
 
Table 2.4: Meta-analysis of association of SCARB1 P376L variant with CHD. CHD 
cases and healthy controls across the MICAD Exome Consortium and CHD Exome+ 
Consortium were genotyped for the SCARB1 P376L variant using the Exome Array. The 
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association of the P376L variant with CHD cases was determined using a Mantel-
Haenszel fixed-effects meta-analysis. Contributions: Genotyping data generated and 
QCed by Nathan Stitziel, Sekar Kathiresan, John Danesh, CHD Exome+ Consortium 
members and CARDIoGRAM Exome Consortium members; analysis performed by SAK 
and Nathan Stitziel. 
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CHAPTER 3 – LOSS-OF-FUNCTION OF GALNT2 LOWERS HIGH-DENSITY 
LIPOPROTEINS IN HUMANS, NONHUMAN PRIMATES, AND RODENTS 
 
Introduction 
Single nucleotide polymorphisms (SNPs) in the first intron of GALNT2 were 
among the first common variants associated with high-density lipoprotein cholesterol 
(HDL-C) and triglycerides (TG) through genome-wide association studies (GWAS) for 
plasma lipids [131,132,137]. We previously showed that Galnt2 overexpression reduced 
and knockdown increased HDL-C in mice, offering further support that GALNT2 was 
indeed the causal gene at the locus for this trait [86]. GALNT2 encodes the enzyme 
UDP-N-Acetyl-D-galactosamine:polypeptide N-Acetylgalactosaminyl-transferase 2 
(GalNAc-T2), which initiates O-glycosylation of proteins through addition of GalNAc to 
specific serine or threonine residues [278,279]. The biological functions of GalNAc-
glycosylation are not fully understood but include regulation of protein processing by 
proprotein convertases [280], protein multimerization [281] and ectodomain shedding 
[282].  Among the proposed targets of GalNAc-T2 that may affect lipoprotein metabolism 
are angiopoietin-like 3 (ANGPTL3) [186] and apolipoprotein C-III (ApoC-III) [184,185], 
both liver-secreted regulators of TG and HDL-C. 
Despite the early association of this locus with plasma lipids from GWAS, the 
mechanisms underlying how GALNT2 regulates lipids have remained unknown and the 
directional relationship between GALNT2 expression and HDL-C has been controversial. 
Our Galnt2 overexpression and knockdown work suggested that GALNT2 is a negative 
regulator of HDL-C levels since overexpression reduced and knockdown increased HDL-
C in mice [86]. This directional relationship was supported by another study identifying 
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heterozygous carriers of a putative loss-of-function (LOF) coding variant in GALNT2, 
p.Asp314Ala (D314A) [184]. Contrasting these two studies, a recent evaluation of the 
GWAS SNPs in GALNT2 showed that alleles associated with increased HDL-C 
correlated with increased hepatic GALNT2 expression [183]. Given these discordant 
findings, here we investigated the mechanisms and directionality relating GALNT2 to 
plasma lipids across humans and mammalian models of GALNT2 loss-of-function.  
 
Materials and Methods 
Linkage analysis and whole exome sequencing  
Identification of the p.Gln289* variant: Genomic DNA was extracted from EDTA blood 
probes by standard methods and genotyped with the Affymetrix Mapping array 6.0 
(Affymetrix, Santa Clara, CA, USA). Analysis did not reveal pathogenic deletions or 
duplications. Mendelian segregation was calculated using PedCheck software and was 
confirmed in all instances. DNA from individual II:2 was enriched using the SureSelect 
Human All Exon Kit, which targets approximately 50 Mb of human genome (Agilent, 
Santa Clara, Ca, USA) and paired-end sequenced on a SOLiD 5500 xl instrument (Life 
Sciences, Carlsbad, CA, U.S.A.). Image analysis and base calling was performed using 
the SOLiD instrument control software with default parameters. Read alignment was 
performed with LifeScope 2.5 using the default parameters with human genome 
assembly hg19 (GRCh37) as reference. Single-nucleotide variants and small insertions 
and deletions (indels) were detected using LifeScope, GATK 2 and samtools/bcftools 
[283,284]. Variant annotation was performed using Annovar, integrating data from a 
variety of public databases [285,286]. Additionally, variants were compared to an in-
house database containing more than 750 sequenced exomes to identify further 
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common variants which are not present in public databases. Finally, the variants were 
validated by PCR and Sanger sequencing according to the standard protocols to 
exclude technical artifacts and to test for segregation. 
Identification of the p.Phe104Ser variant: DNA was extracted from blood samples 
(subjects I.1, I.2, II.1, II.2, II.3, II.4 and II.5 for family II) using a standard protocol. A 
genome-widescreen was performed with microarrays using the Illumina 6K panel at the 
P3S platform (Pitié-Salpêtrière Hospital, France). By haplotype reconstruction, a 
homozygosity region was identified for subject II.2 and II.5 in the 1q41-q42 chromosomal 
region. 
 Exons from 3 µg of genomic DNA from patient II.2 (Family II) were captured using 
the SureSelect kit following the manufacturer’s protocols (Agilent). The whole-exome 
DNA library was sequenced on the Hiseq2000 Illumina Genome Analyzer (Illumina). 
Sequence reads were mapped to the reference human genome using whole genomic 
sequence, refgene.txt file and reflink.txt (UCSC hg19) using the BWA v0.5.9 algorithm 
(http://samtools.sourceforge.net).Variant detection was performed with the SAMTools 
v0.1.17 software (http://samtools.sourceforge.net)and filtered variants were annotated 
according to snp132.txt.  
 
Measurements of plasma ApoC-III and plasma lipids from human subjects 
Human plasma, either crude plasma (1 μl) or C18 microtip purified as previously 
described [185], was separated on an 18% Tris-Glycine protein gel (Novex) for 90 min at 
150 Volts on ice. Subsequently separated proteins were blotted onto a nitrocellulose 
membrane for 2 hours at 100 Volts and non-specific binding was blocked by incubating 
the membrane in 5% fat-free milk in TBS-T. The membranes were incubated overnight 
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with polyclonal rabbit anti-human ApoC-III (abcam ab21032) and subsequently in 
polyclonal swine anti-rabbit IgG-HRP (Dako) 1:4000 in TBS-T for 1 hour at RT. Protein 
bands were visualized by enhanced chemiluminescence (ECL) using a pierce ECL 
Western Blotting substrate (Thermo Scientific, Denmark) and a LAS 4000 (General 
Electric, US). 
Total plasma cholesterol, LDL-C, and HDL-C were measured by Cobas® 
Modular analyzer series in samples from proband 1 (p.Gln289* homozygote) and age- 
and sex-matched noncarriers and with plasma from proband 2 (p.Phe104Ser 
homozygote) and relatives.  
 
Recombinant GalNAc-T2 p.Phe104Ser activity assay  
Recombinant soluble GalNAc-T2 WT and the p.Phe104Ser variant was expressed and 
purified using NiNTA agarose beads as previously described [287]. 
 
Galnt2 -/- rat 
Galnt2-/- rats were created at SAGE labs [288] operating under approved animal 
protocols. Zinc-finger nuclease (ZFN) targeting constructs for Galnt2 were designed with 
the following binding site: AACAAGTTCAACCAGGTGgagagtGACAAGCTACGCA. 
Sprague Dawley rats were used for microinjection and breeding and were housed in 
standard IVC (Individually Ventilated Cages) and racks and maintained under a 12-hour 
light/dark cycle with ad libitum access to food and water. ZFN technology was used to 
generate a 7 bp deletion in GalNAc-T2 exon 3 that resulted in a frame shift and a stop 
codon within the coding region of exon 3 disrupting a region in the Galnt2 gene 
corresponding to its catalytic domain. Genotyping was accomplished with forward 
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primers 5′-GCGACACTCTCTGGTCTCCT -3′ together with reverse primer 5′-
AAGTACAAGGCCCATGCAAC-3′. WT rat DNA produces a 374 bp band, whereas a 
Galnt2 knockout allele generates 161+213 bp bands. Briefly, Galnt2 ZFNs were injected 
into fertilized single-cell embryos from Sprague Dawley rats. Upon confirmation of 
successful disruption of Galnt2, embryos were implanted to mother rats that generated 
progeny that were intercrossed to yield homozygous KOs. Galnt2-/- rats demonstrated 
reduced fertility but were otherwise viable.  
 
Plasma lipids in Galnt2 KO rat 
Rats were fasted for 12-16 hours and anaesthetized using isoflurane before blood was 
drawn from the retro-orbital plexus. Cholesterol and triglyceride was measured by 
enzymatic methods in total plasma samples, fractions with d<1.063 g/l and fractions with 
d>1.063 g/l isolated by fixed-density ultracentrifugation using Beckman Optima MAX-E 
ultracentrifuge (Beckman Coulter) (100.000 rpm and 10°C for 4 hours).   
 
RNA-Seq from rat liver 
Total RNA was extracted from rat WT and Galnt2 KO livers (N=3 per group) using 
RNeasy® kit (Qiagen). RNA integrity and quality was determined using Bioanalyzer 
instrumentation (Agilent Technologies). RNA sequencing was performed by the Beijing 
Genetics Institute (BGI). Briefly, libraries were constructed using the Illumina Truseq 
RNA Sample Preparation Kit. High quality total RNA was DNase I treated, mRNA 
isolated by magnetic bead Oligo (dT) enrichment, followed by mRNA fragmentation, 
cDNA synthesis, single nucleotide A (adenine) addition, and adapter ligation. Agarose 
gel purified fragments (~160 bp) were subjected to PCR amplification and quality control 
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(QC) before and subjected to next generation sequencing using Illumina HiSeq 2000 
System (Illumina, USA). Total reads per sample were around 60 million with an average 
of 75% total mapped reads and an averaged 50% perfect match reads. Gene coverage 
ranged from 90-100% for 60% and 0-10% for 8%.  
Bioinformatics analysis of whole exome sequencing reads were analyzed by 
alignment to the rat (Rattus norvegicus) reference genome (RGSC 5.0/rn5) using the 
CLC Genomic Workbench (Qiagen, Aarhus, Denmark). RPKM values were used for 
gene expression detection and mutant identification was done by aligning reads for 
Galnt2 exon2.   
 
GALNT2-/- mice (Complete Galnt2 KO mice) 
The Galnt2 null allele harbors a deletion of exons 4-6, which contains the region 
essential for catalytic activity. Heterozygous Galnt2 mice on a C57Bl/6 background were 
obtained from Merck Research Laboratories and intercrossed to generate Galnt2-/- mice. 
All KO mice described herein were derived from heterozygous crosses, as both male 
and female KO mice exhibited impaired fertility and were unable to produce viable 
progeny. WT, heterozygous, and KO mice were distinguished by PCR-based genotyping 
of tail DNA, using two independent reactions. The first reaction utilizes primers that flank 
exons 4-6 of mouse GALNT2 (F: 5’-GTACGTGAGACAGGCCTAAGG-3’ R: 5’-
CAAGCTTCATTTAGGACCAAGC-3’), amplifying a 2000 bp band in WT mice, a 334 bp 
band in KO mice, and both bands in heterozygous mice. PCR cycling parameters were 
as follows: 1 cycle of 95°C for 30 seconds; 35 cycles of 95°C for 30 seconds, 60°C for 
30 seconds, 72°C for 2.5 min; and 1 cycle of 72°C for 10 min. The second reaction 
utilizes primers that flank either side of the 5’ deletion site upstream of exon 4 (F: 5’-
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AAGAGTCCACGTGAGTTCTGC-3’ R: 5’-GGCTCTCACAGTATCAAAGG-3’), amplifying 
a 341 bp band in WT and heterozygous mice, and no band in KO mice due to loss of the 
reverse primer annealing site. PCR cycling conditions were identical to those described 
above except for an abbreviated extension time of 1 minute. Mice were subject to 
alternating 12-hour cycles of light and dark and given access to standard chow diet ad 
libitum unless otherwise indicated. Mice selected for experiments were age and gender-
matched littermates, and genotypes were intermixed in cages to avoid undue cage 
effects.  
 
Galnt2fl/fl mice 
The Galnt2 conditional allele harbors loxP sites flanking exons 4-6. Galnt2fl/+ mice were 
obtained from Merck Research Laboratories and intercrossed to generate Galnt2fl/fl mice, 
which were further intercrossed with one another. Conditional KO mice did not display 
any defects in fertility or viability. Mice were distinguished by PCR genotyping using 
primers that flank the 5’ loxP site upstream of exon 4 (same as second primer set 
described above), which amplify a 341 bp band in Galnt2+/+ mice, a 502 bp band in 
Galnt2fl/fl mice, and both bands in Galnt2fl/+ mice.  
Adeno-associated virus serotype 8 (AAV8) vector encoding Cre recombinase 
under control of the liver-specific thyroxine-binding globulin (TBG) promoter was used to 
achieve post-natal deletion of hepatic Galnt2 in Galnt2fl/fl mice. Empty AAV8 particles 
(Null) served as a control. Viruses were provided by the University of Pennsylvania 
Vector Core. 10-12 week old gender-matched Galnt2fl/fl littermates were fasted for 4 
hours, pre-bled from the retro-orbital plexus, and intraperitoneally injected with 5 x 1011 
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viral genomes/mouse. Bleeds were performed at 2, 4, 6 and 8 weeks post-injection for 
lipid analysis. Experimental groups were intermixed in cages to avoid cage effects.  
 
Plasma lipid measurements in mice 
Mice were fasted for 4 hours and anesthetized by isoflurane inhalation prior to retro-
orbital bleed. Plasma was separated from whole blood by centrifugation at 10,000 rpm 
for 7 min at 4°C. Plasma levels of TC, HDL-C, TG, and alanine aminotransferase (ALT) 
were determined using a Cobas Mira autoanalyzer (Roche Diagnostic Systems) and 
Wako Chemicals reagents.  
 
RNA isolation and real-time PCR analysis 
Liver pieces (~50 mg) were homogenized in 1 mL Trizol reagent (Invitrogen) using a 
TissueLyser bead mill (Qiagen). Total RNA was isolated according to the manufacturer’s 
instructions. RNA samples were subjected to DNase digestion using the DNA-free kit 
(Ambion) to remove residual genomic DNA contamination. 1 μg of DNase-treated RNA 
was reverse transcribed using the High Capacity cDNA Reverse Transcription kit 
(Applied Biosystems) according to the manufacturer’s instructions. TaqMan gene 
expression assays (Applied Biosystems) were used to detect mouse Galnt2 
(Mm00519804_g1) and Actb (4352341E). Reactions contained 0.5 μL 20x assay mix, 5 
μL 2x TaqMan reaction mix, and 4.5 μL cDNA (diluted 2:13) and were performed in 
duplicate. Quantitative RT-PCR was performed on an Applied Biosystems 7900HT real-
time PCR system. Relative expression differences were calculated by the delta delta Ct 
method using β-actin as the housekeeping gene.  
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Postprandial TG clearance studies 
Mice were fasted overnight and administered 15 μL olive oil (Sigma) per gram body 
weight by oral gavage. Retro-orbital bleeds were taken immediately prior to gavage and 
at 3, 5 and 7 hours post-gavage. Plasma samples at each time point were individually 
assayed for TG content on 96-well microtiter plates using the Infinity TG kit.  
 
Radiolabeled HDL clearance studies 
Human HDL (d = 1.063–1.21 g/ml) was isolated by conventional ultracentrifugation 
methods and dual-labeled with 125I-tyramine-cellobiose (TCB), which labels primarily 
apoA-I, and 3H-cholesteryl ether, a tracer of the cholesteryl ester core of HDL, as 
previously described [239]. Tyramine cellobiose (TCB) was prepared and provided by 
William Cain, University of Delaware. Both tracers are non-hydrolyzable allowing tissue 
uptake to be accurately assessed. After injection, blood samples were obtained by retro-
orbital bleeding at 2 min and at 1, 3, 6, 9, and 24 hr. At the 24 hr timepoint, fasted 
animals were sacrificed, the vascular system was flushed with 15 ml ice-cold PBS, the 
liver, spleen, adrenals, and kidneys were harvested and radioactivity counted. The 
fractional catabolic rate (FCR) of apoA-I and HDL-cholesteryl ester was determined by 
fitting the corresponding tracer data to a single pool model containing an extravascular 
exchange using data normalized to the 2 min time point. Selective uptake was calculated 
as the difference between the HDL-cholesteryl ester and apoA-I FCRs.  
 
Cynomolgus monkeys 
Potent and efficacious GALNT2 targeting siRNAs were identified following an in vitro 
screen of 20 different siRNA sequences conducted in a cyno hepatocyte cell line. The 
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best GALNT2 siRNA (Sense (5'-3'): GCGUGGUGAUCACGUUUCAUU; Antisense (5'-3'): 
UGAAACGUGAUCACCACGCUG) and the luciferase siRNA (Sense (5’-3’): 
UAAGGCUAUGAAGAGAUACUU; Antisense (5’-3’): GUAUCUCUUCAUAGCCCUAUU) 
were chemically modified for stability, after which they were formulated in lipid 
nanoparticles (Tekmira Pharmaceuticals,Vancouver, CA) for specific delivery to the liver. 
A mixed cohort of male and female cynomolgus monkeys (Macaca fascicularis) 
with body weights between 4-6 kg were obtained from the Bioculture Group (Mauritius) 
and pair-housed. Animals were acclimated to a feeding schedule of standard primate 
chow (Harlan Teklad Global 2050, Frederick, MD) and transferred to single housing in 
standard non-human primate cages one week prior to the start of the study. Water was 
provided ad libitum.  
For the studies described here, plasma HDL-C and TG levels were measured 
several days prior to the start of the study and these lipid measurements were used to 
randomize the cynos into 3 treatment groups: saline (N=4), anti-luciferase siRNA (2.5 
mg/kg, N=4), or anti-GALNT2 siRNA (2.5 mg/kg, N=4). Injection of siRNAs were done as 
a single administration following which liver biopsies were taken on Days 3, 14, and 28 
post-injection to assess GALNT2 knockdown. Blood was also collected for plasma 
measurements on Days 0 (immediately preceding administration of siRNA), 3, 7, 14, 21 
and 28 of dosing. All cynos were fasted daily from 3:45 pm to 8:30 am for the duration of 
the experiment.  
 
Plasma lipid measurements in cynomolgus monkeys 
Plasma lipids were determined using a OLYMPUS AU2700 chemistry analyzer 
(Olympus CO Ltd., Tokyo, Japan) and kits for total cholesterol, 2nd generation direct 
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LDL-C, 3rd generation direct HDL-C, and triglycerides from Roche Diagnostics 
(Indianapolis, IN). 
 
Hepatic gene expression in cynomolgus monkeys 
For quantitative RT-PCR, cyno liver biopsy samples (2.5 mg) were stabilized in RNAlater 
(Qiagen) prior to RNA isolation. Tissues were homogenized in Trizol reagent (Invitrogen) 
using a TissueLyser bead mill (Qiagen) and Total RNA was purified using the QIAGEN 
RNeasy Mini Kit according to the manufacturer’s protocol. Purified RNA samples were 
normalized and converted to cDNA according to the manufacturer’s protocol using the 
High-Capacity cDNA Archive Kit (Life Technologies). Real-time PCR was conducted on 
the Applied Biosystems 7900HT instrument. TaqMan gene expression assays (Life 
Technologies) were used to detect GALNT2 (Hs00954065_m1) and 18S ribosomal RNA 
expression (Hs99999901_s1).  Standard curves for GALNT2 and 18s rRNA were 
generated by serially diluting cDNA from the saline treated animals. All measurements 
were performed in duplicate and expression levels were averaged within treatment 
groups.  
 
Glycoproteomics sample preparation 
For liver O-glycoproteomes, WT and Galnt2 KO rats and mice animals were sacrificed 
and livers were perfused and dissected free. 100 mg rat or mouse liver (N=3 per group, 
pooled together by group) tissue was cut into small pieces using a scalpel and further 
homogenized in 5x volumes of 1% Rapigest in 50 mMAmBic using an Ultra-turrax 
blender keeping the sample on ice. Tissue homogenate suspension was sonicated at 
50-60% Amplitude 3 times for 10 seconds and non-solubilised tissue debris was pelleted 
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at 10,000g for 15 min at 4°C. Solubilized liver proteins were heated at 80 °C for 5 min to 
further activate the RapiGest.  
For plasma O-glycoproteomes from rat and mouse samples, 200 μL EDTA 
plasma was collected from WT or Galnt2 KO rats (N=3 per group, pooled together by 
group), diluted in Acetate buffer treated with 0.1 U/mL Neruramindase (Sigma) for 1 hour 
at 37 °C. The neuraminidase treated plasma was diluted by 20x in PNA binding buffer 
and passed over a 0.8 mL PNA-agarose column. After binding and washing PNA bound 
proteins are eluted using 0.1% Rapigest in 50 mMAmBic and heat. 
Both solubilized liver proteins and plasma glycoprotein-enriched samples were 
reduced (5 mM DTT, 60°C for 45 min) and alkylated (10 mM IAA, RT in the dark for 30 
min) and proteins digested using trypsin (1:100) (Roche) in 50 mMAmBic at 37°C, 
shaking overnight. Prior to purification using SepPak C18 columns, samples were 
acidified and precipitated andRapigest was removed by centrifugation. Eluted peptides 
were treated with neuraminidase 0.1U/mL in Acetate buffer pH 5.0 for 1 hr 37 C to 
remove sialic acid. Quantitative glycoproteomics. Tryptic digests of isogenic pairs of WT 
and KO rat or mouse liver or plasma were labeled with light (L) and medium (M) 
isotopomeric dimethyl labels. Briefly, cleared neuraminidase treated acidified digests 
were loaded in equal amounts (peptide concentration) onto equilibrated SepPak C18 
cartridges (Waters) followed by 3 x CV 0.1% trifluoroacetic acid wash. Digests were 
labeled on-column by adding 5 CV 30 mM NaBH3CN and 0.2% formaldehyde in 50 mM 
sodium phosphate buffer pH 7.5 (L-labelling) or 30 mM NaBH3CN and 0.2% D-
formaldehyde in 50 mM sodium phosphate buffer pH 7.5 (M-labeling). Columns were 
washed using 3 CV 0.1% formic acid and eluted with 0.5 mL 50% MeOH in 0.1% formic 
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acid. Labeled Galb1-3GalNAc glycopeptides were separated from non-glycosylated 
peptides using a long PNA-agarose LWAC as previously described [289]. 
Human plasma O-glycoproteomes were essentially generated as described 
above for rat and mouse samples, except for the human plasma, the labeling step was 
omitted. 500 μL plasma from proband #1 and 500 μL from an age- and sex-matched 
control pool of 8 subjects were prepared as described above and run in two separate 
LWAC steps. 
 
Isoelectric focusing 
Lectin weak affinity chromatography fractions from total cell lysate digests were 
screened by preliminary liquid chromatography-mass spectrometry (LC-MS) for 
glycopeptide content, and fractions most enriched in glycopeptides were pooled 
together, dried by vacuum centrifugation, reconstituted in IPG rehydration buffer, and 
submitted to IEF fractionation [290]. Isoelectric focusing was performed by a 3100 
OFFGEL fractionator (Agilent) using pH 3-10 strips (GE Healthcare) 12 fractions were 
collected and desalted by custom Stage Tips (C18 sorbent from Empore 3 M) and 
submitted to LC-MS and higher energy collisional dissociation/electron transfer 
dissociation tandem MS (HCD/ETD-MS/MS) as described below. 
 
Mass spectrometry 
EASY-nLC 1000 UHPLC (Thermo Scientific) interfaced via nanoSpray Flex ion source to 
an LTQ-Orbitrap Velos Pro mass spectrometer (Thermo Scientific) was used for 
glycopeptide analysis. Briefly, a precursor MS1 scan (m/z 350–1,700) of intact mixture 
was acquired in the Orbitrap at a nominal resolution setting of 30,000, followed by 
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Orbitrap HCD-MS2 and ETD-MS2 (m/z of 100–2,000) of the five most abundant multiply 
charged precursors in the MS1 spectrum; a minimum MS1 signal threshold of 50,000 
was used for triggering data-dependent fragmentation events; MS2 spectra were 
acquired at a resolution of 7,500 for HCD MS2 and 15,000 for ETD MS2. Activation 
times were 30 and 200 ms for HCD and ETD fragmentation, respectively. 
 
Data analysis 
Data processing was performed using Proteome Discoverer 1.4 software (Thermo 
Scientific). All spectra were searched with Sequest HT node applying sequentially full 
and semi-specific enzymatic cleavage. In all cases the precursor mass tolerance was set 
to 6 ppm and fragment ion mass tolerance to 50 mmu. Carbamidomethylation on 
cysteine residues was used as a fixed modification. Methionine oxidation and HexNAc 
attachment to serine, threonine and tyrosine were used as variable modifications for 
ETD MS2. All HCD MS2 were pre-processed as described [291] and searched under the 
same conditions mentioned above using only methionine oxidation as variable 
modification. All spectra were searched against a concatenated forward/reverse human-
specific database (UniProt, January 2013, containing 20,232 canonical entries and 
another 251 common contaminants) using a target false discovery rate (FDR) of 1 %. 
FDR was calculated using target decoy PSM validator node, a part of the Proteome 
Discoverer workflow. The resulting list was filtered to include only peptides with 
glycosylation as a modification. This resulted in a final glycoprotein list identified by at 
least one unique glycopeptide. ETD MS2 data were used for unambiguous site 
assignment. HCD MS2 data were used for unambiguous site assignment only if the 
number of GalNAc residues was equal to the number of potential sites on the peptide. 
	102 
 
Glycopeptide M/L ratios were determined using dimethyl 2plex method. The M/L ratio of 
the detected precursor ions doublet was calculated using sequentially the Event 
Detector Node and the Precursor Ion Node followed by manual validation of the 
precursor ions without reported quantitative values (singlets) within a selected pool as it 
is described previously [291].  
 
In vitro glycosylation assays of PLTP peptides 
Human, rat and mouse C-terminal PLTP peptides were designed and synthesized 
(NeoBioScience). GalNAc-transferase assays using soluble GalNAc transferases 
purified after recombinant expressed and monitored by MALDI-TOF mass spectrometry, 
were performed as previously described (Schjoldager et al., 2010; [185]. 
 
PLTP activity measurement 
PLTP activity measurements from rat plasma samples were performed using the Roar 
assay (Roar Biochemical, Inc). Fluorescent substrate measurements were completed 
using the Biotek Synergy 2 plate reader (BioTek). PLTP activity assays from mouse and 
human plasma samples were performed using a 3H-phosphatidylcholine (PC) substrate 
as previously described [292,293] and measured the transfer of 3H-PC to total human 
HDL over 2 hours at 37 °C. Assays were performed in triplicate and average values for 
each technical replicate were plotted.  
 
Immunoblotting 
All plasma samples subjected to SDS-PAGE for immunoblotting were measured using 
NuPAGE reagents for 1-dimensional SDS-PAGE (Life Technologies). ApoC-III 
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immunoblots from plasma samples were performed by separating 1 μl of plasma on 10% 
Bis-Tris NuPAGE gels using MES buffer, followed by transferring separated proteins to 
nitrocellulose membranes, blocking membranes for 2 hrs at room temperature with 5% 
fat-free milk in PBS (0.05% tween 20). Membranes were then incubated for 2 hrs at 
room temperature with a rabbit polyclonal antibody against murine apoC-III (sc-50378, 
Santa Cruz) at a dilution of 1:2000, followed by 3 x 15 min. washes with PBS / Tween 
solution and incubation with goat anti-rabbit IgG HRP conjugate (sc-2030, Santa Cruz) 
for 30 min. at room temperature. Membranes were again washed for 3 x 15 min. and 
proteins visualized by Luminata Crescendo chemiluminescent reagent (Millipore). PLTP 
immunoblots from plasma were performed in the same manner, but SDS-PAGE was 
completed using 4-12% Bis-Tris gels and MOPs running buffer. The primary antibody 
used for PLTP immunoblots was ab85562 (abcam), which was used at a dilution of 
1:2000 for 2 hrs at room temperature and subsequently goat anti-rabbit IgG HRP (Santa 
Cruz) was used as a secondary antibody.  
 
Lipase activity assays 
Phospholipase activity from plasma samples was assessed by measuring activity from 
post-heparin plasma against an emulsion of thioPEG substrate (Avanti) and 
chromogenic agent 5, 5’-dithiobis (2-nitrobenzoic acid) (DTNB) (Sigma). 20 μl of 1:8 
diluted post-heparin plasma is used as the enzyme source and the release of the 
chromogenic reagent is measured by a kinetic assay at 37 °C for 30 min. The data is 
calculated as the rate of appearance of the chromogenic byproduct of the DTNB-
ThioPEG emulsion over time. All assays were performed in triplicate.  
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Statistics for results of animal studies. Data represent mean ± standard deviation. 
Statistical analysis was performed by two-tailed unpaired Student’s t-test or one-way 
ANOVA with Tukey’s post-test as appropriate. Statistical significance was defined as P < 
0.05. 
 
RNA sequencing of human liver samples and allelic imbalance analysis 
Allele-specific expression (ASE) analysis used data from two cohorts: 40 human liver 
samples processed at the University of Pennsylvania (UPenn data) and 32 human liver 
samples processed as a part of the Genotype Tissue Expression (GTEx) consortium 
(release v4; GTEx data) [150]. UPenn data was genotyped on the Illumina human 610 
quad beadchips (GPL8887) at the Northwestern University Center for Genetic Medicine 
Genomics Core Facility according to the manufacturer’s protocols [294]. One sample 
was removed due to call rate <10%. Of the total 620,901 markers, 583,073 SNPs were 
used for analysis after stringent quality control including Fisher’s exact tests for 
significant deviation from Hardy-Weinberg equilibrium at P<1×10-3 (8,300 SNPs) and 
genotyping rate>0.9 (29,705 SNPs). GTEx data was genotyped on the Illumina Human 
Omni 5.0 Quad and Infinium ExomeChip at the Broad Institute. Detailed information on 
genotype quality control was recently described [150]. Briefly, using the software PLINK 
[295], the following quality control measures were applied: i) removal of SNPs mapping 
to more than one genomic location; ii) SNPs with <0.9 genotyping rate; iii) samples with 
call rate <0.95; iv) samples with inconsistent sex information; v) samples with excess 
heterozygosity or cryptic relatedness; vi) HWE P<1×10-6; vii) SNPs with predicted 
missingness P<1×10-8; viii) testing for batch effects P<1×10-3, and ix) SNPs with 
genotyping rate <0.95.  
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Phasing and imputation were performed using SHAPEIT (v2.r790) [296] and 
IMPUTE2 (v2.3.1) [297]. SNPs were aligned to the 1000 Genomes Project Phase I 
freeze haplotypes by chromosomal position (GRCh37/hg19) and imputed using these 
references(https://mathgen.stats.ox.ac.uk/impute/data_download_1000G_phase1_integr
ated_SHAPEIT2_16-06-14.html). SHAPEIT was run for each chromosome, with default 
parameters. IMPUTE2 was run on non-overlapping 5Mb fragments, with an estimated 
effective population size of 20,000. Phased and imputed genotypes were further filtered 
for best-guessed genotypes at posterior probability >0.9 and HWE<1×10-6. 
Total RNA was extracted from each liver biopsy by homogenization in TRIzol, 
followed by RNAeasy clean up (Qiagen). RNA quality was assessed by Agilent 
Bioanalyzer (minimum RIN = 7). Sequencing libraries were constructed using Illumina’s 
TruSeq stranded mRNA library prep kit. Sequencing was performed using HiSeq2500 at 
the University of Pennsylvania Next Generation Sequencing Core.  All libraries were 
multiplexed into one large pool and sequenced across multiple lanes. RNA sequencing 
reads were aligned to the human genome (GRCh37/hg19) using STAR (v2.3.1z4) [298], 
using the following options: --outSAMattributes Standard  --outFilterMultimapNmax 10   -
-outFilterMismatchNmax 10   --outFilterMismatchNoverLmax 0.3   --alignIntronMin 21   --
alignIntronMax 0   --alignMatesGapMax 0   --alignSJoverhangMin 5   --
alignSJDBoverhangMin 3 --runThreadN 12  --readFilesCommand zcat --. Reads with 
alignment quality scores less than 10 were removed using SAMtools [284]. Coding 
SNPs were identified from the imputed genotypes and reference mapping bias was 
controlled using WASP (http://dx.doi.org/10.1101/011221).  
Reads derived from PCR duplication during library preparation were identified by 
identifying read pairs with identical start and end alignment coordinates; one read pair 
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was randomly retained. Reads overlapping each coding SNP were extracted from each 
BAM file.  Only properly paired reads mapping to the correct strand were retained. 
Overlapping read pairs were only counted once. Heterozygous coding SNPs were 
retained for analysis if the genotype probabilities estimated by IMPUTE2 were > 0.9. We 
then extracted allele-specific read depth at each coding SNP, assigning reads to either 
the ‘A’ or ‘G’ allele of rs4846914 using the phased haplotypes from each individual.  
Imputed, coding SNPs with more than 90% of their RNAseq reads mapping to any 
particular allele were filtered out, under the assumption that the genotype was 
improperly imputed (i.e., the SNP is homozygous).  Allele-specific read depths were 
summed across all coding SNPs in the gene.  Only individuals with more than 30 reads 
meeting these criteria were included in downstream analyses. 
Within each individual, we tested for deviation from the null hypothesis that both alleles 
are expressed at equal levels using a simple binomial test. To combine information 
across individuals (i), we modeled the probability each read is derived from allele A (pi), 
by logistic regression: 
 
Where Xi indicates if the individual i is heterozygous (X=1) or homozygous (X=0) 
at rs4846914. The model was run using the R glm function. To assess the significance 
of the effect of genotype, we computed a Z-score and, from that, a two tailed p-value by 
comparison to the normal distribution.  
 
 
 
ln( pi1− pi
) = β0 +β1Xi
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Rare variant association studies from exome sequencing 
A linear regression was performed separately for each variant with HDL-C after adjusting 
for age, sex, MI status, cohort, and first 4 principal components of ancestry as 
covariates, as was described previously [299]. 
 
Study approval 
All animal protocols for rat studies were approved by the SAGE laboratories at 
Institutional Animal Care and Use Committee (IACUC). Mouse studies were approved by 
the University of Pennsylvania Institutional Animal Care and Use Committee (IACUC). 
Studies in cyno were performed according to American Association for Accreditation of 
Laboratory Animal Care guidelines and protocols were approved by the Bristol-Myers 
Squibb Animal Care and Use Committee. The study of the family of variant 2 was 
approved by the Ethic Committees of the Universities of Bonn and of Erlangen-Nürnberg 
in Germany. Informed consent of all examined persons or of their guardians was 
obtained. 
 
Results  
Humans homozygous for LOF mutations in GALNT2 have low HDL-C 
Through exome sequencing and mapping in two independent studies, we 
identified two unrelated individuals homozygous for different mutations in GALNT2. First, 
using linkage analysis and whole exome sequencing in families in search of causes of 
heritable neurological traits, we identified a female of Moroccan origin homozygous for a 
T>C mutation at position Chr1:230338973 in exon 3 of GALNT2, resulting in a 
p.Phe104Ser mutation (Figure 3.1 A-C). This mutation was absent from the 1000 
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Genomes, NCBI dbSNP, NHLBI Exome Sequencing Project, and Exome Aggregation 
Consortium (ExAC) variant databases and was predicted deleterious by Align GVGD, 
SIFT, Polyphen2, MutationTaster and SNP&GO software. We tested recombinant 
secreted GalNAc-T2 with the p.Phe104Ser variant (mutant) or no variant (WT) for their 
ability to glycosylate peptide substrates corresponding to two targets of GalNAc-T2, 
ApoC-III and immunoglobulin A1 (IgA1). While the WT GalNAc-T2 was highly active with 
both substrates, the p.Phe104Ser GalNAc-T2 mutant was completely inactive with 
ApoC-III and almost inactive with the IgA1 substrate.  
Another exome sequencing study for recessive heritable causes of intellectual 
disability [300] identified a nonsense mutation in GALNT2 (NM_004481.4:c.865C>T; 
p.Gln289*) in a male proband of Pakistani origin. This mutation within the catalytic 
domain leads to a non-functional protein (Figure 3.1 A) [301]. The variant was confirmed 
with Sanger sequencing in the proband and family carriers (Figure 3.1 B-C). Like the 
p.Phe104Ser variant, this variant was also absent from existing variant databases.  
To further validate the LOF mutations in vivo, we analyzed plasma of the 
probands and sampled relatives for ApoC-III glycoforms by SDS-PAGE immunoblotting 
(Figure 3.1 D). While ApoC-III normally circulates as a mono- or di-sialylated protein 
with a molecular weight of ~9.5 kDa, we found only a band for non-glycosylated ApoC-III 
in the plasma of the two probands. In plasma from the heterozygous family members, 
we identified the normal bands with a distribution of mono- and di-sialylated isoforms, 
suggesting that heterozygosity for both GALNT2 LOF mutations retain sufficient enzyme 
activity to glycosylate ApoC-III in vivo. Notably, we found that both probands had 
reduced levels of HDL-C (<5th percentile for age and gender) (Figure 3.1 E). We also 
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found moderately reduced plasma TG in both probands and a moderately reduced LDL-
C in the homozygote for the p.Phe104Ser variant (Figure 3.1 E).  
 
Reduced HDL-C in rodent and nonhuman primate models of GALNT2 deficiency 
To further address the effect of GalNAc-T2 LOF on plasma lipids, we 
investigated GALNT2 deficiency in vivo in multiple mammalian models. We generated 
Galnt2 KO mice and rats, which harbor deletions in exons corresponding to the catalytic 
domain of the enzyme (Figure 3.2 A-B). Galnt2-deficient mice had near complete loss of 
hepatic Galnt2 mRNA levels (Figure 3.2 C-E), with no observed effects on expression of 
other GalNAc-transferase genes (Figure 3.2 G-H). In both chow-fed and Western diet-
fed conditions, complete Galnt2 KO mice demonstrated reduced HDL-C relative to WT 
littermates (20-22% reduction in KOs, P<0.05; Figure 3.3 A). Because rodents lack 
cholesteryl ester transfer protein (CETP), a critical regulator of plasma lipids in humans, 
we tested whether the relationship of Galnt2 to HDL-C was maintained after expression 
of CETP in Galnt2 KO and WT mice through administering AAV vectors expressing 
CETP.  After 4 weeks of CETP expression, Galnt2 KO mice had 40% lower HDL-C 
levels compared to WT littermates (P<0.01, Figure 3.3 A), with similar plasma CETP 
levels in both groups (Figure 3.3 B). Galnt2 KO mice also demonstrated a robust 
elevation in fasting TG (>50% increased TG in Galnt2 KOs on chow diet relative to WT, 
P<0.05), which was also observed upon 3 weeks of feeding a Western-type diet and 
after 4 weeks of AAV-mediated CETP expression (P<0.05 for both; Figure 3.3 C). 
Importantly, in chow fed mice, we observed no intermediate effect of heterozygous 
Galnt2 deficiency on HDL-C or TG (Figure 3.3 A).  
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Given the importance of the liver in HDL-C metabolism, we also generated liver-
specific models of GALNT2 deficiency to test if the association between Galnt2 and 
plasma lipids is mediated by hepatic expression. Liver-specific Galnt2 KO mice (Galnt2 
LSKOs) were generated by injecting Galnt2fl/fl mice with an AAV vector expressing Cre 
recombinase under the regulation of a liver-specific promoter, as well as by breeding 
Galnt2fl/fl mice to Albumin-Cre transgenic mice.  Galnt2 LSKOs showed near-complete 
reduction of liver Galnt2 mRNA levels (Figure 3.2 D). LSKO mice demonstrated 15-22% 
reduced HDL-C relative to WT controls (P<0.01 for both; Figure 3.3 D). While the HDL-
C reduction in the LSKOs was similar to that of complete KOs, plasma TG in LSKOs 
were similar to WT controls (Figure 3.3 E).  
Similarly to the results in mice, Galnt2 KO rats had near complete loss of hepatic 
Galnt2 mRNA levels (Figure 3.2 E) and 30% lower plasma HDL-C levels on a chow diet 
than WT littermates (P<0.01; Figure 3.3 F).  There was a similar reduction in a smaller 
cohort of WT vs. KO rats (3 per group) fed a Western diet for 6 weeks (P<0.05; Figure 
3.3 F). But unlike the complete KO mice, Galnt2 KO rats demonstrated reduced plasma 
TG while fed a chow diet. There were no significant differences in plasma TG after 6 
weeks of Western diet feeding (3 per group) (Figure 3.3 G). This may highlight a 
potentially complex, species-specific regulation of lipoprotein metabolism by GALNT2.  
We also explored the impact of GALNT2 deficiency on non-HDL cholesterol 
(nonHDL-C) levels in our rodent models. Galnt2 KO mice fed a chow diet, a Western 
diet, or administered CETP AAV all demonstrated no differences in plasma nonHDL-C 
(Figure 3.4 A), with similar results when measured by fast-protein liquid chromatography 
(FPLC) of plasma lipoproteins (Figure 3.4 B-C). Similarly, liver-specific KO mice also 
demonstrated no significant differences in nonHDL-C (Figure 3.4 D-E), while KO rats on 
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chow diet demonstrated a modest reduction in nonHDL-C on a chow diet with no 
differences in nonHDL-C after 6 weeks of Western diet feeding (Figure 3.4 F). 
Collectively, these findings suggest a minimal impact of GALNT2 deficiency on nonHDL-
C levels, consistent with the lack of association of this trait with the GALNT2 locus in the 
prior human GWAS.  
 
Impact of GALNT2 deficiency in mice on HDL-C and TG turnover 
Using the LSKO model, we performed clearance studies of HDL radiolabeled 
with both 3H cholesteryl ether and 125I-ApoA-I. Galnt2 LSKO mice demonstrated a 
moderate increase in the clearance of 3H cholesteryl ether but not in 125I-ApoA-I relative 
to controls (Figure 3.5 A-B), consistent with enhanced HDL cholesterol ester-selective 
catabolism. Given the previous implication of ApoC-III and ANGPTL3 as putative 
GalNAc-T2 targets, we also explored postprandial TG clearance in the complete KO and 
liver-specific KO mice (Figure 3.5 C-D). We observed delayed TG clearance in the 
complete KOs but not the liver-specific KO mice. This further supports the notion that the 
regulation of plasma TG levels by Galnt2 in mice may be extra-hepatic. Despite the 
observation of delayed lipolysis ex vivo in the complete KO mice, we observed no 
differences in post-heparin plasma TG or phospholipase activities in these models 
(Figure 3.5 E-H) 
 
Knockdown of hepatic GALNT2 in non-human primates reduces HDL-C levels 
We also studied the effects of hepatic GALNT2 silencing on plasma lipids in a 
nonhuman primate model, the cynomolgus monkey (cyno) using siRNA. Hepatic 
GALNT2 mRNA knockdown mediated by a single dose of siRNA was substantial and 
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persisted for up to 4 weeks (Figure 3.2 F). GALNT2 knockdown in cyno resulted in 
>30% reduction of HDL-C relative to controls as early as 3 days after siRNA treatment 
(Figure 3.3 G).  Knockdown of GALNT2 in cyno resulted in a trend towards elevated 
fasting TG that was 2-fold higher in the knockdown group 7 days after siRNA treatment 
(P<0.05; Figure 3.3 H). Additionally, we found a reduction in nonHDL-C in the anti-
GALNT2 siRNA treated monkeys (Figure 3.4 G), possibly due to the elevation in 
nonHDL-C in that control group itself; there were no differences in nonHDL-C between 
the anti-GALNT2 siRNA treated monkeys and saline-treated controls.  
 
Quantitative differential O-glycoproteomics confirm ANGPTL3 and identify PLTP as O-
glycoprotein targets controlled by GalNAc-T2 
 To understand mechanisms underlying the effect of GALNT2 deficiency on 
plasma lipids we observed in the human subjects and animal models, we employed an 
unbiased quantitative O-glycoproteomics strategy to identify protein targets with altered 
glycosylation [302]. We performed differential quantification of plasma (human, rats and 
mice) and liver (rats and mice) tissue O-glycopeptides from GALNT2 LOF models 
(Figure 3.6 A), revealing multiple glycosites in each model present in WT samples but 
>10-fold reduced or absent in KO samples (Figure 3.7 A-C & Table 3.1-3.3).  
From the human O-glycoproteome, we confirmed ApoC-III (Thr74) as a GalNAc-
T2 dependent substrate. Notably, ApoC-III was not found in the same analysis of rat and 
mouse plasma and liver samples (Table 3.1), in agreement with our finding that the 
rodent sequences around the glycosites are different and not specifically served by 
GalNAc-T2 but redundantly by multiple isoforms [185]. This was confirmed by 
immunoblotting of ApoC-III from rat and mouse plasma showing no difference in SDS-
	113 
 
PAGE migration and levels with only one major band detectable in both WT and KO 
samples (Figure 3.7 D-E). We also confirmed that O-glycosylation of ANGPTL3 
(Thr226) was selectively lost in the human GALNT2-deficient O-glycoproteome (Table 
3.1), in agreement with our previous in vitro studies [185]. The sequence around the Thr 
glycosylation site in ANGPTL3 is conserved in rodents and in vitro analysis of rodent 
ANGPTL3 confirmed that only GalNAc-T2 was active with this substrate, however we did 
not detect the corresponding glycopeptide in our glycoproteomics analysis of rodent 
plasma and liver (Table 3.2). 
Our differential O-glycoproteomics identified phospholipid transfer protein (PLTP) 
as O-glycosylated in the plasma and liver of WT mice but absent in KOs (Table 3.3). 
The identified O-glycosites were located in the C-terminus of PLTP, a region largely 
conserved among humans, mice, and rats (Figure 3.6 B). To validate PLTP as a non-
redundant target of GalNAc-T2, we tested the in vitro specificity of the two main GalNAc-
Ts expressed in liver, GalNAc-T1 and GalNAc-T2, with peptide substrates corresponding 
to the C-terminus of human, rat and mouse PLTP (Figure 3.6 C). We found that 
GalNAc-T2 was more active than GalNAc-T1 with all three peptides and in particular 
with the rodent peptides (Figure 3.6 C). These data support PLTP as a conserved 
preferential target of GalNAc-T2.   
PLTP transfers phospholipids from apoB-containing lipoproteins to HDLs in 
circulation, and is a known regulator of plasma HDL metabolism [303]. Mice lacking 
PLTP activity exhibit reduced HDL-C [304] and increased clearance of HDL-C in vivo 
[305], a finding resembling that of the Galnt2 KO rodents. We hypothesized that GalNAc-
T2 may modulate HDL metabolism at least in part through promoting PLTP function. We 
compared PLTP activity in plasma from PLTP-deficient mice, rats, and humans relative 
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to controls. Galnt2 KO mice and rats both showed >20% lower plasma PLTP activity 
relative to WT littermates (P<0.01 for each; Figure 3.6 D-E), with no apparent difference 
in total plasma PLTP protein was observed by immunoblotting (Figure 3.6 D-E), 
suggesting that the reduction of PLTP activity in the plasma of Galnt2 KO rodents is not 
due to reduced plasma PLTP protein levels but rather reduced function. This finding is 
consistent with prior mutagenesis and deletion studies implicating the final 30 residues 
of PLTP as critical for lipid transfer activity in vitro [306]. We measured plasma PLTP 
activity from the p.Gln289* and p.Phe104Ser homozygotes and family carriers and 
controls (Figure 3.6 F) and found that plasma from both probands had reduced PLTP 
activity relative to the mean of the p.Phe104Ser heterozygotes or noncarriers. 
Furthermore, when we measured a ‘specific activity’ for plasma PLTP, we found a 
reduction in the two homozygotes relative to controls, with the p.Gln289* homozygous 
subject’s activity >60% lower and the p.Phe104Ser homozygous subject’s activity >20% 
lower than the mean of the noncarrier control subjects’ activity (Figure 3.6 G). These 
data suggest that GALNT2 is required for facilitating PLTP function and maintaining 
HDL-C levels in rodents and humans. It has been shown that PLTP deficiency in 
hyperlipidemic mice models attenuated both VLDL secretion and atherosclerosis [307]. 
Thus we measured VLDL-TG secretion in the Galnt2 WT vs. complete KO mice and 
found a ~15% reduction in the rate of secretion in the KOs (P<0.05; Figure 3.5 I). These 
data further support the notion of reduced PLTP function in the setting of GALNT2 
deficiency.  
 We asked if restoration of Galnt2 expression was sufficient to rescue the HDL-C 
and PLTP activity reduction in vivo. We reconstituted murine Galnt2 in the liver of Galnt2 
KO mice using AAV at a dose of 1x1011 genome copies (GC) of virus per mouse, which 
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was 10-fold lower than the dose used in our prior overexpression study of Galnt2 in WT 
mice [86]. We compared hepatic Galnt2 restoration at this dose in Galnt2 KO mice to 
WT mice and Galnt2 KO mice receiving the same dose of Null virus and observed robust 
restoration of hepatic Galnt2 in the rescue group at 28 days after AAV administration 
(Figure 3.8 A). Restoration of hepatic Galnt2 expression markedly raised the reduced 
levels of HDL-C in the KO mice back to the levels in WT controls receiving Null AAV 
(Figure 3.8 B). Similarly, we monitored plasma phospholipid levels, which are low in the 
setting of PLTP deficiency, and found that while KO mice had lower phospholipids 
relative to WT initially, the KO mice with hepatic Galnt2 reconstitution showed elevated 
phospholipids over 4 weeks after dosing (Figure 3.8 C). We also measured plasma TGs 
and found that levels were variable across the different timepoints but hepatic Galnt2 
rescue in the KO mice caused a moderate reduction in TG levels by 2 weeks post-
injection (Figure 3.8 D). We observed similar trends in cholesterol and triglycerides in 
the lipoprotein fractions from FPLC separation of pooled plasma of rescued mice as we 
observed above (Figure 3.8 E-H).   
Since Galnt2 hepatic reconstitution rescued plasma HDL-C levels in the Galnt2 
KO mice, we next assessed the impact of hepatic Galnt2 restoration on plasma PLTP 
activity. We measured plasma PLTP-mediated transfer of phospholipids to HDL using 
plasma from the 3 groups of mice described above both before and after AAV 
administration. Prior to AAV dosing, plasma PLTP activity in the KO groups of mice was 
approximately 33% lower than that of WT mice (P<0.0001; Figure 3.8 I). 28 days after 
Galnt2 reconstitution in KO mice, their plasma PLTP activity had risen to the level of WT 
mice (Figure 3.8 J). At both timepoints, total plasma PLTP levels were comparable 
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(Figure 3.8 I-J, bottom). These data support the notion that hepatic Galnt2 is both 
necessary and sufficient to potentiate full plasma PLTP activity in mice in vivo.   
In addition to PLTP, we identified other specific targets for glycosylation by 
GalNAc-T2 that may contribute to the differences observed in the rodent phenotypes. 
These include a non-redundant site in the C-terminus of ApoE (Thr305), a critical ligand 
for hepatic lipoprotein receptors, in both rat liver and plasma.  Additionally, we identified 
a non-redundant T2-specific glycosite in the N-terminus of hepatic lipase (HL) (Thr38) in 
mouse liver and plasma. HL is a hepatocyte-expressed TG lipase and phospholipase 
that hydrolyzes lipids on TG-rich lipoproteins after secretion from liver cells onto the cell 
surface in a manner dependent on HDL [308]. Mouse liver glycoproteomics also 
identified two GalNAc-T2 specific glycosites in the hepatic lipoprotein receptor low-
density lipoprotein related receptor 1 (LRP1) (Thr27 and Thr3937). LRP1 is a hepatic 
receptor mediating the uptake of ApoE-containing TG-rich lipoprotein-remnant particles.  
 
GALNT2 SNPs associated with lower HDL-C are associated with reduced GALNT2 
expression in human liver  
We next asked if the common SNPs in GALNT2 associated with lipids in GWAS 
impacted GALNT2 expression in direction consistent with that observed in the LOF 
models. To answer this, we sequenced the RNA transcriptome from human liver 
samples and quantified allele-specific GALNT2 expression while accounting for 
genotype at rs4846914, the lead SNP in GALNT2 associated with HDL-C and TG 
(Figure 3.9 A). In a recent GWAS meta-analysis, each copy of the G allele for this SNP 
was associated with a mean reduction in HDL-C of 0.48 standard deviation (S.D.) units 
and a 0.40 S.D. unit increase in TG per copy (Figure 3.9 B). We compared GALNT2 
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mRNA transcript levels arising from the G allele vs. the A allele for the rs4846914 SNP 
for each liver RNA transcriptome. From analysis of rs4846914 G/A heterozygotes, we 
observed an 8% reduction in GALNT2 expression from the G allele relative to the A 
allele (Figure 3.9 C). The heterozygotes thus demonstrated a modest but significant 
allele-specific expression (P < 2 x 10-16; Figure 3.9 D), with the G allele (associated with 
lower HDL-C) having lower expression than the A allele (associated with higher HDL-C), 
consistent with the directionality from LOF variant carriers and animal models. These 
results are also consistent with a prior eQTL study of plasma lipid GWAS SNP effects on 
nearest-gene expression levels in human liver [182], and a recent fine mapping of the 
GWAS-associated GALNT2 noncoding SNPs [183]. We note that the directionality found 
here of reduced GALNT2 expression by alleles associated with higher TG in GWAS 
contrasts with the finding in the two GALNT2 LOF variant carriers of relatively low TG; 
this highlights the complexities of assessing plasma TGs in humans and the need to 
identify additional homozygotes for LOF variants for additional assessment.   
 
Discussion  
Here we aim to better reconcile the contrasting directionalities from our current 
work and these previous efforts by further exploring the prior conclusions. We first 
examined our conclusions from our 2010 report (Teslovich et al., 2010) that showed that 
Galnt2 overexpression reduced HDL-C levels while shRNA-mediated knockdown of 
hepatic Galnt2 raised HDL-C in mice. We subsequently found that at the AAV dose of 
1x1012 GC/mouse used previously, overexpression of Galnt2 reproducibly decreased 
HDL-C by 25-30% 14 days after administration (Figure 3.10 A). This dose also caused a 
>100,000-fold overexpression above endogenous Galnt2 levels of WT mice treated with 
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Null virus (Figure 3.10 B). A dose escalation of Galnt2 AAV in WT mice showed that the 
HDL-C reduction was not observed at AAV doses lower than 3x1011 GC/mouse despite 
high overexpression of Galnt2. We also questioned whether the HDL-C reduction was 
due to Galnt2 enzymatic activity. To test this, we engineered an AAV variant that 
expressed a mutant form of GALNT2 harboring the p.Glu334Gln (E334Q) variant, a 
highly conserved residue in the catalytic domain critical to glycosyltransferase activity 
[309]. Glycosyltransferase activity assays testing this mutant showed that it conferred no 
activity relative to WT GalNAc-T2 (Figure 3.10 C). Comparing WT and E334Q mutant 
Galnt2 AAVs at the high dose of 1x1012 GC/mouse showed that both equally reduced 
HDL-C by 30% after 14 days (Figure 3.10 D). These data support the conclusion that 
Galnt2 overexpression by AAV at the doses we used previously causes a transgene-
specific but glycosyltransferase activity-independent reduction in  HDL-C levels.  
Our prior work also suggested that AAV shRNA-mediated hepatic Galnt2 
knockdown raises HDL-C levels, which contrasts with the findings from the current work 
in multiple LOF models.  Subsequent studies by others have shown that high doses of 
AAV shRNA expression in the liver can mediate hepatotoxicity due to oversaturation of 
microRNA (miRNA) export pathways from the nucleus and reduction of essential 
miRNAs [310]. Importantly, these findings were shown to be shRNA sequence-specific 
but not target gene-specific. Since our 2010 report, we observed that anti-Galnt2 AAV 
shRNA treatment at the high dose of 1x1012 genome copies/mouse caused an elevation 
in HDL-C (Figure 3.10 E) but also hepatic dysfunction as measured by plasma alanine 
aminotransferase (ALT) levels (Figure 3.10 F). In our prior AAV shRNA experiments at 
this dose, we also found reduced levels of miR-122a (Figure 3.10 G), which constitutes 
a majority of miRNAs in the liver [311]. As several other hepatic miRNAs have been 
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shown to modulate HDL-C levels [312-314], we postulate that our results from AAV 
shRNA experiments may be influenced by additional hepatocellular changes as a result 
of the degree of shRNA overexpression. Indeed, experiments with other AAV shRNAs 
targeting Galnt2 at a lower dose of 2.5x1011 GC/mouse caused no elevation in HDL-C 
and also no increase in plasma aminotransferases (Figure 3.10 H-K). We posit that the 
germline Galnt2-deficient models we study here offer a ‘cleaner’ view of the phenotype 
of heritable LOF, which we demonstrate is consistent across multiple species.  
The 2011 study by Holleboom and colleagues [184] reported two probands with 
elevated HDL-C who were found to be heterozygotes for a nonsynonymous missense 
variant in GALNT2, D314A. This report suggested that this variant modestly reduces 
catalytic activity of GalNAc-T2 as measured by an in vitro enzymatic assay. However, a 
subsequent identification of this variant in a cohort of 2,000 Danes and functional testing 
showed the variant to confer normal enzymatic activity [315]. Because the 2011 report 
identified the variant in 2 high HDL-C probands and an additional 6 heterozygotes with 
normal HDL-C levels, we wondered if identification of additional carriers of this variant 
and potentially homozygotes would help us better determine the relationship of this 
variant to HDL-C levels and any allele-dosage effect of the variant on this trait. We 
searched for carriers of the D314A variant in 2 ethnically distinct exome sequencing 
cohorts in which HDL-C levels were measured (Figure 3.11 A). In both cohorts, we 
identified numerous heterozygous carriers of this GALNT2 variant and one homozygote. 
We tested the association of this variant with HDL-C levels in both cohorts and found no 
significant relationship in either cohort; indeed, the D314A homozygote had low HDL-C 
levels (23 mg/dl). For both cohorts, we identified highly significant associations of known 
variants at other HDL-C loci, supporting the validity of these findings. These data 
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suggest that in larger populations across ethnicities, the D314A variant in GALNT2 is not 
associated with higher HDL-C levels and that the initial report was limited by power 
considerations. 
Our data demonstrate that ApoC-III is a human species-specific non-redundant 
substrate for GalNAc-T2, but the role of O-glycosylation in modulating its lipoprotein 
modulatory functions remains unclear. Prior work showed that lack of ApoC-III O-
glycosylation at Thr74 did not impair protein secretion or binding affinity for lipoproteins 
in vitro [97]. Moreover, human subjects lacking ApoC-III glycosylation due to inheritance 
of a missense variant at the glycosylation site Thr74 demonstrate normal plasma TG 
levels and ApoC-III incorporation into lipoproteins [96], suggesting that the glycosylation 
of ApoC-III alone may not substantially impact plasma lipoprotein levels. Indeed, our 
own measurement of in vitro LPL activity inhibition by total plasma ApoC-III (containing 
mostly glycosylated isoforms) and nonglycosylated ApoC-III showed equally potent 
inhibition of lipolysis of a radiolabeled TG substrate in the presence of recombinant LPL 
(Figure 3.11 B). 
Integrating our findings, the data presented here support a working model 
(Figure 3.11 C) of the regulation of lipoprotein metabolism by GALNT2 by which it 
regulates at least three substrates, ANGPTL3, ApoC-III, and PLTP, in ways that may 
have differing impacts on these target proteins with regard to their respective processing 
and functions. These modifications may be species-specific as in the case of ApoC-III 
and it is likely that additional targets underlie the complex phenotypic differences among 
GALNT2 LOF models, which remain our area of continued study.   
To date, few of the novel lipid loci identified by GWAS have been shown to 
physiologically influence plasma lipids in vivo. Strategies for studying function of these 
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novel loci in animal models have largely involved somatic overexpression and 
knockdown in murine models as well as generation of whole-body or tissue-specific KO 
mice. These approaches meet with the challenges of 1) the difficulty in pinpointing the 
causal gene at a newly associated locus harboring multiple genes, 2) the ability to 
appropriately ascertain the relevant tissue(s) in which expression of the candidate gene 
regulates the associated phenotype, and 3) the limitations of relating findings in murine 
models to humans due to the complex physiological differences between rodent and 
human lipoprotein metabolism. This is an exceptionally difficult task when the candidate 
gene is involved in partly redundant glycosylation of a multitude of proteins. Through our 
cross-species studies of GALNT2, we provide an example of how studies of LOF 
mutations in rare individuals combined with multiple animal model systems might be 
leveraged to validate and determine the relationship of GWAS candidate genes to 
complex traits. 
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Figure 3.1 
 
Figure 3.1: Identification and lipid phenotype of human homozygotes with 
GALNT2 loss-of-function coding variants. A. Schematic GALNT2 protein showing 
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position of the two identified variants, p.Phe104Ser and p.Gln289. B. Sanger sequencing 
of identified variants, c.C311T>C: p.Phe104Ser, and c.C865T: p.Gln289*. C. Pedigree of 
family members of probands for variants in A-B. Asterisk denotes individuals analyzed 
by ApoC-III immunoblot. D. Immunoblot of plasma ApoC-III from the probands and 
family controls for the GALNT2 variants. Migration positions of the 3 major ApoC-III 
isoforms, nonsialylated ApoC-III (ApoC-III0) lacking any O-glycan modification; 
monosialylated ApoC-III (ApoC-III1) containing N-acetylgalactosamine, galactose and 1 
terminal sialic acid; and disialylated ApoC-III containing N-acetylgalactosamine, 
galactose, and 2 terminal sialic acids (ApoC-III2), are indicated on the left. E. Plasma 
lipids of GALNT2 variant carriers. Contributions: All data generated by Katrine 
Schjoldager and in part analyzed in final form by SAK and Katrine Schjoldager. 
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Figure 3.2 
 
Figure 3.2: GALNT2 expression in mammalian models of GALNT2 deficiency. A. 
Summary of Galnt2 targeting strategy to excise exons 4-6 of mouse Galnt2 on 
chromosome 8. Conditional KO mice were generated and bred to constitutive Cre-
deleter mice to generate mice heterozygous for the deletion, which were bred to 
generate WT, heterozygous, and KO mice for experiments. B. Representative results 
from genotyping tail DNA from Galnt2 WT, heterozygous and KO mice generated using 
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the strategy in (A). Two PCR reactions were used to identify the deletion of Galnt2 exons 
4-6 with primers that annealed uniquely to the Galnt2 gene at flanking sites. C. Hepatic 
Galnt2 mRNA expression in Galnt2 WT, heterozygous, and complete KO mice as 
measured by quantitative RT-PCR. Cycle number of amplification (Cts) were normalized 
to that of actin. D. Galnt2 mRNA expression in the livers of Galnt2 LSKO mice (Galnt2fl/fl 
mice treated with AAV-TBG-Cre vs. Null AAV-treated floxed control mice). Cts were 
normalized to those of actin. E. Quantification of Galnt2 transcripts in the livers of Galnt2 
WT vs. KO rats by RNA sequencing. F. GALNT2 mRNA expression in livers of cyno 
treated with saline, anti-luciferase siRNA or anti-GALNT2 siRNA, quantitated using RT- 
PCR at 3, 14, and 28 days after a single administration of siRNA. GALNT2 mRNA was 
normalized using 18s rRNA. G. Liver gene expression of Galnt1, the only other major 
GalNAc transferase expressed in liver, from WT mice administered Null AAV, Galnt2 KO 
mice administered Null AAV, and Galnt2 KO mice with reconstituted hepatic Galnt2 by 
AAV. Expression was measured relative to that of actin from the same samples. H. RNA 
sequencing results for glycosyltranferase gene mRNA transcripts from livers of the 
Galnt2 KO rats vs. WT controls (3 per group). For each glycosyltransferase gene, data is 
plotted as reads per kilobase of transcript per million mapped reads (RPKM) for the WT 
vs. Galnt2 KO rats. Data is presented as mean values ± S.D., with error bars showing 
S.D.. * P<0.05, ** P<0.01, *** P<0.001, Student’s unpaired T-test. Contributions: Data in 
panels A-D and G performed and analyzed by SAK. Data in panel E-F and H performed 
and analyzed by Katrine Schjoldager. 
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Figure 3.3 
 
Figure 3.3: Plasma HDL cholesterol in mammalian models of GALNT2 loss-of-function. A. Plasma HDL-C after a 4 hour fast 
from Galnt2 WT, heterozygous (Het), and KO mice fed a chow diet (left), a chow diet after 4 weeks or administration of human CETP 
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AAV (center), or a Western-type diet for 3 weeks (right). B. Plasma CETP concentration after 4 weeks in mice from (A, right). C. 
Plasma triglycerides in mice from (A). D. Plasma HDL-C from Galnt2 WT vs. liver-specific KO mice generated by AAV-Cre delivery in 
Galnt2fl/fl mice (left) or crossing Galnt2fl/fl with Alb-Cre transgenic mice (right). E. Plasma triglycerides in mice from (D). F. Plasma 
HDL-C after fasting for 12-16 hours from Galnt2 WT vs. KO rats fed a chow diet (left) or 6 weeks of Western-type diet (right). G. 
Plasma triglycerides in rats from (F). H.  Plasma HDL-C after overnight fasting in cynomolgus monkeys (cyno) treated with saline, 
anti-luciferase siRNA or anti-GALNT2 siRNA. I. Plasma triglycerides in cyno monkeys from (H). Data is presented as mean values ± 
S.D.. * P<0.05, ** P<0.01, Student’s unpaired T-test. Contributions: Data in panels A-E performed and analyzed by SAK. Data in F-I 
generated by Katrine Schjoldager and Todd Kirchgessner and analyzed by SAK. 
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Figure 3.4 
 
Figure 3.4: Non-HDL cholesterol in GALNT2 loss-of-function models. A. Plasma non-HDL cholesterol (NonHDL-C) in WT, 
heterozygous (het), and complete KO mice fed a chow diet (left), WT vs. KO mice fed a Western diet for 3 weeks (center), and WT 
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vs. KO mice after 4 weeks of AAV CETP administration (right). All measurements were made from plasma from mice after 4 hours of 
fasting. B. Cholesterol (left) and triglycerides in FPLC-separated fractions from plasma from WT, Het, and KO mice fed a chow diet 
(4 hour fasted plasma was used for FPLC measurements). C. Cholesterol (left) and triglycerides (right) from FPLC-separated 
fractions of plasma of WT vs. KO mice fed a Western diet for 3 weeks. D. Plasma NonHDL-C in Galnt2 liver-specific KO mice, 
generated by either administration of AAV-TBG-Cre to Galnt2 floxed mice (left) or crossing Albumin-Cre transgenic mice with Galnt2 
floxed mice (right). Measurements were made on plasma from mice after 4 hours of fasting. E. Cholesterol (left) and triglycerides 
(right) from FPLC-separated plasma from Galnt2 liver-specific KO mice. F. Plasma NonHDL-C in Galnt2 WT vs. KO rats fed a chow 
diet or Western diet for 6 weeks. Measurements were from plasma of rats after 12-16 hours of fasting. G. LDL cholesterol in 
cynomolgus monkeys treated with saline, anti-luciferase control siRNA, or anti-GALNT2 siRNA for 14 days. All measurements 
indicate mean values ± S.D. where applicable, with error bars showing S.D.. *P<0.05, **P<0.01, Student’s unpaired T-test. For cyno 
measurements, comparisons were between the anti-luciferase and anti-GALNT2 groups. Contributions: Data in panels A-E 
generated and analyzed by SAK; data in panels F-G generated by Katrine Schjoldager and Todd Kirchgessner and analyzed by 
SAK. 
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Figure 3.5 
 
Figure 3.5: HDL and TG clearance in Galnt2 KO mice. A. Plasma clearance of 3H-
HDL-cholesteryl ester in Galnt2 liver-specific KO mice vs. controls over 24 hours. Dual-
labeled HDL was administered to the mice intravenously and blood was sampled for 
measurement of activity at the indicated timepoints. Clearance curves are shown on the 
left and fractional catabolic rates calculated through multiexponential modeling are 
shown on the right. B. Plasma clearance of 125I-HDL-ApoA-I in Galnt2 liver-specific KO 
mice vs. controls over 24 hrs. Clearance curves are shown on the left and fractional 
catabolic rates calculated through multiexponential modeling are shown on the right. C. 
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Postprandial TG clearance after oral olive oil gavage in Galnt2 WT vs. complete KO 
mice. D. Postprandial TG clearance after olive oil gavage in WT (Cre-) vs. Galnt2 liver-
specific KO mice (Cre+). E. TG lipase activity from post-heparin plasma of Galnt2 WT 
vs. complete KO mice. F. TG lipase activity from post-heparin plasma of Galnt2 WT 
(AAV-Null) vs. liver-specific KO (AAV-Cre) mice. G. Phospholipase activity from post-
heparin plasma of Galnt2 WT and complete KO mice. H. Phospholipase activity from 
post-heparin plasma of Galnt2 WT (AAV-Null) vs. liver-specific KO (AAV-Cre) mice. I. 
VLDL-TG secretion into plasma of WT vs. complete KO mice. X-axis indicates time after 
pluronic P407 administration by IP injection. Plasma TG were measured at each 
timepoint. Plasma TG levels over time are plotted on the left, and secretion rates as 
measured by the slopes of the curves are shown on the right. Data is presented as 
mean values ± S.D., with error bars showing S.D.. *P<0.05, ** P<0.01, Student’s 
unpaired T-test. Contributions: All data in this figure generated and analyzed by SAK. 
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Figure 3.6 
 
Figure 3.6: Differential glycoproteomics of tissues from Galnt2 WT vs. KO rodents 
identifies PLTP as a candidate target of GalNAc-T2. A. Schematic of differential 
glycoproteomics approach to identify GalNAc-T2 targets from humans and rodent 
models. B. Phospholipid transfer protein (PLTP) schematic and cross-species alignment 
showing the C-terminal HDL-binding region. Asterisk shows conversed residues among 
mice, rats, and humans. Potential O-glycosylated residues (Ser and Thr) are indicated in 
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red. C. In vitro glycosylation assay of PLTP C-terminal peptides by recombinant human 
GalNAc-T1 and –T2 over 1 hour and 16 hours. Yellow squares denote the number of 
GalNAc residues on each peptide. D. (Top) Plasma PLTP activity from Galnt2 WT, 
Galnt2 heterozygous (Het), Galnt2 KO (KO), and PLTP-deficient (PLTP KO) mice. 
(Bottom) Immunoblot of plasma PLTP from mice from activity assay above. E. (Top) 
Plasma PLTP activity from Galnt2 WT vs. KO rats. (Bottom) Immunoblot of plasma 
PLTP from rats from activity assay above.  F. (Top) Plasma PLTP activity from human 
control subjects and homozygotes for GALNT2 nonsynonsymous variants. (Bottom) 
Immunoblot of plasma PLTP from human participants from PLTP activity assay above. 
G. Plasma PLTP specific activity from human participants in (F). Specific activity was 
measured as the plasma activity from (F Top) normalized to the densitometric intensity 
for the immunoblot from (F bottom). Where applicable, data is presented as mean values 
± S.D.. ** P<0.01, ***P<0.001, Student’s unpaired T-test. Contributions: Data in C 
generated and analyzed by Katrine Schjoldager; data in panels D-G performed and 
analyzed by SAK using reagents and samples from SAK and provided by Katrine 
Schjoldager. 
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Figure 3.7 
 
Figure 3.7: Overview of differential O-glycoproteomes from GALNT2 deficient 
humans and rodents. A. & B. Quantitative differential O-glycoproteomes of rat (A) and 
mouse (B) plasma and liver showing the total number unambiguously identified 
glycopeptides, quantitated glycopeptides and isoform-specific glycopeptides and sites. 
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C. Venn diagrams showing the distribution of O-glycoproteins and O-glycosites in 
plasma from GALNT2 p.Gln289* proband and a pool of nonaffected sex- and age- 
matched individuals. Glycoproteins and sites absent from the plasma of p.Gln289* 
proband constitute candidates for GalNAc-T2 specific activity. D. & E. Immunoblot of 
ApoC-III from plasma of Galnt2 WT vs. KO mice (D) and rats (E) after separation of 
plasma proteins by SDS-PAGE. Contributions: Data in panels A-C generated and 
analyzed by Katrine Schjoldager using samples from Katrine Schjoldager and some 
prepared by SAK; data in panels D-E generated and analyzed by SAK.  
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Figure 3.8 
 
Figure 3.8: Reconstitution of hepatic Galnt2 expression in Galnt2 KO mice restores HDL-C and PLTP activity. A. Hepatic 
Galnt2 expression in WT mice transduced with Null AAV (WT – Null), Galnt2 KO mice transduced with Null AAV (KO – Null), and KO 
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mice transduced with Galnt2 AAV (KO – Galnt2). ***P<0.001, Student’s unpaired T-test. B. Plasma HDL-C in mice from (A). C. 
Plasma phospholipids from mice in (A). D. Plasma Triglycerides from mice in (A). For B-D, significance was determined at each 
timepoint. *P<0.05, **P<0.01, Student’s unpaired T-test of comparison of WT – Null to KO – Null. u P<0.05, uuu P<0.001, 
Student’s unpaired T-test of comparison of WT – Null to KO – Galnt2. E. Day 0 cholesterol in fractions after FPLC separation from 
pooled plasma from each of the groups in (A). F. Day 28 cholesterol from FPLC fractions of pooled plasma from groups in (A). G. 
Day 0 triglycerides in FPLC fractions from pooled plasma from groups in (A). H. Day 28 triglycerides in FPLC fractions from pooled 
plasma from groups in (A). I. (Top) Plasma PLTP activity from Day 0 plasma from mice in (A). (Bottom) Immunoblot of plasma PLTP 
from PLTP activity assay above. J. (Top) Plasma PLTP activity from Day 28 plasma from mice in (A). (Bottom) Immunoblot of plasma 
PLTP from PLTP activity assay above. For I-J, ****P<0.0001, Student’s unpaired T-test for comparisons between the indicated 
groups. Data is presented as mean values ± S.D.. Contributions: All data in this figure generated and analyzed by SAK. 
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Figure 3.9 
 
Figure 3.9: Common variants in GALNT2 associated with HDL-C confer allelic 
imbalance of GALNT2 expression in human liver. A. Manhattan plot of association of 
GALNT2 SNPs with HDL-C from the Global Lipids Genetics Consortium (GLGC) GWAS. 
Colors indicate the amount of linkage disequilibrium between plotted SNPs. Purple 
colored circle indicates lead SNP rs4846914 in GALNT2 intron 1. B. Relative change in 
HDL-C and TG (in S.E. units) per copy of rs4846914 allele from the GLGC GWAS. C. 
Allele-specific expression (ASE) of the rs4846914 SNP on GALNT2 expression from 72 
human liver samples as measured by RNA-Seq. The fraction of GALNT2 reads arising 
from either the A or G allele for the rs4846914 SNP relative to total GALNT2 reads is 
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plotted. Triangles indicate samples with significant ASE while circles indicate 
nonsignificant ASE. D. One-sided binomial test used to assess ASE for the distribution 
of GALNT2 transcripts arising from rs4846914 A vs. G allele in samples with A/A or A/G 
genotype for each sample.  Data shows mean ± S.D.. Contributions: Data in panels A-B 
generated previously by consortia (publicly available) and analyzed here by SAK; data in 
panels C-D generated and analyzed by SAK, Casey Brown, and YoSon Park. 
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Figure 3.10 
 
Figure 3.10: Investigation of AAV-mediated Galnt2 overexpression and 
knockdown. A. Dose-titration experiment of AAV-Galnt2 at indicated doses and impact 
on HDL-C. Measurements indicate percent changes in HDL-C relative to Day 0 (pre-
injection) HDL-C levels. **P<0.01, indicated group vs. Null 1E12 group, Student’s 
unpaired t-test for Day 14 data. B. Hepatic Galnt2 expression in mice from (A). Values 
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above bars indicate relative fold-change compared to Null 1E12 group. C. In vitro 
glycosyltransferase activity of WT vs. E334Q mutant GalNAc-T2. Recombinant FLAG-
tagged enzymes were made through transfection in COS7 cells and immunoprecipitated. 
Immunoprecipitates were used in an assay to measure transfer of [14C]-UDP-GalNAc to 
a peptide substrate over 1 hour at 37 °C. Immunoblot of equal volumes of 
immunoprecipitates is shown below kinetic assay curves. D. Impact of WT vs. E334Q 
Galnt2 AAV overexpression on HDL-C (change from baseline after 14 days). *P<0.05, 
**P<0.01, indicated group vs. Null 1E12, Student’s unpaired T-test. E. Plasma HDL-C in 
mice treated with either an AAV-shRNA with no murine target (Control) vs. that of mice 
treated with an anti-Galnt2 AAV shRNA at 0 and 14 days after AAV administration. This 
experiment is a representative experiment of 7 in total that evaluated these anti-Galnt2 
AAV-shRNAs at a dose of 1x1012 genome copies (GC) per mouse. Similar results were 
obtained using another shRNA against Galnt2 at this dose and at a dose of 3x1011 
GC/mouse. F. Plasma ALT levels in mice from (A). G. Liver gene expression from mice 
in (A). H. Plasma HDL-C at 14 days after treatment of mice with saline, a control AAV-
shRNA, or 2 different AAV-shRNAs with sequences targeting Galnt2. This study, 
performed by Merck, was done at a dose of 2.5x1011 GC/mouse. I. Plasma ApoA-I levels 
measured by autoanalyzer at 14 days after AAV administration from mice in (D). J. 
Plasma ALT and AST levels at 14 days after AAV administration from mice in (D). K. 
Hepatic Galnt2 expression in mice from (D). Data is presented as mean values ± S.D., 
where error bars show S.D.. *P<0.05, ** P<0.01, Student’s unpaired T-test. 
Contributions: Data in all panels generated by SAK, Andrew Edmondson and Merck 
Research Laboratories and analyzed by SAK. 
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Figure 3.11 
 
 
Figure 3.11: Relationship of the previously reported D314A variant with HDL-C. A. 
Association of GALNT2 D314A with HDL-C in the MIExSeq rare variant association 
study (top) and the PROMIS study (bottom). For each association test, representative 
variants significantly associated with HDL-C for each respective study are given below 
the results for the GALNT2 D314A variant. Each study was 100% powered to detect a 1 
S.D. change in HDL-C with significance level α=0.05. B. In vitro LPL activity in the 
presence of 0 μM ApoC-III, 20 μM total plasma ApoC-III, and 20 μM nonglycosylated 
ApoC-III. Data is shown as mean values ± S.D.. ****P<0.0001, Student’s unpaired T-test. 
C. Model for proposed targets of GALNT2 that modulate lipoprotein metabolism. Green 
lines show activating roles of GalNAc-T2 mediated O-glycosylation. Black dotted line 
indicates yet unclear regulatory effect of the glycosylation of indicated targets. 
Contributions: Data generated and analyzed by SAK, Gina Peloso, and Wei Zhao. 
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Trait Position rsID Gene Ref. allele Alt. allele Amino Acid Change 
No. of 
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HDL-C Chr1:230386238 rs78164071 GALNT2 A C D314A 9381 73 0.004 -1.61 1.58 0.308 
HDL-C Chr18:47109955 rs77960347 LIPG A G N396S 9381 208 0.01 2.2 0.95 0.02 
HDL-C Chr12:125284671 rs74830677 SCARB1 G A P376L 9381 8 0.0004 11.8 4.91 0.02 
Pakistan Risk of Myocardial Infarction Study (PROMIS) 
Trait Position rsID Gene Ref. allele Alt. allele Amino Acid Change 
No. of 
Participants No. of Carriers MAF Beta S.E. P-value 
HDL-C Chr1:230386238 rs78164071 GALNT2 A C D314A 6864 25 0.00182 -0.4262 1.954 0.827 
HDL-C Chr16:56996288 rs708272 CETP G A intronic  (c.118+279G>A) 6864 4878 0.466 1.683 0.167 1.11x10
-23 
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Table 3.1 
Table 3.1: Glycopeptides identified from ANGPTL3, ApoC-III, and PLTP from Human Controls and GALNT2 
p.Gln289* Homozygote 
Human Control Plasma Glycopeptides Identified from Lectin Weak-Affinity Glycoproteomics 
Gene Accessions Protein Name (UniProt) Sequence Unambigious Glycan Addition 
ANGPTL3 Q9Y5C1 Angiopoietin-related protein 3 
TSIQEPTEISLSSKPR S10(Hex1HexNAc1); S12(Hex1HexNAc1) 
RTSIQEPTEISLSSKPR S11(Hex1HexNAc1); S13(Hex1HexNAc1) 
RTSIQEPTEISLSSKPR S11(Hex1HexNAc1); S13(Hex1HexNAc1) 
SRIDQDNSSFDSLSPEPK S14(Hex1HexNAc1) 
TTPFLQLNEIR T2(Hex1HexNAc1) 
TSIQEPTEISLSSKPR T7(Hex1HexNAc1) 
TSIQEPTEISLSSKPR T7(Hex1HexNAc1) 
TSIQEPTEISLSSK T7(Hex1HexNAc1) 
TSIQEPTEISLSSKPR T7(Hex1HexNAc1) 
TSIQEPTEISLSSKPR T7(Hex1HexNAc1) 
TSIQEPTEISLSSKPR T7(Hex1HexNAc1) 
TSIQEPTEISLSSKPR T7(Hex1HexNAc1) 
RTSIQEPTEISLSSKPR T8(Hex1HexNAc1) 
RTSIQEPTEISLSSKPR T8(Hex1HexNAc1) 
RTSIQEPTEISLSSKPR T8(Hex1HexNAc1) 
APOC3 P02656 Apolipoprotein C-III 
WDLDPEVRPTSAVAA T10(Hex1HexNAc1) 
PEVRPTSAVAA T6(Hex1HexNAc1) 
PEVRPTSAVAA T6(Hex1HexNAc1) 
DPEVRPTSAVAA T7(Hex1HexNAc1) 
LDPEVRPTSAVAA T8(Hex1HexNAc1) 
LDPEVRPTSAVAA T8(Hex1HexNAc1) 
LDPEVRPTSAVAA T8(Hex1HexNAc1) 
LDPEVRPTSAVAA T8(Hex1HexNAc1) 
LDPEVRPTSAVAA T8(Hex1HexNAc1) 
PLTP P55058 Phospholipid transfer protein 
ASTAPTPSTAAV T3(Hex1HexNAc1) 
ASTAPTPSTAAV T6(Hex1HexNAc1) 
GALNT2 p.Gln289* Homozygote Plasma Glycopeptides Identified from Lectin Weak-Affinity Glycoproteomics 
Gene Accessions Protein Name (UniProt) Sequence Unambigious Glycan Addition 
ANGPTL3 Q9Y5C1 Angiopoietin-related protein 3 
RTSIQEPTEISLSSKPR S11(Hex1HexNAc1); S13(Hex1HexNAc1) 
TSIQEPTEISLSSKPR S12(Hex1HexNAc1) 
RTSIQEPTEISLSSKPR S13(Hex1HexNAc1) 
SRIDQDNSSFDSLSPEPK S14(Hex1HexNAc1) 
TSIQEPTEISLSSKPR T7(Hex1HexNAc1) 
TSIQEPTEISLSSKPR T7(Hex1HexNAc1) 
RTSIQEPTEISLSSKPR T8(Hex1HexNAc1) 
RTSIQEPTEISLSSKPR T8(Hex1HexNAc1) 
APOC3 P02656 Apolipoprotein C-III 
PEVRPTSAVAA S7(Hex1HexNAc1) 
PEVRPTSAVAA T6(Hex1HexNAc1) 
PLTP P55058 Phospholipid transfer protein 
ASTAPTPSTAAV T3(Hex1HexNAc1) 
ASTAPTPSTAAV T3(Hex1HexNAc1) 
ASTAPTPSTAAV T3(Hex1HexNAc1) 
ASTAPTPSTAAV T3(Hex1HexNAc1); T6(Hex1HexNAc1) 
ASTAPTPSTAAV T6(Hex1HexNAc1) 
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Table 3.1: Glycopeptides identified from ANGPTL3, ApoC-III, and PLTP from 
Human Controls and GALNT2 p.Gln289* Homozygote. Weak lectin-affinity 
glycoproteomics was used to identify glycopeptides in ANGPTL3, ApoC-III, and PLTP 
from of a control pool of plasma and plasma from the participant homozygous for the 
p.Gln289* variant. Peptide sequences and glycan modifications for each glycopeptide 
identified are provided for each of the samples generated after alignment to a human 
proteome database and glycan site assignment as described in the Materials and 
Methods. Contributions: All data in this table generated and analyzed by Katrine 
Schjoldager. 
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Table 3.2 
Table 3.2: Differential Glycoproteomes of Galnt2 KO vs. WT Rats 
Differential Plasma Glycoproteomes 
Gene Accessions Protein Name (UniProt) Sequence 
Unambigious Glycan 
Addition 
Fold-difference 
KO vs. WT for 
Glycopeptide 
[log10 (fold 
difference)] 
Adamtsl4 Q4FZU4 ADAMTS-like protein 4  qPHPFsPVTR S6(Hex1HexNAc1) -5.00 
A1i3 P14046 Alpha-1-inhibitor 3  gmYEsLPVVAVk S5(Hex1HexNAc1) -5.00 
A1i3 P14046 Alpha-1-inhibitor 3  eDNSIHWERPQkPtk T14(Hex1HexNAc1) -5.00 
Abca5 Q8CF82 
ATP-binding cassette 
sub-family A member 
5  
vSDIELSPMDkSILSNLILG
YtPVTNTTSSVmQRVSTD
HLPDVLVTEEYASEk 
T22(Hex1HexNAc1) -5.00 
F10 Q63207 Coagulation factor X  vGPtSEtPRLTHPPY T4(Hex1HexNAc1);T7(Hex1HexNAc1) -5.00 
Fetub Q9QX79 Fetuin-B  nTAPTsSPSITAPR S6(Hex1HexNAc1) -5.00 
Fetub Q9QX79 Fetuin-B  tAPtSSPSITAPR T4(Hex1HexNAc1) -5.00 
Fetub Q9QX79 Fetuin-B  nTAPtSSPSITAPR T5(Hex1HexNAc1) -5.00 
Fetub Q9QX79 Fetuin-B  nTAPtSSPSITAPR T5(HexNAc) -5.00 
Fetub Q9QX79 Fetuin-B  nTAPtSSPSITAPR T5(HexNAc) -5.00 
Fga P06399 Fibrinogen alpha chain  msPVPDLVPGSFk S2(Hex1HexNAc1) -5.00 
Fga P06399 Fibrinogen alpha chain  mHPELGsFYDSR S7(Hex1HexNAc1) -5.00 
Gsn Q68FP1 Gelsolin  vSETRPsTmVVEHPEFLk S7(Hex1HexNAc1) -5.00 
Gsn Q68FP1 Gelsolin  vSETRPsTmVVEHPEFLk S7(Hex1HexNAc1) -5.00 
Gsn Q68FP1 Gelsolin  vSETRPsTmVVEHPEFLk S7(Hex1HexNAc1) -5.00 
Gsn Q68FP1 Gelsolin  vSETRPsTmVVEHPEFLk S7(Hex1HexNAc1) -5.00 
Hrg Q99PS8 Histidine-rich glycoprotein  lSPtNcDASkPLAEk T4(Hex1HexNAc1) -5.00 
Ighd P01883 Ig delta chain C region (Fragment)  hYIEAtkPTATk T6(Hex1HexNAc1) -5.00 
Ighd P01883 Ig delta chain C region (Fragment)  nHYIEAtkPTATk T7(Hex1HexNAc1) -5.00 
Il1r2 P43303 Interleukin-1 receptor type 2  vsESPVTSEk S2(Hex1HexNAc1) -5.00 
Csf1 Q8JZQ0 Macrophage colony-stimulating factor 1  tEGSSLLPsDLPLR S9(Hex1HexNAc1) -5.00 
Mug1 Q03627 Murinoglobulin-1  sAPAVESELSPR S1(HexNAc) -5.00 
Pam P14925 
Peptidyl-glycine alpha-
amidating 
monooxygenase  
fHQLEStLRPAESR T7(Hex1HexNAc1) -5.00 
Serping1 Q6P734 Plasma protease C1 inhibitor  dSVPERDGsR S9(Hex1HexNAc1) -5.00 
Pigr P15083 
Polymeric 
immunoglobulin 
receptor  
gSPHINPtDANAR T8(Hex1HexNAc1) -5.00 
F2 P18292 Prothrombin  tTDAEFHTFFDER T1(Hex1HexNAc1) -5.00 
Alb P02770 Serum albumin  kQtALAELVk T3(Hex1HexNAc1) -5.00 
Speg Q63638 
Striated muscle-
specific 
serine/threonine-
protein kinase  
vASPPPGAsEkRVPSAR S9(HexNAc) -5.00 
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Differential Liver Glycoproteomes 
Gene Accessions Protein Name (UniProt) Sequence 
Unambigious Glycan Addition 
(ETD) 
Fold-difference 
KO vs. WT for 
Glycopeptide 
[log10 (fold 
difference)] 
Aebp1 A2RUV9  Adipocyte enhancer-binding protein 1 FSTVAPLETPER 
 S2(Hex1HexNAc1); 
T3(Hex1HexNAc1) -5.00 
Ahsg P24090  Alpha-2-HS-glycoprotein 
FSPVASVESASGEVL
HSPK  S17(Hex1HexNAc1) -5.00 
Anpep P15684  Aminopeptidase N DLSVIPVINR  S3(Hex1HexNAc1) -5.00 
Apoe P02650  Apolipoprotein E IQASVATNSIASTTVPLENQ  T13(Hex1HexNAc1) -5.00 
St6gal1 P13721 
 Beta-galactoside 
alpha-2,6-
sialyltransferase 1 
MGSASQVVFSNSK  S3(Hex1HexNAc1) -5.00 
St6gal1 P13721 
 Beta-galactoside 
alpha-2,6-
sialyltransferase 1 
MGSASQVVFSNSK  S5(Hex1HexNAc1) -5.00 
St6gal1 P13721 
 Beta-galactoside 
alpha-2,6-
sialyltransferase 1 
EDIPILSYHRVTAK  T12(Hex1HexNAc1) -5.00 
Adar P55266 
 Double-stranded 
RNA-specific 
adenosine deaminase 
DSGQPEELSNCPME
EDPEKPAESQPPSS
SATSL 
 S9(HexNAc); S23(HexNAc) -5.00 
Man1b1 B2GUY0 
 Endoplasmic 
reticulum mannosyl-
oligosaccharide 1,2-
alpha-mannosidase 
AEASIKPLFLASR  S4(Hex1HexNAc1) -5.00 
Man1b1 B2GUY0 
 Endoplasmic 
reticulum mannosyl-
oligosaccharide 1,2-
alpha-mannosidase 
AEASIKPLF  S4(Hex1HexNAc1) -5.00 
Fetub Q9QX79  Fetuin-B TAPTSSPSITAPR  T4(Hex1HexNAc1) -5.00 
Fetub Q9QX79  Fetuin-B NTAPTSSPSITAPR  T5(Hex1HexNAc1) -5.00 
Fetub Q9QX79  Fetuin-B NTAPTSSPSITAPR  T5(Hex1HexNAc1) -5.00 
Fgb P14480  Fibrinogen beta chain ATTDSDKVDLSIAR  S5(Hex1HexNAc1) -5.00 
Fstl1 Q62632  Follistatin-related protein 1 
SVSPSASPVVCYQA
NR  S3(Hex1HexNAc1) -5.00 
Gsn Q68FP1  Gelsolin VSETRPSTMVVEHPEFLK  T8(Hex1HexNAc1) -5.00 
Golim4 Q5BJK8  Golgi integral membrane protein 4 
AAHLLDGRPQAEIEH
STKAATNFR  S16(Hex1HexNAc1) -5.00 
Mug1 Q03626-2  Isoform 2 of Murinoglobulin-1 
GGEFEMMPLGVNKS
PLPK  S14(Hex1HexNAc1) -5.00 
Fgg P02680-2 
 Isoform Gamma-A of 
Fibrinogen gamma 
chain 
LSIGDGQQHHMGGS
KQVGDM  S14(Hex1HexNAc1) -5.00 
Kng1 P08934  Kininogen-1 STTVSPSYIAR  T3(Hex1HexNAc1) -5.00 
Mxi1 O09015  Max-interacting protein 1 MDSIGSTISSDR  S9(HexNAc);S10(HexNAc) -5.00 
Mme P07861  Neprilysin DLQNLMSWRFIMDLVSSLSRNYK 
 
S16(HexNAc);S17(Hex1HexNAc
1);S19(Hex1HexNAc1) 
-5.00 
Nid1 P08460  Nidogen-1 (Fragment) GYPDPHNVPRTLAPSY  T11(Hex1HexNAc1) -5.00 
Nucb1 Q63083  Nucleobindin-1 AAPHQEDNQATETPDTGLYYHRY  T11(Hex1HexNAc1) -5.00 
Nucb2 Q9JI85  Nucleobindin-2 KFQQGIAPSGPAGELK  S9(Hex1HexNAc1) -5.00 
Pigr P15083 
 Polymeric 
immunoglobulin 
receptor 
GSPHINPTDANAR  T8(Hex1HexNAc1) -5.00 
Pigr P15083 
 Polymeric 
immunoglobulin 
receptor 
GSPHINPTDANAR  T8(Hex1HexNAc1) -5.00 
Pcolce O08628 
 Procollagen C-
endopeptidase 
enhancer 1 
VQPVEKPEGSPATQ
ATPVAPDAPSITCPK  S10(Hex1HexNAc1) -5.00 
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Lman1 Q62902  Protein ERGIC-53 VSGVQHPGSAGVYETTQHFMDIK  T15(Hex1HexNAc1) -5.00 
Smo P97698  Smoothened homolog SAGGSARRNAPVTSPPPPLLSHCGR 
 
S5(HexNAc);T13(Hex1HexNAc1
); S14(HexNAc) 
-5.00 
Slc9a1 P26431  Sodium/hydrogen exchanger 1 
LNPTASTIRGSEPPR
ER 
 
T4(Hex1HexNAc1);S11(Hex1He
xNAc1) 
-5.00 
Knt2 P08932  T-kininogen 2 AGPAPDHQAEASTVT  T13(Hex1HexNAc1) -5.00 
Knt2 P08932  T-kininogen 2 AGPAPDHQAEASTVTP  T13(Hex1HexNAc1) -5.00 
Knt2 P08932  T-kininogen 2 AGPAPDHQAEASTVTP  T13(Hex1HexNAc1) -5.00 
Fn1 P04937 Fibronectin GAAEPSPDGTTGHTYNQYTQR  S6(Hex1HexNAc1) -5.00 
 
Table 3.2: Differential Glycoproteomes of Galnt2 KO vs. WT Rats. Quantitative 
differential lectin-affinity glycoproteomics was used to identify glycopeptides differentially 
observed in plasma (top) and livers (bottom) from Galnt2 KO vs. WT rats. Peptide 
sequences and glycan modifications for each glycopeptide identified are provided for 
each of the samples generated after alignment to a rat proteome database and glycan 
site assignment as described in the Materials and Methods. Fold-differences in 
glycopeptide levels in WT vs. KO models were determined by relative quantification of 
light vs. medium chain dimethyl isotopomeric labels in the WT vs. KO samples, 
respectively. Contributions: All data in this table generated and analyzed by Katrine 
Schjoldager. 
 
 
 
 
 
 
 
Table 3.3 
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Table 3.3: Differential Glycoproteomes of Galnt2 KO vs. WT Mice 
Differential Plasma Glycoproteomes 
Gene Accessions Protein Name (UniProt) Sequence 
Unambiguous Glycan 
Addition 
Fold-difference KO vs. 
WT for Glycopeptide 
[log10 (fold 
difference)] 
B4galn
t1 Q09200 
Beta-1,4 N-
acetylgalactosamin
yltransferase 1 
YRYPGSLDQSQVAK S6(HexNAc) -5.00 
Bmp3 Q8BHE5 
Bone 
morphogenetic 
protein 3 
ATGGSPSPDLRPHDK S5(Hex1HexNAc1) -5.00 
Bmp3 Q8BHE5 
Bone 
morphogenetic 
protein 3 
ATGGSPSPDLRPHDK ND -5.00 
Ccdc9
7 Q9DBT3 
Coiled-coil domain-
containing protein 
97 
EEFTSRMHQR T4(HexNAc); S5(HexNAc) -5.00 
Cd55 Q61475 
Complement 
decay-accelerating 
factor, GPI-
anchored 
VSATQHVPVTK T4(Hex1HexNAc1); T10(Hex1HexNAc1) -5.00 
Cd55 Q61475 
Complement 
decay-accelerating 
factor, GPI-
anchored 
VSATQHVPVTK T4(Hex1HexNAc1); T10(Hex1HexNAc1) -5.00 
Ecm1 Q61508 Extracellular matrix protein 1 VDHSVTSLHDPPLFEEQR 
T6(Hex1HexNAc1); 
S7(Hex1HexNAc1) -5.00 
Ecm1 Q61508 Extracellular matrix protein 1 NVALVAGDTGNATGLGEQGPTR T21(HexNAc) -5.00 
Ecm1 Q61508 Extracellular matrix protein 1 EVKPHTLAGQLPPEPR T6(Hex1HexNAc1) -5.00 
Extl1 Q9JKV7 Exostosin-like 1 ITSTHASACLWDR ND -5.00 
F10 O88947 Coagulation factor X VGPTAETPR T4(HexNAc) -5.00 
F10 O88947 Coagulation factor X VGPTAETPR T4(HexNAc) -5.00 
Fam20
c Q5MJS3 
Extracellular 
serine/threonine 
protein kinase 
Fam20C 
VPPPGPSGDGSLLAK S7(Hex1HexNAc1) -5.00 
Fam20
c Q5MJS3 
Extracellular 
serine/threonine 
protein kinase 
Fam20C 
VPPPGPSGDGSLLAK S7(Hex1HexNAc1) -5.00 
Fetub Q9QXC1 Fetuin-B NTAPTSSPSVTAPR T2(HexNAc) -5.00 
Fn1 P11276 Fibronectin LGVRPSQGGEAPR S6(Hex1HexNAc1) -5.00 
Ghr P16882 Growth hormone receptor INPSLGTSSSGKPR S4(Hex1HexNAc1) -5.00 
Gpbp1l
1 Q6NZP2 
Vasculin-like 
protein 1 GHDGMSQRSGGSSTGNHR T14(HexNAc) -5.00 
Grn P28798 Granulins CVSPTGTHTLLK T5(Hex1HexNAc1) -5.00 
Gsn P13020 Gelsolin VSEARPSTMVVEHPEFLK S7(Hex1HexNAc1) -5.00 
Gsn P13020 Gelsolin VSEARPSTMVVEHPEFLK S7(Hex1HexNAc1); T8(Hex1HexNAc1) -5.00 
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Gsn P13020 Gelsolin VSEARPSTMVVEHPEFLK S7(Hex1HexNAc1) -5.00 
Gsn P13020 Gelsolin VSEARPSTMVVEHPEFLK S7(HexNAc); T8(HexNAc) -5.00 
Heg1 E9Q7X6 Protein HEG homolog 1 TSSDHTDHGYVPSTFTK T6(Hex1HexNAc1) -5.00 
Heg1 E9Q7X6 Protein HEG homolog 1 ISDSPSQAQPK 
S2(Hex1HexNAc1); 
S4(Hex1HexNAc1) -5.00 
Igfbp5 Q07079 
Insulin-like growth 
factor-binding 
protein 5 
FVGGAENTAHPR T8(HexNAc) -5.00 
Igh-3 P01867 Ig gamma-2B chain C region KLEPSGPISTINPCPPCK T10(Hex1HexNAc1) -5.00 
Itih1 Q61702 
Inter-alpha-trypsin 
inhibitor heavy 
chain H1 
RTFVLSAIQPSPTAHPIDSK T13(Hex1HexNAc1) -5.00 
Itih1 Q61702 
Inter-alpha-trypsin 
inhibitor heavy 
chain H1 
RTFVLSAIQPSPTAHPIDSK S11(Hex1HexNAc1); S19(Hex1HexNAc1) -5.00 
Itih1 Q61702 
Inter-alpha-trypsin 
inhibitor heavy 
chain H1 
TFVLSAIQPSPTAHPIDSK S10(Hex1HexNAc1) -5.00 
Itih1 Q61702 
Inter-alpha-trypsin 
inhibitor heavy 
chain H1 
TFVLSAIQPSPTAHPIDSK S10(HexNAc); T12(Hex1HexNAc1) -5.00 
Itih1 Q61702 
Inter-alpha-trypsin 
inhibitor heavy 
chain H1 
RTFVLSAIQPSPTAHPIDSK S11(Hex1HexNAc1) -5.00 
Itih1 Q61702 
Inter-alpha-trypsin 
inhibitor heavy 
chain H1 
RTFVLSAIQPSPTAHPIDSK S11(Hex1HexNAc1); S19(Hex1HexNAc1) -5.00 
Klhl1 Q9JI74 Kelch-like protein 1 TDTWTMVAPLSMPR T5(HexNAc) -5.00 
Kng1 O08677 Kininogen-1 TESLASSSEYSTTSTQMQGR 
S11(Hex1HexNAc1); 
T12(HexNAc); 
T13(HexNAc); 
T15(HexNAc) 
-5.00 
Kng1 O08677 Kininogen-1 IAPSKAPILK S4(Hex1HexNAc1) -5.00 
Kng1 O08677 Kininogen-1 TEGPTLTPPR T5(HexNAc) -5.00 
Kng1 O08677 Kininogen-1 TEGPTLTPPR T1(HexNAc); T5(Hex1HexNAc1) -5.00 
Lipc P27656 
Hepatic 
triacylglycerol 
lipase 
SLGATEASKPLK T5(HexNAc) -5.00 
Lipc P27656 
Hepatic 
triacylglycerol 
lipase 
SLGATEASKPLK T5(Hex1HexNAc1); S8(Hex1HexNAc1) -5.00 
Madca
m1 Q61826 
Mucosal addressin 
cell adhesion 
molecule 1 
TLSSEGPCRPK S4(Hex1HexNAc1) -5.00 
Nid1 P10493 Nidogen-1 GVPTERTR T4(Hex1HexNAc1); T7(Hex1HexNAc1) -5.00 
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Pam P97467 
Peptidyl-glycine 
alpha-amidating 
monooxygenase 
LESTLRPAESR T4(Hex1HexNAc1); S10(Hex1HexNAc1) -5.00 
Pi16 Q9ET66 Peptidase inhibitor 16 SSATSVSPK S5(Hex1HexNAc1) -5.00 
Pltp P55065 Phospholipid transfer protein NRPADVAASHVPPPSAAAA S9(Hex1HexNAc1) -5.00 
Plxnb1 Q8CJH3 Plexin-B1 APSTASDVLPGAKPSR T4(Hex1HexNAc1); S15(Hex1HexNAc1) -5.00 
Prg4 Q9JM99 Proteoglycan 4 TSDKDVEPTSTTPK T9(Hex1HexNAc1); T11(Hex1HexNAc1) -5.00 
Prg4 Q9JM99 Proteoglycan 4 TSDKDVEPTSTTPK T9(Hex1HexNAc1); T11(Hex1HexNAc1) -5.00 
Ptprg Q05909 
Receptor-type 
tyrosine-protein 
phosphatase 
gamma 
TAAEGGHQTIPGR T9(HexNAc) -5.00 
Ptprg Q05909 
Receptor-type 
tyrosine-protein 
phosphatase 
gamma 
TAAEGGHQTIPGRR T9(Hex1HexNAc1) -5.00 
Ptprg Q05909 
Receptor-type 
tyrosine-protein 
phosphatase 
gamma 
TAAEGGHQTIPGRR T1(Hex1HexNAc1); T9(Hex1HexNAc1) -5.00 
Qsox1 Q8BND5 Sulfhydryl oxidase 1 IAPTVWKFADR T4(Hex1HexNAc1) -5.00 
Qsox1 Q8BND5 Sulfhydryl oxidase 1 DMQENAPGQQHLSKR S13(Hex1HexNAc1) -5.00 
Rgma Q6PCX7 Repulsive guidance molecule A VRTLPPAGDSQER T3(Hex1HexNAc1) -5.00 
Rgma Q6PCX7 Repulsive guidance molecule A SDSPEICHYEK S1(Hex1HexNAc1) -5.00 
Sdc1 P18828 Syndecan-1 QTPSTWK T2(Hex1HexNAc1) -5.00 
Serpinf
2 Q61247 
Alpha-2-
antiplasmin ADFHGGKTFGPDLK T8(Hex1HexNAc1) -5.00 
Serpinf
2 Q61247 
Alpha-2-
antiplasmin TFGPDLK T1(Hex1HexNAc1) -5.00 
Shc1 P98083 SHC-transforming protein 1 LSGGGGRRTR T9(HexNAc) -5.00 
Sparcl
1 P70663 
SPARC-like protein 
1 AVSTEPTDAAVVPR T7(Hex1HexNAc1) -5.00 
St5 Q924W7 
Suppression of 
tumorigenicity 5 
protein 
NSSITHGTGGTK T5(HexNAc); T8(HexNAc) -5.00 
Sybu Q8BHS8 Syntabulin IGMVGEGSIQSAR S8(HexNAc) -5.00 
Tgoln2 Q62314 
Trans-Golgi 
network integral 
membrane protein 
2 
DQDKTTLAAVSSK T5(Hex1HexNAc1); S12(Hex1HexNAc1) -5.00 
Vtn P29788 Vitronectin TDGTLKPTAFLDPEEQPSTPAPK T8(Hex1HexNAc1); T19(HexNAc) -5.00 
Vwce Q3U515 
von Willebrand 
factor C and EGF 
domain-containing 
protein 
QQPSPHGELAK S4(Hex1HexNAc1) -5.00 
Differential Liver Glycoproteomes 
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Gene Accessions Protein Name (UniProt) Sequence 
Unambiguous Glycan 
Addition 
Fold-difference KO vs. 
WT for Glycopeptide 
[log10 (fold 
difference)] 
Itih1 Q61702 
Inter-alpha-trypsin 
inhibitor heavy 
chain H1 
TFVLSAIQPSPTAHPIDSK 
 
S5(Hex1HexNAc1);S10
(Hex1HexNAc1) 
-5.00 
Gsn P13020 Gelsolin VSEARPSTMVVEHPEFLK 
 
S7(HexNAc);T8(HexNA
c) 
-5.00 
Plxnb1 Q8CJH3 Plexin-B1 STASDVLPGAKPSR 
 
T2(Hex1HexNAc1);S13(
Hex1HexNAc1) 
-5.00 
Ptprg Q05909 
Receptor-type 
tyrosine-protein 
phosphatase 
gamma 
EKSEATHTAAESDRTAPAPTPSSPHR 
 
T6(Hex1HexNAc1);S22(
Hex1HexNAc1);S23(He
x1HexNAc1) 
-5.00 
Itih1 Q61702 
Inter-alpha-trypsin 
inhibitor heavy 
chain H1 
TFVLSAIQPSPTAHPIDSK  S10(Hex1HexNAc1) -5.00 
Acaa2 Q8BWT1 
3-ketoacyl-CoA 
thiolase, 
mitochondrial 
VSGGAIALGHPLGGSGSR  S2(HexNAc) -5.00 
Gsn P13020 Gelsolin ARPSTMVVEHPEFLK  S4(Hex1HexNAc1) -5.00 
Gsn P13020 Gelsolin SEARPSTMVVEHPEFLK  S6(Hex1HexNAc1) -5.00 
Slc38a
10 Q5I012 
Putative sodium-
coupled neutral 
amino acid 
transporter 10 
GRPAPSQDMGQHLPGEVK  S6(Hex1HexNAc1) -5.00 
Col18a
1 P39061 
Collagen alpha-
1(XVIII) chain AGQGGSPATPAVPIPLVAPAASPDMK  S6(Hex1HexNAc1) -5.00 
Slc38a
10 Q5I012 
Putative sodium-
coupled neutral 
amino acid 
transporter 10 
GRPAPSQDMGQHLPGEVK  S6(Hex1HexNAc1) -5.00 
Col18a
1 P39061 
Collagen alpha-
1(XVIII) chain AGQGGSPATPAVPIPL  S6(Hex1HexNAc1) -5.00 
Gsn P13020 Gelsolin VSEARPSTMVVEHPEFLK  S7(Hex1HexNAc1) -5.00 
Gsn P13020 Gelsolin VSEARPSTMVVEHPEFLK  S7(Hex1HexNAc1) -5.00 
Gsn P13020 Gelsolin VSEARPSTMVVEHPEFLK  S7(Hex1HexNAc1) -5.00 
Gsn P13020 Gelsolin VSEARPSTMVVEHPEFLK  S7(Hex1HexNAc1) -5.00 
Gsn P13020 Gelsolin VSEARPSTMVVEHPEFLK  S7(Hex1HexNAc1) -5.00 
Gsn P13020 Gelsolin VSEARPSTMVVEHPEFLK  S7(Hex1HexNAc1) -5.00 
Gsn P13020 Gelsolin VSEARPSTMVVEHPEFLK  S7(Hex1HexNAc1) -5.00 
Traf3 Q60803 TNF receptor-associated factor 3 VSLLQNESVEKNK  S8(Hex1HexNAc1) -5.00 
Tgoln2 Q62314 
Trans-Golgi 
network integral 
membrane protein 
2 
TTLAAVSSK  T1(Hex1HexNAc1) -5.00 
Ebp P70245 
3-beta-
hydroxysteroid-
Delta(8),Delta(7)-
isomerase 
TTNTVPLHPYWPR  T1(Hex1HexNAc1) -5.00 
Klhl1 Q9JI74 Kelch-like protein 1 TWTVLPPMSTHR  T10(HexNAc) -5.00 
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Ctsd P18242 Cathepsin D TTEPVSELLK  T2(Hex1HexNAc1) -5.00 
Tgoln2 Q62314 
Trans-Golgi 
network integral 
membrane protein 
2 
TTRPTDGQGQK  T2(Hex1HexNAc1) -5.00 
Fetub Q9QXC1 Fetuin-B NTAPTSSPSVTAPR  T5(Hex1HexNAc1) -5.00 
Gpc4 P51655 Glypican-4 EQRPTTAAGTSLDR  T5(Hex1HexNAc1) -5.00 
Fetub Q9QXC1 Fetuin-B NTAPTSSPSVTAPR  T5(Hex1HexNAc1) -5.00 
Itih1 Q61702 
Inter-alpha-trypsin 
inhibitor heavy 
chain H1 
IQPSPTAHPIDSK  T6(Hex1HexNAc1) -5.00 
Itih1 Q61702 
Inter-alpha-trypsin 
inhibitor heavy 
chain H1 
AIQPSPTAHPIDSK  T7(Hex1HexNAc1) -5.00 
Gpc4 P51655 Glypican-4 HPEQRPTTAAGTSLDR  T7(Hex1HexNAc1) -5.00 
Kng1 O08677 Kininogen-1 AETEQGPTHGHGWLHEK  T8(Hex1HexNAc1) -5.00 
Chga P26339 Chromogranin-A AGPEEVPTAASSSHFHAGYK  T8(Hex1HexNAc1) -5.00 
Slc38a
10 Q5I012 
Putative sodium-
coupled neutral 
amino acid 
transporter 10 
AAPPEVPKSPEK  S9(Hex1HexNAc1) -5.00 
Slco1a
4 Q9EP96 
Solute carrier 
organic anion 
transporter family 
member 1A4 
TQTLKPTQDPTECVK  T7(Hex1HexNAc1) -5.00 
Kng1 O08677 Kininogen-1 IGCVHAISTDSPDLEPVLK  T9(Hex1HexNAc1) -5.00 
Lrp1 Q91ZX7 
Prolow-density 
lipoprotein 
receptor-related 
protein 1 
MDAPKTCSPK  T6(Hex1HexNAc1) -5.00 
 
Table 3.3: Differential Glycoproteomes of Galnt2 KO vs. WT Mice. Quantitative 
differential lectin-affinity glycoproteomics was used to identify glycopeptides differentially 
observed in plasma (top) and livers (bottom) from Galnt2 KO vs. WT mice. Fold-
differences in glycopeptide levels in WT vs. KO models were determined by relative 
quantification of light vs. medium chain dimethyl isotopomeric labels in the WT vs. KO 
samples, respectively. Contributions: All data in this table generated by Katrine 
Schjoldager with samples processed by SAK. 
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CHAPTER 4 – APOC3 A43T VARIANT CONFERS VARIANT CONFERS LOSS-OF- 
FUNCTION THROUGH DISRUPTING APOC-III BINDING AND ACCELERATING 
TRIGLYCERIDE-RICH LIPOPROTEIN CLEARANCE 
Introduction 
ApoC-III is a small apolipoprotein (~8.8 kDa) secreted from the liver and small intestine 
that circulates on both TRLs such as VLDL and chylomicrons in addition to high-density 
lipoproteins (HDLs). In biochemical studies and animal models, ApoC-III has been 
shown to increase plasma TGs by both directly inhibiting the activity of lipoprotein lipase 
(LPL) on TRLs and by inhibiting the clearance of TRLs by the liver, possibly through 
competitive interactions with ApoE, a critical ligand on TRLs for receptor-mediated 
clearance [98-100,316,317]. In a murine model of delayed ApoB clearance through LDL 
receptor deficiency, human ApoC-III overexpression increased circulating TRLs and 
exacerbated the development of atherosclerosis [318], offering early support for the 
notion that ApoC-III may be positive mediator of CHD risk.  
Genetic discoveries of the last decade have highlighted the potential importance 
of ApoC-III to CHD risk in humans. Common noncoding polymorphisms in APOC3 are 
associated with plasma TGs, HDL and non-HDL cholesterol and CHD risk through 
genome-wide association studies (GWAS) [117]. In 2008, a GWAS in the Lancaster 
Amish identified a rare truncation variant in APOC3, Arg19Ter (R19X) that was 
associated with reduced levels of serum ApoC-III, improved fasting and postprandial 
TGs, and reduced coronary artery calcification, a surrogate measure of atherosclerosis 
[105]. More recently, two large sequencing efforts identified multiple rare coding variants 
in APOC3 associated in aggregate with ~40% reduced TGs and an equal reduction in 
risk of CHD [91,106]. One of these efforts, utilizing whole-exome sequencing for 
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discovery followed by exome-wide genotyping in >110,000 individuals [106], identified 
four APOC3 nonsynonymous variants that constituted the protective association, R19X, 
two splice-site variants IVS2+1 G>A and IVS3+1 G>T, and a missense variant A43T 
(A23T of the mature secreted protein lacking the 20 residue signal peptide) and also 
showed that these variants were associated with lower ApoC-III levels in carriers vs. 
controls, thus positing them as LoF variants. The other study performed targeted APOC3 
exon sequencing and genotyping and confirmed three of these four variants as 
protective from TG levels and risk of ischemic heart and vascular diseases [91]. 
Importantly, in both studies, APOC3 variants were not associated with LDL-C 
concentrations, suggesting a protective impact of the mutations is independent of LDL-C 
lowering.  
These genetic data and other subsequent studies posit that reducing circulating 
ApoC-III concentrations may be a novel therapeutic approach to reduce CHD risk 
potentially synergistic with and orthogonal to existing LDL-C focused treatments. Indeed, 
at least one ApoC-III-targeting therapy, an antisense oligonucleotide to APOC3, has 
already passed preclinical screening [103] and is currently under clinical development 
and has shown efficacy in TG lowering in patients with extreme hypertriglyceridemia 
[102,104]. We sought to identify mechanisms of lowering ApoC-III that would be 
efficacious and safe, and thus hypothesized that studying the mechanism of protection 
by the identified APOC3 LoF variants may offer insights for therapeutic discovery.  
 
Materials and Methods  
Ethics Statement 
	155 
 
All human participants for this study and all analyses performed were completed 
following the Declaration of Helsinki and were approved by the Institutional Review 
Board of the Perelman School of Medicine at the University of Pennsylvania and all 
participants provided informed consent. 
 
Human Subject Identification and Ascertainment 
Human participants were recruited from two independent cohorts for ascertainment of 
APOC3 loss-of-function variants and subsequent phenotyping. The first cohort, the Penn 
High HDL Study (HHDL), is a cross-sectional study of heritable factors contributing to 
elevated levels of HDL-C. Participants were recruited with HDL-C levels greater than the 
95th percentile for age and gender by physician referrals or through the Hospital of the 
University of Pennsylvania clinical lipid laboratory. Relatives of high HDL-C probands 
were also invited to participate in the study. Participants were consented for additional 
plasma lipid analysis and research genetic studies including targeted sequencing of 
candidate genes, exome sequencing, and SNP array genotyping under a protocol 
approved by the Institutional Review Board (IRB) of the University of Pennsylvania. Over 
2,500 participants have been recruited for the HHDL study, with recruitment ongoing. 
The second cohort, the Complex Genomics Initiative and BioBank cohort (CGI BioBank), 
is a collection of banked plasma samples from participants who were treated at the 
University of Pennsylvania Health System and were consented for genetic analysis and 
biochemical studies of collected plasma for the study of the heritable risk factors and 
novel biomarkers related to CHD risk. Approximately 10,000 participants have been 
recruited so far, with recruitment of additional participants ongoing through IRB approved 
protocols of the University of Pennsylvania.  
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For both studies, genomic DNA was isolated from whole blood from participants 
and prepared for genotyping using the Exome Chip SNP genotyping array (Human 
Exome BeadChip v1.0, Illumina, Inc., San Diego, CA, USA). The Exome Chip contains 
more than 240,000 SNP markers mostly corresponding to coding regions across the 
genome that are derived from variants found two or more times across more than one 
data set among 23 unique data sets of >12,000 exome or whole genome sequences. 
This included the four APOC3 coding variants studied here, R19X (rs76353203), IVS2+1 
G>A (rs138326449), IVS3+1 G>T (rs140621530) and A43T (rs147210663). After 
removing subjects from analysis for which genotyping quality control measures failed or 
demographic covariates were not available, a total of 2,736 participants from the HHDL 
study and 5,244 subjects from the CGI BioBank cohort were genotyped. APOC3 variant 
genotypes for participants with identified variants from Exome Chip genotyping were 
confirmed by Sanger sequencing. A 674 bp fragment of the APOC3 gene sequence was 
amplified by PCR from 200 ng of genomic DNA from identified variant carriers using the 
following oligonucleotide primers: F – CTCCTTCTGGCAGACCCAGCTAAGG, R – 
CCTAGGACTGCTCCGGGGAGAAAG. PCR products were purified using a QIAquick 
PCR purification Kit (Qiagen, Germantown, MD, USA) and Sanger sequenced by 
Genewiz (South Plainfield, NJ, USA). Sequence chromatograms were aligned to the 
APOC3 reference from NCBI using Sequencher (Gene Codes, Ann Arbor, MI, USA).  
 
Lipid Phenotyping of Human Participants 
Carriers of any of the four APOC3 coding variants along with noncarriers from the same 
identification cohorts matched for age, gender, and ethnicity were selected for further 
lipid analysis from collected plasma samples. Plasma total cholesterol (TC), HDL-C, TG, 
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ApoC-III, ApoA-I, ApoB, and ApoE were measured by an Axcel clinical autoanalyzer 
(Alfa Wassermann Diagnostic Technologies, West Caldwell, NJ, USA). Non-HDL 
cholesterol (NonHDL-C) was calculated by the difference of the TC and HDL-C 
measurements. All measurements were made from overnight fasted plasma samples.  
 
Selective Reaction Monitoring of ApoC-III from Human Plasma 
Fasting plasma from A43T carriers (N=17) and noncarriers (N=24) was processed for 
measurement of the relative amounts of WT vs. mutant protein using multiple reaction 
monitoring assays. AspN protease was used to digest 0.15 μl of plasma for each 
sample. A total of 0.3 μl was ultimately used for each reaction. Synthetic deuterium-
labeled peptides corresponding to 20-mers harboring the Ala or Thr43 residues 
(residues 25-44 of the full-length ApoC-III protein) were added to each plasma sample 
for selective monitoring. The following mass-to-charge (m/z) ratios were used for 
monitoring protease-digested ApoC-III peptides and transitions on a TSQ Quantiva 
triple-stage quadrupole mass spectrometer (Thermo Fisher Scientific) with UltiMate 3000 
Nano Liquid Chromatography (LC) Systems: WT light (unlabeled) – 557.8 à 547.9, 
577.0, 614.7; WT heavy (deuterium-labeled) – 559.5 à 547.9, 577.0, 617.0; mutant light 
(unlabeled) – 565.3 à 557.9, 587.0, 625.7; mutant heavy (deuterium-labeled) – 567.0 à 
557.9, 587.0, 627.0. Ratios of light to heavy peptides for WT and mutant 20-mer 
peptides were measured for each sample and compared to that measured for a standard 
curve of combinations of WT and mutant full-length proteins at known molar ratios and 
subject to the same AspN digest conditions as the plasma samples. From this, the 
mutant:WT ratio for each sample was calculated.  
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In silico Analysis of Splicing Effects of APOC3 Variants 
Impact of the four APOC3 coding variants on APOC3 exon splicing was assessed using 
the Automated Splice Site and Exon Definition Analyses (ASSEDA) server 
(MutationForcaster, https://www.mutationforecaster.com/learn.php#asseda [319]). 
 
Cloning of human APOC3 cDNA and Adeno-associated Virus Generation 
The cDNA of the human APOC3 gene (NM_000040) was obtained from OriGene 
(Rockville, MD, USA) and cloned in the pcDNA3.1/V5-His TOPO expression plasmid 
(Thermo Fisher Scientific, Waltham, MA, USA). The A43T variant was introduced into 
the pcDNA3.1/V5-His plasmid containing the WT APOC3 cDNA using the Quickchange 
II site-directed mutagenesis kit (Agilent technologies, Wilmington, DE, USA) using the 
following primers: F – GCACGCCACCAAGACCACCAAGGATGCACTGAGCAG, R – 
CTGCTCAGTGCATCCTTGGTGGTCTTGGTGGCGTGC, where the bolded and 
underlined nucleotide indicates the position of the variant in the primer sequences. The 
APOC3 WT and A43T variant cDNA sequences were further amplified by PCR to 
introduce KpnI and SalI restriction sites using the following primers: F – 
ACGCGTGGTACCATGCAGCCCCGGGTACTCCTTG, R – 
CCGCCCGGGTCGACTCAGGCAGCCACGGCTGAAG. Amplified PCR products 
corresponding to the WT and A43T variant cDNA sequences of APOC3 were digested 
with KpnI and SalI and ligated with an adeno-associated virus (AAV) serotype 8 vector 
plasmid containing the liver-specific thyroxine binding globulin (TBG) promoter provided 
by the Vector Core of the University of Pennsylvania [232-234,320].  The ligation of the 
AAV plasmids and integrity of sequences were confirmed by Sanger sequencing and 
restriction digest and agarose gel electrophoresis analysis. AAV production, purification, 
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and titering from the cloned APOC3 WT and A43T vector plasmids was performed by 
the Vector Core.  
 
125I Radiolabeling of ApoC-III  
Mature forms of WT and A43T variant ApoC-III (79 residues for each and lacking the 
signal peptide) were produced by solid-state peptide synthesis by Pierce Custom 
Peptides (Thermo Fisher Scientific). Purified peptides were confirmed by matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry to be of >95% purity. 
Proteins were solubilized in 10 mM ammonium bicarbonate buffer, pH 7.4 to a 
concentration of approximately 0.2-0.4 mg/ml.  
Solubilized proteins were iodinated with 125I directly using the iodine 
monochloride (ICl) method [321] or through incorporation with 125I tyramine cellobiose 
(TCB) [322]. For direct 125I labeling of ApoC-III by the ICl method, approximately 0.5 ml 
of ApoC-III in 10 mM ammonium bicarbonate buffer (0.2-0.4 mg/ml) was iodinated with 1 
mCi of 125I, 300 µl of 1 M glycine, and 150 µl of 1.84 M NaCl / 2.84 µM ICl solution, 
vortexed and applied to a PG-10 desalting column (Amersham Biosciences) that was 
pre-equilibrated with 0.15 M NaCl / 1 mM EDTA solution. Iodinated proteins were eluted 
in a final volume of 2.5 ml in NaCl/EDTA solution and dialyzed against PBS before 
measurement of protein concentration by BCA assay and 125I activity by gamma 
counting.  
For iodination of TCB, 180 µl of 0.4 M sodium phosphate, Pierce iodination 
beads (Thermo Fisher Scientific), and 1 mCi of 125I were combined and then added with 
20 µl of 0.2 µM TCB (a kind gift from Dr. David Usher and Dr. William Cain, University of 
Delaware, Newark, DE, USA). This mixture was incubated at room temperature for 30 
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minutes with shaking every five minutes, and then 10 µl of 0.1 M NaI and 20 µl of 0.1 M 
NaHSO3 were added to stop the reaction. Next, 40 µl of 0.2 µM cyanuric chloride was 
added to activate the 125I-TCB. The activated 125I-TCB was then added to the ApoC-III 
protein samples (solubilized in ammonium bicarbonate buffer at a concentration of 0.2-
0.4 mg/ml) and incubated at room temperature for three hours. Finally, the reaction was 
fractionated over a PD-10 desalting column to remove unbound iodine, and fractions 
containing iodinated protein were pooled together and dialyzed against PBS for further 
use.  
 
Animal Models 
C57BL/6 wild-type (WT) mice were purchased from The Jackson Laboratory (Cat# 
000664). Additionally, Apoc3 KO mice on a C57BL/6 background (Cat# 002057) were 
recovered from cryo-preservation from The Jackson Laboratory and bred at the 
University of Pennsylvania. Apoc3 KO mice were bred with Apobec1-deficient, human 
APOB transgenic mice that either were wild-type (LahB WT), heterozygous (LahB Het), 
or deficient (LahB KO) for the murine Ldlr gene. Mice were maintained in monitored 
small animal facility at the University of Pennsylvania under IACUC-approved protocols, 
were fed ad libitum with a standard chow diet or Western diet containing 0.21% 
cholesterol from OpenSource Diets (Cat# D12079B, Research Diets, New Brunswick, 
NJ, USA) for the indicated periods of time. All mice were provided access to water ad 
libitum and were maintained with a 12 hour on/off light cycle with lights off from 7:00pm 
to 7:00am daily. All blood samples from mice were collected by retro-orbital bleeding 
from mice anesthetized with isoflurane using EDTA-coated glass tubes under approved 
protocols. 
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For APOC3 AAV expression experiments in mouse models, mice were initially 
fasted for four hours, bled, and administered a control AAV serotype 8 vector lacking a 
transgene (Null), APOC3 WT AAV (WT), or APOC3 A43T (A43T), all at a dose of 3x1011 
genome copies of virus per mouse as determined by digital PCR based titering by the 
Vector Core. AAVs were diluted in sterile phosphate-buffered saline (PBS) in a sterile 
chemical hood and drawn in individual insulin syringes for administration by 
intraperitoneal injection. For some experiments, CETP AAV, which was generated as 
described previously, was co-administered with Null or APOC3 AAVs at a dose of 3x1010 
genome copies per mouse; for these experiments, appropriate amounts of CETP AAV 
vector was mixed with Null or APOC3 AAV vectors and PBS for administration by 
intraperitoneal injection. Subsequent blood collections were performed after fasting the 
mice for four hours and under isoflurane anesthesia at the indicated timepoints. Blood 
was separated to obtain plasma by centrifugation in a microcentrifuge at 4 °C at 10,000 
RPM for seven minutes. All mouse experiments were performed with six mice per group 
unless otherwise noted.  
Lipid and human apolipoprotein measurements were performed on mouse 
plasma using an Axcel autoanalyzer. In addition, for some experiments, plasma was 
pooled by experimental group freshly after collection and 150 µl of plasma was 
separated by fast-protein liquid chromatography (FPLC) on a Superose 6 gel-filtration 
column (GE Healthcare Life Sciences, Pittsburgh, PA, USA) into fractions of 0.5 ml 
volume each. Total cholesterol and TG were measured from FPLC-separated fractions 
using Infinity Liquid Stable cholesterol and triglyceride reagents (Thermo Scientific, 
Waltham, MA, USA) in 96-well microplates using a Synergy Multi-Mode Microplate 
Reader (BioTek, Winooski, VT, USA). 
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Oral Fat Tolerance Tests 
Oral fat tolerance tests (OFTTs) were performed in APOC3 WT, A43T, and Null AAV 
treated mice four weeks following AAV administration. For these experiments, mice were 
fasted for 12 hours and weighed. Olive oil (Sigma, St. Louis, MO, USA) was prepared in 
1.0 ml syringes at a volume of 10 µl x fasting body weight (in grams) for each mouse. 
Mice were bled prior to olive oil administration to measure pre-gavage plasma TGs after 
fasting and then were gavaged orally with olive oil and bled subsequently at 1, 3, 5, and 
7 hours after gavage. Plasma TGs at each timepoint were measured by colorimetric 
assays in 96-well microplates as described above.  
 
TRL Clearance Studies 
For 3H-TRL clearance studies in mouse, human TRLs were obtained from pooled human 
nonfasted plasma from the Hospital of the University of Pennsylvania by density-gradient 
ultracentrifugation in a Beckman XL-90 Ultracentrifuge (Beckman Coulter, Brea, CA, 
USA) using a 70.1 Ti rotor (Beckman Coulter) at a speed of 40,000 RPM for 18 hours. 
Ultracentrifugation of the plasma enabled a white, cream-like TRL layer (d<1.006) to 
float, and this was collected and subjected to another ultracentrifugation at a density of 
1.006. The top cream-like layer was collected and measured for total protein 
concentration by bicinchoninic assay (Thermo Fisher Scientific, Waltham, MA, USA). 
Approximately 3 mg of TRL protein was used for labeling with 0.5 mCi of 3H-Triolein 
(Perkin Elmer, Waltham, MA, USA). 0.5 mCi of 3H-Triolein in toluene was dried under a 
nitrogen gas evaporator and resolubilized in 150-200 µl ethanol and then added 
dropwise to a mixture of TRLs (3 mg protein) and lipoprotein-deficient human serum 
(d>1.220, 100 mg protein per 3 mg TRL protein) in a glass tube. The mixture was then 
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incubated at 37 °C with gentle shaking for 12-14 hours. Then the mixture was subjected 
to ultracentrifugation again by addition of d=1.006 KBr solution and the cream-like top 
layer (approx. 2.5-3.0 ml) was collected, dialyzed against PBS, and fractionated by 
FPLC to measure TG and 3H activity in the TRL fractions (5-12) relative to 
unincorporated 3H activity. Dialyzed 3H-TRLs were then administered by intravenous tail-
vein injection into mice expressing Null, WT, or A43T AAVs. Mice were bled at 1, 8, 15, 
30, 60, and 120 minutes after 3H-TRL administration. 3H activity in 10 µl of plasma from 
each timepoint was measured by scintillation counting and relative 3H activity remaining 
the in circulation was calculated by normalizing the activity from each timepoint by that of 
the 1 minute timepoint for each mouse.   
 
VLDL-TG, ApoC-III, and ApoB Secretion Studies 
Hepatic VLDL secretion was measured in mice expressing Null or APOC3 AAVs using 
35S metabolic labeling as previously described [323]. Briefly, mice expressing Null or 
APOC3 AAVs at four weeks after AAV administration were fasted for four hours and 
then administered the surfactant Poloxamer P407 (25 mg in 0.4 ml PBS) by 
intraperitoneal injection to inhibit peripheral lipolysis. Fifteen minutes after P407 
administration, each mouse was administered 35S-labeled Cysteine / Methionine (0.5 
mCi in 0.2 ml PBS, Perkin Elmer, Waltham, MA, USA) by intravenous tail-vein injection. 
Mice were bled at 0, 30, 60, 90, and 120 minutes after radioisotope administration for 
plasma collection. Plasma TGs were measured at each timepoint with the Infinity 
Triglycerides reagent (Thermo Scientific) in 96-well microplates. 60 and 120 minute 
plasma samples were also used for measuring the secretion rate of newly synthesized, 
35S-labeled ApoB and ApoC-III. For ApoB measurements, 2 µl of each plasma sample 
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from these timepoints was subjected to SDS-PAGE under reducing conditions using 
NuPAGE 3-8% Tris-Acetate gels (Thermo Fisher Scientific). Gels were then fixed in 25% 
methanol / 20% acetic acid solution for 30 minutes and then with AutoFluor intensifier 
solution (National Diagnostics, Atlanta, GA, USA) for 30 minutes. Gels were then dried 
using a vacuum pump for four hours at 65 °C and then exposed to autoradiography film 
for one week at -80 °C and films were then developed. Visible bands on the film 
corresponding to ApoB-100 and ApoB-48 were marked and positions correlated on the 
dried gels, and then those bands were excised from the gels, solubilized with Solvable 
reagent (0.5 ml, Perkin Elmer) at 55 °C for three hours and then 35S activity measured by 
liquid scintillation counting. Activity of each band was normalized to the activity 
measured after trichloroacetic acid precipitation of proteins from 5 µl of plasma from the 
same plasma sample used for the ApoB SDS-PAGE. Normalized 35S activity from the 60 
and 120 minute timepoints was used to calculate the relative ApoB-100 and ApoB-48 
secretion rates. For ApoC-III secretion measurements, the procedure followed was the 
same as written above for measuring ApoB secretion, except NuPAGE 4-12% Bis-Tris 
gels were used for SDS-PAGE instead of 3-8% Tris-Acetate gels.  
 
ApoC-III Kinetic Studies 
For 125I ApoC-III clearance studies, iodinated ApoC-III [specific activity of approx. 
300,000-500,000 counts per minute (CPM) / µg protein] was mixed with plasma from 
recipient mice ex vivo at a ratio of 1 µg 125I-labeled protein / 200 µl plasma. Iodinated 
ApoC-III and mouse plasma mixtures were incubated at 37 °C for one hour were then 
administered by intravenous tail-vein injection in mice expressing either WT or A43T 
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variant APOC3 by AAV. Mice expressing WT APOC3 received 125I-WT ApoC-III protein 
and those expressing A43T APOC3 received 125I-A43T ApoC-III. Mice were bled 1 
minute, 15 minutes, 30 minutes, 1 hour, 3 hours, 5 hours, 9 hours, and 24 hours after 
radioisotope administration and sacrificed at the 24 hour timepoint. 125I activity was 
measured from 10 µl of each plasma sample by counting on a Packard Cobra II Auto-
Gamma counter. Relative activity at each timepoint was measured as the fraction of 
activity from the one minute timepoint for each mouse respectively. For experiments with 
125I-TCB labeled ApoC-III, the above procedure was followed, and in addition liver and 
kidneys were collected from mice at the 24 hour timepoint after perfusion with 10 ml of 
cold PBS. 30 mg of each tissue was homogenized in PBS and measured for 125I activity. 
Tissue 125I activity was normalized to the one minute plasma 125I activity for each mouse 
respectively. For experiments measuring urinary clearance of 125I-ApoC-III, mice were 
administered 125I-labeled proteins in the manner above, but mice were bled at 1 minute, 
3 hours, 6 hours, and 24 hours after administration only. For these experiments, mice 
were housed singly in rodent metabolic cages (Tecniplast, West Chester, PA, USA) and 
urine was collected from 0-6 hours, 6-12 hours, and 12-24 hours during the course of the 
study. Plasma and urine samples (20 µl of each sample) were counted for total 125I 
activity by gamma counting. In addition, proteins were separated by TCA precipitation 
from 20 µl of each sample and the TCA soluble (degraded) and TCA pellet (intact 
protein) fractions were counted for 125I activity.  
 
Liver Gene Expression  
For gene expression measurements, approximately 20 ng of liver tissues from each 
mouse was snap-frozen at -80 °C. Total RNA was extracted from tissues using TRIzol 
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reagent (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s 
protocol. Synthesis of cDNA was completed using 1 µg of RNA following extraction using 
the High Capacity cDNA  Reverse Transcription Kit (Thermo Fisher Scientific). 
Quantitative real-time reverse transcriptase PCR (RT-PCR) was performed on the 
synthesized cDNA using a QuantStudio 7 Real-Time PCR System using the following 
Taqman primer sets (Thermo Fisher Scientific): human APOC3 - Hs00163644_m1, 
mouse Apoc3 - Mm00445670_m1, mouse Actb (actin) - Mm00607939_s1. Relative 
expression of human APOC3 and mouse Apoc3 in the liver was analyzed for each 
mouse by normalizing to actin expression from the same sample.   
Hepatic AAV vector DNA content in each mouse was also assessed by 
quantitative real-time RT-PCR. Total hepatic DNA was isolated from 25 mg of liver for 
each mouse using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). Isolated liver 
DNA was used for quantitative RT-PCR with Taqman primers targeting the rabbit beta-
globin poly-A sequence of the AAV vector backbone. Cycle numbers from this assay 
were compared to those from a standard curve of serial dilutions of a linearized AAV 
plasmid of known quantity.  
 
Immunoblotting 
For immunoblotting of ApoC-III from mouse liver samples, 30 µg of liver was separated 
on 10% Bis-Tris NuPAGE gels using MES buffer by one-dimensional sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Separated proteins were 
transferred to nitrocellulose membranes and membranes were then blocked with 5% fat-
free milk in PBS (0.05% tween 20) for three hours. Membranes were then incubated for 
two hours at room temperature with a rabbit polyclonal antibody against human ApoC-III 
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(33A-R1a, Academy Biomedical, Houston, TX, USA) at a dilution of 1:2000, followed by 
3 x 15 minute washes with PBS / Tween solution and incubation with goat anti-rabbit IgG 
HRP conjugate (sc-2030, Santa Cruz) for 30 min. at room temperature. Membranes 
were again washed for 3 x 15 minutes and proteins visualized by Luminata Crescendo 
chemiluminescent reagent (Millipore). Mouse β-actin was used as a loading control and 
was detected from the same membranes of separated hepatic proteins after incubation 
with mouse anti-actin primary antibody (sc-81178, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) at a dilution of 1:200 for two hours at room temperature, washed, and 
then incubated with goat anti-mouse IgG HRP (sc-2302, Santa Cruz Biotechnology) at a 
dilution of 1:5000 for 30 minutes at room temperature.  
 
ApoC-III-Lipoprotein Binding Measurements  
Human TRLs and HDL3 were isolated from pooled plasma from the Hospital of the 
University of the Pennsylvania by density-gradient ultracentrifugation. Isolated 
lipoproteins were dialyzed against PBS and protein concentration measured by BCA 
assay. Radio-iodinated WT or A43T ApoC-III, generated as described above, was also 
solubilized in 10 mM ammonium bicarbonate buffer and dialyzed against PBS. For 
binding studies of ApoC-III with plasma lipoproteins, 1 µg of 125I-ApoC-III was combined 
with 200 µl of pooled donor plasma and incubated at 37 °C for one, five, or 24 hours with 
gentle shaking. Immediately after incubation, mixtures were fractionated on a Superose 
6 gel-filtration column. FPLC fractions were measured for TG and cholesterol in 0.1 ml of 
each fraction by colorimetric assays in a 96-well microplate and for 125I activity by 
gamma counting. The percentage of total activity administered through the FPLC column 
in each FPLC fraction was calculated, and the sum of total area for the lipoprotein 
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fractions vs. free protein fractions was calculated and compared across replicate 
experiments. For binding of ApoC-III to TRLs or HDL3, the procedure above was 
followed, with the exception that 200 µg of TRL protein or 100 µg of HDL3 protein was 
used for each experiment in combination with 1 µg of 125I-ApoC-III.  
Binding of 125I-ApoC-III to apolipoprotein-free lipid emulsions was also measured. 
Large lipid emulsions were prepared as described previously[324]. Briefly, a mixture of 
300 mg triolein (Sigma Aldrich) and 18 mg egg-phosphatidylcholine (Sigma Aldrich) 
were dried under a nitrogen gas evaporator and then sonicated after addition of 5 ml 
glycerol (Thermo Fisher Scientific) using a Branson 450 microtip sonicator for five 
minutes. Concentrated emulsions were allowed to clear overnight. 15 µl of this 
concentrated emulsion was combined with 90 µl distilled water, 15 µl of 1.0 M Tris pH 
8.0, 15 µl of 15% BSA solution, and 15 µl of 3.0 M NaCl to give a final volume of 150 µl 
of working emulsions. 1 µg of 125I-ApoC-III was combined with 150 µl of working 
emulsions and incubated at 37 °C for one hour and then mixtures were fractionated by 
FPLC and analyzed for 125I-activity in the emulsion-containing fractions vs. unbound 
protein fractions as detailed above. Preliminary FPLC fractionation experiments with 
emulsions alone showed that they eluted in fractions 5-15 of the 79 fractions obtained 
from gel-filtration analysis, which mirrored the fractionation pattern of human TRLs on 
the same Superose 6 column under the same conditions.  
 
LPL Activity Assays  
In vitro LPL activity in the presence of WT vs. A43T variant ApoC-III was measured by 
two independent methods. First, activity was measured against a large lipid emulsion 
made as described above but with the addition of 3H-Triolein (Perkin Elmer; 99 µg per 
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300 mg nonradioactive triolein) prior to glycerol addition and sonication as described 
previously [324]. Working emulsions were made by the method above, except that 75 µl 
of water was used and in addition 15 µl of heat-inactivated human serum was added to 
provide a source of ApoC-II. Working emulsion substrate (150 µl) was combined with 
conditioned media (100 µl) from COS7 cells expressing human LPL through adenoviral 
transduction, as described previously [324]. 50 µl of WT vs. A43T ApoC-III (final reaction 
concentration of 20 µM for each) or culture medium without ApoC-III was added to give a 
final reaction volume of 300 µl. Reactions were incubated at 37 °C for 30 minutes with 
gentle shaking prior to addition of 3.25 ml of methanol:chloroform:heptane solvent 
(1.41:1.25:1.00) to stop the reactions and subsequent addition of 1.05 ml of pH 10.0 
Buffer (Thermo Fisher Scientific). Stopped reactions were then spun at 2,000 RPM for 
20 minutes to complete the extraction, and the upper phase containing liberated fatty 
acids was used for scintillation counting (0.5 ml per sample). The relative amount of 
hydrolysis of 3H-Triolein to 3H-oleic acid was calculated for each sample and compared 
across groups. A second LPL activity assay was measured using an Intralipid TG 
substrate in the presence or absence of WT vs. A43T ApoC-III, as described before 
[113]. Briefly, 10% Intralipid substrate (Santa Cruz; 1.2 nM per reaction) and WT or 
A43T ApoC-III (range of 0-58 µM per reaction) were combined in 96-well microplates to 
a volume of 40 µl and incubated at 30 °C for 15 minutes, followed by the addition of  
purified LPL (Sigma Aldrich; 40 nM per reaction) to give a final reaction volume of 60 µl. 
Reactions were incubated at 30 C for 30 minutes and then 100 µl of Wako NEFA-HR(2) 
R1 reagent (Wako Chemicals) was added along with Orlistat to inhibit further lipolysis 
(Santa Cruz; 20 µM final reaction concentration), and the reactions were incubated for 
another 15 minutes at 30 °C. Then 50 µl of Wako NEFA-HR(2) R2 reagent was added 
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and the reactions were incubated for another five minutes at 30 °C and absorbance was 
measured at 550 nm wavelength from each sample. All LPL assays were performed with 
three independent replicate experiments.  
 
Statistical Analysis 
All discrete data shown are represented as mean standard deviation, with error bars 
showing standard deviation. Statistical comparisons between two groups were 
performed using a two-tailed Student’s t-test or one-way ANOVA as appropriate. 
Comparisons between three experimental groups were performed using two-way 
ANOVA. For measurement of mutant:WT ApoC-III ratios in A43T heterozygous carriers, 
the mean of the ratios among carriers was compared to an expected theoretical mean of 
1.0 using a one-sample t-test. Statistical significance was defined as P < 0.05 for all 
analyses.  
 
Results  
Human APOC3 A43T heterozygotes have reduced TRLs and reduced ApoC-III 
We thus searched for carriers of any of the four LoF coding variants by 
genotyping for the variants in two human cohorts using the Exome Chip. Given that prior 
studies have reported both an inverse relationship of ApoC-III levels to HDL-C levels and 
that APOC3 LoF carriers were observed to have higher levels of HDL-C than matched 
noncarriers, we questioned whether we could enrich for the discovery of APOC3 LoF 
variants in participants with high HDL-C levels. We genotyped the variants in a cohort of 
2,736 individuals with HDL-C >95th percentile for age and gender (HHDL Cohort; Table 
4.1).  In this cohort, we identified a total of 36 carriers (all heterozygous) for any of the 
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four LoF variants; this constitutes a carrier frequency of 1/76 for any LoF variant. We 
also genotyped APOC3 variants in an additional cohort of 5,744 participants from the 
Complex Genomics Initiative BioBank of the Hospital of the University of Pennsylvania 
(CGI BioBank), a cohort not enriched for high HDL-C levels. In this cohort, we identified 
an additional 28 APOC3 LoF variant carriers, with a cohort-wide carrier frequency of 
~1/205 (Table 4.1). We compared the carrier frequency in the HHDL cohort to the CGI 
BioBank cohort and the previously reported carrier frequencies from the NHLBI Exome 
Sequencing Project [106], all of which were not enriched for high HDL-C participants. 
Comparing the carrier frequencies in our HHDL Cohort with those from these normal 
HDL-C cohorts, we found a significant enrichment of APOC3 LoF variants with high 
HDL-C relative to a normally distributed population (P<0.0001 vs. CGI BioBank, 
P=0.0028 vs. NHLBI ESP Cohort, P<0.0001 vs. NHLBI ESP CHD Case-Control Cohort, 
chi-square test; Table 4.1).  
We measured fasting plasma lipids and apolipoproteins in APOC3 LoF variant 
carriers and age- and gender-matched noncarriers from the HHDL and CGI BioBank 
cohorts. Consistent with previous reports, LoF variant carriers exhibited marked 
reductions in TG levels (P<0.0001 for both cohorts; Figure 4.1 A), and increased HDL-C 
and ApoA-I (P<0.05 in the CGI BioBank Cohort, P<0.0001 in the HHDL Cohort; Figure 
4.1 B-C). We also found modest reductions in nonHDL-C and ApoB in the LoF variant 
carriers in CGI BioBank Cohort but not in the HHDL Cohort (P<0.05, Figure 4.1 D-E).  
In aggregate, carriers of APOC3 LoF variants displayed reduced ApoC-III levels 
in plasma relative to noncarriers (P<0.0001 for both cohorts; Figure 4.2 A). While 
previous studies grouped these four APOC3 LoF variants together, we hypothesized that 
they may differ in their mechanisms conferring a reduction in ApoC-III levels. Since three 
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of the four variants (R19X, IVS2+1 G>A, IVS3+1 G>T) occur at intron-exon junctions of 
the APOC3 gene, we assessed their predicted impact on RNA processing and intron 
splicing of APOC3 using information-theory based predictions about the impact of each 
variant on the thermodynamic requirements for RNA processing [319,325] (Table 4.2). 
We found that the R19X variant is predicted to increase binding of heterogeneous 
nuclear ribonucleoprotein A1 (hnRNP A1), a ubiquitously expressed regulator of nascent 
mRNA processing (Table 4.2). Additionally, both splice site variants IVS2+1 G>A and 
IVS3+1 G>T are predicted to abolish splice-donor sites (Table 4.2), causing retention of 
the adjacent introns. Since these three variants are thus predicted to disrupt APOC3 
gene expression, we assessed their combined impact on ApoC-III levels and found that 
heterozygotes for these variants had markedly reduced ApoC-III levels relative to 
noncarriers (Figure 4.2 B). Notably, their ApoC-III levels were less than half the levels of 
noncarriers (P<0.01 for CGI BioBank Cohort & P<0.05 for HHDL Cohort), suggesting 
that partial APOC3 loss-of-function may further promote reduction in circulating ApoC-III.  
The A43T missense variant is not predicted to impact binding of RNA processing 
proteins hnRNP H and hnRNP A1 and is not predicted to alter any splice-donor or 
splice-acceptor sites in the nascent APOC3 transcript (Table 4.2). Because the A43T 
variant differs from the other three variants in that it is not predicted to disrupt expression 
of the protein, we studied the mechanism by which it confers LoF to APOC3 further as it 
could uncover a different facet of regulation of ApoC-III’s metabolism and functions. We 
measured plasma lipids and ApoC-III levels in carriers of A43T vs. matched controls 
from each of our identification cohorts and found that, like the other LoF variant carriers, 
A43T heterozygotes displayed decreased fasting TGs (Figure 4.3 A), increased HDL-C 
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(Figure 4.3 B), and no differences in nonHDL-C or ApoB levels (Figure 4.4). In addition, 
A43T carriers displayed approx. 50% reduced levels of plasma ApoC-III (Figure 4.3 C).   
Since A43T is not predicted to impact splicing or expression of APOC3 mRNA, 
we questioned the cause of the lower circulating ApoC-III in the heterozygous carriers of 
A43T. We reasoned that the A43T allele might result in a mutant form of ApoC-III that is 
expressed and secreted into the circulation of the carriers. To determine if a mutant form 
of ApoC-III exists in the plasma of A43T heterozygotes, we developed a multiple 
reaction monitoring assay to simultaneously measure peptides corresponding to the 
wild-type (WT) or A43T mutant forms of ApoC-III from the plasma of A43T heterozygotes 
by liquid chromatography and tandem mass spectrometry. After proteolysis of the 
plasma samples by AspN protease, a 20 amino acid peptide corresponding to either the 
WT form of ApoC-III containing alanine in original residue position 43 (Figure 4.3 D), 
and an analogous peptide with threonine corresponding to the mutant form (Figure 4.3 
E), were monitored for fragments of expected m/z ratios and the relative amount of 
mutant to WT peptides were quantified for each sample. From this measurement, we 
found that A43T carrier plasma exhibited a detectable amount of A43T mutant ApoC-III 
peptides while noncarriers for ApoC-III variants demonstrated no observable mutant 
peptides (Figure 4.3 F). Notably, the ratio of mutant to WT ApoC-III, as assessed by 
ratio of the relative amounts of the mutant to WT peptides used for monitoring, was 
0.14:1, which was lower than an expected ratio of 1:1. This suggests a significant 
imbalance in the amount of mutant ApoC-III in the circulation relative to WT (P<0.0001, 
one-sample T-test; Figure 4.3 F). Using the observed ratios to determine the amount of 
WT vs. mutant ApoC-III in the plasma of the carriers, we found that A43T carriers also 
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demonstrate a trend towards reduced levels of the WT ApoC-III relative to that expected 
from the levels observed in noncarriers (Figure 4.3 G).  
APOC3 A43T confers improved TRL metabolism in mice in vivo 
Given the presence of a mutant ApoC-III protein in the plasma of A43T carriers, 
we concluded that A43T alleles encode for a secreted ApoC-III form and sought to 
further understand how this variant may confer LoF. We generated murine models to 
compare WT to A43T human ApoC-III in vivo through expression of adeno-associated 
virus (AAV) vectors expressing either form of the human APOC3 transgene. AAV-
mediated WT APOC3 expression caused a dose-dependent elevation in circulating 
human ApoC-III, as well as plasma TGs in WT mice relative to controls administered a 
Null vector lacking a transgene (Figure 4.5). Because an AAV dose of 3 x 1011 genome 
copies (GC)/mouse conferred a robust increase in circulating ApoC-III to approx. 10-15 
mg/dL, mirroring the range of normal ApoC-III concentration in humans, and also 
increased fasting TGs by two weeks of administration, we used this dose to compare the 
effect of Null, WT, and A43T APOC3 AAVs on plasma lipids and ApoC-III levels in 
multiple murine models, including WT mice, Apoc3 KO mice, and multiple humanized 
hyperlipidemic models (Table 4.3). In all models, WT APOC3 expression raised while 
A43T expression failed to elevate fasting plasma TGs over five weeks after AAV 
administration (Figure 4.6 A-C & Table 4.3). In WT mice co-expressing cholesteryl ester 
transfer protein (CETP), a key mediator of lipid exchange between TRLs and HDL in 
humans but absent in rodents, A43T expression conferred markedly lower fasting TGs 
(Figure 4.6 C), higher HDL-C (Figure 4.6 D), and lower nonHDL-C (Figure 4.6 E), 
which was also observed after fractionation of plasma into lipoprotein fractions by fast-
protein liquid chromatography (Figure 4.6 F-G). The effects of A43T on plasma lipids 
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through AAV-mediated expression in this ‘humanized’ mouse model thus recapitulate 
the protective lipoprotein profile of the human A43T variant carriers.  
 Given the roles of ApoC-III in delaying postprandial TG clearance through both 
inhibiting LPL activity on circulating TRLs and blunting hepatic TRL remnant clearance, 
we sought to understand if A43T impairs postprandial TG metabolism as well. We tested 
the in vivo activity of LPL mediated TG clearance in mice expressing Null, WT, or A43T 
APOC3 by measuring TGs after intragastric administration of olive oil. Mice expressing 
WT APOC3 demonstrated a robust increase in plasma TGs and delayed postprandial 
TG clearance relative to mice treated with Null virus (Figure 4.6 H). Mice expressing 
A43T exhibited no increase in postprandial TGs relative to Null treated mice, thus 
showing a significant increase in TG clearance relative to WT expressing mice. To test 
the impact of post-absorptive TG clearance, we administered 3H-triolein labeled TRLs in 
mice expressing Null, WT, or A43T APOC3. Similarly to the results for postprandial TG 
clearance, we observed a faster TRL-TG clearance of labeled TRLs in A43T expressing 
mice relative to WT expressing mice (Figure 4.6 I). Some prior reports have suggested 
that ApoC-III may also increase circulating TGs by promoting hepatic VLDL-TG 
secretion by facilitating the fusion of TG droplets on nascent VLDL particles[326,327]; 
we measured VLDL-TG secretion into blood in mice after administration of Poloxamer 
P407 [328], a competitive inhibitor of LPL, and found no differences in TG, ApoB100 or 
ApoB48 secretion rates in mice expressing A43T vs. WT or Null virus (Figure 4.7). 
Collectively, these data support a role for A43T in weakening ApoC-III’s effects on the in 
vivo metabolism of postprandial TRLs.  
 Because we observed a reduced amount of A43T mutant ApoC-III in the plasma 
of human A43T carriers, we next asked the impact of the A43T variant on circulating 
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ApoC-III levels in mice expressing A43T via AAV. Compared to mice expressing WT 
APOC3, mice expressing A43T demonstrated a <50% steady state levels of ApoC-III in 
fasting plasma (Figure 4.6 J). Notably, ApoC-III was present in the plasma of A43T 
expressing mice and was relatively constant from two to five weeks after AAV 
administration, while no detectable ApoC-III was observed in mice given Null virus. We 
next asked whether the cause of the reduced ApoC-III levels in A43T expressing mice 
was related to reduced expression of APOC3 in mice treated with this AAV. We noted no 
differences in total hepatic copies of APOC3 AAV in mice treated with WT vs. the mutant 
virus (Figure 4.8), suggesting that viral delivery to the liver did not differ between the 
viruses. Hepatic levels of human APOC3 mRNA were also comparable in the mice 
expressing WT vs. A43T (Figure 4.6 K), as were relative levels of total hepatic ApoC-III 
protein as measured by immunoblotting (Figure 4.6 L). To determine if A43T impacted 
ApoC-III secretion from the liver, we administered 35S labeled cysteine and methionine 
intravenously to mice expressing Null, WT, or A43T APOC3 AAVs and measured newly 
synthesized, metabolically labeled ApoC-III secreted from the liver. Because ApoC-III 
exchanges between TRLs and HDLs and can be cleared by hepatic receptors when on 
metabolized TRL remnants, we blunted TRL clearance during this measurement by 
inhibiting LPL activity with Poloxamer P407. We compared the activity of labeled ApoC-
III in plasma up to two hours after metabolic labeling and observed increased ApoC-III 
secretion in mice expressing either WT or A43T relative to Null treated mice (Figure 4.6 
M), consistent with increased total ApoC-III production due to the transgene. Notably, we 
observed no difference in the secretion rate of ApoC-III from mice expressing A43T vs. 
WT ApoC-III (Figure 4.6 N). These findings are thus consistent with those from human 
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carriers and demonstrate that A43T confers expression of a mutant form of ApoC-III that 
is secreted and appears in the circulation.  
A43T increases clearance and renal excretion of circulating ApoC-III  
 Since ApoC-III secretion did not differ between mice expressing A43T vs. WT 
ApoC-III, we asked if the cause of the lower steady-state ApoC-III conferred by A43T 
expression could be due to more rapid catabolism of the mutant protein. This notion is 
supported by the predicted helical structure of ApoC-III, which suggests that the alanine 
43 residue (residue 23 of the mature ApoC-III protein after signal peptide cleavage) 
exists on the hydrophobic face of a predicted alpha helix that could mediate binding to 
lipids[327]. We tested the impact of A43T on the circulating stability of ApoC-III in vivo by 
measuring the clearance rate of 125I tyramine cellobiose (TCB) labeled WT or A43T 
ApoC-III. Mice expressing WT or A43T APOC3 were administered labeled ApoC-III of 
the same form pre-incubated with plasma from the same mice to allow initial binding to 
lipoproteins, and then this mixture was administered to mice intravenously. ApoC-III 
containing the A43T mutant exhibited a marked increase in clearance from the 
circulation over 24 hours after administration relative to that of WT (Figure 4.9 A), with a 
>3-fold increase in the total fractional catabolic rate in plasma (Figure 4.9 B). These 
results were also observed in mice administered 125I labeled ApoC-III without the 
tyramine cellobiose modification, suggesting that the observed clearance and relative 
differences were not a result of conformational changes caused by the tyramine 
cellobiose moiety (Figure 4.10 A-B).  
 ApoC-III clearance is thought to occur largely through two pathways: receptor-
mediated remnant lipoprotein clearance by the liver and filtration of unbound ApoC-III by 
the kidney [329-333]. However, the relative contributions of these two clearance 
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pathways and how they may contribute to the functional pool of circulating ApoC-III that 
promotes TRL retention remains unclear. We compared the uptake of 125I TCB-labeled 
WT to A43T ApoC-III in the two main tissues mediating ApoC-III catabolism, the liver 
and kidney, at the end of the 24 hours of clearance and found that the A43T mutant 
protein was cleared ~40% less by the liver and ~40% more by the kidney than the WT 
(Figure 4.9 C-D). Additional clearance studies with radio-iodinated ApoC-III lacking the 
trapped TC moiety allowed the measurement of urinary ApoC-III clearance and showed 
that the A43T mutant protein was degraded and cleared into the urine at a higher rate 
than the WT protein (Figure 4.9 E & Figure 4.10 C-E). Indeed, the TCA precipitable 
activity of the mutant ApoC-III in the plasma constituted a lower fraction of the total 
activity at the one minute, three hour and six hour timepoints compared to that of the 
WT, suggesting that the mutant protein is degraded more rapidly and then filtered by the 
kidney for urinary excretion (Figure 4.10 F-G).  
Since that we observed faster total ApoC-III clearance and increased renal 
uptake with decreased hepatic uptake for the A43T mutant, we hypothesized that the 
A43T mutant may impact the relative pools of lipoprotein-bound vs. free ApoC-III. To test 
this, we fractionated plasma from mice administered 125I TCB labeled WT vs. A43T 
ApoC-III one minute after administration of the ApoC-III / plasma mixture and measured 
the relative amount of ApoC-III bound to lipoprotein fractions vs. free. For WT ApoC-III, 
approximately 40% of the total radiolabeled protein was bound to either VLDL/TRLs or 
HDL fractions, with the remainder of the protein being unbound. In contrast, TRLs from 
mice given the A43T mutant lacked the radiolabeled ApoC-III entirely, and HDL-bound 
ApoC-III was also reduced. A ~35% increase in unbound ApoC-III was observed from 
the fractionated plasma from this group (Figure 4.9 F). We further tested whether A43T 
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also blunted binding of ApoC-III to human lipoproteins by measuring the association of 
radiolabeled ApoC-III with human plasma lipoproteins in vitro. Consistent with the ex 
vivo findings from mouse plasma, ~50% of total WT ApoC-III bound to TRL and HDL 
fractions after incubations for one, five, and 24 hours at 37 °C (Figure 4.9 G & Figure 
4.11 A-C). In contrast, the A43T mutant demonstrated reduced binding to TRL fractions 
and HDL with ~45% increased activity in the unbound fractions. We further explored the 
impact of A43T on lipoprotein binding by testing the individual association of WT vs. 
mutant ApoC-III with isolated human lipoproteins. A43T exhibited similar 50-60% 
reductions in binding to TRLs (Figure 4.9 H & Figure 4.11 D) and HDLs (Figure 4.9 I & 
Figure 4.11 E), with increased free protein appearing in unbound fractions. Similar 
results were obtained in experiments in which VLDL and HDL were mixed with 
radiolabeled WT or A43T mutant ApoC-III and lipoprotein-bound ApoC-III content was 
measured after ultracentrifugation (data not shown). These results support the notion 
that A43T impairs the binding capacity of ApoC-III for lipoproteins, thus promoting its 
dissociation from lipoproteins in vivo and resulting in increased free ApoC-III clearance 
via the renal clearance pathway.  
The mechanism of A43T-mediated disruption of ApoC-III’s ability to bind 
lipoproteins may have implications for the development of targeted therapies to block 
ApoC-III function in the circulation. We thus wanted to better understand how A43T 
impairs ApoC-III:lipoprotein association, and the potential implications this might have on 
ApoC-III’s ability to impair TG clearance. To this end, we first asked if the binding 
impairment by A43T was a result of a protein:lipid vs. protein:protein interaction. We 
generated large TRL-like emulsions composed of TG and phospholipids but devoid of 
any apolipoproteins and tested the ability of 125I labeled ApoC-III to bind these emulsions 
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compared to binding of isolated TRLs and similar emulsions containing the same lipid 
content in the presence of albumin. For all measurements, A43T mutant ApoC-III 
exhibited approximately the same 50% reduction in binding to emulsions or TRLs with 
commensurate increases in the amount of unbound ApoC-III (Figure 4.11 F-G). These 
data were suggestive of an ApoC-III:lipid interaction mediating the association of ApoC-
III to lipoproteins that is reduced by the A43T mutant. Consistent with this, we found that 
A43T ApoC-III exhibited a ~five-fold dissociation constant (KD) in binding to an 
immobilized surface of phospholipids in vitro by surface plasmon resonance (Figure 4.9 
J). Consistent with the lipid-binding deficits driving the LoF conferred by A43T, we 
observed that, for equal concentrations of ApoC-III, the A43T mutant was less capable 
of inhibiting LPL activity in vitro against large TG-rich emulsions (Figure 4.12 A-B) and 
an Intralipid TG substrate in vitro relative to WT (2.7-fold increased IC50, P<0.001, 
Figure 4.12 C-D).   
 
Discussion 
Our data thus unveil one mechanism of LoF of APOC3 as revealed by the study 
of a naturally occurring missense variant, A43T. We show that, though the lipid 
phenotype and steady state ApoC-III levels conferred by this variant are similar to other 
APOC3 LoF variants, A43T confers ApoC-III LoF and thus protection from dyslipidemia 
and CHD risk by a different mechanism. Notably, the increased ApoC-III turnover and 
renal clearance of the mutant ApoC-III as a consequence of the A43T variant 
predominately enhances the lipolytic pathway of TG turnover in vivo. This contrasts with 
prior studies suggesting that ApoC-III may primarily inhibit TRL turnover at the level of 
delaying remnant particle clearance rather than inhibiting the LPL pathway [99,100,333-
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335]. Our results here suggest that the A43T variant may be most relevant in 
rebalancing the pool of lipoprotein-bound to free ApoC-III in the circulation, which may 
thus promote lipolysis of TRL-TGs in the periphery as the mutant ApoC-III is no longer 
retained on the particles due to defective binding. The impact of this variant, and more 
broadly, the promotion of ApoC-III dissociation from TRLs in the peripheral circulation on 
the relative ApoC-III content of the remnant particles that interface with hepatic receptors 
thus remains an important area for continued investigation.  
Based on our findings, therapeutic discovery related to promoting disruption of 
ApoC-III binding to lipoprotein particles may be efficacious in reducing ApoC-III levels by 
promoting renal clearance, a mechanism which appears safe both from human and 
murine model studies of this variant. Prior studies of murine models of human APOC3 
and CETP co-expression demonstrated a synergistic proatherogenic effect resembling 
the human familial combined hyperlipidemia phenotype [318]; our data here from the 
humanized murine models expressing CETP suggest that the protective effect of 
reduced ApoC-III binding to lipoproteins is possibly enhanced in the setting of CETP-
mediated lipid exchange between TRLs and HDL. This supports the notion that such a 
strategy to reduced ApoC-III function would be efficacious in humans. Therapeutic 
leveraging of this pathway based on the findings from APOC3 A43T to lower TGs could 
mirror the approach to targeting PCSK9 to reduce LDL-C [336,337], which emerged from 
human genetics studies of both LoF and gain-of-function nonsynonymous coding 
variants [32,38,39], which were shown to be protective from CHD. As supported by that 
example, the success and safety of developing treatments for ApoC-III lowering may 
benefit from further comparisons between a putative drug in development with the 
metabolic signatures of LoF variant carriers and appropriate animal models.  
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Figure 4.1 
 
Figure 4.1: Plasma lipids in carriers of all APOC3 LoF variants vs. noncarriers in CGI BioBank and HHDL cohorts. A. 
Triglycerides (TGs) in overnight fasted plasma of carriers of any of the four APOC3 LoF variants vs. matched controls. Carriers were 
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identified in two cohorts, the CGI BioBank cohort (left) and the HHDL cohort (right). Controls were matched for age and gender for 
each cohort. B. HDL cholesterol (HDL-C) from fasting plasma of APOC3 LoF variant carriers vs. controls shown in A. C. ApoA-I 
concentration in fasting plasma from APOC3 LoF variant carriers vs. controls shown in A. D. Non-HDL cholesterol concentration in 
APOC3 LoF variant carriers vs. controls. E. ApoB concentration in APOC3 LoF variant carriers vs. controls. All measurements show 
mean ± S.D. where appropriate. For A-C and G, *P<0.05, ****P<0.0001, Student’s unpaired T-test. Contributions: All data in this 
figure generated and analyzed by SAK.   
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Figure 4.2 
 
Figure 4.2: Plasma ApoC-III levels in carriers of APOC3 LoF variants vs. controls 
from CGI BioBank and HHDL cohorts. A. Plasma ApoC-III levels in overnight fasted 
plasma from carriers of any of the four APOC3 LoF variants vs. noncarriers. 
Measurements were made in a sample of carriers and age- and gender-matched 
controls from the CGI BioBank cohort (left) and HHDL cohort (right). B. ApoC-III 
concentrations in carriers of the three LoF variants predicted to abolish splicing or 
expression (R19X, IVS2+1 G>A, IVS3+1 G>T) vs. controls in the CGI BioBank cohort 
(left) and HHDL cohort (right). Mean total concentrations for each group are indicated 
above the data points.  Half of the mean levels observed in the noncarriers for each 
cohort are indicated by the red dotted line. All measurements show mean ± S.D. where 
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appropriate. For comparisons of total ApoC-III concentrations between carriers and 
controls in A and B, ****P<0.0001, Student’s unpaired T-test. For comparisons of the 
concentrations of carriers of R19X, IVS2+1 G>A and IVS3+1 G>T to the value of half of 
the mean total concentration of the noncarriers for each cohort in B, ****P<0.0001, one-
sample T-test with an expected value of the half-mean of the noncarriers for each 
respective cohort. Contributions: All data in this figure generated and analyzed by SAK. 
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Figure 4.3 
 
Figure 4.3: Human APOC3 A43T carriers exhibit reduced ApoC-III levels due to lower mutant protein. A. Triglycerides (TGs) in 
overnight fasted plasma of carriers of A43T vs. matched controls. Carriers were identified in two cohorts, the CGI BioBank cohort 
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(left) and the HHDL cohort (right). Controls were matched for age and gender for each cohort. B. HDL cholesterol (HDL-C) from 
fasting plasma of A43T carriers vs. controls shown in A. C. ApoC-III concentration in fasting plasma from A43T carriers vs. controls 
shown in A. D. (Top) Peptide sequence for AspN-generated 20 amino acid peptide corresponding to WT ApoC-III. Position of the 
variant amino acid between WT and mutant peptides is shown in red. (Bottom) Mass spectra of fragment ions generated and 
observed from peptide above after fragmentation in triple quadrupole mass spectrometer (left), and fragment ion intensities for 
respective retention time (right). For each peptide, four fragment ions were monitored that contained the variant amino acid. E. (Top) 
Peptide sequence and (Bottom) mass spectra of fragment ions for AspN-generated 20 amino acid peptide corresponding to mutant 
ApoC-III. Position of the variant amino acid between WT and mutant peptides is shown in red. F. Ratio of mutant:WT ApoC-III as 
determined by fitting relative intensities of mutant:WT fragment ions for the parent peptides shown in D-E from plasma samples of 
A43T carriers (left) vs. noncarriers (right). The mutant:WT ratio of the group of A43T carriers was compared to an expected ratio of 
1:1 for no imbalance by a one-sample T-test with expected mean of 1.0. G. Allele-specific ApoC-III concentration in plasma samples 
of noncarriers and A43T carriers as measured in F. Mutant:WT ratios from A43T carriers in F were multiplied by total ApoC-III 
concentrations for each participant to determine mutant and WT ApoC-III concentrations. For noncarriers, total ApoC-III 
concentration was divided by two to estimate allele-specific ApoC-III levels. All measurements show mean ± S.D. where appropriate. 
For A-C and G, *P<0.05, **P<0.01, ***P<0.001, Student’s unpaired T-test. Contributions: Data in panels A-C generated and analyzed 
by SAK; data in panels D-G generated and analyzed by SAK, Xuemei Zeng, and Nathan Yates using samples processed by SAK. 
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Figure 4.4 
 
Figure 4.4: Additional lipids measurements in carriers of the APOC3 A43T variant 
vs. noncarrier controls in the CGI BioBank and HHDL cohorts. A. Non-HDL 
cholesterol in overnight fasted plasma of A43T carriers vs. age- and gender-matched 
controls from the CGI BioBank cohort (left) and HHDL cohort (right). B ApoB 
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concentrations in A43T variant carriers vs. controls from the two cohorts in A. C. ApoA-I 
concentrations in A43T carriers vs. controls from the two cohorts in A. All measurements 
show mean ± S.D. where appropriate. *P<0.05, Student’s unpaired T-test. Contributions: 
All data in this figure generated and analyzed by SAK. 
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Figure 4.5 
 
Figure 4.5: Dose-optimization studies of WT APOC3 AAV in mice. A. Plasma human 
ApoC-III concentration in C57BL/6 WT mice administered the indicated doses (genome 
copies of vector per mouse) of WT APOC3 AAV by intraperitoneal injection (N=3 mice 
per group). Measurements were made eight weeks after AAV administration. B. Plasma 
TGs from four hour fasted plasma from mice in A over eight weeks. C. Plasma HDL-C 
from mice in A. D. Plasma Non-HDL-C in mice from A. E. Plasma phospholipids from 
mice in A. F. Plasma alanine aminotransferase (ALT) levels in mice from A. All 
measurements show mean ± S.D. where appropriate. *P<0.05, ***P<0.001, Student’s 
unpaired T-test compared to Null group. Contributions: All data generated and analyzed 
by SAK. 
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Figure 4.6 
 
Figure 4.6: Mice expressing APOC3 A43T have reduced TRLs and circulating 
ApoC-III in vivo. A. Fasting plasma TGs in Apoc3 KO mice expressing Null, WT 
APOC3, or A43T APOC3 after AAV-mediated expression in the liver for the indicated 
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timepoints. Plasma was drawn after 4 hours of fasting. B. Fasting plasma TGs in human 
APOB transgenic, Apobec1 KO (LahB WT) mice expressing the indicated transgenes. C. 
Fasting TGs in WT mice expressing the indicated transgenes and co-expressing human 
CETP by AAV. D. Plasma HDL-C in the mice from C. E. Non HDL-C in the mice from C. 
F. TGs in FPLC-separated plasma fractions from Day 28 plasma from mice in C. 
Lipoprotein fractions are indicated above fraction numbers. G. Cholesterol in FPLC 
fractions from F. H. Postprandial TGs in Apoc3 KO mice expressing indicated 
transgenes by AAV and co-expressing CETP following olive oil gavage. I. Plasma 3H 
activity (expressed as fraction of activity in 1 minute plasma samples) in WT mice 
expressing indicated transgenes after intravenous administration of 3H triolein-labeled 
human TRLs. J. Plasma ApoC-III concentration in fasting plasma from mice from C. K. 
Hepatic APOC3 mRNA levels (normalized to that of actin) in mice from C. L. Total 
hepatic ApoC-III immunoblots from liver lysates of mice from C after sacrificing 28 days 
after AAV administration. Blots for actin are shown below for each corresponding ApoC-
III blot as a loading control. M. Plasma 35S total ApoC-III activity (normalized to activity in 
2 μl of plasma after TCA precipitation) for mice expressing the indicated transgenes 35 
days after AAV administration. N. Secretion rates as measured by the slope of the 
curves in M. All measurements show mean ± S.D. where appropriate. **P<0.01, 
***P<0.001, ****P<0.0001, Two-way ANOVA, WT vs. A43T groups. Contributions: All 
data in this figure generated and analyzed by SAK.  
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Figure 4.7 
 
Figure 4.7: VLDL TG and ApoB secretion in mice expressing WT vs. A43T APOC3. 
A. (top) Plasma TG levels over time after Poloxamer P407 and 35S administration in WT 
mice expressing Null or APOC3 AAVs for four weeks. Curves were fitted to a line in 
GraphPad Prism. (bottom) Secretion rates as measure by the slope of the curves in A. 
B. (top) Plasma 35S-ApoB100 activity (normalized to activity in 2 μl of plasma after TCA 
precipitation) for mice expressing the indicated transgenes four weeks after AAV 
administration. ApoB100 bands were excised from gels after SDS-PAGE and activity 
measured by scintillation counting and normalized to the TCA precipitable activity from 
plasma from the same plasma samples. (bottom) Secretion rates as measure by the 
slope of the curves in B. C. Plasma 35S-ApoB48 activity from mice in A and B. ApoB48 
bands were excised after SDS-PAGE, measured for activity and normalized to TCA 
precipitable activity from the same plasma samples. (bottom) Secretion rates as 
measured by the slope of the curves in C. All measurements show mean ± S.D. where 
appropriate. Contributions: All data generated and analyzed by SAK.  
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Figure 4.8 
 
Figure 4.8: Hepatic AAV vector levels in mice expressing WT vs. A43T APOC3 
AAVs. AAV vector DNA copy number was measured in the livers of mice expressing WT 
vs. A43T APOC3 AAV. Total DNA was isolated from 25 mg of liver from each mouse 
and used to measure AAV copy number by quantitative RT-PCR for the rabbit beta-
globin polyA sequence. Measurements show mean ± S.D. where appropriate. 
Contributions: All data generated and analyzed by SAK. 
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Figure 4.9 
 
Figure 4.9: A43T promotes circulating ApoC-III clearance and augments renal uptake by perturbing binding to lipoproteins. 
A. Plasma 125I tyramine cellobiose (TCB) labeled WT or A43T ApoC-III clearance in plasma in LahB WT mice over 24 hours. Mice 
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expressing WT APOC3 by AAV were administered WT labeled ApoC-III and those expressing A43T were administered the 
radiolabeled A43T ApoC-III. Normalized 125I activity relative to 1 minute plasma activity is shown. B. Fractional catabolic rate of 
plasma 125I activity, as measured by WinSAAM multi-exponential modeling program. Catabolic rates were calculated for each mouse 
individually. C. Hepatic 125I TCB activity in 30 mg of tissue for mice in A. Activity was normalized to 1 minute plasma activity. D. 
Kidney 125I TCB activity in 30 mg of tissue from mice in A. E. Total 125I activity measured in urine collected from WT vs. A43T 
expressing mice at the end of 24 hours of collection following intravenous 125I ApoC-III administration. F.125I activity in FPLC fractions 
of 1 minute plasma from mice in A after pooling by indicated group. Activity is expressed as fraction of total activity in plasma pool 
prior to FPLC separation. G. 125I activity in FPLC fractions after incubation of 125I labeled WT vs. A43T ApoC-III (1 μg) with human 
plasma (200 μl) for one hour at 37 °C. Results show mean of three replicate experiments. H. Relative 125I activity in VLDL fractions 
vs. unbound protein fractions after incubation of 125I labeled WT vs. A43T ApoC-III (1 μg) with isolated human VLDL (200 μg protein) 
for one hour at 37 °C. I. Relative 125I activity in HDL fractions vs. unbound protein fractions after incubation of 125I labeled WT vs. 
A43T ApoC-III (1 μg) with isolated human HDL (200 μg protein) for one hour at 37 °C. J. Dissociation constant from measurement of 
Kon and Koff constants from binding of WT or A43T ApoC-III to dimyristoylphosphatidylcholine surfaces by surface plasmon 
resonance. For H-J, bars indicate mean of results from three replicate experiments. All measurements show mean ± S.D. where 
appropriate. *P<0.05, **P<0.01, ***P<0.001, Student’s unpaired T-test; ****P<0.0001, 2-way ANOVA (A), ****P<0.0001, Student’s 
unpaired T-test (B). Contributions: All data generated and analyzed by SAK. 
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Figure 4.10 
 
Figure 4.10: Urinary clearance of 125I-labeled WT vs. A43T ApoC-III in mice. A. 
Plasma 125I clearance curves over 24 hours for radiolabeled WT vs. A43T ApoC-III in WT 
mice expressing either WT or A43T APOC3 AAVs (N=4 mice per group). Mice 
expressing WT APOC3 AAV received WT iodinated ApoC-III by intravenous 
administration and A43T APOC3-expressing mice received iodinated A43T ApoC-III 
protein. B. Fractional catabolic rate of plasma 125I activity, as measured by WinSAAM 
multi-exponential modeling program. Catabolic rates were calculated for each mouse 
individually. C. Total urinary 125I activity at the indicated time intervals over the course of 
the 125I ApoC-III clearance study. Urine was collected individually at the indicated 
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timepoints for each mouse and 125I activity was measured and removed from metabolic 
cages prior to the next collection period up through 24 hours. D. 125I activity in TCA 
soluble fraction of urine collected from each mouse at the indicated time intervals. 20 µl 
of urine was subjected to TCA precipitation and TCA soluble fractions were collected 
and re-measured for 125I activity. The fraction of the 20 µl of urinary 125I activity appearing 
in the TCA soluble fraction was used to calculate the proportion of TCA soluble 125I 
activity in the total urine collected for each mouse for the indicated time intervals. E. 125I 
activity in the TCA precipitable fraction of the urine collected from each mouse at the 
indicated time intervals. The TCA precipitable activity from the urine used in D was 
measured for 125I activity and the fraction of total urinary 125I activity prior to TCA 
precipitation that appeared in the TCA precipitate from 20 µl urine was used to calculate 
the TCA precipitable 125I activity from the total urine collected for each mouse at each 
time interval. F. Fraction of plasma 125I activity in TCA supernatant vs. pellet for each 
timepoint from 20 µl of plasma from mice administered 125I-labeled WT vs. A43T ApoC-
III. G. Fraction of urinary 125I activity in TCA supernatant vs. pellet for each time interval 
of urine collection for mice administered 125I labeled WT vs. A43T ApoC-III. TCA soluble 
vs. precipitable 125I activity was measured from 20 µl of urine for each mouse for each 
time interval as indicated in D-E. All measurements show mean ± S.D. where 
appropriate. For A, **P<0.01, two-way ANOVA of WT vs. A43T clearance curves. For B-
F, *P<0.05, ***P<0.001, Student’s unpaired T-test. For F, comparisons are of the fraction 
of total activity in TCA precipitable fraction for WT vs. A43T for a given time interval. 
Contributions: All data generated and analyzed by SAK.   
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Figure 4.11 
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Figure 4.11: Binding of WT vs. A43T ApoC-III to lipid and human lipoprotein fractions. A. 125I activity from FPLC-separated 
fractions of human plasma after incubation of 125I-labeled WT vs. A43T ApoC-III with human plasma (1 µg ApoC-III and 200 µl 
plasma) for 1 hour at 37 °C. Activity is expressed as the fraction of total 125I activity in the ApoC-III:plasma mixture prior to FPLC 
separation. B. 125I activity from FPLC-separated fractions of human plasma incubated with 125I-labeled WT vs. A43T ApoC-III for 5 
hours at 37 °C. C. 125I activity from FPLC-separated fractions from human plasma incubated with 125I-labeled WT vs. A43T ApoC-III 
for 24 hours at 37 °C. D. 125I activity from FPLC-separated fractions of human TRLs incubated with 125I-labeled WT vs. A43T ApoC-III 
(1 µg ApoC-III and 100 µg TRL protein) for 1 hour at 37 °C. Graphs show mean ± S.D. of three replicate experiments. E. 125I activity 
from FPLC-separated fractions of human HDL3 incubated with 125I-labeled WT vs. A43T ApoC-III (1 µg ApoC-III and 200 µg HDL3 
protein) for 1 hour at 37 °C. Graphs show ± S.D. of three replicate experiments. F. 125I activity from FPLC-separated fractions of large 
lipid emulsions incubated with 125I-labeled WT vs. A43T ApoC-III for 1 hour at 37 °C. Graphs show ± S.D. of three replicate 
experiments. G. Relative 125I activity in lipid emulsion fractions vs. unbound protein fractions from experiments in F. Bars indicate 
sum of relative amount of activity in fractions from three replicate experiments. All measurements show mean ± S.D. where 
appropriate. For A-C and G, **P<0.01, Student’s unpaired T-test. Contributions: All data generated and analyzed by SAK.   
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Figure 4.12 
 
Figure 4.12: Impact of A43T on LPL inhibition by ApoC-III. A. Relative LPL activity 
against 3H-triolein labeled large lipid emulsion substrate with increasing reaction 
concentrations of WT ApoC-III. LPL activity was measured as the amount of 3H-oleic 
acid released over 30 minutes of incubation at 37 °C. Data is shown as the fraction of 
3H-oleic acid released relative to that from the 0 µM ApoC-III group. Each bar represents 
triplicate reactions. B. Relative LPL inhibition of WT vs. A43T ApoC-III using the assay in 
A with an ApoC-III concentration of 20 µM. LPL inhibition is graphed as the relative 
difference in LPL activity between a 0 µM ApoC-III group and each of the 20 µM ApoC-III 
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groups (WT and A43T). All reactions took place for 30 minutes at 37 °C and were 
performed in triplicate. C. Relative LPL activity against an Intralipid emulsion substrate 
with concentrations of WT or A43T ApoC-III as indicated. LPL activity was measured as 
the amount of free fatty acids released for each reaction as measured by relative light 
units after addition of colorimetric reagent to reaction incubations. Each reaction was 
performed in triplicate.  D. IC50 concentration of ApoC-III for WT vs. A43T from the 
activity curves in C. Each bar represents triplicate reactions. All measurements show 
mean ± S.D. where appropriate. **P<0.01, ***P<0.001, Student’s unpaired T-test. 
Contributions: Data in panels A-B generated and analyzed by SAK; data in panels C-D 
generated by a James Landro and analyzed by SAK.  
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 Table 4.1 
Table 4.1: Discovery and Carrier Frequency of APOC3 LoF Variants through Exome 
Chip Genotyping 
Discovery 
Cohort 
Total 
Number of 
Participant
s 
APOC3 LoF Variant Carriers 
Identified 
Total 
Number of 
APOC3 LoF 
Variant 
Carriers 
Identified 
APOC3 LoF 
Allele 
Frequency  
Carrier 
Frequency  
Association of 
LoF Carrier 
Frequency in 
HHDL vs. Other 
Cohorts (Chi-
square test) R19X IVS2+1 G>A 
A43
T 
IVS3+
1 G>T 
HHDL 
Cohort 2,736 6 14 14 2 36 
0.0066 
(~1/152) 
0.0132 
(~1/76)   
CGI 
BioBank 
Cohort  
5,744 4 17 6 1 28 0.0024 (~1/410) 
0.0049 
(~1/205) P < 0.0001 
NHLBI ESP 
Participants 6,496 3 19 15 6 43 
0.0033 
(~1/302) 
0.0066 
(~1/151) P = 0.0028 
NHLBI ESP 
APOC3 CHD 
Case-
Control 
Genotyping 
Cohort 
110,970         498 0.0022 (~1/446) 
0.0045 
(~1/223) P < 0.0001 
 
Table 4.1: Discovery and carrier frequency of APOC3 LoF variants through exome 
chip genotyping. The indicated numbers of participants for the HHDL cohort (HDL-C 
>95th percentile for age and gender) and CGI BioBank cohort (normally distributed HDL-
C cohort) were genotyped using the Exome Chip for the four APOC3 LoF variants, with 
the indicated number of carriers for each variant identified. For comparison, the carriers 
of the APOC3 LoF variants were also determined for the National Heart Lung and Blood 
Institute Exome Sequencing Project (NHLBI ESP) participants 
(http://evs.gs.washington.edu/EVS/) and the previously reported NHLBI ESP CHD case-
control genotyping participants[106]. The aggregate variant allele frequency for any of 
the four APOC3 LoF variants was determined based on the total number of variant 
alleles identified relative to the total number of alleles in the cohort. The carrier 
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frequency was determined to be twice the LoF allele frequency for each cohort. The 
carrier frequencies for each of the normally distributed HDL cohorts (CGI BioBank cohort 
and the two NHLBI ESP participant groups) were compared to that of the HHDL cohort 
by a Chi-square test for which the P-value for significantly different carrier frequencies is 
given. Contributions: Genotyping data generated by core facilities and analyzed by SAK; 
final analysis and statistical testing performed by SAK. 
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Table 4.2 
Table 4.2: Predicted Impact of APOC3 LoF Variants on mRNA processing and splicing  
 R19X (g.116701353C>T; rs76353203) 
Genomic 
Coordinates  
Position 
relative to 
natural 
site  
Initial(Ri) Final(Ri) Δ Ri Fold change 
% Binding 
(Final/Initial)  Predicted Change 
hnRNP H binding prediction 
116701372 19 0.9 0.9 0 1 100 No change 
116701378 25 4.4 4.4 0 1 100 No change 
116701379 26 4.2 4.2 0 1 100 No change 
116701386 33 4.8 4.8 0 1 100 No change 
hnRNP A1 binding prediction 
116701318 -35 1.5 1.5 0 1 100 No change 
116701321 -32 1.5 1.5 0 1 100 No change 
116701332 -21 0.1 0.1 0 1 100 No change 
116701362 9 2.4 2.4 0 1 100 No change 
116701371 18 2.2 2.2 0 1 100 No change 
116701376 23 4.7 4.7 0 1 100 No change 
116701377 24 0.3 0.3 0 1 100 No change 
116701383 30 4.9 4.9 0 1 100 No change 
116701388 35 0.5 0.5 0 1 100 No change 
116701398 45 4.5 4.5 0 1 100 No change 
116701399 46 1.2 1.2 0 1 100 No change 
116701352 -1 -4.5 4.7 9.2 26.1 2610.9 Increased 
Genome-wide splice donor prediction 
116701311 -42 0.3 0.3 0 1 100 No change 
116701354 1 2.5 3.8 1.3 2.5 249.1 Increased 
116701365 12 2.5 2.5 0 1 100 No change 
116701387 34 1.3 1.3 0 1 100 No change 
Gene-specific splice-donor prediction 
116701311 -42 1.8 1.8 0 1 100 No change 
116701354 1 5.2 6 0.7 1.7 165.8 Increased 
116701365 12 4.2 4.2 0 1 100 No change 
116701387 34 3 3 0 1 100 No change 
	206 
 
Splice branch-point prediction 
116701396 43 0.4 0.4 0 1 100 No change 
Genome-wide splice-acceptor prediction 
116701334 -19 0 0 0 1 100 No change 
Gene-specific splice-acceptor prediction 
116701334 -19 3.3 3.3 0 1 100 No change 
116701335 -18 0 0 0 1 100 No change 
116701343 -10 1.2 1.2 0 1 100 No change 
116701358 5 1.3 1.5 0.2 1.1 114 Increased 
116701357 4 -0.5 0.1 0.6 1.1 107.8 Increased 
 IVS2+1 G>A (g.116701354 G>A; rs138326449) 
Genomic 
Coordinates  
Position 
relative to 
natural 
site  
Initial(Ri) Final(Ri) Δ Ri Fold change 
% Binding 
(Final/Initial)  Predicted Change 
hnRNP H binding prediction 
116701372 18 0.9 0.9 0 1 100 No change 
116701378 24 4.4 4.4 0 1 100 No change 
116701379 25 4.2 4.2 0 1 100 No change 
116701386 32 4.8 4.8 0 1 100 No change 
hnRNP A1 binding prediction 
116701318 -36 1.5 1.5 0 1 100 No change 
116701321 -33 1.5 1.5 0 1 100 No change 
116701332 -22 0.1 0.1 0 1 100 No change 
116701362 8 2.4 2.4 0 1 100 No change 
116701371 17 2.2 2.2 0 1 100 No change 
116701376 22 4.7 4.7 0 1 100 No change 
116701377 23 0.3 0.3 0 1 100 No change 
116701383 29 4.9 4.9 0 1 100 No change 
116701388 34 0.5 0.5 0 1 100 No change 
116701398 44 4.5 4.5 0 1 100 No change 
116701399 45 1.2 1.2 0 1 100 No change 
Genome-wide splice donor prediction 
116701311 -43 0.3 0.3 0 1 100 No change 
116701365 11 2.5 2.5 0 1 100 No change 
116701387 33 1.3 1.3 0 1 100 No change 
116701354 0 2.5 -16.1 -18.6 -5.8 NA Decreased 
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Gene-specific splice-donor prediction 
116701311 -43 1.8 1.8 0 1 100 No change 
116701365 11 4.2 4.2 0 1 100 No change 
116701387 33 3 3 0 1 100 No change 
116701354 0 5.2 -7.6 -12.8 -38 NA Decreased 
Splice branch-point prediction 
116701396 42 0.4 0.4 0 1 100 No change 
Genome-wide splice-acceptor prediction 
116701334 -20 0 0 0 1 100 No change 
Gene-specific splice-acceptor prediction 
116701334 -20 3.3 3.3 0 1 100 No change 
116701335 -19 0 0 0 1 100 No change 
116701343 -11 1.2 1.2 0 1 100 No change 
116701358 4 1.3 1.6 0.3 1.2 123.3 Increased 
A43T (g.116701560 G>A; rs147210663) 
Genomic 
Coordinates  
Position 
relative to 
natural 
site  
Initial(Ri) Final(Ri) Δ Ri Fold change 
% Binding 
(Final/Initial)  Predicted Change 
hnRNP H binding prediction 
116701531 -29 1 1 0 1 100 No change 
116701580 20 1.2 1.2 0 1 100 No change 
hnRNP A1 binding prediction 
116701530 -30 4.9 4.9 0 1 100 No change 
116701539 -21 4.6 4.6 0 1 100 No change 
116701563 3 4.6 4.6 0 1 100 No change 
116701572 12 2.4 2.4 0 1 100 No change 
116701584 24 5.2 5.2 0 1 100 No change 
116701585 25 0.1 0.1 0 1 100 No change 
116701593 33 3 3 0 1 100 No change 
Genome-wide splice donor prediction 
116701596 36 2.2 2.2 0 1 100 No change 
Gene-specific splice-donor prediction 
116701596 36 4.2 4.2 0 1 100 No change 
Splice branch-point prediction 
116701521 -39 1.3 1.3 0 1 100 No change 
116701555 -5 0.9 0.9 0 1 100 No change 
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116701564 4 0.4 0.9 0.5 1.4 140 Increased 
116701575 15 1.1 1.1 0 1 100 No change 
Genome-wide splice-acceptor prediction 
116701532 -28 6 6 0 1 100 No change 
Gene-specific splice-acceptor prediction 
116701532 -28 9.7 9.7 0 1 100 No change 
116701607 47 0.3 0.3 0 1 100 No change 
IVS3+1 G>T (g.116701613G>T; rs140621530) 
Genomic 
Coordinates  
Position 
relative to 
natural 
site  
Initial(Ri) Final(Ri) Δ Ri Fold change 
% Binding 
(Final/Initial)  Predicted Change 
hnRNP H binding prediction 
116701580 -33 1.2 1.2 0 1 100 No change 
116701606 -7 3 -1.9 -4.9 -8.2 NA Decreased 
hnRNP A1 binding prediction 
116701563 -50 4.6 4.6 0 1 100 No change 
116701572 -41 2.4 2.4 0 1 100 No change 
116701584 -29 5.2 5.2 0 1 100 No change 
116701585 -28 0.1 0.1 0 1 100 No change 
116701593 -20 3 3 0 1 100 No change 
116701610 -3 3.9 3.1 -0.9 -1.8 54.8 Decreased 
Genome-wide splice donor prediction 
116701596 -17 2.2 2.2 0 1 100 No change 
116701613 0 3 -15.6 -18.6 -8.1 NA Decreased 
Gene-specific splice-donor prediction 
116701596 -17 4.2 4.2 0 1 100 No change 
116701613 0 4.5 -3.3 -7.8 -22.9 NA Decreased 
Splice branch-point prediction 
116701564 -49 0.4 0.4 0 1 100 No change 
116701575 -38 1.1 1.1 0 1 100 No change 
116701637 24 1 1 0 1 100 No change 
Genome-wide splice-acceptor prediction 
116701650 37 4.3 4.3 0 1 100 No change 
Gene-specific splice-acceptor prediction 
116701607 -6 0.3 0.3 0 1 100 No change 
116701646 33 1.7 1.7 0 1 100 No change 
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116701650 37 9.4 9.4 0 1 100 No change 
116701653 40 0.7 0.7 0 1 100 No change 
116701638 25 -0.3 0.6 0.9 1.5 146.9 Increased 
 
Table 4.2: Predicted impact of APOC3 LoF variants on APOC3 mRNA splicing. 
Each of the four APOC3 LoF variants were assessed for impact on interaction with 
mRNA processing machinery and on the relative energetic changes to splice-donor and 
splice-acceptor site usage using the Automated Splice Site and Exon Definition 
Analyses information theory based prediction tool (http://splice.uwo.ca/). Genomic 
Coordinates indicate genomic position on chromosome 11 for which a particular 
prediction is made. Position relative to the natural site indicates the position on the (+) 
strand of of the variant assessed relative to the Genomic Coordinates. Initial and Final Ri 
indicate the information content of the base in the WT or variant form, respectively, and 
∆Ri indicates the difference between Final Ri and Initial Ri. Fold change indicates the 
difference in binding affinity for a site in the variant vs. WT form based on the ∆Ri. % 
Binding indicates the percentage increase or decrease in binding propensity for a given 
binding factor. Predicted change indicates the overall predicted effect for the given 
measure based on the ∆Ri and predicted fold change for a given position. Contributions: 
All data in this table analyzed by SAK and Paolo Zanoni using in silico tool. 
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Table 4.3 
Table 4.3: Plasma Lipids in Murine Models of WT vs. A43T APOC3 Expression 
Measure: Total Cholesterol (mg/dL) HDL-C (mg/dL) NonHDL-C (mg/dL) TG (mg/dL) ApoC-III (mg/dL) ApoB (mg/dL) 
Group:  Null WT A43T Null WT A43T Null WT A43T Null WT A43T Null WT A43T Null WT A43T 
C57BL/6 WT 95.8 (5.4) 
97.0 
(3.4) 
94.3 
(8.4) 
76.2 
(5.7) 
73.8 
(4.3) 
73.5 
(8.3) 
19.7 
(1.0) 
23.2 
(2.9) 
20.9 
(1.3) 
46.0 
(10.2) 
104.8 
(21.0) 
58.2 
(15.6) ** 
0.0 
(0.0) 
14.8 
(3.0) 
6.0 
(1.4) 
**** 
      
Apoc3 KO 86.4 (12.3) 
101.0 
(9.7) 
90.6 
(4.4) 
65.3 
(11.6) 
74.9 
(7.2) 
70.7 
(6.4) 
21.1 
(2.0) 
26.1 
(3.5) 
19.9 
(2.1) ** 
33.0 
(2.4) 
76.4 
(15.5) 
43.6 
(7.3) ** 
0.0 
(0.0) 
14.2 
(1.2) 
3.8 
(3.2) ***       
LahB WT 157.7 (11.4) 
169.8 
(8.6) 
166.3 
(14.8) 
83.8 
(7.0) 
76.7 
(6.1) 
75.2 
(6.1) 
73.9 
(5.3) 
93.1 
(5.6) 
91.1 
(9.0) 
165.5 
(10.1) 
260.6 
(33.3) 
190.2 
(22.2) ** 
0.0 
(0.0) 
13.7 
(2.6) 
6.4 
(1.9) ***       
LahB Het 291.3 (26.1) 
268.5 
(28.3) 
281.2 
(7.4) 
108.7 
(7.3) 
113.4 
(10.0) 
114.0 
(3.8) 
182.6 
(18.9) 
155.1 
(19.4) 
167.2 
(7.9) 
268.3 
(29.1) 
335.8 
(73.0) 
257.4 
(5.5) * 
0.0 
(0.0) 
24.0 
(13.4) 
5.4 
(4.5) * 
171.4 
(12.4) 
147.1 
(19.0) 
157.9 
(7.4) 
C57BL/6 WT 
+ CETP  
69.0 
(20.2) 
58.7 
(4.9) 
58.7 
(2.1) 
43.7 
(19.4) 
21.9 
(2.9) 
32.9 
(2.4) 
**** 
25.3 
(5.7) 
36.7 
(2.5) 
25.8 
(1.2) **** 
61.3 
(10.2) 
252.0 
(18.7) 
90.7 
(14.6) 
**** 
0.0 
(0.0) 
16.4 
(1.8) 
4.5 
(1.0) 
**** 
      
Apoc3 KO + 
CETP 
70.8 
(15.5) 
63.8 
(5.9) 
61.6 
(3.0) 
43.4 
(14.3) 
26.3 
(4.3) 
33.6 
(2.9) * 
27.5 
(5.3) 
37.5 
(6.5) 
27.8 
(2.5) ** 
42.3 
(9.2) 
192.4 
(35.8) 
55.0 
(14.2) 
**** 
0.0 
(0.0) 
16.7 
(2.2) 
2.4 
(1.6) 
**** 
      
LahB KO + 
CETP  
376.0 
(139.4) 
575.6 
(90.2) 
457.6 
(133.6) 
119.7 
(38.3) 
139.4 
(8.6) 
140.1 
(12.2) 
256.3 
(103.5) 
436.2 
(92.2) 
317.5 
(127.6) * 
124.2 
(60.2) 
242.0 
(74.0) 
144.4 
(64.2) * 
0.0 
(0.0) 
16.5 
(1.3) 
3.9 
(3.3) 
**** 
121.0 
(85.9) 
210.2 
(59.2) 
146.8 
(85.8) * 
 
Table 4.3: Plasma lipids in murine models of WT vs. A43T APOC3 expression. Mean and S.D. values [shown as mean(S.D.)] 
are given for each group of mice expressing Null, WT APOC3, or A43T APOC3 AAVs by intraperitoneal administration at a dose of 
3x1011 genome copies (GC)/mouse. Measurements show data from plasma drawn after four hours of fasting at four weeks after AAV 
administration. Each experiment utilized N=6 male mice per group at approximately 10-12 weeks of age. LahB WT mice are Apobec1 
KO; human APOB transgenic; Ldlr WT mice. LahB Het mice are Apobec1 KO; human APOB transgenic; Ldlr heterozygous mice. 
LahB KO mice are Apobec1 KO; human APOB transgenic; Ldlr KO mice. Groups with “+CETP” were co-transduced with 3x1010 
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GC/mouse of human CETP AAV vector along with the indicated Null or APOC3 AAV vectors. Bold sets of data indicate significant 
results (P<0.05) by two-way ANOVA. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, comparison of WT and A43T groups by Tukey’s 
post-test after two-way ANOVA. Contributions: All data included in this table generated and analyzed by SAK. 
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CHAPTER 5 – MULTIPLEXED TARGETED RESEQUENCING USING MOLECULAR 
INVERSION PROBES IDENTIFIES RARE NONCODING VARIANTS ASSOCIATED 
WITH HIGH HDL CHOLESTEROL LEVELS 
 
Introduction 
Coronary heart disease (CHD) is the leading cause of death in Western societies, and 
despite a substantial environmental contribution, risk of disease is highly heritable. Blood 
cholesterol levels are among the heritable biomarkers of disease risk and protection. 
High-density lipoprotein cholesterol (HDL-C) have been inversely associated with risk of 
CHD for several decades [338-343], supporting this measure as a biomarker for 
assessing disease risk and prevention. While epidemiological findings supporting an 
inverse association of HDL-C with CHD have been consistent, the direct role that HDL 
and HDL-C plays in modulating CHD risk has been highly controversial, with doubt 
concerning the validity of HDL-C as a causal intermediate of CHD risk protection 
increasing over the last decade [53,344]. This doubt has arisen in part from multiple 
failed pharmacological attempts to raise HDL-C specifically to lower CHD risk 
[65,66,345,346]. Human genetics discoveries of the last decade have also cast doubt on 
the causality of HDL-C in mediating CHD risk protection. Mendelian randomization 
studies of low-frequency coding variants in candidate loci associated with HDL-C 
elevation have not translated to reduction in the incidence of CHD or myocardial 
infarction (MI) [193,194,204,347,348]. Recently, we also identified a nonsynonymous 
coding variant in one HDL candidate gene, SCARB1, which was associated with a 
marked elevation in HDL-C levels but increased risk of CHD in humans [349]. The 
disparate conclusions about the directionality of HDL-C to CHD from these collective 
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data have motivated efforts to identify genes and pathways involving HDL function that 
causally impact CHD.  
Unbiased genetics discoveries have provided the opportunity to identify novel loci 
and pathways involved in HDL metabolism for further investigation into their causality to 
CHD. Genome-wide association studies (GWAS) for plasma lipid traits have uncovered 
at least 70 loci to date significantly associated with HDL-C levels through testing of 
common variants (minor allele frequency or MAF > 0.05) on genome-wide genotyping 
arrays [117]. However, pinpointing the causal variants and genes in these loci is 
challenging. Current efforts to resolve this have included fine mapping of the identified 
loci to determine causal variants, but even if successful, these methods are limited in 
that they focus on common single nucleotide polymorphisms (SNPs) with generally small 
effect sizes. Given that common SNPs are estimated to explain only ~1.6% of the total 
heritability of HDL-C levels [117], the missing heritability is likely contained in low 
frequency and rare variants that have been largely underexplored. 
One strategy to uncover the missing heritably and identify putatively causal 
variants at HDL-C candidate loci is targeted resequencing of genes at these loci. Indeed, 
this approach has been applied to the follow-up of initial association studies for myriad 
complex traits, including additional lipid traits LDL-C [350-352] and TG [109,350,353-
355], obesity [356-361], Alzheimer’s disease [85,362-365], and many others. Nearly all 
such efforts have focused on sequencing coding regions of candidate genes, with the 
goal of identifying protein-altering variants that may have a profound functional impact. 
However, given that the majority of GWAS-implicated variants are in the noncoding 
genome [366,367], and many lie in “gene deserts”, the contribution of rare noncoding 
variants to these traits is underexplored and may be critical determinants of the missing 
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heritability underlying many complex traits including HDL-C and CHD. Furthermore, the 
identification of rare, causal, noncoding variants with strong effect sizes on HDL-C may 
help further to reveal causal genes at GWAS loci and delineate specific mechanisms of 
HDL-C regulation that could directly relate to CHD risk. One limitation hampering 
targeted sequencing efforts for the noncoding genome is the relatively poor annotation of 
functional elements most likely to harbor variants of significance, and difficulty in readily 
ascertaining the functional consequences and directionality of noncoding variants 
identified to the associated trait. A related complication is that targeted sequencing 
efforts are costly and scale with the size of the genomic targets, so methods have largely 
been developed for reliably amplifying and sequencing coding regions of genes. Thus, 
there is a need for efficiently capturing the noncoding genome for the identification of 
rare, noncoding variants in manner that could be applied to sufficient numbers of 
participants to identify relationships to complex traits such as HDL-C. 
Here, we sought to identify the feasibility of targeting the noncoding genome for 
candidate gene loci underlying HDL-C that could be extended to larger numbers of 
samples. We performed targeted resequencing of seven HDL-C loci including both 
coding and noncoding regions in a cohort of 1,532 subjects with either extremely high 
vs. low HDL-C. We adapt a recently reported target capture method involving molecular 
inversion probes (MIPs) [368,369] for amplifying genomic targets and show for the first 
time the ability to capture noncoding regions of the genome by this method. Our results 
validate previously reported coding and noncoding SNP associations with HDL-C, 
identify gene-level associations in these seven regions with this trait, and also show the 
promise of large-scale targeted resequencing of noncoding regions for complex traits. 
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Materials and Methods 
Ethics statement  
All human participants of this study and all analyses performed were completed following 
the Declaration of Helsinki and were approved by the Institutional Review Board of the 
Perelman School of Medicine at the University of Pennsylvania and all participants 
provided informed consent. 
 
Subject Selection and Ascertainment 
1532 participants mostly of European ancestry, with either extremely high HDL-C (>95th 
percentile for age and sex), or low HDL-C (20 mg/dL or higher to 25th percentile for age 
and sex) were recruited for targeted sequencing. Participants were recruited as part of 
the University of Pennsylvania High HDL Study (HHDL), a cross-sectional study of 
genetic factors contributing to elevated HDL-C levels. Individuals with elevated HDL-C 
(>90th percentile for age and gender) were identified by physician referrals or through the 
Hospital of the University of Pennsylvania clinical laboratory. Plasma lipids for all 
subjects were measured after fasting by a clinical autoanalyzer (Hitachi). HDL-C 
percentiles for inclusion were calculated for individuals of European ancestry from the 
Framingham Heart Study Offspring cohort adjusted for age and sex. 
 
MIP Design 
Molecular inversion probes (MIPs) were designed according to the method and pipeline 
previously described by O’Roak et al [368]. Briefly, MIPs capturing chosen targets were 
all designed using a common 30 bp linker sequence flanked by an extension arm of 16-
20 bp and a ligation sequence of 20-24 bp, with a total MIP length of 70 bp. The unique 
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arms of the MIPs that anneal to the target sequence by complementary base pairing 
were designed to amplify a specific 112 bp target region by gap-filling and circularization. 
After MIP capture, a PCR amplification reaction using Nextera-like (Illumina) sequencing 
adaptor-containing primers (Illumina) allowed amplification with the primers annealing to 
the 30 bp common linker sequence (Figure 5.1). Given prior demonstration of significant 
variability in MIP capture efficiency due to properties of annealing arm base pairing with 
sequences adjacent to individual targets, an initial set of 549 MIPs were designed to 
cover all of the proposed target, and a pilot-phase MIP sequencing study was performed 
to evaluate per sample and per MIP coverage depth in an initial set of 95 DNA samples. 
Based on the coverage from this run, MIPs demonstrating less than 10-fold coverage 
per base for more than 50% of sequenced samples were redesigned and redesigned 
MIPs were used to replace poorly performing MIPs in a repeat pilot-phase sequencing 
run of the same samples. From this second and final pilot-phase sequencing run, 569 
MIPs were included in total to capture the targeted regions. These 569 MIPs were used 
for subsequent sequencing of genomic DNA samples from the 1,532 participants. 
 MIPs were designed to capture the coding sequences (exons) of the following 
genes (GRC37/hg19): GALNT2 (Chr1:230338882-230415202), APOA5 
(Chr11:116660886-116663095), APOC3 (Chr11:116700650-116703573), CCDC92 
(Chr12:124421729-124428847), ZNF664 (Chr12:124488089-124497396), SCARB1 
(Chr12:125267297-125348261), CETP (Chr16:56995891-57017572), and LIPG 
(Chr18:47088681-47110124) (Supplementary File 1: MIP Sequences and 
Coordinates). The total coding sequence designed to be captured by the 569 MIPs 
corresponding to these regions was 29,288 bp. In addition, noncoding sequences 
proximate to these loci were chosen if they were previously shown to harbor variants 
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significantly associated with HDL-C (P<5E-08; GLGC+Metabochip GWAS), and also 
were found to overlap DNase I hypersensitivity sites in HepG2 cells (human 
hepatocellular carcinoma) from the ENCODE project [370] or enhancers in HepG2 cells 
from the Epigenome-Roadmap project [371]. Regions with 250 bp flanking the positions 
harboring these elements were selected for MIP design. The total noncoding target 
across the loci for which MIPs were designed to capture was 16,696 bp. MIP 
oligonucleotides were purchased from Eurofins Genomics with high-purity salt-free 
purification and at a scale of 50 nmol per oligonucleotide. Lyophilized MIPs were 
hydrated with 1x TE buffer to a concentration of 100 μM and stored at -20 °C. 
 
MIP Capture and Amplification of Targeted Sequences 
MIP oligonucleotides were used to capture targets from genomic DNA derived from 
whole blood from the participants in a manner described previously. Hydrated MIP 
oligonucleotides were pooled together and phosphorylated with T4 polynucleotide kinase 
(NEB) at 37 °C for 45 min, followed by heat inactivation at 65 °C for 20 min. 
Phosphorylated MIPs were used to capture genomic targets by combining with genomic 
DNA from each participant (100 ng of each individual sample; ratio of 800:1 of each MIP 
copy to haploid genome copy) using NEB Hemo Klentaq (NEB) and Ampligase for 24 
hrs at 60 °C in a thermocycler. 96 samples were individually captured in one reaction by 
individually plating reactions in a 96-well thermocycler plate. A total of 16 plates of 96 
samples apiece were processed. Reactions were digested with Exonuclease I and 
Exonuclease III (NEB) after incubations for 45 min at 37 °C and then 2 min at 95 °C. 
Digested MIP capture reactions were PCR amplified using primers with barcoded 
adapter sequences (Table 5.1). In order to sequence all 1532 samples from a single 
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multiplexed pool, a dual-barcoding strategy similar to that of Illumina’s Nextera protocol 
was employed. To provide unique combinations of forward and reverse primers for all 
1536 samples (1532 individual subjects plus 4 ddH2O controls) across the 16 plates, a 
common forward barcoded adapter primer was used for each plate, and 96 unique 
reverse barcoded adapter primers were used for each of the 96 samples within a plate. 
PCR reactions to ligate adapters and barcode MIP capture reactions were completed 
with iProof master mix reagent (BioRad). Barcoded and PCR amplified MIP capture 
reactions were then pooled together at equal volumes, purified using AMPure magnetic 
bead purification (Agencourt) at 0.9-fold the total volume of the pooled reaction, and 
visualized on agarose gels. Purified, pooled capture reactions were then sequenced in 
paired-end mode (150 bp X 150 bp) on Illumina MiSeq and HiSeq2500 sequencers 
using standard Nextera sequencing reagents plus a custom pool of Nextera-like 
sequencing primers (Table 5.2). All MIP oligonucleotides, adapters, PCR primers and 
sequencing primers were synthesized by Eurofins MWG Operon.  
 
Sequencing and Data Analysis 
Initial MIP sequences were obtained as paired-end FASTQ reads from three separate 
sequencing runs (one lane of sequences from a single MiSeq run and two lanes of 
HiSeq2500 RapidRun from two independent runs). De-multiplexing was performed using 
CASAVA v1.8.2’s bcl2fastq conversion script (Illumina), and all reads were processed 
using Trimmomatic v0.32 to remove adapter artifacts, sequencing artifacts, and low 
quality bases [372]. Sequences were aligned to the UCSC hg19 human genome build on 
a per-sample and per-sequencing run basis using BWA v0.7.8 (MEM algorithm; [373]), 
and the resulting alignment files were compressed and sorted using SAMtools v0.1.19 
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[374]. The variant calling was conducted utilized Genome Analysis Toolkit v3.5 (GATK; 
[283]), and pre-processing of each sample’s lane-specific alignment files was performed 
in accordance with the GATK’s ‘Best Practices’ workflow [375,376]. This workflow 
featured duplicate read removal using Picard v1.141 (Picard website: 
http://broadinstitute.github.io/picard), and run-specific insertion-deletion (indel) 
realignment and base recalibration using GATK and hg19 “gold-standard” variant 
catalogs (dbSNP v138 database: http:www.ncbi.nlm.nih.gov/SNP/, [377,378]). Run-
specific alignments were then merged for each sample, and subjected to a second round 
of indel realignment and base recalibration with GATK. Preliminary sample-level variants 
were called using GATK’s HaplotypeCaller tool in gVCF mode at base-pair, and all 
known variants were annotated with dbSNP v138 identities. Sample-level variant callsets 
were then combined and joint-genotyped with GATK. SNPs and indels called at this 
stage were evaluated using metrics collected by Picard and GATK, and then hard-
filtered on the basis of variant-class-specific criteria (Table 5.3) in order to flag potential 
false positives. Filtered variant calls were then further annotated with RefSeq gene 
coordinates for human genome build hg19 (RefSeq database: 
http://www.ncbi.nlm.nih.gov/books/NBK21091/) using VCFtools v0.1.9.0 [379] to include 
features such as full gene lengths, protein coding sequences, exon and intron 
boundaries, and five- and three-prime untranslated regions (UTRs). The final annotated 
and filtered SNP and indel call sets were then combined, and the union of these variants 
was input into the association testing pipeline. Variant statistics, including MAF, were 
computed across the sequencing cohort. Some extremely rare variants were removed 
from the analysis due to lack of validation during filtering.  
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Association Testing and Statistics 
Single variant association results for targeted sequencing analysis were computed using 
the Score test statistic with HDL-C levels treated as a dichotomous phenotype of high (> 
95th percentile for age and gender) or low (<25th percentile for age and gender). 
Ashkenazi ethnicity ascertained by self-identification was included as a covariate in the 
regression analysis. Single variant associations were considered statistically significant if 
P-values for associations were below the Bonferroni corrected P-value, and associations 
with P<0.01 were considered nominally significant. Gene-burden tests were computed 
after grouping variants by gene region and performing a logistic Walt test after grouping 
samples by HDL-C levels treated as a dichotomous phenotype. Additionally, a separate 
grouping of noncoding variants across the targeted regions was compared in high vs. 
low HDL-C participants using HDL-C as a dichotomous variable using the SKAT-O test. 
For all gene- and region-wide burden testing, P<0.05 was considered significant.  
 
Validation by Exome Array Genotyping 
Genomic DNA from 1,139 of the 1,532 participants were also subject to genotyping 
using the Exome Array (HumanExome BeadChip v1.0, Illumina, Inc., San Diego, CA). 
The Exome Chip contains >240,000 coding SNPs derived from all mutations found >2 
times across >1 dataset among 23 separate datasets comprising a total of >12,000 
individual exome and whole genome sequences. In total, 704 high HDL-C participants 
and 458 low HDL-C participants were genotyped using the Exome Array.  
 
Tools used 
VCFtools v0.1.9.0 [379]. 
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bgzip; tabix v0.2.6; bcftools v1.3.1; samtools v0.1.19. [284]. 
Ensembl Variant Effect Predictor [380]. 
Ensembl API and SNP Effect Predictor [381]. 
Ensembl 2016 [382]. 
Ensembl REST API [383]. 
LOFTEE (LOFTEE website: https://github.com/konradjk/loftee) 
dbNSFP v2.9.1. [374]. 
EPACTS v3.2.6 (EPACTS website: http://csg.sph.umich.edu/kang/epacts/home) 
R v3.2.5 (R Core Team 2015). 
 
Results 
Candidate regions for targeted sequencing 
We sought to test the hypothesis that noncoding variants contribute to the allelic 
spectrum of extremely high HDL-C in a manner similar to coding variants, and that 
multiplexed targeted sequencing, previously applied only in sequencing coding regions 
of candidate loci, could also identify noncoding variants making this contribution. To that 
end, we performed a targeted resequencing study of HDL-C candidate gene regions in 
1,532 participants with either extremely high HDL-C (plasma HDL-C >95th percentile for 
age and sex, 797 participants) vs. low HDL-C controls (plasma HDL-C between 20 
mg/dL and 25th percentile for age and sex, 735 participants; Table 5.4). 
For this effort, we chose seven candidate loci for targeted sequencing of coding 
and noncoding regions in our cohorts (Figure 5.2). Among these regions, four loci, 
APOC3 (Chr11:116700624-116703787), SCARB1 (Chr12:125262174-125348519), 
CETP (Chr16:56995835-57017756) and LIPG (Chr18:47088401-47119279) have known 
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roles in HDL metabolism for which loss-of-function has been shown to elevate HDL-C in 
humans [384]. In addition to these loci, we also explored the hypothesis that rare 
noncoding variants may underlie GWAS-implicated loci for HDL-C levels and thus 
included two novel HDL-C GWAS loci, GALNT2 (chr1:230202942-230417876) and the 
CCDC92-ZNF664 region (Chr12:124,420,955-124499986), in our targeted sequencing. 
The directional relationship of GALNT2 SNPs to HDL-C levels has not been conclusively 
established, but previous discoveries of coding variants in GALNT2 have suggested that 
loss-of-function may segregate with high HDL-C levels [184,385,386]. Similarly, the 
contribution to HDL-C levels of rare variants at the CCDC92-ZNF664 locus, including 
coding variants in both genes, remains completely unexplored. We evaluated these loci 
from GWAS for rare coding and noncoding variants to better determine the directional 
relationship of these genes with HDL-C beyond the initial common variant associations. 
 
Variants identified by MIP sequencing 
We performed multiplexed capture of the genomic targets using 569 MIPs in 1,532 
participants and sequenced all samples together after dual-index barcoding through 
Illumina HiSeq2500 sequencing runs.  Multiplexed sequencing of our designated 
genomic targets, which included 29,288 bp of coding sequence and 16,686 bp of 
noncoding sequence, across the 1,532 samples resulted in a median sequencing 
coverage of 110-fold per base for an individual HiSeq2500 sequencing platform.  We 
observed a high uniformity of target coverage per MIP across the subjects in our cohort, 
with approximately 489 MIPs (86% of total) demonstrating coverage of >10-fold depth in 
each sequenced participant. 
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To validate the variants identified from our MIP sequencing, we genotyped 1,162 
of the 1,532 participants (704 high HDL-C individuals and 458 low HDL-C individuals) on 
the probe-based Illumina Exome Array [387]. Among the variants genotyped on this 
array, 51 were within our target regions. We observed a high concordance rate in variant 
discovery between MIP sequencing and genotyping results, with 48 of 51 SNPs (94.1%) 
on the Exome Array called with 100% concordance across all participants, and 1088 of 
1162 participants (93.6%) demonstrating 100% concordance of all genotyped SNPs 
(Figure 5.3). Including these variants present on the Exome array, we identified 2,657 
individual SNPs and 2,342 insertions or deletions (indels) from targeted sequencing. 
Among these variants, 4,371 were novel discoveries without and previous annotation 
(Table 5.5). We tested the association of the individual SNPs and indels identified with 
high vs. low HDL levels, and observed 28 variants with significantly increased frequency 
in the high HDL-C participants (P<2.5E-05, Score test, Table 5.5). 
 
Association of single variants from targeted sequencing with extremely high HDL-C 
To assess the ability of our MIP sequencing approach to identify noncoding variants that 
may influence HDL-C levels, we assessed variants associated with elevated HDL-C with 
an association of P<0.01 using the Score test statistic (Table 5.5 & Table 5.6). We 
identified 276 such SNPs and indels, which included 75 noncoding variants (variant 
positions occurring outside of exons), 32 rare or low frequency variants (MAF < 0.05), 
and 17 novel variants. In total, we identified 15 rare or low-frequency, novel, noncoding 
variants across our regions targeted that were nominally associated with high HDL-C 
from MIP sequencing. 
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 We sought to further explore the biological mechanisms underlying the novel 
associations of noncoding variants associated with HDL-C from MIP sequencing. We 
chose a subset of variants significantly associated with HDL-C from our MIP sequencing 
that were either novel variants or previously identified but for which HDL-C associations 
and functional impact remained unknown to further assess their functional 
consequences. In selecting noncoding variants, we focused on those present in the 
proximal promoter or 5′ untranslated regions (UTRs) of candidate genes, intronic 
variants, and 3′ UTR variants. 
 
Replication of HDL-C associations from GWAS through MIP sequencing 
In addition to rare, noncoding variants identified from MIP sequencing, our 
targeting of noncoding regions of candidate gene loci allowed us to also identify common 
noncoding variants previously associated with HDL-C through GWAS. We identified 28 
SNPs across our targeted regions that had been previously associated with HDL-C 
measured as a continuous trait in GWAS for plasma lipids [117]. We validated all 30 
SNPs as significantly associated with elevated HDL-C from our targeted sequencing. All 
30 SNPs displayed a consistent MAF and directional relationship of the minor allele to 
HDL-C levels with the previous associations (Table 5.7). 
 
Gene-burden associations across target regions with extremely high HDL-C 
Finally, we tested the hypothesis that the genomic regions we targeted harbor variants 
that in aggregate contribute to the relationship of these genes with HDL-C levels. First, 
we performed variant aggregation over the coding regions of the individual gene targets 
and tested the association of each region’s variant burden with HDL-C after filtering 
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coding variants based on their predicted impact on protein function. We grouped coding 
variants into the following categories: disruptive (nonsense, splice-donor, splice-
acceptor, and frameshift variants), and missense variants. We further classified 
missense variants by their in silico predicted deleteriousness and grouped variants as 
either hypothesized to confer deleteriousness by at least one of five variant scoring tools 
vs. those predicted to be deleterious by all five predictions (see Materials and Methods). 
When we performed gene-burden association analysis of high vs. low HDL-C 
participants, we found that the CETP gene region demonstrated a significant burden of 
variants associated with HDL-C (Collapsing test; Table 5.8). This association was 
observed with inclusion of disruptive variants only as well as inclusion of missense 
variants predicted by one tool or all five tools to be deleterious to protein function. In 
addition, we observed that GALNT2, APOA5, and CCDC92 coding variants that were 
either deleterious or missense variants predicted by at least one bioinformatics tool to 
confer deleteriousness also demonstrated a significant gene-level variant burden with 
HDL-C (Table 5.8). Additionally, we asked if noncoding variants across these targets 
collectively contributed to HDL-C and thus performed an aggregation of all noncoding 
variants across our eight targeted regions and tested the association of the burden of 
these variants in high vs. low HDL-C participants. We found a significant association of 
noncoding variants with HDL-C (P=0.05, SKAT-O test; Table 5.8). 
 
Discussion 
Translating novel loci from complex trait GWAS efforts of the last decade to bona fide 
causal variants and genes has been a major challenge for human genetics. Part of this 
difficulty lies in the small effect sizes of GWAS SNPs, and thus resequencing of 
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candidate genes at GWAS loci at the phenotypic extremes of complex traits has been 
one predominant approach to identify rare variants with larger effects. To date, this 
approach has been applied to coding regions of GWAS candidate genes. However, 
coding variants account for a small fraction (< 20%) of all variants in genetic association 
studies for complex traits [366], underscoring the need for further study of the noncoding 
genome for rare, putatively causal variants. Here, we present an inexpensive and 
scalable targeted sequencing approach for identifying rare noncoding variants in 
candidate genes influencing HDL-C, a complex trait with 72 associated loci from GWAS 
[117]. Our proof-of-principle resequencing study of seven candidate gene regions in 797 
extremely high HDL-C vs. 735 low HDL-C participants revealed more than 2,700 
variants in noncoding regions of targets, including rare, novel noncoding variants 
associated with HDL-C and validation of prior GWAS-implicated tag SNPs. As such, our 
findings provide the first example of a multiplexed targeted resequencing study of 
noncoding variants at the phenotypic extremes of a complex trait. 
  Our targeted resequencing study of subjects with HDL-C extremes successfully 
identified multiple rare, novel noncoding variants in target regions that were significantly 
enriched in either cases or controls. While the functional contributions of all of the newly 
identified variants remain unknown, several of these variants overlap important 
regulatory elements that promote gene expression or transcript stability, including gene 
promoters, 5′ UTRs and 3′ UTRs, and other epigenetic signatures of gene transcription 
and transcription factor binding. The identification here of 13 rare, novel noncoding 
variants associated with HDL-C contrasts with a recent targeted resequencing study of 
the coding regions of genes at 95 loci previously implicated in GWAS for plasma lipids in 
a smaller cohort of extremely high vs. low HDL-C [350]. This study involving the 
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sequencing of exons in 939 candidate genes in 684 high or low HDL-C participants with 
replication in 6,424 individuals, failed to identify any novel coding nonsynonymous 
variants associated with HDL-C. The authors argue that their results highlight the 
importance of noncoding variants, either rare or common, at these GWAS-implicated loci 
as causal contributors to HDL-C and the other lipid traits measured, a notion supported 
by our findings here. 
Several variants identified from our study lie in gene regions of known candidate 
genes for which loss-of-function variants have been previously shown to raise HDL-C 
levels in humans. In particular, several noncoding variants significantly enriched in high 
HDL-C participants were observed in CETP and LIPG. CETP is a critical mediator of 
exchange of triglycerides from proatherogenic low-density and very low-density 
lipoproteins to HDL in exchange for HDL cholesterol [19,387]. Higher CETP plasma 
activity is associated with reduced HDL-C levels [19,388,389], while pharmacological 
inhibition of CETP raises HDL-C in humans [388,390,391]. Importantly, several common 
coding and noncoding variants in CETP that putatively reduce CETP levels or 
expression have been identified in individuals with high HDL-C levels [196,385,392-398]. 
Our discovery of novel CETP noncoding variants individually associated with high HDL-
C levels, as well as the finding of a significant gene-level burden of CETP variants with 
HDL-C levels, further supports the notion that CETP is a critical genetic mediator of 
HDL-C in humans. In addition to CETP, LIPG was among the targets demonstrating 
several rare noncoding variants significantly increased in frequency in high HDL-C 
subjects through MIP sequencing. Our group and others identified LIPG as a gene 
encoding endothelial lipase (EL) and showed that it physiologically mediated catabolism 
of circulating HDLs through its lipolytic enzymatic activity [399-401]. We also identified 
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both rare coding and noncoding loss-of-function variants in LIPG that were significantly 
associated with high HDL-C levels in humans [402-404]. Here, through an expanded 
targeted sequencing effort of the LIPG noncoding region, we identified an additional 
novel noncoding variant in the LIPG promoter significantly associated with elevated 
HDL-C, thus furthering the notion that LIPG regulatory variants also contribute to HDL-C 
likely through disruption of LIPG gene expression and plasma EL levels. 
 In addition to the novel variants associated with HDL-C through MIP sequencing, 
we also verified several previously implicated variants in our cohort. We identified six 
rare (MAF < 0.01) or low frequency (MAF < 0.05) nonsynonymous coding variants 
across our selected targeted that were significantly associated with HDL-C levels with 
directionalities consistent with previous reports. These included the CETP Ala390Pro 
and Arg468Gln variants, the APOC3 Ala43Thr variant, and the LIPG Asn396Ser 
variants. We further demonstrated that 28 SNPs associated with HDL-C from GWAS 
were significantly associated with HDL-C cohort status in our MIP high vs. low HDL-C 
sequencing study, with consistent directionality and overall MAF to the previously 
reported results. Though the latest GWAS for HDL-C from the Global Lipids Genetics 
Consortium involved 188,577 participants [117], we were able to replicate these 
associations in less than 1/100th a cohort size through our case-control design. 
Collectively, these findings support the utility of candidate gene and noncoding locus 
resequencing at the extremes of a continuous trait distribution to enrich for trait-
associated alleles, which may allow ascertainment of genetic associations in smaller 
populations than historical sizes for complex trait GWAS, such as understudied 
ethnicities and population isolates. 
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Our study also has methodological implications for future targeted resequencing 
efforts. To date, MIP-sequencing has been applied to targeted sequencing of coding 
regions of candidate genes with a sample preparation cost of less than $1 per participant 
[368,405,406]. Our application of MIPs to noncoding regions of HDL-C candidate genes 
represents one of the first applications of this methodology for regulatory DNA regions. 
Our sequencing efforts were completed at a comparable cost to the prior applications, 
with similar target coverage depths for both the coding and noncoding targets. 
Additionally, our approach allowed us to multiplex all 1,532 individually barcoded capture 
libraries for sequencing in a single lane of an Illumina HiSeq2500 sequencing run with a 
median base coverage per participant of 110-fold, a robust depth for novel and rare 
variant identification at a cost of approximately $1,800 for sequencing. Thus, our study 
supports the putative application of MIP-based sequencing of noncoding regions for 
much larger targeted resequencing efforts at a relatively low per-sample cost. 
 Our study has limitations, which highlight areas for further investigation. Our 
population of high and low HDL-C participants was largely of European ancestry, thus 
limiting the ability to extrapolate the variants discovered to other populations. 
Additionally, our total cohort size of 1,532 participants may be too small to sufficiently 
identify the spectrum of very rare variants that may underlie extremely high HDL-C 
levels. An additional limitation of our work is the selection of the noncoding regions for 
targeting by MIPs and yet untested MIP capture efficiency across any region of the 
genome.  
 In conclusion, our MIP-based targeted sequencing approach has pioneered the 
capture of noncoding regions for the discovery of rare, noncoding variants associated 
with HDL-C in a cohort of extremely high vs. low HDL-C participants. Our results support 
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the promise of future, larger candidate loci resequencing efforts for the discovery of 
putatively causal noncoding variants. These efforts, coupled with appropriate functional 
investigation of identified variants for impact on gene regulation, may substantially help 
in refining the causal genes at loci implicated from GWAS studies and also help further 
explain the missing heritability underlying complex traits such as HDL-C. Though efforts 
to better identify the spectrum of noncoding variants underlying complex traits have 
initiated, including denser genotyping of noncoding variants [407] and whole-genome 
sequencing [408], these approaches remain expensive and not readily applicable to the 
study of large populations or large case-control designs. 
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Figure 5.1 
 
Figure 5.1: Diagram of MIP target capture and sequencing reaction. MIPs were 
designed to capture target sequences of 112 bp from genomic DNA of participants 
isolated from whole blood, as described in the Materials and Methods. Adapter ligation 
involving a dual-index barcoding strategy allowed the efficient barcoding of all 1,532 MIP 
capture libraries and simultaneous multiplexing of all samples together after PCR 
amplification for the Illumina sequencing reactions, which were performed on HiSeq2500 
instruments with 150x150 bp paired end sequencing reads. Contributions: Figure 
generated by SAK and Paul Babb.  
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Figure 5.2 
 
Figure 5.2: Candidate gene regions for MIP targeted sequencing. All coordinates 
correspond to genomic build GRC37/hg19. Contributions: Figure generated by SAK and 
Paul Babb. 
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Figure 5.3 
 
Figure 5.3: Concordance of variants identified from MIP sequencing with Exome 
Chip genotyping. Single nucleotide variants identified in the targeted regions by MIP-
sequencing were compared to the discovery of those variants by genotyping on the 
Exome Chip in a subset of 1,139 participants who were included in both variant 
discovery efforts. 39 SNPs that were included in the Exome Chip were found to overlap 
the targeted regions by MIPs. Box plot on the left shows the percentage of total SNPs 
that were found by both discovery methods for each individual. Plot on right shows the 
percentage of individuals for which a given SNP was found to be concordant across the 
two discovery methods. Contributions: Data generated by SAK and analyzed by SAK 
and Paul Babb; genotyping data generated by core facility.   
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Table 5.1 
Table 5.1: Indexed Adapter Oligo Sequences 
Forward Indexed Primers 
Name Sequence Pool According to DNA Plate  
SLXA_PE_MIPBC_F
OR 
AATGATACGGCGACCACCGAGATCTACACATACGAGATCC
GTAATCGGGAAGCTGAAG 1 
FOR_001 AATGATACGGCGACCACCGAGATCTACACAAAGATACTCCGTAATCGGGAAGCTGAAG 2 
FOR_002 AATGATACGGCGACCACCGAGATCTACACACAGTCTCTCCGTAATCGGGAAGCTGAAG 3 
FOR_003 AATGATACGGCGACCACCGAGATCTACACCAAGGTGATCCGTAATCGGGAAGCTGAAG 4 
FOR_004 AATGATACGGCGACCACCGAGATCTACACCAGTCTGGTCCGTAATCGGGAAGCTGAAG 5 
FOR_005 AATGATACGGCGACCACCGAGATCTACACGACACTACTCCGTAATCGGGAAGCTGAAG 6 
FOR_006 AATGATACGGCGACCACCGAGATCTACACGTGCTTATTCCGTAATCGGGAAGCTGAAG 7 
FOR_007 AATGATACGGCGACCACCGAGATCTACACTGGAGCTGTCCGTAATCGGGAAGCTGAAG 8 
FOR_008 AATGATACGGCGACCACCGAGATCTACACTGGCACCTTCCGTAATCGGGAAGCTGAAG 9 
FOR_009 AATGATACGGCGACCACCGAGATCTACACTTACGGTGTCCGTAATCGGGAAGCTGAAG 10 
FOR_010 AATGATACGGCGACCACCGAGATCTACACTTTCATAGTCCGTAATCGGGAAGCTGAAG 11 
FOR_011 AATGATACGGCGACCACCGAGATCTACACGTTTCAGATCCGTAATCGGGAAGCTGAAG 12 
FOR_012 AATGATACGGCGACCACCGAGATCTACACTCAAAAAGTCCGTAATCGGGAAGCTGAAG 13 
FOR_013 AATGATACGGCGACCACCGAGATCTACACTATGCTGCTCCGTAATCGGGAAGCTGAAG 14 
FOR_014 AATGATACGGCGACCACCGAGATCTACACTAGCTGCCTCCGTAATCGGGAAGCTGAAG 15 
FOR_015 AATGATACGGCGACCACCGAGATCTACACAGCGAATGTCCGTAATCGGGAAGCTGAAG 16 
Reverse Indexed Primers 
Name Sequence Position according to schematic for each plate 
SLXA_PE_MIPBC2_
REV_001 
CAAGCAGAAGACGGCATACGAGATGTTAAGACACACGCAC
GATCCGACGGTAGTGT Position 1 
SLXA_PE_MIPBC2_
REV_002 
CAAGCAGAAGACGGCATACGAGATTCTAAGTTACACGCAC
GATCCGACGGTAGTGT Position 2 
SLXA_PE_MIPBC2_
REV_003 
CAAGCAGAAGACGGCATACGAGATTGTACATTACACGCAC
GATCCGACGGTAGTGT Position 3 
SLXA_PE_MIPBC2_
REV_004 
CAAGCAGAAGACGGCATACGAGATAATACCGCACACGCAC
GATCCGACGGTAGTGT Position 4 
SLXA_PE_MIPBC2_
REV_005 
CAAGCAGAAGACGGCATACGAGATTGTCTATGACACGCAC
GATCCGACGGTAGTGT Position 5 
SLXA_PE_MIPBC2_
REV_006 
CAAGCAGAAGACGGCATACGAGATTCACTGTTACACGCAC
GATCCGACGGTAGTGT Position 6 
SLXA_PE_MIPBC2_
REV_007 
CAAGCAGAAGACGGCATACGAGATTTGTATTCACACGCAC
GATCCGACGGTAGTGT Position 7 
SLXA_PE_MIPBC2_
REV_008 
CAAGCAGAAGACGGCATACGAGATAGACTAACACACGCAC
GATCCGACGGTAGTGT Position 8 
SLXA_PE_MIPBC2_
REV_009 
CAAGCAGAAGACGGCATACGAGATATTGTCAAACACGCAC
GATCCGACGGTAGTGT Position 9 
SLXA_PE_MIPBC2_
REV_010 
CAAGCAGAAGACGGCATACGAGATGTTCTACAACACGCAC
GATCCGACGGTAGTGT Position 10 
SLXA_PE_MIPBC2_
REV_011 
CAAGCAGAAGACGGCATACGAGATTTCATTCGACACGCAC
GATCCGACGGTAGTGT Position 11 
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SLXA_PE_MIPBC2_
REV_012 
CAAGCAGAAGACGGCATACGAGATAAGCGTCAACACGCAC
GATCCGACGGTAGTGT Position 12 
SLXA_PE_MIPBC2_
REV_013 
CAAGCAGAAGACGGCATACGAGATCGTAGGATACACGCAC
GATCCGACGGTAGTGT Position 13 
SLXA_PE_MIPBC2_
REV_014 
CAAGCAGAAGACGGCATACGAGATAGTTAGCGACACGCAC
GATCCGACGGTAGTGT Position 14 
SLXA_PE_MIPBC2_
REV_015 
CAAGCAGAAGACGGCATACGAGATGAACGTCTACACGCAC
GATCCGACGGTAGTGT Position 15 
SLXA_PE_MIPBC2_
REV_016 
CAAGCAGAAGACGGCATACGAGATAGAACACTACACGCAC
GATCCGACGGTAGTGT Position 16 
SLXA_PE_MIPBC2_
REV_017 
CAAGCAGAAGACGGCATACGAGATTGTTGGCAACACGCAC
GATCCGACGGTAGTGT Position 17 
SLXA_PE_MIPBC2_
REV_018 
CAAGCAGAAGACGGCATACGAGATGGCTAATAACACGCAC
GATCCGACGGTAGTGT Position 18 
SLXA_PE_MIPBC2_
REV_019 
CAAGCAGAAGACGGCATACGAGATGCTAGAATACACGCAC
GATCCGACGGTAGTGT Position 19 
SLXA_PE_MIPBC2_
REV_020 
CAAGCAGAAGACGGCATACGAGATTGTACTAAACACGCAC
GATCCGACGGTAGTGT Position 20 
SLXA_PE_MIPBC2_
REV_021 
CAAGCAGAAGACGGCATACGAGATAGTTACACACACGCAC
GATCCGACGGTAGTGT Position 21 
SLXA_PE_MIPBC2_
REV_022 
CAAGCAGAAGACGGCATACGAGATGTACACGAACACGCAC
GATCCGACGGTAGTGT Position 22 
SLXA_PE_MIPBC2_
REV_023 
CAAGCAGAAGACGGCATACGAGATACTGTAAGACACGCAC
GATCCGACGGTAGTGT Position 23 
SLXA_PE_MIPBC2_
REV_024 
CAAGCAGAAGACGGCATACGAGATGATCATGAACACGCAC
GATCCGACGGTAGTGT Position 24 
SLXA_PE_MIPBC2_
REV_025 
CAAGCAGAAGACGGCATACGAGATTGCTAACGACACGCAC
GATCCGACGGTAGTGT Position 25 
SLXA_PE_MIPBC2_
REV_026 
CAAGCAGAAGACGGCATACGAGATTAATGCTCACACGCAC
GATCCGACGGTAGTGT Position 26 
SLXA_PE_MIPBC2_
REV_027 
CAAGCAGAAGACGGCATACGAGATCTTGTTGAACACGCAC
GATCCGACGGTAGTGT Position 27 
SLXA_PE_MIPBC2_
REV_028 
CAAGCAGAAGACGGCATACGAGATGATACAAGACACGCAC
GATCCGACGGTAGTGT Position 28 
SLXA_PE_MIPBC2_
REV_029 
CAAGCAGAAGACGGCATACGAGATATACAGCGACACGCAC
GATCCGACGGTAGTGT Position 29 
SLXA_PE_MIPBC2_
REV_030 
CAAGCAGAAGACGGCATACGAGATCTGGATAGACACGCAC
GATCCGACGGTAGTGT Position 30 
SLXA_PE_MIPBC2_
REV_031 
CAAGCAGAAGACGGCATACGAGATTCATCAGCACACGCAC
GATCCGACGGTAGTGT Position 31 
SLXA_PE_MIPBC2_
REV_032 
CAAGCAGAAGACGGCATACGAGATTTATACCGACACGCAC
GATCCGACGGTAGTGT Position 32 
SLXA_PE_MIPBC2_
REV_033 
CAAGCAGAAGACGGCATACGAGATGCTGATTCACACGCAC
GATCCGACGGTAGTGT Position 33 
SLXA_PE_MIPBC2_
REV_034 
CAAGCAGAAGACGGCATACGAGATATAAGGCCACACGCAC
GATCCGACGGTAGTGT Position 34 
SLXA_PE_MIPBC2_
REV_035 
CAAGCAGAAGACGGCATACGAGATAAGACTAGACACGCAC
GATCCGACGGTAGTGT Position 35 
SLXA_PE_MIPBC2_
REV_036 
CAAGCAGAAGACGGCATACGAGATTAGCAACAACACGCAC
GATCCGACGGTAGTGT Position 36 
SLXA_PE_MIPBC2_
REV_037 
CAAGCAGAAGACGGCATACGAGATCAAGTAATACACGCAC
GATCCGACGGTAGTGT Position 37 
SLXA_PE_MIPBC2_
REV_038 
CAAGCAGAAGACGGCATACGAGATTCATGATGACACGCAC
GATCCGACGGTAGTGT Position 38 
SLXA_PE_MIPBC2_
REV_039 
CAAGCAGAAGACGGCATACGAGATTAGCTCTTACACGCAC
GATCCGACGGTAGTGT Position 39 
SLXA_PE_MIPBC2_
REV_040 
CAAGCAGAAGACGGCATACGAGATACTACATGACACGCAC
GATCCGACGGTAGTGT Position 40 
SLXA_PE_MIPBC2_
REV_041 
CAAGCAGAAGACGGCATACGAGATTGTGCCATACACGCAC
GATCCGACGGTAGTGT Position 41 
SLXA_PE_MIPBC2_
REV_042 
CAAGCAGAAGACGGCATACGAGATGACTTCCAACACGCAC
GATCCGACGGTAGTGT Position 42 
SLXA_PE_MIPBC2_
REV_043 
CAAGCAGAAGACGGCATACGAGATTATTCTCGACACGCAC
GATCCGACGGTAGTGT Position 43 
SLXA_PE_MIPBC2_
REV_044 
CAAGCAGAAGACGGCATACGAGATCACTAGATACACGCAC
GATCCGACGGTAGTGT Position 44 
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SLXA_PE_MIPBC2_
REV_045 
CAAGCAGAAGACGGCATACGAGATCTTCGCATACACGCAC
GATCCGACGGTAGTGT Position 45 
SLXA_PE_MIPBC2_
REV_046 
CAAGCAGAAGACGGCATACGAGATCTAGCGATACACGCAC
GATCCGACGGTAGTGT Position 46 
SLXA_PE_MIPBC2_
REV_047 
CAAGCAGAAGACGGCATACGAGATTACGTTAAACACGCAC
GATCCGACGGTAGTGT Position 47 
SLXA_PE_MIPBC2_
REV_048 
CAAGCAGAAGACGGCATACGAGATAAGTAGTCACACGCAC
GATCCGACGGTAGTGT Position 48 
SLXA_PE_MIPBC2_
REV_049 
CAAGCAGAAGACGGCATACGAGATGACGTATCACACGCAC
GATCCGACGGTAGTGT Position 49 
SLXA_PE_MIPBC2_
REV_050 
CAAGCAGAAGACGGCATACGAGATACGTTCAGACACGCAC
GATCCGACGGTAGTGT Position 50 
SLXA_PE_MIPBC2_
REV_051 
CAAGCAGAAGACGGCATACGAGATAGCTATATACACGCAC
GATCCGACGGTAGTGT Position 51 
SLXA_PE_MIPBC2_
REV_052 
CAAGCAGAAGACGGCATACGAGATAGTGCGAAACACGCAC
GATCCGACGGTAGTGT Position 52 
SLXA_PE_MIPBC2_
REV_053 
CAAGCAGAAGACGGCATACGAGATCAATGGTAACACGCAC
GATCCGACGGTAGTGT Position 53 
SLXA_PE_MIPBC2_
REV_054 
CAAGCAGAAGACGGCATACGAGATATTCCGATACACGCAC
GATCCGACGGTAGTGT Position 54 
SLXA_PE_MIPBC2_
REV_055 
CAAGCAGAAGACGGCATACGAGATAGCTGTTGACACGCAC
GATCCGACGGTAGTGT Position 55 
SLXA_PE_MIPBC2_
REV_056 
CAAGCAGAAGACGGCATACGAGATTTCGACTCACACGCAC
GATCCGACGGTAGTGT Position 56 
SLXA_PE_MIPBC2_
REV_057 
CAAGCAGAAGACGGCATACGAGATCGAATGGTACACGCAC
GATCCGACGGTAGTGT Position 57 
SLXA_PE_MIPBC2_
REV_058 
CAAGCAGAAGACGGCATACGAGATTAGTGTACACACGCAC
GATCCGACGGTAGTGT Position 58 
SLXA_PE_MIPBC2_
REV_059 
CAAGCAGAAGACGGCATACGAGATACGCATGAACACGCAC
GATCCGACGGTAGTGT Position 59 
SLXA_PE_MIPBC2_
REV_060 
CAAGCAGAAGACGGCATACGAGATTTCGTACAACACGCAC
GATCCGACGGTAGTGT Position 60 
SLXA_PE_MIPBC2_
REV_061 
CAAGCAGAAGACGGCATACGAGATTTCTGCTAACACGCAC
GATCCGACGGTAGTGT Position 61 
SLXA_PE_MIPBC2_
REV_062 
CAAGCAGAAGACGGCATACGAGATTGGAAGCAACACGCAC
GATCCGACGGTAGTGT Position 62 
SLXA_PE_MIPBC2_
REV_063 
CAAGCAGAAGACGGCATACGAGATGATGCTCAACACGCAC
GATCCGACGGTAGTGT Position 63 
SLXA_PE_MIPBC2_
REV_064 
CAAGCAGAAGACGGCATACGAGATAGCCTGAAACACGCAC
GATCCGACGGTAGTGT Position 64 
SLXA_PE_MIPBC2_
REV_065 
CAAGCAGAAGACGGCATACGAGATCACCAGTAACACGCAC
GATCCGACGGTAGTGT Position 65 
SLXA_PE_MIPBC2_
REV_066 
CAAGCAGAAGACGGCATACGAGATGTTACACCACACGCAC
GATCCGACGGTAGTGT Position 66 
SLXA_PE_MIPBC2_
REV_067 
CAAGCAGAAGACGGCATACGAGATGCGTTAGTACACGCAC
GATCCGACGGTAGTGT Position 67 
SLXA_PE_MIPBC2_
REV_068 
CAAGCAGAAGACGGCATACGAGATTGACGTTCACACGCAC
GATCCGACGGTAGTGT Position 68 
SLXA_PE_MIPBC2_
REV_069 
CAAGCAGAAGACGGCATACGAGATTAGGCGTAACACGCAC
GATCCGACGGTAGTGT Position 69 
SLXA_PE_MIPBC2_
REV_070 
CAAGCAGAAGACGGCATACGAGATAAGTGAGCACACGCAC
GATCCGACGGTAGTGT Position 70 
SLXA_PE_MIPBC2_
REV_071 
CAAGCAGAAGACGGCATACGAGATCCGGAATAACACGCAC
GATCCGACGGTAGTGT Position 71 
SLXA_PE_MIPBC2_
REV_072 
CAAGCAGAAGACGGCATACGAGATAATAGGCAACACGCAC
GATCCGACGGTAGTGT Position 72 
SLXA_PE_MIPBC2_
REV_073 
CAAGCAGAAGACGGCATACGAGATTTCAGGTCACACGCAC
GATCCGACGGTAGTGT Position 73 
SLXA_PE_MIPBC2_
REV_074 
CAAGCAGAAGACGGCATACGAGATTAATCGCTACACGCAC
GATCCGACGGTAGTGT Position 74 
SLXA_PE_MIPBC2_
REV_075 
CAAGCAGAAGACGGCATACGAGATCTTAGGTGACACGCAC
GATCCGACGGTAGTGT Position 75 
SLXA_PE_MIPBC2_
REV_076 
CAAGCAGAAGACGGCATACGAGATTTGATCTCACACGCAC
GATCCGACGGTAGTGT Position 76 
SLXA_PE_MIPBC2_
REV_077 
CAAGCAGAAGACGGCATACGAGATTCTTACTGACACGCAC
GATCCGACGGTAGTGT Position 77 
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Table 5.1: Indexed adapter oligo sequences. 16 forward barcoded adapter oligos (one 
for each plate of 96 DNA samples comprising genomic DNA used for this study) were 
used along with 96 individual reverse barcoded adapter oligos in the PCR amplification 
step to allow for individual barcoding of all 1,532 samples across the experiment. 
Reverse barcode positions refer to positions on the 96 well plate of DNA samples that 
were maintained for the MIP capture reactions and subsequent amplifications. 
Contributions: primers generated by commercial facility after being designed by SAK and 
Ben Voight.  
 
SLXA_PE_MIPBC2_
REV_078 
CAAGCAGAAGACGGCATACGAGATGAGTACACACACGCAC
GATCCGACGGTAGTGT Position 78 
SLXA_PE_MIPBC2_
REV_079 
CAAGCAGAAGACGGCATACGAGATACGTTACAACACGCAC
GATCCGACGGTAGTGT Position 79 
SLXA_PE_MIPBC2_
REV_080 
CAAGCAGAAGACGGCATACGAGATTGGTAAGCACACGCAC
GATCCGACGGTAGTGT Position 80 
SLXA_PE_MIPBC2_
REV_081 
CAAGCAGAAGACGGCATACGAGATGATAGCACACACGCAC
GATCCGACGGTAGTGT Position 81 
SLXA_PE_MIPBC2_
REV_082 
CAAGCAGAAGACGGCATACGAGATGACTTAGGACACGCAC
GATCCGACGGTAGTGT Position 82 
SLXA_PE_MIPBC2_
REV_083 
CAAGCAGAAGACGGCATACGAGATAGTCGTTAACACGCAC
GATCCGACGGTAGTGT Position 83 
SLXA_PE_MIPBC2_
REV_084 
CAAGCAGAAGACGGCATACGAGATCGTGATTAACACGCAC
GATCCGACGGTAGTGT Position 84 
SLXA_PE_MIPBC2_
REV_085 
CAAGCAGAAGACGGCATACGAGATTCAGTAGAACACGCAC
GATCCGACGGTAGTGT Position 85 
SLXA_PE_MIPBC2_
REV_086 
CAAGCAGAAGACGGCATACGAGATATGTGTCTACACGCAC
GATCCGACGGTAGTGT Position 86 
SLXA_PE_MIPBC2_
REV_087 
CAAGCAGAAGACGGCATACGAGATCAGAATATACACGCAC
GATCCGACGGTAGTGT Position 87 
SLXA_PE_MIPBC2_
REV_088 
CAAGCAGAAGACGGCATACGAGATTAAGTCTGACACGCAC
GATCCGACGGTAGTGT Position 88 
SLXA_PE_MIPBC2_
REV_089 
CAAGCAGAAGACGGCATACGAGATATCGACATACACGCAC
GATCCGACGGTAGTGT Position 89 
SLXA_PE_MIPBC2_
REV_090 
CAAGCAGAAGACGGCATACGAGATACAGCTGTACACGCAC
GATCCGACGGTAGTGT Position 90 
SLXA_PE_MIPBC2_
REV_091 
CAAGCAGAAGACGGCATACGAGATATCACAAGACACGCAC
GATCCGACGGTAGTGT Position 91 
SLXA_PE_MIPBC2_
REV_092 
CAAGCAGAAGACGGCATACGAGATGTCGAATTACACGCAC
GATCCGACGGTAGTGT Position 92 
SLXA_PE_MIPBC2_
REV_093 
CAAGCAGAAGACGGCATACGAGATTGCCGATTACACGCAC
GATCCGACGGTAGTGT Position 93 
SLXA_PE_MIPBC2_
REV_094 
CAAGCAGAAGACGGCATACGAGATACTAATGCACACGCAC
GATCCGACGGTAGTGT Position 94 
SLXA_PE_MIPBC2_
REV_095 
CAAGCAGAAGACGGCATACGAGATCTAGTAGGACACGCAC
GATCCGACGGTAGTGT Position 95 
SLXA_PE_MIPBC2_
REV_096 
CAAGCAGAAGACGGCATACGAGATTTAAGCCAACACGCAC
GATCCGACGGTAGTGT Position 96 
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Table 5.2 
 
Table 5.2: Sequencing primers. 16 individual sequencing primers, each corresponding 
to the 16 respective forward indexed adapters, were used in an eqimolar pool along with 
a common reverse sequencing primer and sequencing index primer to sequence 
through the barcode index 2 that was ligated from the 96 individual reverse indexed 
adapters for the Illumina HiSeq2500 sequencing reactions. Contributions: Primers 
designed by SAK and Paul Babb. 
 
Table 5.2: Sequencing Primers 
Name Sequence 
Sequencing Forward Primers to sequence Barcode Index 2 (16 oligos pooled together) 
SLXA_PE_MIPBC_FOR-SeqRead1 CATACGAGATCCGTAATCGGGAAGCTGAAG 
FOR_001-SeqRead1 CAAAGATACTCCGTAATCGGGAAGCTGAAG 
FOR_002-SeqRead1 CACAGTCTCTCCGTAATCGGGAAGCTGAAG 
FOR_003-SeqRead1 CCAAGGTGATCCGTAATCGGGAAGCTGAAG 
FOR_004-SeqRead1 CCAGTCTGGTCCGTAATCGGGAAGCTGAAG 
FOR_005-SeqRead1 CGACACTACTCCGTAATCGGGAAGCTGAAG 
FOR_006-SeqRead1 CGTGCTTATTCCGTAATCGGGAAGCTGAAG 
FOR_007-SeqRead1 CTGGAGCTGTCCGTAATCGGGAAGCTGAAG 
FOR_008-SeqRead1 CTGGCACCTTCCGTAATCGGGAAGCTGAAG 
FOR_009-SeqRead1 CTTACGGTGTCCGTAATCGGGAAGCTGAAG 
FOR_010-SeqRead1 CTTTCATAGTCCGTAATCGGGAAGCTGAAG 
FOR_011-SeqRead1 CGTTTCAGATCCGTAATCGGGAAGCTGAAG 
FOR_012-SeqRead1 CTCAAAAAGTCCGTAATCGGGAAGCTGAAG 
FOR_013-SeqRead1 CTATGCTGCTCCGTAATCGGGAAGCTGAAG 
FOR_014-SeqRead1 CTAGCTGCCTCCGTAATCGGGAAGCTGAAG 
FOR_015-SeqRead1 CAGCGAATGTCCGTAATCGGGAAGCTGAAG 
Sequencing Reverse Primer to sequence Barcode Index 2 
MIPBC_SEQ_REV ACACGCACGATCCGACGGTAGTGT 
Sequencing Index Primer to sequence Barcode Index 2 
MIPBC_SEQ_INDX ACACTACCGTCGGATCGTGCGTGT 
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Table 5.3 
Table 5.3: Variant Filtering Criteria  
Variant type Filtering criteria 
SNPs 
Quality by Depth < 2.0, Fisher Strand Test > 60.0, Mapping 
Quality < 30.0, Strand Odds Ratio Test > 4.0, Mapping Quality 
Rank Sum Test < -12.5, Read Position Rank Sum Test < -8.0 
INDELs 
Quality by Depth < 2.0, Read Position Rank Sum Test < -20.0, 
Inbreeding Coefficient < -0.8, Fisher Strand Test > 200.0, 
Strand Odds Ratio Test > 10.0 
 
Table 5.3: Variant Filtering Criteria. Criteria for inclusion of SNP and insertion-deletion 
(INDEL) variants using the GATK pipeline for variant annotation during analysis of 
sequencing run data, as described in the Materials and Methods. Contributions: Analysis 
relevant to this table performed by Paul Babb. 
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Table 5.4  
Table 5.4: Characteristics of Participants for Targeted Sequencing 
High HDL Cohort Low HDL Cohort High vs. Low HDL Cohort (T test) 
		 All  (N=789) 
Males 
(N=228) 
Females 
(N=561) 		
All 
(N=743) 
Males 
(N=454) 
Women 
(N=289) 		
Age (SD) 58 (13) 59 (15) 58 (12) Age 55 (13) 56 (12) 53 (15) P<0.0001 
Caucasian % 86.2 89.9 84.7 Caucasian 61.5 65 56.1 N/A 
Ashkenazi % 7.9 8.3 7.7 Ashkenazi 2.6 3.5 1 N/A 
Black % 4.6 2.2 5.5 Black 27.5 23.3 33.9 N/A 
Total Cholesterol 
(mg/dL) 240 (42) 227 (40) 245 (42) 
Total 
Cholesterol 177 (72) 172 (74) 185 (68) P<0.0001 
HDL-C (mg/dL) 107 (21) 94 (19) 112 (19) HDL-C 32 (11) 31 (12) 34 (8) P<0.0001 
LDL-C (mg/dL) 127 (60) 127 (40) 127 (71) LDL-C 100 (59) 96 (58) 105 (61) N.S. 
TG (mg/dL0 77 (34) 78 (37) 77 (32) TG 266 (566) 270 (537) 259 (610) P<0.0001 
 
Table 5.4: Characteristics of participants for MIP targeted sequencing. Participants were recruited from the Penn High HDL 
Study as previously described. All lipid measurements were performed on plasma collected after participants fasted overnight. 
Comparisons of absolute measurements were performed using a Student’s unpaired T-test of all High HDL Cohort participants vs. all 
Low HDL Cohort participants. All absolute data is reported as mean ± S.D.. Contributions: Data generated by clinical laboratory and 
analyzed by SAK. 
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Table 5.5 
Table 5.5: Variants identified by MIP targeted sequencing of high HDL-C 
participants 
All variants identified (4999) 
Region 
Total 
number 
of  
variants 
(SNPs & 
Indels)  
Known Novel  
Variants associated 
with HDL-C 
(P<2.5x10E-05, 
Score test) 
GALNT2 958 127 831 0 
APOC5-APOC3 709 77 632 0 
SBNO1  83 5 78 0 
CCDC92-
ZNF664 900 107 793 2 
SCARB1  813 90 723 0 
CETP 633 95 538 22 
LIPG  903 127 776 4 
Total 4999 628 4371 28 
Variants nominally associated with high HDL-C (P<0.01, Score Test)  
Region Coding Noncoding 
Common 
(MAF>0.0
5)   
Rare & 
Low-
frequency 
(MAF<0.0
5) 
Known  Novel  
GALNT2 0 10 8 2 8 2 
APOC5-APOC3 2 8 8 2 7 3 
SBNO1  0 0 0 0 0 0 
CCDC92-
ZNF664 2 14 11 5 14 2 
SCARB1  2 3 0 5 3 2 
CETP 6 25 21 10 28 3 
LIPG  5 15 12 8 15 5 
Total 17 75 60 32 75 17 
 
Table 5.5: Variants identified by MIP sequencing of high HDL-C participants. Single 
nucleotide variants (SNPs) and insertion-deletion variants (INDELs) were assessed for 
each gene region (GRC37/hg19),. Known variants were those for which an rsID existed 
or were able to be ascertained in publically available variant databases including dbSNP, 
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1000 Genomes, the NHLBI Exome Variant Server and the Exome Aggregation 
Consortium (ExAC) database. Minor alleles of identified variants were compared for 
frequency in the high vs. low HDL cohort by the Score test statistic. Noncoding variants 
included any variants that were not present in protein-coding regions of the gene 
regions, including splice-site, intronic, 5’UTR, 3’UTR and intergenic variants. 
Contributions: All data in this table generated from bench experiments performed by 
SAK and analyses of sequencing data performed by a Paul Babb and then by SAK. 
Final data analyses and QC performed by SAK.  
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Table 5.6 
Table 5.6: Variants nominally associated with high HDL-C (P<0.01, Score Test)  
Region Chromosome Position Variant  rsID (if known variant) Variant call rate
1  MAF Score statistic P-value (Score test) 
GALNT2 
1 230293530 C/T rs4631704 0.97781 0.4723 2.5884 0.009643 
1 230294185 A/T rs910502 0.99478 0.11975 2.9236 0.0034603 
1 230294989 C/A rs1555290 0.98303 0.1328 2.7426 0.0060964 
1 230295245 C/T rs12065546 0.96932 0.13737 2.9757 0.0029235 
1 230295307 C/G rs17315646 0.99413 0.48424 2.7679 0.0056412 
1 230295691 G/A rs4846914 0.98368 0.47545 2.7894 0.0052813 
1 230296153 C/T rs10864726 0.98368 0.48142 3.3998 0.00067442 
1 230296492 G/A rs4846916 0.60444 0.18143 3.3858 0.00070963 
1 230416051 C/T   0.43277 0.021116 3.3749 0.00073839 
1 230417044 AC/A   0.99608 0.0022936 -2.5816 0.0098341 
APOC5-APOC3 
11 116662331 G/T rs12287066 0.99413 0.082075 -3.1879 0.0014332 
11 116662407 G/C rs3135506 0.87663 0.078183 -3.4676 0.00052513 
11 116662579 C/T rs651821 0.98042 0.096538 3.4607 0.00053868 
11 116663707 G/A rs662799 0.99217 0.096053 2.8851 0.0039128 
11 116678249 CAA/CAAA   0.76893 0.25806 3.4891 0.00048469 
11 116680918 G/A rs1263172 0.96802 0.38065 2.7578 0.0058186 
11 116681008 G/A rs1263173 0.95104 0.45504 2.8793 0.0039852 
11 116684516 C/A   0.98499 0.00066269 3.2042 0.0013543 
11 116684562 C/G rs2727791 0.98303 0.40604 2.9501 0.0031764 
11 116703697 A/G   0.9876 0.0019828 2.7368 0.0062034 
CCDC92-ZNF664 12 124421453 T/C rs9863 0.99608 0.40957 3.5326 0.00041144 
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12 124427306 T/A rs11057401 0.99543 0.33967 4.5426 5.56E-06 
12 124428162 T/A rs4930725 0.99739 0.36257 3.8431 0.00012147 
12 124428331 T/C rs4930726 0.9752 0.37383 3.9729 7.10E-05 
12 124428459 GCACC/G   0.90927 0.00035894 3.1688 0.0015308 
12 124428577 AT/A rs143840819 0.97063 0.0090787 -2.8329 0.0046133 
12 124429279 G/A rs3186071 0.98695 0.32474 4.0264 5.66E-05 
12 124430612 G/A rs4765305 0.95496 0.48154 3.7265 0.00019412 
12 124430812 G/A rs4765335 0.98825 0.39861 3.5877 0.00033365 
12 124431049 G/A rs11835839 0.96214 0.41689 4.4826 7.37E-06 
12 124431109 GT/G   0.97715 0.000334 3.1966 0.0013907 
12 124472571 T/C rs4765562 0.98433 0.39025 3.1208 0.0018036 
12 124496316 A/G rs1054852 0.95561 0.42418 2.7152 0.0066242 
12 124497177 A/G rs377752073 0.99347 0.040736 -2.5847 0.0097451 
12 124499129 T/TG rs34578644 0.99804 0.015697 -2.6971 0.0069944 
12 124499839 C/T rs3768 0.99282 0.22485 3.8327 0.00012677 
SCARB1  
12 125260864 TCC/T   0.99413 0.003283 2.676 0.0074497 
12 125263061 C/T rs3825140 0.50522 0.0096899 3.0476 0.0023067 
12 125266613 A/G   0.062663 0.026042 2.6595 0.0078265 
12 125271101 A/C rs2293439 0.99086 0.006917 2.7355 0.0062292 
12 125298877 G/A rs5889 0.99347 0.0098555 3.7806 0.00015646 
CETP 
16 56995236 C/A rs1800775 0.87337 0.32175 7.307 2.73E-13 
16 56995814 G/A rs34498052 0.94321 0.0010381 4.2945 1.75E-05 
16 56995908 T/A rs34119551 0.98564 0.00033113 3.201 0.0013696 
16 56996104 C/A rs17231534 0.98303 0.072709 3.2765 0.0010511 
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16 56996158 T/C rs3816117 0.98433 0.47513 9.7264 2.33E-22 
16 56996211 G/A rs711752 0.97911 0.42967 7.9663 1.63E-15 
16 56996288 G/A rs708272 0.97977 0.44204 7.8132 5.58E-15 
16 56997136 G/A   0.36292 0.0017986 3.3039 0.00095353 
16 56997137 G/A   0.36162 0.0018051 3.3026 0.00095806 
16 56998918 A/G rs12720926 0.92102 0.36464 8.1117 4.99E-16 
16 56999184 AT/A rs35585922 0.99608 0.08519 3.6898 0.00022441 
16 56999258 A/C rs7203984 0.96345 0.23103 -8.5873 8.90E-18 
16 56999328 C/T rs11508026 0.97846 0.3956 9.7472 1.90E-22 
16 57001216 C/T rs4784741 0.9654 0.26775 7.7259 1.11E-14 
16 57001254 T/TCACA rs12720908 0.96606 0.19527 -7.8463 4.29E-15 
16 57001274 AC/A rs200751500 0.87337 0.13229 6.1576 7.39E-10 
16 57001438 G/A rs12444012 0.23825 0.49315 4.4254 9.63E-06 
16 57001547 A/G rs142093596 0.38316 0.0017036 3.0925 0.0019848 
16 57004889 G/A rs7205804 0.96345 0.35637 7.3489 2.00E-13 
16 57005300 G/A   0.97258 0.0026846 -2.6028 0.0092458 
16 57005301 C/T rs1532625 0.96997 0.35834 8.4272 3.54E-17 
16 57005883 G/A rs374409989 0.8577 0.0022831 4.5547 5.24E-06 
16 57007353 C/T rs5883 0.97454 0.073007 4.9778 6.43E-07 
16 57007446 T/G rs11076176 0.98303 0.1836 -7.0854 1.39E-12 
16 57015084 C/G rs7192120 0.99086 0.0098814 -2.6659 0.0076776 
16 57015091 G/C rs5880 0.99021 0.034608 -4.7289 2.26E-06 
16 57016092 G/A rs5882 0.99151 0.37261 -4.38 1.19E-05 
16 57017319 G/A rs1800777 0.99151 0.024358 -5.3247 1.01E-07 
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16 57017474 G/A rs289741 0.91971 0.3577 -4.7505 2.03E-06 
16 57017662 G/A rs1801706 0.98172 0.17121 5.0081 5.50E-07 
16 57017796 G/A rs289743 0.93016 0.22561 -2.988 0.0028081 
LIPG  
18 47088548 CT/C   0.98368 0.0023225 3.1977 0.0013855 
18 47088690 C/A rs874565 0.98433 0.020889 -2.8211 0.0047863 
18 47088741 C/T rs874566 0.99347 0.02661 -3.7617 0.00016877 
18 47088830 C/G rs35816125 0.99086 0.29249 2.679 0.007384 
18 47093864 C/T rs2000813 0.99347 0.26905 3.2313 0.0012322 
18 47096016 G/A rs1320700 0.95692 0.27729 4.276 1.90E-05 
18 47109955 A/G rs77960347 0.9765 0.01738 3.4682 0.0005239 
18 47110088 C/T   0.96475 0.0023681 -2.6056 0.0091717 
18 47113196 G/T   0.99935 0.00032658 3.195 0.0013981 
18 47117376 C/T rs3744840 0.99543 0.043934 3.1834 0.0014553 
18 47157400 T/C rs2000825 0.9876 0.14243 3.3521 0.00080214 
18 47157439 C/T rs2000826 0.98172 0.34973 3.6989 0.00021654 
18 47158186 T/C rs10438978 0.99608 0.19397 5.0649 4.09E-07 
18 47158234 C/T rs9304381 0.99608 0.17857 4.7841 1.72E-06 
18 47158307 AC/A   0.022846 0.071429 -2.7203 0.0065219 
18 47164926 T/C rs6507937 0.98042 0.13848 3.3464 0.00081856 
18 47167214 T/C rs4939883 0.99739 0.20844 5.0238 5.07E-07 
18 47167344 G/C   0.98042 0.00033289 3.1924 0.0014108 
18 47167407 T/C rs4939884 0.98107 0.13373 3.3699 0.00075194 
18 47179516 G/A rs1943973 0.98499 0.10835 3.4066 0.0006578 
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Table 5.6: Single variant associations with high HDL-C. Variants (SNPs and INDELs) across targets were compared for 
frequency of the minor allele in high vs. low HDL participants by Score test statistic. P<0.01 was considered nominally statistically 
significant. MAF refers to minor allele frequency within the sequencing cohort. Call rate refers to the fraction of 1,532 samples for 
which variant position was sequenced and passed variant quality filtering. Contributions: All data in this table generated from bench 
experiments performed by SAK and analyses of sequencing data performed by Paul Babb and then by SAK. Final data analyses and 
QC performed by SAK.  
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Table 5.7 
Table 5.7: Replication of GWAS-significant HDL-C associations with MIP sequencing 
Region Chr. Position Ref. allele 
Alt. 
allele rsID 
GLGC+Metabochip 
GWAS 
1000 
Genomes MIP sequencing 
P-value, association 
with HDL-C MAF Call rate 
Overall 
MAF 
MAF - High 
HDL Cohort 
MAF - Low 
HDL Cohort 
Score 
statistic P-value 
GALNT2 
1 230295245 C T rs12065546 1.50E-15 0.8443 0.96932 0.13737 0.87857 0.84545 2.9757 0.0029235 
1 230295307 C G rs17315646 1.35E-36 0.5844 0.99413 0.48424 0.57785 0.44884 2.7679 0.0056412 
1 230295691 G A rs4846914 3.51E-41 0.5844 0.98368 0.47545 0.59073 0.45411 2.7894 0.0052813 
1 230296153 C T rs10864726 8.65E-24 0.5858 0.98368 0.48142 0.58869 0.44376 3.3998 0.00067442 
APOC5-
APOC3 
11 116662331 G T rs12287066 1.08E-20 0.94195 0.99413 0.082075 0.061083 0.10494 -3.1879 0.0014332 
11 116662407 G C rs3135506 7.74E-16 0.94327 0.87663 0.078183 0.055866 0.10367 -3.4676 0.00052513 
11 116662579 C T rs651821 7.72E-26 0.91953 0.98042 0.096538 0.93266 0.87133 3.4607 0.00053868 
11 116663707 G A rs662799 4.16E-37 0.91953 0.99217 0.096053 0.92522 0.88098 2.8851 0.0039128 
CCDC92-
ZNF664 
12 124427306 T A rs11057401 4.53E-08 0.2504 0.99543 0.33967 0.37894 0.29713 4.5426 5.56E-06 
12 124428331 T C rs4930726 1.53E-09 0.3641 0.9752 0.37383 0.3947 0.35139 3.9729 7.10E-05 
CETP 
16 56995236 C A rs1800775 3.33E-644 0.4802 0.87337 0.32175 0.75943 0.59852 7.307 2.73E-13 
16 56996211 G A rs711752 1.28E-641 0.4222 0.97911 0.42967 0.52635 0.32548 7.9663 1.63E-15 
16 56999258 A C rs7203984 3.59E-517 0.777 0.96345 0.23103 0.12092 0.34951 -8.5873 8.90E-18 
16 56999328 C T rs11508026 2.63E-318 0.4142 0.97846 0.3956 0.51677 0.26588 9.7472 1.90E-22 
16 57004889 G A rs7205804 5.27E-675 0.4235 0.96345 0.35637 0.46414 0.24412 7.3489 2.00E-13 
16 57005301 C T rs1532625 2.25E-397 0.4235 0.96997 0.35834 0.46084 0.24931 8.4272 3.54E-17 
16 57007353 C T rs5883 1.76E-31 0.06069 0.97454 0.073007 0.094716 0.049512 4.9778 6.43E-07 
16 57015091 G C rs5880 1.37E-233 0.94063 0.99021 0.034608 0.019133 0.05116 -4.7289 2.26E-06 
16 57016092 G A rs5882 2.21E-58 0.3325 0.99151 0.37261 0.61111 0.64512 -4.38 1.19E-05 
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16 57017474 G A rs289741 7.64E-160 0.3219 0.91971 0.3577 0.61172 0.67471 -4.7505 2.03E-06 
16 57017662 G A rs1801706 1.09E-15 0.1939 0.98172 0.17121 0.20968 0.13032 5.0081 5.50E-07 
LIPG 
18 47093864 C T rs2000813 1.08E-23 0.2902 0.99347 0.26905 0.31266 0.22199 3.2313 0.0012322 
18 47157400 T C rs2000825 2.93E-24 0.8245 0.9876 0.14243 0.87739 0.8363 3.3521 0.00080214 
18 47157439 C T rs2000826 1.36E-07 0.6649 0.98172 0.34973 0.6982 0.59904 3.6989 0.00021654 
18 47158186 T C rs10438978 1.56E-27 0.8179 0.99608 0.19397 0.86398 0.74317 5.0649 4.09E-07 
18 47158234 C T rs9304381 3.06E-24 0.8193 0.99608 0.17857 0.86839 0.77049 4.7841 1.72E-06 
18 47164926 T C rs6507937 6.52E-24 0.8259 0.98042 0.13848 0.87773 0.84414 3.3464 0.00081856 
18 47167214 T C rs4939883 1.80E-66 0.8193 0.99739 0.20844 0.85076 0.72752 5.0238 5.07E-07 
18 47167407 T C rs4939884 5.13E-24 0.8206 0.98107 0.13373 0.87916 0.85229 3.3699 0.00075194 
18 47179516 G A rs1943973 2.75E-54 0.843 0.98499 0.10835 0.90857 0.87345 3.4066 0.0006578 
 
Table 5.7: Replication of GWAS-significant HDL-C associations with MIP sequencing. Variants identified by MIP sequencing 
were compared for associations with HDL-C with the Global Lipids Genetics Consortium+MetaboChip GWAS results [117]. 30 
variants identified by MIP sequencing in the targeted regions were also associated with HDL-C in GWAS. All 30 variants displayed 
consistent directionality of association with HDL-C through MIP sequencing (P<0.01, Score test), as observed by GWAS. MAFs were 
obtained from 1000 Genomes for the given variants and compared with the MAFs observed in the MIP sequencing discovery cohort. 
Contributions: All data in this table generated from bench experiments performed by SAK and analyses of sequencing data 
performed by Paul Babb and then by SAK. Final data analyses and QC performed by SAK.  
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Table 5.8 
Table 5.8: Gene-burden level association of variants from MIP sequencing with HDL-C  
Aggregation of coding 
variants in each gene 
region 
Disruptive variants1 Disruptive + Missense (1/5)2 Disruptive + Missense (5/5)3 
Gene Region Number of variants β(SE) 
P-value 
(Collapsing test) 
Number of 
variants β(SE) 
P-value 
(Collapsing test) 
Number of 
variants β(SE) 
P-value 
(Collapsing test) 
GALNT2 1:230338882-230415203 50 0.17737(0.1656) 0.28414 75 0.37613(0.13308) 0.0047096 50 0.17737(0.1656) 0.28414 
APOA5 11:116660886-116663095 47 -0.1072(0.14206) 0.45047 69 -0.28607(0.12272) 0.01975 47 -0.1072(0.14206) 0.45047 
APOC3  11:116701515-116703575 17 -0.30959(0.26308) 0.23928 20 -0.35348(0.25918) 0.17262 17 -0.30959(0.26308) 0.23928 
CCDC92  12:124421620-124428847 53 0.18717(0.18344) 0.30759 73 0.53371(0.12312) 1.46E-05 53 0.18717(0.18344) 0.30759 
ZNF664 12:124488089-124497235 8 0.84513(0.46749) 0.07064 22 0.13866(0.17381) 0.425 8 0.84513(0.46749) 0.07064 
SCARB1 12:125267297-125348261 68 0.17916(0.13531) 0.18547 92 0.042176(0.11697) 0.71842 68 0.17916(0.13531) 0.18547 
CETP 16:56995891-57017577 46 -0.34005(0.18686) 0.068783 59 -0.48798(0.13732) 0.00037992 46 -0.34005(0.18686) 0.068783 
LIPG 18:47088681-47110121 48 -0.003131(0.1718) 0.98546 67 0.21127(0.14962) 0.15793 48 -0.003131(0.1718) 0.98546 
Aggregation of all noncoding 
variants across targeted regions  
Number of variants Number of single variants ρ statistic P-value (SKAT-O test)  
3436 467 0 0.05 
 
Table 5.8: Gene-burden associations of identified variants with high HDL-C 
1Disruptive coding variants included nonsense (stop-gained), frameshift, splice-donor and splice-acceptor variants, as annotated from 
dbSNP.  
2Missense variants were defined as nonsynonymous amino acid-altering variants. Variants were included in this grouping if they were 
identified as ‘deleterious’ or ‘damaging’ by one of the five in silico prediction tools: SIFT (deleterious), PolyPhen2 HDIV (‘possibly 
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damaging’ or ‘probably damaging’), PolyPhen2 HVAR (‘possibly damaging’ or ‘probably damaging’), MutationTaster, and LRT 
(disruptive). 
3Missense variants were included in this grouping if they were predicted to be ‘deleterious’ or ‘damaging’ by all five prediction tools as 
described in the Materials and Methods.  
Contributions: All data in this table generated from bench experiments performed by SAK and analyses of sequencing data 
performed by Paul Babb and then by SAK. Final data analyses and QC performed by SAK.  
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CHAPTER 6 – SUMMARY AND FUTURE DIRECTIONS 
 
Summary 
 At the time this dissertation work started, there had already been ample progress 
in both the understanding of the heritable basis of plasma lipid traits and the 
development of life-saving therapies to reduce the burden of CHD and MI through 
lowering atherogenic lipoprotein concentrations in the blood. Statins were already 
recognized as remarkably effective drugs for LDL-C lowering and disease risk reduction 
[409-411], and the translation of human genetics discoveries in the PCSK9 realm, fueled 
in part by in vivo physiological and biochemical investigation, was already well underway 
with phase I studies of PCSK9-inhibitory monoclonal antibodies showing promise in 
LDL-C lowering [412]. The major players in the physiological pathways regulating LDL-
C, HDL-C and TG metabolism were likewise discovered and their biology explored 
through study of Mendelian disorders of lipoprotein metabolism and animal models of 
gain- and loss-of-function. GWAS for lipids had expanded to more than 100,000 
participants, yielding 95 genomic loci, most of which were novel, associated with at least 
one blood lipid trait [86]. This era was aptly termed by one investigator as a “treasure 
trove for lipoprotein biology” [413] because it marked the beginning of an entirely new 
approach for mechanistic and physiological discovery of the regulation of lipid 
metabolism and offered the potential for new therapeutic targets. Finally, the application 
of exome sequencing to the study of rare human phenotypes had just begun, and one of 
the first uses of this methodology had successfully identified LOF of the lipase inhibitory 
gene ANGPTL3 as a genetic cause of a novel Mendelian disorder of lipoprotein 
metabolism, Familial Combined Hypolipidemia [118].  
	253 
 
 However, for all of these successes and potentials for further discovery, this 
period of time also bore much uncertainty about the biological and clinical relevance of 
some lipid traits to disease and the ways to translate the novel genomics findings to 
discrete biological pathways and targets. The role of HDL-C as a protective factor 
against CHD became hotly questioned after low-frequency genetic variant studies using 
Mendelian randomization did not support a causal role for HDL-C elevation itself in CHD 
risk reduction [204,414], and several therapeutic efforts to raise HDL-C failed to 
demonstrate any clinical benefit [19]. The causal relationship of TGs with CHD risk was 
also debated because of the pleiotropic effects of TG-altering variants on other blood 
lipids [124], and no existing drug trials completed to appropriately address the question 
of whether TRL lowering itself in hyperTG patients could orthogonally reduce CHD risk in 
addition to conventional LDL-C reduction. The need for additional therapies was 
especially pressing as increasing evidence mounted that LDL-C lowering alone still may 
leave significant residual vascular risk, and many patients were intolerant to the doses of 
statins needed to achieve optimal LDL-C levels [19]. And while the era of GWAS and 
next-generation sequencing allowed the discovery of additional pathways for targeting, 
the progress from locus discovery to causal gene, causal variant, tissue of action, and 
mechanism had proven difficult [415]. The goal of this dissertation work was thus to use 
the existing and newly developed methodologies to address key questions and 
controversies that have arisen regarding the disease causality, novel biology, and 
potential clinical promise of HDL and TGs from the vantage point of human genetics.  
I first sought to address the controversial relationship of HDL to CHD risk by 
discovering and investigating a LOF variant in SCARB1, a gene encoding the HDL 
cholesterol receptor that in experimental models is critical for the hepatic clearance of 
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HDL cholesterol and the RCT pathway postulated to confer protection from CHD 
[207,277]. This study identified the first homozygote for a LOF variant in SCARB1 and 
showed that human SR-BI deficiency results in extremely high HDL-C levels due to 
ineffective CE clearance by the liver from HDLs. Consistent with prior animal model data 
but challenging the human epidemiology, SCARB1 LOF was associated with increased 
CHD risk despite the marked HDL-C elevation. This work supports and provides the 
foundation for further study of the specific contribution of the RCT pathway of cholesterol 
removal via HDL that may be a more clinically relevant measure of disease risk than 
HDL-C alone.   
I next asked a question central to the utility of GWAS for complex traits – what is 
the causal gene and mechanism of action of a newly identified GWAS-associated locus?  
I addressed the role of GALNT2, one of the top novel genes implicated in HDL-C and TG 
metabolism through GWAS [86,117], through studies of LOF in humans, mice, rats and 
nonhuman primates. We compared the lipid phenotypes and consequences of absent 
GALNT2 across models and identified a biochemical target of GALNT2’s gene product 
whose function in mediating HDL-C levels was impaired by GALNT2 deficiency. Through 
this work, we provide an example for the systematic evaluation of GWAS-implicated 
genes to uncover underlying conserved and species-specific biological functions.  
Thirdly, I sought to understand how recently identified genetic variation 
underlying TGs and CHD could be leveraged for therapeutic gain. I performed a 
structure-function analysis of a the A43T LOF variant in APOC3 identified from exome 
sequencing [91,106] that reduces TGs and CHD risk independently of LDL-C. Through 
studying human A43T carriers and humanized mice expressing A43T, I have shown that 
	255 
 
this variant confers LOF through promoting ApoC-III clearance and have outlined a 
mechanism that may be informative for developing ApoC-III-focused therapies.  
Lastly, I tested methods to better uncover the noncoding genome for variants 
underlying phenotypic extremes of lipid traits. I applied a recently reported multiplexed 
sequencing capture method [368] for targeted resequencing of both the coding and 
noncoding regions of HDL-C candidate genes in high HDL-C vs. low HDL-C participants. 
Through a proof-of-principle study, I confirmed reported associations between common 
and low frequency variants and HDL-C and identified several novel variants in these 
genes for further study. This work supports the potential for large-scale targeted 
sequencing to better explain the heritable basis of the extremes of lipid traits. As is the 
case for any scientific endeavor, my work on these projects raised many questions, 
perhaps more than they answered, but thus afford many opportunities for exciting new 
and continued exploration, which I will discuss below.  
 
Future Directions 
Role of SCARB1 in HDL metabolism and CHD risk in humans 
The discovery that genetic LOF of SCARB1 in humans is tolerated and largely 
recapitulates the phenotype of the murine models allows an exciting opportunity to 
directly assess the contribution of this gene and the RCT pathway to CHD risk in 
humans. We found a moderate association of the variant with increased CHD in our 
study of heterozygotes from a multi-ethnic population (P=0.018). Though this variant is 
extremely rare in the general population (MAF in Europeans of 0.0003 in our study), the 
variant appears to be enriched in the Ashkenazi Jewish community. Indeed, our high 
HDL-C cohort demonstrated that almost all of the identified carriers were of Ashkenazi 
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descent. Independently, genotyping in 256 participants of the Ashkenazi Genome 
Consortium (https://ashkenazigenome.org/) showed that the P376L variant was present 
with a MAF of 2.344%, a nearly ~100-fold higher frequency than in our cohort. Thus, 
search for this variant specifically in the Ashkenazi population may yield more 
heterozygous and homozygous carriers that would allow further study of the relationship 
of the variant to CHD, along with insight about the penetrance of the HDL-C  and other 
metabolic phenotypes in carriers.  
Additional P376L carriers provide the opportunity to directly assess RCT in 
humans via novel methods. Our laboratory developed a protocol to study macrophage-
to-feces RCT in vivo in animal models that has become the mainstay of RCT studies in 
the HDL field [223,416-418]. We recently modified this protocol for the study of RCT in 
humans (under review for publication). Briefly, an isotope-labeled tracer of cholesterol is 
administered intravenously to human participants and the appearance of this tracer in 
the plasma, relative distribution among lipoproteins, proportion of free vs. esterified 
cholesterol, and clearance is measured, along with the appearance of the tracer in the 
feces (a measure of biliary excretion). This assay has been applied in a limited number 
of human participants to date, including a patient with ABCA1 deficiency (Tangier 
disease) and LCAT deficiency, two Mendelian disorders of HDL metabolism leading to 
extremely low HDL-C levels. With the identification of homozygous SCARB1 deficiency, 
there may now be potential to directly interrogate the RCT pathway via this assay in 
human subjects homozygous for the SCARB1 P376L variant or other confirmed LOF 
variants yet to be identified.  
Systematic gene-by-gene dissection of the RCT pathway through human 
homozygotes for LOF variants could provide unequivocal evidence of the existence and 
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relevance of this pathway in humans. If this is coupled to measures of atherosclerotic 
burden (e.g. coronary calcium scores, carotid intimal medial thickness), this method 
could help relate the RCT hypothesis and HDL functionality over HDL-C levels with CHD 
risk in humans. This effort could also resolve a controversy raised from a prior study of 
cholesterol flux using tracer-labeled isotopes in humans, which purported that most of 
the hepatic cholesterol taken up from lipoproteins occurs through the LDLR pathway 
[269]. This study posited that CETP drives CE flux from HDLs to ApoB-containing 
lipoproteins which then deliver the CE to the liver. This contrasts with the conclusions 
from my data showing massive HDL-C and specifically CE elevation with human 
SCARB1 deficiency. Our work supports the SR-BI pathway as a mediator of at least 
some of the CE flux to the liver via HDLs. An alternative conclusion from our findings is 
that ‘constipation’ of this pathway through SR-BI deficiency may have indirect effects on 
the ability of the CE to be delivered via the other receptors by ApoB-lipoprotein mediated 
transport. The comparison of RCT in humans with SR-BI, LDLR, and CETP deficiency, 
along with those with variants in upstream mediators of the pathway (LOF of APOA1, 
ABCA1, and LCAT) would provide thus invaluable insight. Moreover, such an 
experiment would aid in pinpointing specific nodes of the pathway most relevant for 
therapeutic intervention.  
 The identification of SCARB1 deficiency also allows the exploration of the other, 
non-RCT related roles of SR-BI. SR-BI is critical for cholesterol uptake for steroid 
hormone biosynthesis in the adrenal glands and gonads in mice, and indeed SR-BI 
deficiency in these animals results in profound metabolic consequences, including 
infertility, adrenal glucocorticoid insufficiency, thrombocytopenia and platelet activity 
dysfunction [208,277]. Many of these findings were absent in the SCARB1 homozygote 
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we identified, who presented with normal fertility and no observable endocrine 
anomalies. In this regard, it is noteworthy that the phenotype of the P376L homozygote 
resembles that of the PDZK1 KO mouse, a mouse deficient in an adapter protein for SR-
BI localization to the cell membrane in hepatocytes [275]. Thus, it is possible that our 
homozygote displays the liver findings of SR-BI deficiency but not the findings seen from 
the global SCARB1 KO mouse. Additional variant discovery to identify more LOF 
variants of SCARB1 in humans may help further dissect the set of phenotypes of SR-BI 
deficiency that affect HDL metabolism and other metabolic phenotypes in humans.  
Likewise, additional studies of the P376L variant, both in animal models 
recapitulating the variant such as CRISPR/Cas9 knock-in mice and also in human 
derived cell types from iPSCs, may further elucidate the myriad functions of SR-BI to 
vascular homeostasis that are altered with this variant. Paramount to these studies is a 
deeper inspection of how this variant’s impact on SR-BI post-translational processing 
ultimately modulates its varied functions (Figure 6.1). Specifically, previous investigators 
have shown that endothelial SR-BI is a critical mediator of vasodilation through an HDL-
mediated signaling program that drives nitric oxide production [276], and thus SR-BI may 
confer atheroprotection through this mechanism as well. Future ongoing work will 
undoubtedly assess the role of SR-BI in CHD through all of these mechanisms using the 
vantage point of the natural variant and potential for identifying more carriers for 
phenotyping and translational investigation as a starting point.  
 
Biology of GALNT2 and lipoprotein metabolism 
Our interrogation of the GALNT2 locus started with the GWAS association of this locus 
with HDL-C and TGs in 2008 [131,132] and resulted in a cross-species comparison of 
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GALNT2 deficiency across mammalian models. Our eight-year effort has resulted in 
several new areas for potential study. These include the molecular functions of GALNT2 
in lipid metabolism and its broader biological roles, the reasons for the cross-species 
differences in phenotypes across the spectrum of GALNT2 LOF, and the implications of 
our approach for the elucidation of other GWAS loci for complex traits.  
 The impact of GALNT2 on lipoprotein metabolism remains an important area for 
continued focus, as it will shed light on the broader biological roles of GalNAc 
transferases and O-glycosylation. We identified a consistent reduction in HDL-C with 
GALNT2 deficiency across the models tested, however there were notable differences in 
the O-glycoproteomes between WT vs. KO organisms for each species. This suggests 
that multiple glycosylation modifications of different protein targets may act to elicit the 
same HDL-C phenotype that we saw across the different species. In addition to PLTP, 
we identified hundreds of target proteins that were differentially glycosylated between 
WT vs. KO animals or control vs. LOF homozygous humans. Each of these targets is 
worthy of further inspection to understand the role of the glycosylation modification on 
the target protein’s function. For example, the mouse plasma differential glycoproteomes 
also identified glycopeptides in hepatic triglyceride lipase (HL), one of the extracellular 
lipases involved in remodeling of TRL remnants and HDLs through its TG lipase and 
phospholipase activities [419]. Additionally, mouse liver differential glycoproteomics 
identified glycopeptides in LRP1, one of the LDL receptor family members that mediates 
TRL remnant clearance and mediates signaling in extrahepatic tissues [420]. Systematic 
surveying of the results from our O-glycoproteomics across the humans, mice and rats 
will facilitate the understanding of the varied functions of O-glycosylation in regulating 
protein functions.  
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 With regard to the observation that GALNT2 modulates PLTP to regulate HDL 
metabolism, additional experiments will be required to determine the physiological 
impact of O-glycosylation on the molecular and biochemical properties of PLTP. Studies 
such as site-directed mutagenesis of the glycosylation sites at the C-terminus of PLTP 
will help determine the exact residue and fold the glycosylation modulates, and will be a 
key first step in identifying the molecular mechanism. Further studies of isolated or 
recombinant glycosylated vs. nonglycosylated PLTP such as Michaelis-Menten kinetics 
will also define the biochemical consequences of PLTP’s molecular activity. Likewise, 
measurement of the association of glycosylated vs. nonglycosylated PLTP with HDLs,  
TRLs, and phospholipid vesicles will help determine if O-glycosylation stabilizes PLTP’s 
molecular interactions.  
Further work in animal models will also be critical in determining the molecular 
and physiological impact of PLTP O-glycosylation on both PLTP metabolism itself and 
atherosclerosis (Figure 6.2). To study glycosylation and PLTP metabolism, PLTP could 
be isolated from GALNT2 WT vs. KO animals or synthesized with or without the 
glycosylation and radiolabeled to measure PLTP turnover and production, in ways 
analogous to the ApoC-III turnover studies described to study the A43T missense variant 
in Chapter 4. This experiment would help determine if PLTP clearance is affected by the 
O-glycosylation and could be related to the binding of the glycosylated vs. 
nonglycosylated protein to lipoproteins as mentioned above. To better understand the 
epistatic relationship between GALNT2 and PLTP, the Pltp/Galnt2 double knockout 
(DKO) mouse could be generated and compared to the single KO models. Similarly, the 
overexpression of PLTP in the setting of GALNT2 deficiency could be used to 
understand if glycosylation is a necessity for maximally functional PLTP activity and HDL 
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maintenance. Finally, the impact of GALNT2 function on the physiological consequences 
of altered PLTP activity could be assessed using these animal models to study RCT, 
HDL and TRL kinetics, and atherosclerosis in vivo. Given the small modulation in HDL-C 
levels with the absence of GALNT2 and moderately reduced PLTP activity, the likelihood 
of a profound effect on atherosclerosis is low, but these studies would be informative to 
better understand the regulation of PLTP function nonetheless.  
The additional targets of GALNT2 that were identified in humans, ANGPTL3 and 
ApoC-III, also open the door to many questions about the role of GALNT2 in the 
regulation of TRL metabolism pathway proteins. At this point, our data and prior 
evidence suggest that while ApoC-III is a bona fide target of GalNAc-T2 in humans, the 
absence of O-glycosylation does not appear to impact steady-state TG levels [95-97]. 
Yet it is still unclear what the function of the O-glycosylation modification of this target is. 
For ANGPTL3, evidence establishing a physiological role for glycosylation of ANGPTL3 
in vivo is also lacking. For both cases, the study of the human homozygotes for GALNT2 
LOF variants will undoubtedly be informative. Mass spectrometry methods may help 
resolve cleaved vs. intact ANGPTL3 in the plasma of variant carriers vs. controls, an 
experiment which may confirm results from the prior biochemical studies suggesting that 
O-glycosylation inhibits ANGPTL3 cleavage and activation [186,279]. For the study of 
both proteins, glycosylated vs. nonglycosylated forms could be generated and studied 
for their metabolism in animal model using isotope-labeling methods to track the 
clearance of the different proteins and their association with the various lipoprotein 
fractions.  
 As in the case for the SCARB1 variant carrier, much is yet to be learned from 
further study of the humans homozygous for LOF variants in GALNT2. We are especially 
	262 
 
interested in the possible role of GalNAc-T2 mediated O-glycosylation in the regulation 
of neuronal development and behavior, because limited observation of the homozygous 
carriers has demonstrated neurodevelopmental delay and seizure disorders in addition 
to the lipid phenotypes central for our work. Through additional unpublished work using 
our GALNT2 KO mouse, I have found that global GALNT2 deficiency reduces inhibition, 
increases fearlessness, decreases social interaction and reduces cerebellar learning 
capacity in vivo. Glycomic measurements of the sugar structures in the plasma of the 
human GALNT2 LOF carriers as well as plasma and CNS tissues of GALNT2 KO mice 
have shown a consistent and dramatic reduction in O-GalNAc glycosylation with 
compensatory increases in other forms of glycosylation. While this work is certainly 
preliminary, the potential to connect GALNT2 to a syndrome of neurobehavioral function 
through studies in humans and mice would be exciting. Indeed, it would be one of the 
few studies establishing deficiency of a GalNAc transferase gene as the cause for a 
genetic disorder, reminiscent of the seminal discovery of GALNT3 deficiency as the 
cause of the Mendelian bone disorder Familial Tumoral Calcinosis [421]. Further studies 
in the GALNT2 KO mice and GALNT2 deficient humans to identify glycoprotein targets 
differentially regulated in the CNS tissues and their relationship to the observed 
phenotypes is certainly needed to further this effort.  
 
Therapeutically relevant mechanisms of APOC3 loss-of-function 
Our work on APOC3 LOF variants associated with reduced TGs and protection 
from CHD set out to identify the mechanisms of putative ApoC-III lowering or inactivation 
conferred by the variants. We found that three of the four variants expectedly reduced 
ApoC-III levels likely through reducing expression of the protein. Meanwhile, the fourth 
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variant, A43T, increased ApoC-III catabolism due to perturbation of binding of ApoC-III 
to lipoproteins in the circulation, a mechanism distinct from that of the other three 
variants. Nevertheless, all four variants in aggregate have been associated with a 
favorable lipoprotein profile and protection from CHD, suggesting that these various 
mechanisms of ApoC-III LOF are potentially avenues for therapeutic targeting.  
One can view the currently developing anti-APOC3 antisense oligonucleotide 
(ASO) as a therapy that attempts to mimic the effect of the three APOC3 LOF variants 
that reduce APOC3 expression. This therapy has shown some promise so far in 
preclinical models and phase I and II studies in severely hyperTG patients [102-104]; 
however, recent reports of profound thrombocytopenia with ASO treatment have 
temporarily halted ASO trials, including the APOC3 ASO program. By elucidating the 
mechanism of the A43T variant (Figure 6.3), I hope that our findings will serve as a 
foundation for pharmacological endeavors to reduce circulating ApoC-III levels through 
promoting its clearance.  One strategy for this would be to design monoclonal antibodies 
that target ApoC-III by binding the dynamic region of the protein harboring the Ala43 
residue and promoting dissociation of ApoC-III from lipoproteins to augment renal 
clearance. Alternatively, antibodies that promote the dissociation of ApoC-III without 
allowing the renal catabolism of the ApoC-III:antibody complex could still reduce TRLs if 
the complexes are incapable of inhibiting LPL or remnant particle clearance. Other 
strategies that could be envisioned involving monoclonal antibodies would include those 
that promote the ApoC-III:LDLR interaction and thus promote hepatic TRL remnant 
uptake. However, experimental data supporting the plausibility of such as mechanism 
does not yet exist. Indeed, the current scope for novel APOC3-focused therapies is 
broad and many are looking to the examples from other genetics discoveries-turned-
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therapies, namely the PCSK9 chronicle, for guidance in designing pharmacological 
approaches here.  
From a physiological vantage point, the study of APOC3 LOF variants has also 
allowed the potential to address the relative contributions of the different functions of 
ApoC-III on TRL metabolism. Our study of the A43T variant identified clear 
consequences of the variant on LPL function in vivo and in vitro, but it did not rule out 
the possibility that the variant confers an atheroprotective lipid profile through 
accelerating remnant particle clearance. The issue of a ‘primary-lipolysis’ vs. ‘primary-
clearance’ effect of ApoC-III is an age-old debate that started when the APOC3 
transgenic mouse was shown to have ‘normal’ tissue LPL activity but impaired remnant 
particle clearance in vivo [99]. Since then, several mouse studies have attempted to 
address the issue of whether ApoC-III does actually compete with ApoE for mediating 
remnant clearance or if the LPL inhibitory functions are predominant [317,422]. Most 
recently, use of the mouse anti-Apoc3 ASO in a series of mouse models lacking different 
hepatic lipoprotein receptors suggested that promotion of remnant clearance was the 
primary means by which APOC3 silencing reduced TGs [333]. This study utilized an 
inducible LPL KO mouse to further suggest that LPL activity was not required to elicit a 
TG reduction in the setting of APOC3 silencing, thus supporting the notion that the 
remnant clearance effect is more relevant. Clear from all these studies is that the 
methodologies to assess in vivo LPL activity and in vivo remnant particle clearance in 
mouse models are not straightforward and subject to significant inter-user differences in 
performance. Simultaneous studies of gain- and loss-of-function of ApoC-III, such as 
through the identification and in vivo study of gain-of-function variants, could help in 
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assessing the relative contributions of the differing functions of ApoC-III in addition to 
methods standardization.  
Finally, the study here of APOC3 LOF variant carriers illustrates the utility of 
heterozygotes for LOF variants to study gene function. We were able to assess the 
impact of variants that putatively reduce APOC3 expression by 50% on downstream 
effects on ApoC-III protein levels. Doing so allowed us to remark that half-normal 
APOC3 expression may reduce the total circulating pool of ApoC-III by >50%. For the 
three LOF variants that reduce APOC3 expression, we observed robust reductions of 
ApoC-III levels beyond 50% of the expected values from noncarrier controls. I postulate 
that this may be due to the enhanced clearance of TRLs and remnants that are partially 
devoid of ApoC-III due to improved lipolysis, more efficient particle remodeling, and 
possibly more accessibility for key ligands such as ApoE to be retained on the remnants. 
These properties increase the clearance of the remnants by the liver and thus may 
account for the very low (often zero) levels of ApoC-III we observed in the heterozygous 
carriers. This has implications for developing therapies as drugs that even partially 
reduce ApoC-III levels may still yield benefits by promoting further ApoC-III clearance 
indirectly by this proposed mechanism. Through collaboration with the Pakistan Risk of 
Myocardial Infarction Study (PROMIS) led by Dr. Danish Saleheen at Penn, we have 
been able to identify dozens of APOC3 R19X homozygotes born in consanguineous 
unions and have initiated studies of noncarriers, R19X heterozygotes and homozygotes 
to address questions related to the impact of gene-dosage of APOC3 on lipoprotein 
phenotypes, kinetics, and other metabolic processes in addition to evaluating any 
adverse effects of complete APOC3 deficiency. These studies will hopefully also shape 
future pharmacological efforts of ApoC-III lowering.  
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Resequencing the noncoding genome for rare causal variation 
Targeted sequencing of a handful of HDL-C candidate loci through the use of 
molecular inversion probes was an economical means to interrogate the coding and 
noncoding regions of selected targets and identified almost 5,000 variants, most of 
which was novel and in noncoding regions. Appreciation of the value of rare noncoding 
variants will only increase with the advent of whole-genome sequencing studies, which is 
currently in its earliest phase. Targeted sequencing of candidate regions will remain a 
reasonable way to improve coverage of targets of known relevance to a disease or trait 
process.  
In the case of our targeted sequencing, the identified rare, noncoding novel 
variants we identified will have to be tested for their impact on gene expression through 
a number of ways. These include assessment of their abilities to impact reporter gene 
expression, endogenous gene expression in patient-derived cells, and elucidation of the 
transcriptional machinery that regulates the regions harboring these variants. For 
promising variants, human carriers could also be recruited for deeper phenotyping 
related to their extreme HDL-C phenotype. Broadly speaking, the approach we have 
undertaken here can be applied with the workflow and analysis tools we have generated 
to large population-based resequencing efforts for noncoding regions or larger 
phenotypic extreme case-control designs. Such studies are likely to benefit from the 
combination of other variant interrogation tools that have been used throughout this 
dissertation work, such as exome chip genotyping, GWAS, and exome sequencing. 
Through such parallel investigations of different types of variants in the same 
participants, we may also better answer age-old questions regarding the missing 
heritability underlying these complex traits from the coding vs. noncoding genome.  
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Figure 6.1  
 
Figure 6.1: Proposed mechanism of disruption of folding of SR-BI due to SCARB1 
P376L variant. On the left is shown a model of the SR-BI protein, which forms a loop 
with two transmembrane components at the cell surface. Proline 376 spans a region of 
multiple cysteines and disulfide bonds at the C-terminus of the protein at the 
extracellular loop. Disruption of the natural fold through the P376L variant may perturb 
disulfide bond formation, proper folding, and thus post-translational N-glycosylation and 
mature, endoglycosidase H-resistant forms of the SR-BI normally destined for the cell 
surface as functional receptors (right). This may result in the observed reduction in cell-
surface SR-BI and selective cholesterol uptake from HDLs due to the variant, as 
discussed in Chapter 2. 
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Figure 6.2  
 
Figure 6.2: Possible role of C-terminal O-glycosylation of PLTP in mediating 
phospholipid binding capacity and transfer to HDLs. On the top is shown a 
molecular model for human PLTP, with the C-terminal pocket serving as the lipid binding 
domain. Multiple residues at the extreme C-terminus in this pocket were determined to 
be O-glycosylated and isoform-specific targets of GalNAc-T2 in vitro and ex vivo. These 
residues may impact the phospholipid binding affinity of PLTP and ability to mediate 
transfers from ApoB-containing lipoproteins to discoidal (immature) HDLs to yield 
spherical (mature) HDLs. Alternatively, O-glycosylation of PLTP may modulate its ability 
to associate with HDL proteins and already present on immature particles.  
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Figure 6.3 
 
Figure 6.3: Impact of APOC3 A43T variant on lipid binding affinity of ApoC-III. On 
the top left is shown a helical wheel diagram for ApoC-III, demonstrating that the alanine 
43 residue (residue 23 of the mature protein after signal peptide cleavage) lies in a 
hydrophobic (lipid-opposing) face of an alpha helix. Below is a model of ApoC-III 
indicating that this alanine is part of a lipid-facing helix. Our data discussed in Chapter 4 
demonstrates a reduced lipid binding affinity for this variant likely due to perturbed 
interaction with lipid surfaces due to the more polar threonine residue imparted by the 
variant. This results in reduced binding to lipoprotein surfaces suchas as that of TRLs, 
causing dissociation to an unbound state and increased renal clearance (right). 
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